

American Psychiatric Association




162ND ANNUAL MEETING

San Francisco

**SHAPING OUR FUTURE:
SCIENCE AND SERVICE**

MAY 16-21, 2009



**2009 PROGRAM
& NEW RESEARCH
PROGRAM**

2009 SCIENTIFIC PROGRAM COMMITTEE



Seated (left to right): Drs. Jayaram, Crone, Ahmed, Cheong (**Chairperson**), Pato, Boland, Worley, **2nd Row Standing (left to right):** Drs. Matorin, Lapid, Matthews, Silk, Pandya, Nand, Myers, Pi, **3rd Row Standing (left to right):** Drs. Lou, Foulks, Scully, Sen, Moreno, Marks, Spurgeon, **Not Pictured:** Alarcon, Baron, Guynn, Hilty, Licinio, Mancuso, Spitz.

May 16, 2009

Dear Colleagues and Guests:

A warm welcome to San Francisco and the 162nd Annual Meeting of the American Psychiatric Association, the largest psychiatric meeting in the world. Our city and our meeting are full of exciting opportunities for you. Experts in every subspecialty and on every current psychiatric issue will present hundreds of educational sessions. You can catch up with old friends and meet new ones from every corner of the globe.

My meeting theme is *“Shaping Our Future: Science and Service.”* At this moment in history, we enjoy an explosion of useful knowledge about the brain and the psyche, about prevention, diagnosis, and treatment. At the same time, the world is struggling with an economic crisis and escalating health care costs. It is time for us to play an active role in shaping the future of our science and our clinical care. At this meeting, you can acquire the tools you need to shape our future. World famous scientists will present their latest research, with multiple opportunities for small group discussions with senior clinicians and educators. Sessions address subspecialties including geriatric, child and adolescent, addiction, forensic, and consultation liaison psychiatry. There are workshops and symposia on issues such as mental health care for returning military, college mental health, practical psychopharmacology, new directions in psychotherapy, electronic health records, ethics, and nearly any topic you can mention. You can test yourselves at the “Focus: Live” sessions or watch “Mind Games,” a Jeopardy-like contest for residents. Take some time at the outset to go through the program and plan your stay. Make time to enjoy the mild weather, beautiful vistas, colorful buildings, interesting museums, varied shops, and superb restaurants of San Francisco.

Please join me at the Opening Session Sunday from 5:00 p.m.–6:30 p.m., when we officially welcome world leaders and all attendees, and plan to attend the Convocation of Distinguished Fellows Monday at 5:30 pm, when we will honor colleagues being inducted as Fellows, and the APA award winners. Do not miss Dr. Atul Gawande of Harvard Medical School, MacArthur ‘genius grant’ recipient, author of prize-winning books including “Better,” groundbreaking thinker about the scientific and humanistic improvement of care, and outstanding speaker, who will present the William C. Menninger Memorial Lecture at the Convocation.

My thanks to Josepha Cheong, MD, Chair, and members of the Scientific Program Committee, and to APA staff members Deborah Hales, MD, and Cathy Nash, and their teams, for the rich content and the complex logistics of this enormous meeting. Please contact any member of the staff if you have problems or questions.

And, again, and most importantly, welcome.

Sincerely,

A handwritten signature in black ink, which appears to read "Nada L. Stotland, MD, MPH". The signature is fluid and cursive.

Nada L. Stotland, MD, MPH.
President, American Psychiatric Association



American Psychiatric Association

1000 Wilson Boulevard
Suite 1825
Arlington, VA 22209-3901
Telephone: 703.907.7808
Fax: 703.907.1090
E-mail: apa@psych.org

May 16, 2009

162st Annual Meeting San Francisco May 16-21, 2009

President

Nada L. Stotland, M.D.

Scientific Program Committee 2008-2009

Josepha Cheong, M.D.
Chairperson

Donald M. Hilty, M.D.
Vice-Chairperson

Iqbal Ahmed, M.D.
Renato Alarcon, M.D.
Catherine M. Crone, M.D.
Edward Foulks, M.D., Ph.D.
Robert Guynn, M.D.
Julio Licinio, M.D.
Geetha Jayaram, M.D.
Maria Lapid, M.D.
Julio Licinio, M.D.
Anu Matorin, M.D.
Annette Matthews, M.D.
Michael F. Myers, M.D.
Surinder Sucha Nand, M.D.
Michelle Pato, M.D.
Edmond Hsin T. Pi, M.D.
Kenneth Silk, M.D.
Deborah Spitz, M.D.

SAMHSA Fellow

Srijan Sen, M.D., Ph.D.

Consultants

David Baron, M.D.
Robert J. Boland, M.D.
John Lou, M.D.
Donna M. Mancuso, M.D.
Tracey Marks, M.D.
Arnaldo Moreno, M.D.
Anand Pandya, M.D.
Joyce Spurgeon, M.D.
Linda Worley, M.D.

Committee on Commercial Support

David Baron, M.D.
Chairperson
Philip Pardee, *Associate Director*
Commercially-Supported
Activities
(703) 907-7841

Office of Scientific Program

Joy Raether, *Associate Director*
(703) 907-8599
Diane Runels
Administrator, Courses
(703) 907-7379
Chermuir M. Kennedy
Conference CME Coordinator
(703) 907-7807

Dear APA Members and Guests:

Welcome to San Francisco, and the 162nd Annual Meeting of the American Psychiatric Association. This unique city, with its vibrancy, cultural diversity, and excitement, provides a perfect setting for the scientific presentations we have planned. As you read through the Program Book, you will notice a number of sessions related to the theme "Shaping Our Future: Science and Service," chosen by our President, Dr. Nada Stotland. Let me draw your attention to just a few of the many exciting sessions presented this week., including several Presidential Symposia which will be presented on Monday-Wednesday from 2:00 p.m.-5:00 p.m.

The Business Meeting and the Opening Session will be held at the Moscone Center on Sunday, May 17. At the Opening Session, from 5:00 p.m.-6:30 p.m. on Sunday, Dr. Stotland will officially welcome the leaders from psychiatric societies in the U.S. and around the world, and will present her Presidential Address. Please also make sure to attend the Convocation of Distinguished Fellows on Monday night at 5:30 p.m., where honor is given to all those being inducted as fellows and distinguished fellows and many receiving awards from the APA. The William C. Menninger Memorial lecture will also be presented immediately following the Convocation.

A great way to begin this years' meeting is to attend the "Advances in Series," which will focus on the latest advances in neuropsychiatry and clinical neurosciences, psychosomatic medicine and psychotherapeutic psychiatry, forensic psychiatry, substance abuse, and personality disorders. We also have Small Interactive Sessions, consisting of 12 clinically-based seminars with outstanding clinician educators. These sessions are held Monday-Thursday and have become an excellent way to start off the Annual Meeting's research programs, in conjunction with the Young Investigators' Poster and Oral/Slide Sessions also on Monday. Throughout the week, you will find an expanded number of small group sessions, including Debate/Roundtable Discussions; and Medical Updates with selected experts in the field. This year, we are also offering a new Clinical Knowledge and Skills Series and an ABPN Board Review course. These are special in-depth courses designed to broaden and enhance your professional skills and knowledge in specialized areas.

A special series of sessions will be presented in collaboration with the National Institute on Alcohol Abuse and Alcoholism. Outstanding leaders in psychiatry and neuroscience research will present across formats from lectures to symposia and discussion groups. The APA is extremely appreciative of their support of these sessions. For detailed information on the sessions, please consult the separate program on this series, which is included your registration packet.

It is extremely important that you fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year's Annual Meeting. Once again, welcome to San Francisco. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Josepha Cheong, M.D.

KEY LOCATIONS

MOSCONE CONVENTION CENTER

American Journal of Psychiatry and Psychiatric Services
North/South Concourse Exhibit Level

APA News Room
Rooms 250 Mezzanine Level West

APA Meetings and Conventions Office
Room 208A Mezzanine Level East

APA Member Center
North/South Concourse Exhibit Level

APA Scientific Program Office
Room 206, Mezzanine Level East

Audiotape and CD Sales
South Lobby/Esplanade Level

A/V Preview Room
Room 230/Mezzanine Level East

Course Enrollment
Hall D, Exhibit Level

CME Certificate of Attendance
Hall D, Exhibit Level

Daily Bulletin
Room 264/Mezzanine Level West

Exhibitor Registration
South Lobby/Esplanade Level

Exhibits/Publishers' Bookfair
Halls A-C, Exhibit Level

Housing Desk
South Lobby/Esplanade Level

Lost & Found
Room 208A, Mezzanine Level East

Message Centers
South and South Lobby, Hall D

On-Site Job Bank and Placement Center
North/South Concourse, Exhibit Level

Registration
Hall D, Exhibit Level

FUTURE APA MEETINGS

APA ANNUAL MEETINGS

2010 May 22-27	New Orleans, LA
2011 May 14-19	Honolulu, HI
2012 May 5-10	Philadelphia, PA

INSTITUTES ON PSYCHIATRIC SERVICES

2009 October 8-11	New York, NY
2010 October 14-17	Boston, MA
2011 October 27-30	San Francisco, CA

Preliminary Programs for the 2009 Institute on Psychiatric Services are included in the registration packet.

FIRST AID

Located across from **Room 106**, and across from **Room 124, Exhibit Level, Moscone Convention Center** hours of operation: **Monday, May 11, through Thursday, May 21**, opens 30 minutes prior to show opening and closes 30 minutes after the last event of the evening.

COURTESY SHUTTLE BUS SERVICE

Service will begin on **Saturday, May 16**, at approximately **7:00 a.m.**, and will operate daily throughout the meeting commensurate with the scientific program schedule and will conclude on **Thursday, May 21, at 6:00 p.m.** The Moscone Convention Center will serve as the "hub" for all shuttle bus routes. The Shuttle Bus Desk will be located in the **South Lobby, Esplanade Level, Moscone Convention Center**, a detailed Shuttle Bus Schedule is included in your registration packet and will be posted in the lobbies of participating hotels. Refer to the city and hotel maps page for the location of hotels in relation to the Moscone Convention Center.

EXHIBITS

Commercial and educational exhibits will be located in Halls A-C, Exhibit Level, Moscone Convention Center, along with the Publishers' Bookfair. For your convenience, the Publishers' Bookfair will be open **Saturday, May 16, 10:00 a.m.-5:00 p.m.** Educational and commercial exhibit hours are: **Sunday, May 17, 10:00 a.m.-4:30 p.m.; Monday, May 18, and Tuesday, May 19, 10:00 a.m.-5:00 p.m.;** and the final day, **Wednesday, May 20, 10:00 a.m.-3:00 p.m.**

MESSAGE CENTERS

Located in **South Lobby, North Lobby, and Hall D** in the **Moscone Center** and open during registration hours (with the exception of **Thursday, May 21**, when the Centers will be open until 5:00 p.m.). Messages can be left and picked up at the Message Center Registrants whose names appear on these monitors should pick up their messages at one of the three Message Centers.

APA MEMBER CENTER

Located in **North/South Concourse, Exhibit Level, Moscone Convention Center**. Hours of operation will be: **Saturday, May 16, 10:00 a.m.-5:00 p.m.;** **Sunday, May 17, 10:00 a.m.-4:30 p.m.;** **Monday, May 18, 10:00 a.m.-5:00 p.m.;** **Tuesday, May 19, 10:00 a.m.-5:00 p.m.;** and **Wednesday, May 20, 10:00 a.m.-3:00 p.m.** A few of the many APA activities exhibited include: membership, APA's internet-based programs, continuing medical education, quality improvement, psychiatric services, clinical resources, advocacy tools, career development, practice management, and APA periodicals.

APA JOB BANK

Visit the APA Job Bank Hall D Foyer Exhibit Level, Moscone Center to search the most comprehensive online listing of psychiatric positions! Candidates: Register to post your resume, receive instant job alerts, use the career tools and more. Employers: Post your job opening during the meeting to get results asap. For more information on the Job Bank, visit www.psych.org/jobbank. A representative will be available on-site to provide assistance.

APA NEWS ROOM

Located in **Rooms 250, Mezzanine Level West, Moscone Convention Center**. Hours of operation: **Saturday, May 16, 11:00 a.m.-5:00 p.m.;** **Sunday-Wednesday, May 17-20, 8:00 a.m.-6:00 p.m.;** and **Thursday, May 21, 8:00 a.m.-2:00 p.m.** This room is

KEY LOCATIONS

for the use of registered press only and credentialed/non-profit public relations representatives only.

DAILY BULLETIN

The *Daily Bulletin* accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the *Monday, Tuesday, and Wednesday/Thursday issues* can be dropped off in **Room 264, Mezzanine Level West**, by **Noon** prior to the date of publication.

AIRPORT AND LUGGAGE CHECK-IN

You can now check-in at the **North Lobby, Moscone Convention Center** and bypass the airport lines! This unique service allows you to check your bags and receive your boarding pass at the **Moscone Convention Center**, leaving you more time to visit the exhibits and attend sessions. It's safe and secure: The first TSA-approved remote skycap service; Agents are highly trained and credentialed to issue boarding passes and print bag tags on demand. Participating **Airlines (Domestic Flights Only): AirTran/Alaska, American, Continental, Delta, JetBlue, Northwest and United**. Rates: **\$10 per passenger**. Normal airline baggage constraints apply. Hours of Operation: **Wednesday and Thursday, May 20-21, 8:00 a.m.– 1:00 p.m.**, in the main lobby of the **Moscone Convention Center**. Flights may be checked in anytime the day of departure. Luggage must be checked a minimum of three hours before scheduled flight departure.

REGISTRATION

Admission to all sessions by registration badge

Located in **Hall D, Exhibit Level, Moscone Convention Center**. Hours of operation: **Friday, 12 noon-5:00 p.m., Saturday to Wednesday, 7:30 a.m.-5:00 p.m.**; and **Thursday, 7:30 a.m.-2:00 p.m.**

ON-SITE REGISTRATION FEE:

APA MEMBERS

Full-Time Registration (<i>North American Members</i>)	\$350
Full-Time Registration (<i>International Members</i>)	\$355-\$580*
Members in Training (<i>Member Class MT</i>)	\$ 90
Daily Registration (<i>North American Members</i>)	\$190
Daily Registration (<i>International Members</i>)	\$350
Medical Students	no charge

*Fee determined by country's gross national income according to the World Bank.

NONMEMBERS

Full-Time Registration	\$940
Nonmember Residents, Students, Advocacy Group Members, or Mental Health Chaplains	\$130
Daily Registration (<i>all Nonmember categories</i>)	\$500
Medical Students	no charge

FAMILY MEMBER REGISTRATION

One only per full-time registrant **\$130**
Only one family member is allowed to register with each full-time meeting registrant. The family member must reside in the same household and be able to receive mail at the same address. APA members cannot register as a "family member"; they must register as an APA member. ID may be required.

One-Day Exhibit Hall Only Pass (18 and older) **\$25**
(Only paid registrant can purchase an exhibit hall pass)

On-site fees can be paid by U.S. dollar cash, check, money order, American Express, VISA, or MasterCard. Registration fees are waived only for Course Faculty, APA Honorary Fellows (does not include APA Distinguished Fellows/Fellows/Life Fellows/Distinguished Life Fellows), medical students (with proper identification), and District Branch Executive Staff (who are not APA members).

Nonmember psychiatric residents and other full-time students, non-member Advocacy Group members, or Mental Health Chaplains must present documentation to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hours per semester] student ID; a letter from your advocacy/Chaplain institution, or from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

Note: There are no exemptions or reduced fees available for courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the Program Book, APA Member Center Guide, and New Research Program and Abstracts Books, and for most categories, a copy of the Syllabus.

REGISTRATION BADGES

Badges are required for all sessions and the exhibit hall. Only an APA member badge will admit you to the Business Meeting.

Badge Color Codes: Blue-Members, Yellow-Nonmembers, Silver-Press, Red-Exhibitors, Green-APA Staff, and Clear-Temporary Personnel.

Registered exhibitors will receive red badges, which allow access only to his or her exhibit booth in the exhibit hall and to ride the shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

COURSE ENROLLMENT

Ticket purchase required for Courses

Located in **Hall D, Exhibit Level, Moscone Convention Center**. Hours of operation are the same as registration. Tickets not sold in advance will be available online at the on-site fee after **April 10**, and on-site at the Course Enrollment Area beginning at **12 noon on May 15**. You must be registered for the meeting before you can enroll in courses.

APA ART ASSOCIATION

Located in the **North Lobby, Esplanade Level, Moscone Convention Center** and open during the commercial exhibit hours, the exhibit includes paintings, photography, ceramics, and crafts created by APA members and/or their significant others. Stop by for information on joining the APA Art Association.

APA ALLIANCE BOOTH

Located in the **South Lobby, Esplanade Level, Moscone Convention Center**. Hour of operation: **Saturday, May 16, through Wednesday, May 20, 9:00 a.m.-5:00 p.m.** Stop by the booth to obtain information on the Alliance's program schedule and information on membership.

APA PERIODICALS

Editorial staff of *The American Journal of Psychiatry, Psychiatric Services, Academic Psychiatry, Journal of Neuropsychiatry and Clinical Neurosciences, Psychosomatics*, and APA's CME journal, FOCUS will be on hand to demonstrate online access for subscribers, and answer questions regarding submissions. Visitors

KEY LOCATIONS

can also purchase or renew subscriptions to all APA/APPI journals at the booth. Complimentary copies of *Psychiatric News* will be available at stands located throughout the Moscone Convention Center. Persons who wish to contact editors or reporters of *Psychiatric News* are asked to leave a message on the message board in the **Annual Meetings Office located in 208A Level 2**. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper's consideration may be left with staff at the Periodicals Exhibit.

CONTINUING MEDICAL EDUCATION

Educational Objectives: At the conclusion of this meeting, participants will be able to:

- Review new research findings in the fields of psychiatry and neuroscience and address gaps in knowledge.
- Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
- Identify and remove barriers to the transfer of new knowledge for their practice, including provision of culturally competent care for diverse populations;
- Assess a variety of treatment choices, including psychotherapeutic and pharmacological options; and
- Recognize mental health service delivery issues, including barriers to care.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 66 AMA PRA Category 1 Credits.TM Physicians should only claim credit commensurate with the extent of their participation in the activity.

Please note: Formats of the scientific program, as outlined below, have been approved for CME credit.

The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for AMA PRA Category 1 Credit.TM Sessions in the following program formats are designated as category 1:

Advances in... Series, Case Conferences, CME Courses, Clinical Knowledge and Skills Courses, Focus Live, Forums, Industry-Supported Symposia, Lectures, Presidential Symposia, Scientific and Clinical Reports, Small Interactive Sessions, Symposia, and Workshops. Other scientific sessions not listed may be reported as category 2 (Debates and New Research Poster Sessions). Scientific sessions are open to all Annual Meeting registrants, except for the Case Conferences which are open to APA members only.

To document CME credit earned at the Annual Meeting, participants should maintain a list of sessions they attended. Credit is earned on an hour-for-hour basis. A page for listing your sessions and credits is provided in the program.

ANNUAL MEETING EVALUATION AND ANNUAL MEETING CERTIFICATE

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year's Annual Meeting. The General Evaluation is available online at the CME Certificate of Attendance Booth located in Hall B, Lower Level, Moscone Center.

By completing the General Evaluation, you will receive a personalized Certificate of Attendance. The certificate can be obtained either on-site by visiting the CME Certificate of Attendance Booth

OR attendees may access the web-based evaluation from their own computer during or after the meeting by visiting www.psych.org and browse the Lifelong Learning & CME section. PLEASE NOTE: APA NO LONGER OFFERS A PAPER GENERAL EVALUATION FORM FOR THE ANNUAL MEETING.

SESSION CAPACITY

So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

- Please find seating as far forward as possible.
- Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
- Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
- If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

AUDIO RECORDINGS OF SESSIONS

Over 100 hours of CME programs will be available, for purchase on DVD and the APA Online Library. Sale booth located in Hall D Moscone Center.

SMOKING POLICY

There will be **NO SMOKING** in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use. Registrants are welcome to use their own small, portable audiotape recorders to record any session except Case Conferences, unless prohibited by the presenters. Larger, professional tape recorders are not permitted except for use by registered members of the working press in accordance with APA Press Policies. APA has authorized a professional taping firm to audiotape sessions. Badges of personnel representing this firm will clearly identify them. Registrants are not permitted to photograph (including with cell phone cameras) or videotape any session because the intrusive nature of the recording may disrupt the session.

KEY LOCATIONS

PROGRAM BOOK TABLE OF CONTENTS

Floor Plans for Moscone Convention Center and Hilton San Francisco	VI-XI
Special Acknowledgments	XII-XIII
Format Descriptions.....	XIV
Advertisements	XV-XXIV
Disclosure Index	XXV-XLIII
Saturday Sessions.....	1-2
Sunday Sessions.....	3-6
2009 Presidents of Allied Organizations.....	6a-6c
Monday Sessions	7-24
Tuesday Sessions	25-39
Wednesday Sessions	40-52
Thursday Sessions.....	53-60
Topic Index	61-67
Participant Index	68-78
New Research Program Book	A-Q, 1-52
Certificate of Attendance Ad and Chart	Final Page
2009 Institute on Psychiatric Service	Inside Back Cover
APA Member Center.....	Back Cover

News reports or summaries of APA presentations contained in these program materials may not be published or broadcast before the local time and date of the presentation.


Refer to the APA Exhibits Guide for information on: Exhibits, Publishers' Bookfair, and Dining Facilities in the Moscone Convention Center.

If you have any questions about this book or the scientific sessions, please feel free to stop by the Scientific Programs Office in **Room 206, Mezzanine Level East, Moscone Convention Center**, and APA Staff will be glad to help you. All APA staff will be wearing green badges. Please feel free to direct your questions to them.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.

© American Psychiatric Association


MOSCONE CONVENTION CENTER
EAST MEZZANINE FLOOR PLAN



EAST MEZZANINE FLOOR PLAN


EAST MEZZANINE

MOSCONE CONVENTION CENTER
EXHIBIT LEVEL - NORTH & SOUTH



HILTON SAN FRANCISCO
GRAND BALLROOM/BLDG. 2


HILTON SAN FRANCISCO - GRAND BALLROOM LEVEL



- 1. BALLROOM FOYER
- 2. GREEN ROOM

Click  for a 360 Panorama of the space.

HILTON SAN FRANCISCO
BALLROOM LEVEL/BLDG. 1, 2, 3



HILTON SAN FRANCISCO
FOURTH FLOOR/BLDG. 3



SPECIAL ACKNOWLEDGEMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

American Academy of Psychiatry and Law: co-support of the Manfred S. Guttmacher Award Lecture Sunday, May 17

American Psychiatric Foundation: support of the APIRE Practice Research Network; Transformational Leadership Academy and Reception, May 20, and 21.

American Association of Psychiatric Administrators: support of the Administrative Psychiatry Award Lecture to be given at the IPS.

Association of Gay and Lesbian Psychiatrists: partial support for the John Fryer Award Lecture, May 19.

Association of Women Psychiatrists: support of the joint AWP/APA Women's Caucus reception and meeting, Monday, 18, 7:30 p.m. Alexandra Symonds Award Lecture, Monday, May 18, 2009.

AstraZeneca Pharmaceuticals: support of the Industry-Supported Symposia, "Delivering Optimal Care for Complex Bipolar Patients: An Audience Guided Symposium," Sunday, May 17, 12:30 – 2:30 p.m.; "Augmentation Strategies for Major Depressive Disorder: The Evidence for Effective Clinical Decision-Making in Improving Patient Care," Monday, May 18, 7:00 – 9:00 a.m.; the George Tarjan Award Lecture, Monday, May 18, 11:00 a.m.-12:30 p.m.; the American Psychiatric Foundation "Conversations" event, Tuesday, May 19, 5:30 p.m.; the APA/AstraZeneca Young Minds International Award; and Mind Games, Tuesday, May 19, 5:00 p.m.; and the APA/AstraZeneca Minority Fellowship, minority fellows poster session and reception, Tuesday, May 19, 7:00 p.m.

Bristol-Myers Squibb Company: partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 16, 7:00 p.m.; support of the Industry Supported Symposium "Augmentation Strategies for Major Depressive Disorder: The Evidence for Effective Clinical Decision-Making in Improving Patient Care", Sunday May 17, 7:00p.m.-9:00p.m.; APA Fellowship on Public Psychiatry; and the Solomon Carter Fuller Award Lecture and Reception, May 18.

Bristol-Myers Squibb Sweden: support of Global Psychiatry: A Session for U.S. and International Residents, Sunday, May 17, 2:00 p.m.

Dainippon Sumitomo Pharma America, Inc.: support of the Industry-Supported Symposium, "Development of New Agents for the Treatment of Schizophrenia," Sunday, May 17, 7:00 – 9:00 p.m.

Estate of Kun-Po Soo, M.D. Ph.D.: support of the Kun-Po Soo Award Lecture, May 19, 11:00 a.m.-12:30 p.m.

Estate of Judd Marmor, M.D.: support of the Judd Marmor Award Lecture.

Estate of Frank Rundle, M.D.: partial support for the John Fryer Award Lecture, May 19.

Forest Laboratories, Inc.: support of the Industry-Supported Symposium, "Effective Treatment of Alzheimer's Disease – Translating Guidelines Into Practice: An Interactive Panel Discussion", Sunday, May 17, 12:30 – 2:30 p.m.

GlaxoSmithKline: support of the American Psychiatric Leadership Fellowship Program and reception.

Ittleson Foundation: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Janssen Pharmaceutical and Research Foundation: The APIRE/Jansse Resident Psychiatric Research Scholars Program., Committee of Asian American Psychiatrists recruitment reception.

Lilly USA, LLC: support of the Industry-Supported Symposia, "Neurobiology, Prediction and Management of Antipsychotic Non-Response in Patients With Schizophrenia", Sunday, May 17, 7:00 – 9:00 p.m.; "Novel Approaches to Assessing and Treating Depression in the Medically Ill", Tuesday, May 19, 7:00 – 9:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 16, 7:00 p.m.; partial support of the Simon Bolivar Award Lecture, May 20, 1:00 p.m.-2:00 p.m., the APA/Lilly Psychiatric Research Fellowship, APA/Lilly Resident Research Award; and the Chief Resident Leadership Program, May 18, 8:00 a.m.-5:30 p.m.

National Institute on Alcohol Abuse and Alcoholism (NIAAA): sponsorship of the Special Annual Meeting Research Track, "Alcohol and Health: New Discoveries and Future Directions."

National Institute of Mental Health (NIMH): support of the Research Colloquium for Junior Investigators; support of the American Psychiatric Institute for Research in Education (APIRE) Annual Meeting activities for research trainees; the Program for Minority Research Training in Psychiatry (PMRTP).

Pfizer, Inc.: partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 16, 7:00 p.m.; and partial support the Simon Bolivar Award Lecture, Saturday, May 16, partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 16, 7:00 p.m; upport of the Industry Supported Symposium "Bipolar Disorder Throughout the Life Cycle: Treatment and Treatment Experience," Tuesday May 19, 7 a.m.-9 a.m.

SPECIAL ACKNOWLEDGEMENTS

Professional Risk Management Services, Inc.: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 21, 2:30 p.m.

Shire US, Inc.: support of the Industry-Supported Symposia, “The Pathophysiology of ADHD: Implications for Treatment,” Sunday, May 17, 7:00 p.m. - 9:00 p.m.; “ADHD FAQs: Practical Answers for the Office-Based Practitioner”, Monday, May 18, 7:00 - 9:00 a.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 16, 7:00 p.m.; and the APA/Shire Child and Adolescent Psychiatry Fellowship.

Substance Abuse and Mental Health Services Administration (CMHS, CSAP, CSAT): sponsorship of the APA/SAMHSA Minority Fellowship Program, the APIRE Practice Research Network (PRN); and the APA’s HIV-related education programs and materials.

Takeda Pharmaceuticals North America, Inc.: support of the Industry-Supported Symposium, “Anxious Depression: Diagnostic and Treatment Issues”, Monday, May 18, 7:00 p.m. – 9:00 p.m.

Wyeth Pharmaceuticals: support of the American Psychiatric Foundation’s ‘Benefit by the Bay’ Gala, Saturday, May 16, 7:00 p.m.; sponsorship of the Jean Spurlock Congressional Fellowship and the APA/Wyeth MD/PhD Psychiatric Research Fellowship.

FORMAT DESCRIPTIONS

ADVANCES IN.....SERIES

These three-hour and thirty-minute sessions are intended to highlight important new advances occurring in the field of psychiatry involving selected disorders or treatments. The sessions are chaired by editors of recent textbooks published by the American Psychiatric Publishing, Inc (APPI) and feature selected chapter authors from these texts. The books discussed at these sessions may be purchased at the APPI book store or online at www.appi.org.

CASE CONFERENCES

During these 90-minute or three-hour sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. Some cases will review the progress of psychotherapy in two successive sessions. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

COURSES

Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day), six-hour (full-day), and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Participants must purchase tickets to attend.

DEBATES

Experts in the field, including psychiatrists and nonpsychiatrists will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

FOCUS LIVE

These 90-minute sessions allow participants to test their knowledge using an interactive Audience Response System (ARS), offering a new and entertaining way to learn. ARS sessions can make a group of 300 feel like they are having a small group consultation with an expert clinician. Experts, who served as guest editors of FOCUS, will lead lively multiple choice question-based discussions, and the audience will enter their answers with hand-held devices. Results are instantly tallied and projected on the screen.

FORUMS

These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

LECTURES

Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

NEW RESEARCH

This format allows for presentation of the very recent findings. The three types of presentations include: Posters, which are visual, self-explanatory presentations; Young Investigators' Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators' Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

SCIENTIFIC AND CLINICAL REPORT SESSIONS

Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

SMALL INTERACTIVE SESSIONS

This 90-minute format allows small groups to meet informally with either selected experts in psychiatry to: discuss topics chosen by the expert; obtain consultations around problems in research from senior researchers; or, hear clinically-based seminars presented by outstanding educators. Some of these sessions are reserved for residents only. These sessions are limited to 25 participants who are admitted on a first-come, first-served basis.

SYMPOSIA

Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposia" in this Program Book.


WORKSHOPS

Workshops are 90-minute sessions which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for highly interactive audience participation. Media Workshops are three-hour sessions in which a feature-length film is shown and discussed.

FOCUS

The Journal of Lifelong Learning in Psychiatry

Editors: Deborah Hales, M.D., and Mark Hyman Rapaport, M.D.



FOCUS is the best system for recertification, self-assessment, and lifelong learning. In one easy subscription, *FOCUS* provides a comprehensive review of current clinical practice based on the content outlined by the ABPN recertification exam. Each issue offers: Clinical Reviews, Patient Management Exercise, Seminal

Articles, and a CME quiz with 20 hours of CME per year for the journal (20 additional hours can be earned through completion of the Self-Assessment Exam). All current and back issues are accessible online with available CME credits for your subscription year.

The *FOCUS* Self-Assessment Exam is an annual 100-question, multiple-choice supplement written by practicing psychiatrists and academic experts that allows you to earn 20 CME credits and the opportunity to anonymously compare your knowledge to that of your peers either online or on paper. Each question is similar to those used in board-type exams. The *FOCUS* Self-Assessment Exam is listed by the ABPN as an approved self-assessment activity that fulfills the requirement of psychiatrists applying for and taking the recertification examination.

FOCUS addresses the core content in psychiatry in four-year cycles.

Each issue briefs you on new developments and reviews the current state of practice in that topic area through:

- Clinical synthesis articles and reviews
- Interactive Patient Management Exercise and “Ask-the-Expert” column
- Influential publications: reprints of new and classic articles that influence practice

FOCUS updates you in core content areas:

- **Volume V (2007):** Bipolar Disorder; Substance Abuse: Diagnosis and Treatment; OCD and Other Anxiety Disorders; Ethics and Professionalism: Including End of Life Care
- **Volume VI (2008):** Major Depressive Disorder; Schizophrenia: Cognition and Outcomes; Child and Adolescent Psychiatry; Panic and Social Phobia
- **Volume VII (2009):** Geriatric Psychiatry; HIV AIDS Psychiatry and Psychosomatic Medicine; PTSD and Disaster Psychiatry; Sleep, Eating, and Sexual Disorders
- **Volume VIII (2010):** Psychotherapy; Personality Disorders and Temperament; Psychiatric Genetics and Clinical Neuroscience; Psychopharmacology

The American Board of Psychiatry and Neurology has reviewed *FOCUS: The Journal of Lifelong Learning in Psychiatry* and the *FOCUS* Self-Assessment Examination and has approved this program as part of a comprehensive lifelong learning and self-assessment program, which is mandated by the ABMS as a necessary component of maintenance of certification.

ABPN approval is time limited to 3 years for each *FOCUS* CME course. Refer to APA's CME website for ABPN approval status of each course.

The *FOCUS* Self-Assessment Program is approved for up to 20 hours of continuing professional development per year under Section 3 of the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Psychiatric Association designates the *FOCUS* educational program for a maximum of 40 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Please Visit the APPI Bookstore for More Information

One-Year Prices:

- U.S. APA Members: ~~\$296~~ **\$246** ■ International Member: ~~\$373~~ **\$323**
- APA MIT (Online Only): ~~\$96~~ **\$46**
- U.S. Non-Member price: ~~\$476~~ **\$426** ■ International Non-Members: ~~\$552~~ **\$502**



The First and Last Word in Psychiatry

American Psychiatric Publishing, Inc.

Web: www.appi.org and focus.psychiatryonline.org

Email: appi@psych.org

Phone: 1-800-368-5777 | 703-907-7322 | Fax: 703-907-1091

When ordering, please reference priority code AH910AA.

Certificate of Attendance

How do you obtain it?



Get your certificate (A) in person or (B) online.

A. To receive your certificate in person:
complete the general evaluation form at the CME Certificate of Attendance Booth located in the Moscone Convention Center in **Exhibit Hall D** on the exhibit level.

Types of Certificate

- Certificate of Credit for physicians
- Certificate of Attendance for non-physicians

CME Certificate of Attendance Booth Exhibit Hall D

Hours of Operation:

Saturday	May 16	12:00PM—5:30PM
Sunday	May 17	8:00AM—5:00PM
Monday	May 18	8:00AM—5:30PM
Tuesday	May 19	8:00AM—5:30PM
Wednesday	May 20	8:00AM—5:30PM
Thursday	May 21	8:00AM—5:00PM

During or After the Annual Meeting

B. To receive your Certificate Online:

complete the online evaluation at: www.psych.org/annualmeetingCME.

This website will remain active until August 2009.

Follow these simple steps:

1. Use your 6-digit badge number to access the General Evaluation form
2. Complete the Evaluation
3. Confirm your personal details
4. Enter the number of credits earned
5. Email certificate to yourself
6. Print certificate for your records

Accreditation & Designation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Psychiatric Association designates this educational activity for a maximum of 66 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The scientific program offers a variety of sessions that meet the criteria for AMA PRA Category 1 Credit™

For questions, contact the
American Psychiatric Association
Department of CME
E-mail: educme@psych.org

THE APA ANNUAL MEETING ONLINE



Your One-Stop Educational eResource Library

- Audio-visual programs conveniently available 24/7
- Special attendee pricing available on-site
- Includes up to 100 hours of new 2009 meeting highlights
- Review presentations from world renowned faculty
- Earn CME credit
- Free online access to selected Industry-Supported Symposia

Visit the booths located in the
South Hall or in Hall D, Exhibit Level
for more information.

The American Psychiatric Association is accredited by the ACCME to provide continuing medical education for physicians.
The APA designates (each of the presentations) in this educational activity for a maximum of 1-3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


THE APA ANNUAL MEETING ONLINE WWW.PSYCH.ORG/AMLIBRARY

THE FIRST AND LAST

Visit the APPI BOOKSTORE at the 2009 APA ANNUAL MEETING in San Francisco, CA!

Psychiatry's premiere publisher brings the cutting-edge titles you've been waiting for directly to you! Come check out APPI's latest groundbreaking selection, from the newest textbooks, review series, and journals, to electronic products for your handheld or online—including **PsychiatryOnline.com**.


The APPI Bookstore is the one place you can go to gather all the resources you'll need in the next year. Update subscriptions, complete your series collections, browse through hard to find titles, and even develop your course adoptions—all in one stop. Don't miss Author Book Signings or discounts for APA Members—see you there!



Textbook of Psychotherapeutic Treatments

Edited by Glen O. Gabbard, M.D.

2009 • 896 pages • ISBN 978-1-58562-304-4 • Hardcover
\$95.00 • Item #62304



Textbook of Hospital Psychiatry

Edited by Steven S. Sharfstein, M.D., M.P.A.

Deputy Editors: Faith B. Dickerson, Ph.D., M.P.H., and John M. Oldham, M.D., M.S.

2009 • 528 pages • ISBN 978-1-58562-322-8 • Hardcover • \$125.00 • Item #62322



Approach to the Psychiatric Patient

Case-Based Essays

Edited by John W. Barnhill, M.D.

2009 • 565 pages • ISBN 978-1-58562-300-6 • Paperback
\$62.00 • Item #62300



Cognitive-Behavior Therapy for Severe Mental Illness

An Illustrated Guide


Jesse H. Wright, M.D., Ph.D., Douglas Turkington, M.D., David G. Kingdon, M.D., and Monica Ramirez Basco, Ph.D.

2009 • 374 pages • ISBN 978-1-58562-321-1 • Paperback • \$65.00 • Item #62321

Clinical Manual for Evaluation and Treatment of Sleep Disorders

Martin Reite, M.D., Michael Weissberg, M.D., and John Ruddy, M.D.

2009 • 395 pages • ISBN 978-1-58562-271-9 • Paperback • \$55.00 • Item #62271




Clinical Study Guide for the Oral Boards in Psychiatry, Third Edition

Nathan R. Strahl, M.D., Ph.D.

2009 • 501 pages • ISBN 978-1-58562-293-1 • Paperback
\$59.00 • Item #62293

APPI Bookstore Hours

Saturday,	May 16	10:00 am – 5:00 pm
Sunday,	May 17	10:00 am – 4:30 pm
Monday,	May 18	10:00 am – 5:00 pm
Tuesday,	May 19	10:00 am – 5:00 pm
Wednesday,	May 20	10:00 am – 3:00 pm




Brain Stimulation Therapies for Clinicians

Edmund S. Higgins, M.D., and Mark S. George, M.D.

With foreword by Michael Trimble, M.D., F.R.C.P., F.R.C.Psych.

2009 • 203 pages • ISBN 978-1-58562-280-1 • Hardcover
\$70.00 • Item #62280



Casebook of Psychosomatic Medicine

James A. Bourgeois, O.D., M.D., Debra Kahn, M.D., Kemuel L. Philbrick, M.D., and John Michael Bostwick, M.D.

2009 • 323 pages • ISBN 978-1-58562-299-3 • Paperback
\$57.00 • Item #62299



Clinical Manual for Diagnosis and Treatment of Psychotic Depression

Anthony J. Rothschild, M.D.

2009 • 207 pages • ISBN 978-1-58562-292-4 • Paperback
\$55.00 • Item #62292



Clinical Manual of Drug Interaction Principles for Medical Practice

Gary H. Wynn, M.D., Jessica R. Oesterheld, M.D., Kelly L. Cozza, M.D., and Scott C. Armstrong, M.D.

2008 • 608 pages • ISBN 978-1-58562-296-2 • Paperback
\$55.00 • Item #62296



ADHD Comorbidities

Handbook for ADHD Complications in Children and Adults

Edited by Thomas E. Brown, Ph.D.

2009 • 478 pages • ISBN 978-1-58562-158-3 • Hardcover
\$89.00 • Item #62158



Resident's Guide to Clinical Psychiatry

Lauren B. Marangell, M.D.

2009 • 410 pages • ISBN 978-1-58562-324-2 • Paperback
\$44.95 • Item #62324

WORD IN PSYCHIATRY

JANUARY

Stress-Induced and Fear Circuitry Disorders

Refining the Research Agenda for DSM-V

Edited by Gavin Andrews, M.D., Dennis S. Charney, M.D., Paul J. Sirovatka, M.S., and Darrel A. Regier, M.D., M.P.H.

2009 • 330 pages • ISBN 978-0-89042-344-8

Paperback • \$60.00 • Item #2344

The Psychiatrist as Expert Witness, Second Edition

Thomas G. Guthel, M.D.

2009 • 165 pages • ISBN 978-1-58562-342-6

Paperback • \$55.00 • Item #62342


Clinical Manual for Management of Bipolar Disorder in Children and Adolescents

Robert A. Kowatch, M.D., Ph.D., Mary A. Fristad, Ph.D., ABPP, Robert L. Findling, M.D., and Robert M. Post, M.D.

2009 • 355 pages • ISBN 978-1-58562-291-7

Paperback • \$59.00 • Item #62291

FEBRUARY



The American Psychiatric Publishing Textbook of Geriatric Psychiatry, Fourth Edition

Edited by Dan G. Blazer, M.D., Ph.D., and David C. Steffens, M.D., M.H.S.

2009 • 694 pages • ISBN 978-1-58562-277-1

Hardcover • \$149.00 • Item #62277

Study Guide to Geriatric Psychiatry

A Companion to The American Psychiatric Publishing Textbook of Geriatric Psychiatry, Fourth Edition

Robert E. Hales, M.D., M.B.A., Narriman C. Shahrokh, Dan G. Blazer, M.D., Ph.D., and David C. Steffens, M.D., M.H.S.

2009 • 240 pages • ISBN 978-1-58562-352-5

Paperback • \$49.00 • Item #62352

MARCH

What Your Patients Need to Know About Psychiatric Medications, Second Edition

Robert H. Chew, Pharm.D., Robert E. Hales, M.D., M.B.A., and Stuart C. Yudofsky, M.D.

2009 • 440 pages • ISBN 978-1-58562-356-3

Paperback • \$82.00 • Item #62356

Somatic Presentations of Mental Disorders

Refining the Research Agenda for DSM-V

Edited by Joel E. Dimsdale, M.D., F.A.P.M., Yu Xin, M.D., Arthur Kleinman, M.D., Vikram Patel, Ph.D., William E. Narrow, M.D., M.P.H., Paul J. Sirovatka, M.S., and Darrel A. Regier, M.D., M.P.H.

2009 • 208 pages • ISBN 978-0-89042-342-4


Paperback • \$60.00 • Item #2342

Essentials of Personality Disorders

Edited by John M. Oldham, M.D., M.S., Andrew E. Skodol, M.D., and Donna S. Bender, Ph.D.

2009 • 432 pages • ISBN 978-1-58562-358-7

Paperback • \$85.00 • Item #62358



The American Psychiatric Publishing Textbook of Alzheimer Disease and Other Dementias

Edited by Myron F. Weiner, M.D., and Anne M. Lipton, M.D., Ph.D.

2009 • 560 pages • ISBN 978-1-58562-278-8

Hardcover • \$125.00 • Item #62278

MAY

The American Psychiatric Publishing Board Review Guide for Psychiatry

Edited by James A. Bourgeois, O.D., M.D., Robert E. Hales, M.D., M.B.A., Julie S. Young, M.D., and Stuart C. Yudofsky, M.D.

2009 • pages TBA • ISBN 978-1-58562-297-9

Paperback • \$125.00 • Item #62297

DSM-IV-TR® Casebook and Treatment Guide for Child Mental Health

Edited by Cathryn A. Galanter, M.D., and Peter S. Jensen, M.D.

2009 • 752 pages • ISBN 978-1-58562-310-5

Paperback • \$85.00 • Item #62310

Study Guide to Psychopharmacology

A Companion to The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition

Robert E. Hales, M.D., M.B.A., Narriman C. Shahrokh, Alan F. Schatzberg, M.D., and Charles B. Nemeroff, M.D., Ph.D.

2009 • 240 pages • ISBN 978-1-58562-354-9


Paperback • \$49.00 • Item #62354

Medical Illness and Schizophrenia, Second Edition

Edited by Jonathan M. Meyer, M.D., and Henry A. Nasrallah, M.D.

2009 • 544 pages • ISBN 978-1-58562-346-4

Paperback • \$57.00 • Item #62346



The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition

Edited by Alan F. Schatzberg, M.D., and Charles B. Nemeroff, M.D., Ph.D.

2009 • 1632 pages • ISBN 978-1-58562-309-9

Hardcover • Special Prepublication Price of \$245.00

until May 31, 2009 (thereafter \$275.00)

Item #62309



The First and Last Word in Psychiatry

American Psychiatric Publishing, Inc.
1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209-3901

Web: www.appi.org

Phone: 703-907-7322 or 1-800-368-5777

Mon.-Fri., 9 am to 5:30 pm, ET

Fax: 703-907-1091 Email: appi@psych.org

Please reference priority code AH920 when ordering.



● How Do I Qualify?

You may qualify if you:

1. Are a psychiatrist residing in the U.S. or Canada and,
2. Have paid the full-time registration fee for the Annual Meeting (\$850.00 Advance, \$940.00 on-site).

● How Do I Apply?

1. Stop by one of the APA Membership Booths either in the Registration area (near the Registrar) or in the APA Member Center (North/South Concourse, Exhibit Level) to fill out an APA Membership Application. The application must be submitted on-site during the meeting at one of these locations.
2. Additional documentation—proof of ACGME-ACOA or RCPSIC—approved psychiatry residency training and a current, valid medical license must be received by APA no later than June 30, 2009.

● How Does the Rebate Work?

1. Your local psychiatric District Branch must approve the application no later than September 30, 2009.
2. The difference between the member and non-member Annual Meeting registration fee will be applied towards your pro-rated 2009 national and local dues. The remaining balance of the rebate amount will be sent directly to you, or if you choose, we can apply the remaining balance to your 2010 dues.*—it's up to you!

● Why Should I Join?

With more than 38,000 members in the U.S., Canada, and worldwide, the APA is the voice of psychiatry for your patients and our profession. We offer advocacy, information, support, and educational opportunities to help you serve your patients and enhance your career. Please stop by one of the Membership Booths or go to www.psych.org to learn more about the many benefits of APA membership.

* Outstanding dues from previous years may be deducted in some cases.



Where will you be when the clock chimes?

*Join the American Psychiatric Foundation for an event
(or two!) at the 2009
APA Annual Meeting
in San Francisco!*



2009 "Benefit by the Bay"

**Saturday, May 16, 2009
7:00 - 10:00 pm
Ferry Building**



The American Psychiatric Foundation invites you to our annual fundraising event, "Benefit by the Bay" a special evening at the San Francisco Ferry Building. Enjoy tasty cuisine and live music in the historic Ferry Building, first opened in 1898! The evening's program includes a silent auction and the presentation of the Awards for Advancing Minority Mental Health. Event proceeds support the foundation's grants, programs, research funding and awards that advance public understanding that mental illnesses are real and treatable. Tickets cost \$225* and are available online at www.psychfoundation.org or by calling (703) 907-8503.

*Ticket price includes a \$17 tax-deductible gift to the foundation.

"Conversations" featuring Maureen McCormick

**Tuesday, May 19, 2009
5:30 - 6:30 pm
Moscone Center, Exhibit Hall E**

Don't miss our 8th annual "*Conversations*" event, an interactive series that offers meeting attendees an opportunity to hear unique perspectives on mental illness. Maureen McCormick, best known for her role as Marcia Brady, will be our special guest. Ms. McCormick will share her story of surviving substance abuse and depression. This actress, singer, and mother just became an author, releasing *Here's the Story: Surviving Marcia Brady and Finding My True Voice* in October, 2008. *Conversations* is free to all APA Annual Meeting attendees.

"Conversations" is supported by a charitable contribution from AstraZeneca to the American Psychiatric Foundation

A *Special Event* sponsored by the
Northern California Psychiatric Society


Monday, May 18, 2009
2:00 P.M.-5:00 P.M.
Room 304, Esplanade Level
Moscone Convention Center

Breaking the Barriers

... a dynamic review of two decades (1970-1992) of unprecedented social change and how American psychiatry and the APA navigated the turbulent times.

Moderator: Richard Shadoun, M.D.

- ★ **Michael Blumenfield, M.D.**, will interview **Alfred Freedman, M.D.**, APA's 102nd President (participating by call-in), regarding when the APA Board's 1973 vote to remove homosexuality as a mental disorder.
- ★ The 1978 election of the first openly gay supervisor, **Harvey Milk**, in San Francisco and his later assassination will be discussed by **Jeanine Yeomans**, Emmy Award-winning journalist, television news reporter and Manager of Public Affairs at AAA in San Francisco, showing excerpts from the Oscar winning documentary, *The Times of Harvey Milk*, in which she appears.
- ★ **Carol Nadelson, M.D.**, first woman APA President (1985-1986), will share her memories of the election and serving as APA President.
- ★ The 1991 election of **Larry Hartmann, M.D.**, gave APA its first openly gay President (1991-1992). He will also discuss his memories of the election and serving as APA President.
- ★ **Melvin Sabshin, M.D.**, Medical Director of APA for 23 years (1974-1997), and present APA President **Nada Stotland, M.D., M.P.H.**, will give closing remarks.



The NCPS Event Planning Committee: Richard Shadoun, M.D., Ralph Furr, M.D., Dave Kassler, M.D., Gene Nabajima, M.D., Jerry Gelbart, M.D.

2009 Annual Meeting sponsored by the American Psychiatric Association

Effective Treatment of Alzheimer's Disease

An Interactive Panel Discussion **Translating Guidelines into Practice**

Sunday, May 17, 2009

12:00-12:30 PM Lunch San Francisco Marriott
12:30-2:30 PM Symposium Station 7/8, Lower B-2 Level
55 Fourth Street
San Francisco, California



Learning Objectives

At the end of this activity, participants should be able to:

1. Evaluate and contrast pharmacologic therapies available for treating patients with Alzheimer's disease (AD)
2. Appraise and contrast the published guidelines for pharmacologic management of patients with AD
3. Have increased confidence in the pharmacologic and nonpharmacologic management of patients with AD

Accreditation and Credit Designation Statements

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7304 (within the United States or Canada) or 1-703-907-7300.

Registered conference participants and registered guests may attend any industry-sponsored symposium at the APA meeting.

Agenda

12:00-12:30 PM Lunch

12:30-12:45 PM Introduction/Welcome

12:45-1:00 PM *The Clinical Pharmacology of Approved AD Therapies*

1:00-1:15 PM *The Psychiatry Point of View: The ACP and APA Guidelines for Pharmacologic Management of Patients With AD*

1:15-1:30 PM *The Neurology Point of View: The AAN Guidelines for Pharmacologic Management of Patients With AD*

1:30-1:45 PM *The General Practice Point of View: The ACP and ACP Guidelines for Pharmacologic Management of Patients With AD*

1:45-2:25 PM *Medical Debate and Question & Answer Session*

2:25-2:30 PM *Closing Remarks*

George T. Greenberg, MD
Saint Louis University
School of Medicine

Wesley H. Gardner, MD
Saint Louis University
School of Medicine

Gary W. Small, MD
David Golos, School of Medicine
University of California,
Los Angeles

Martha R. Finkbein, MD
Indiana University
School of Medicine

Charles A. Cahn, MD, MS
Louisiana State University
Health Sciences Center and
School of Medicine
at New Orleans



Sponsored by the American Psychiatric Association



Forest Laboratories, Inc. Supported by an educational grant from Forest Laboratories, Inc.

BIPOLAR DISORDER THROUGHOUT THE LIFE CYCLE: Treatments and Treatment Experience

TUESDAY, MAY 19, 2009
6:30 AM Breakfast and Sign-In
7:00 AM-9:00 AM Education of Activity

SAN FRANCISCO MARRIOTT
82 Level, Station 7 and 8
San Francisco, California

AGENDA

6:30 AM
BREAKFAST AND SIGN-IN

7:00 AM
WELCOME AND OVERVIEW
Joseph E. Calabrese, MD
Activity Chairperson
Case Western Reserve University
School of Medicine

7:10 AM
UNDERSTANDING THE
CHALLENGES OF REPRODUCTIVE
MENTAL HEALTH: PREGNANCY
AND LACTATION
Adele C. Vignera, MD, MPH
Harvard Medical School
Massachusetts General Hospital

7:30 AM
TREATMENT OPTIONS IN
CHILDHOOD AND ADOLESCENT
BIPOLAR DISORDER

7:50 AM
TREATMENT AND TREATMENT-
EXPERIENCE: FROM ADULT TO
LATE LIFE

Martha Sokolovic, MD
Case Western Reserve University
School of Medicine
University Hospital of Cleveland

8:10 AM
MANAGEMENT OF METABOLIC
SYNDROME ACROSS THE LIFE
CYCLE IN BIPOLAR DISORDER
David E. Kemp, MD
Case Western Reserve University
School of Medicine

8:30 AM
QUESTION AND
ANSWER SESSION

9:00 AM
AD JOURNMENT

WHO SHOULD PARTICIPATE

This activity is designed for clinical psychiatrists and other healthcare professionals interested in the diagnosis and treatment of bipolar disorder throughout the life cycle.

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

1. Compare the risk of continuation or discontinuation of treatment among pregnant women with bipolar disorder.
2. Review the clinically useful treatment guidelines that can be used in the care of children and adolescents with bipolar disorder.
3. Discuss treatment and treatment experience of gestating patients receiving medication for bipolar disorder.
4. Describe the metabolic side effects of traditional mood stabilizers and novel psychotropic agents.

ACCREDITATION STATEMENT

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The APA designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURE STATEMENT

Participating faculty will disclose any industry affiliations, sponsorship, honoraria, monetary support, and other potentially biasing factors to the audience.

Attendees must be registered for the APA 2009 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1.888.357.7304 (within the US or Canada) or 703.907.7300.



Sponsored by the American Psychiatric Association

Supported by an educational grant from Pfizer



ADHD FAQ's

Practical Answers for the Office-Based Practitioner

APA 2009 Annual Meeting • San Francisco, California
Monday, May 18, 2009 • Marriott-San Francisco, Salons 7/8

Breakfast

6:30 AM–7:00 AM

Scientific Session

7:00 AM–9:00 AM

Welcome and Preactivity Educational Outcomes Measurement

7:00 AM–7:05 AM Gabriel Kaplan, MD

How Do I Identify and Treat Adult ADHD?

7:05 AM–7:25 AM Gabriel Kaplan, MD

Cardiovascular Effects of Stimulants—Is There Cause for Concern?

7:25 AM–7:45 AM Donald E. Greydanus, MD

How Do I Approach the Bipolar vs ADHD Issue?

7:45 AM–8:05 AM Jeffrey H. Newcorn, MD

How Do I Manage the ADHD/SUD Comorbidity?

8:05 AM–8:25 AM Iliyan Ivanov, MD

Postactivity Measurement

8:25 AM–8:30 AM Gabriel Kaplan, MD

Discussion, Q&A

8:30 AM–9:00 AM Gabriel Kaplan, MD and Faculty

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 2 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Learning Objective

At the conclusion of this session, the participant should be able to enumerate adult ADHD criteria, and understand the cardiovascular risks of stimulants, the process of ADHD/bipolar differential diagnosis, and the outcome findings of ADHD/SUD comorbidity.

Program Chair

Gabriel Kaplan, MD

Clinical Associate Professor
of Psychiatry

University of Medicine and Dentistry
of New Jersey

Newark, New Jersey

Executive Director, Psychiatry

Hoboken University Medical Center
Hoboken, New Jersey

Distinguished Faculty

Donald E. Greydanus, MD

Pediatrics Program Director

MSU/Kalamazoo Center for
Medical Studies

Kalamazoo, Michigan

Iliyan Ivanov, MD

Assistant Professor, Psychiatry

Mt Sinai School of Medicine

New York, New York

Jeffrey H. Newcorn, MD

Associate Professor, Psychiatry and

Pediatrics

Mount Sinai School of Medicine
New York, New York

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served.

For more information about the meetings, please visit the APA web site at

www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.

Registered conference participants and registered guests may attend any industry-supported symposium at the APA meeting.

Sponsored by



Supported by an
educational grant from

Shire

DISCLOSURE INDEX

AMERICAN PSYCHIATRIC ASSOCIATION CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliation with commercial organization(s) that may have a direct or indirect interest in the subject matter of the scientific program. A “financial interest” may include, but is not limited to: being an employee, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An “affiliation” may include holding a position on an advisory committee, speakers bureau or some other role or benefit to a supporting organization.

In compliance with the ACCME’s Standards for Commercial Support, the APA has a management of conflict (MCI) process for all CME activities. This process ensures that all potential conflicts of interest are identified, managed and resolved prior to the educational activity. The prospective audience must be informed of the presenter’s affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The presenters on the following pages have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s), and the company name is listed.

The second group of presenters has indicated neither they nor an immediate family member has any significant relationship to disclose.

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Adler, Mats MA				BMS		
Alsuwaidan, Mohammad				Forest Labs., Novartis	Sanofi Aventis	
Anderson, Allan A			Medivation		Pfizer	
Andreoli, Antonio			Wyeth-Ayerst Research			
Anton, Raymond F.	Lilly Research Labs., Merck		Merck, Hyrthiam, Eli Lilly			Johnson & Johnson PRD, Merck (advisory boards)
Armsten, Amy F	Shire, Marinus					
Bailey, Rahn K	BMS, Lilly Research Labs., Ortho McNeil, Wyeth-Ayerst		Janssen, BMS, Ortho McNeil, Pfizer, Lilly Research Labs	BMS, Lilly Research Labs., Ortho McNeil		
Baron, David A	Eli Lilly		Eli Lilly, NIDA	Eli Lilly		
Beezhold, Julian				Lundbeck, AZ, BMS, Eli Lilly, Janssen Cilag, Otsuka		
Black, Donald W.	Jazz, Forest Labs.		NIMH, Forest Labs.			
Bianco-Jerez, Carlos			GSK, NIMH, NIDA			
Boess, Frank G		Lilly				
Brady, Kathleen	Abbott Labs., GSK, Forest Labs., Eli Lilly, Ovation, Marinus	Deutschland	Abbott Labs., GSK, Forest Labs., Wyeth-Ayerst	Pfizer, Abbott Labs., GSK, Forest Labs., Eli Lilly		Embera Neuro Therapeutics Scientific (advisory board)
Brams, Jolie	Novartis					
Bransfield, Robert C				AZ, Forest, Jazz, Lilly, McNeil, Nove, Pfizer, Sanofi Aventis, Sepracor, Takeda		
Brown, Thomas E.	Abbott Labs., Eli Lilly, Shire Pharm. Dev., Novartis		Eli Lilly			
Buckingham, U. Diane	Shire			Novartis, Shire Pharm.		
Bystritsky, Alexander	Neuronetics, Jazz			Dev., UCB Pharma		
Callahan, William E				Jazz		
Camarena, Enrique	Janssen-Cilag			BMS, Otsuka		
Campbell, William H.						
Caroff, Stanley N				Pfizer		
Carpenter, Linda L	Neuronetics, Medtronic, Novartis, Wyeth-Ayerst, BMS, Abbott Labs., Cyberonics, Sepracor, Pfizer		Pfizer			
Carpenter, William T	Wyeth-Ayerst, Cephalon		NIMH, Cyberonics, Pfizer, Sepracor, UCB Pharma, NARSAD	Pfizer, Wyeth-Ayerst, Cyberonics, AZ		Neuronetics (travel support, 2007)
Casey, David A						
Choi-Kain, Lois W			NIMH	Eisai, Pfizer		
Chung, Henry				Jazz, Pfizer		
Clayton, Paula J				Forest Labs.		
Cohen, Judith A			NIH			Guilford Publ. (book royalties)

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Cohen, Lisa J			BMS			
Conant-Norville, David O			AZ, BMS, Eli Lilly, Otsuka, Supernus, Pfizer	McNeil, Novartis Janssen, AZ, BMS, Otsuka, Eli Lilly		AZ, BMS, Eli Lilly, Organon, Otsuka, Solvay, Supernus, Vanda (advisory boards)
Correll, Christoph U						
Crasta, Jovita	Forest Labs., GSK, Pfizer		GSK, Forest, Lilly, Takeda	AZ, Sanofi Aventis, Eli Lilly		
Croft, Harry	Shire			Pfizer		
Crow, Scott J	BMS			Lundbeck Canada		
D'Mello, Dale				Eli Lilly		
Davine, Jon JD				BMS, AZ, Pfizer, GSK		
Deas, Deborah						
DeBello, Melissa	Eli Lilly, AZ, Pfizer, BMS, NIDA, GSK		Abbott Labs., AZ, Eli Lilly, Shire, Janssen, Pfizer, BMS, NARSAD, Somerset, NIDA, NIMH			
Desai, Abhilash K	Forest Labs.			Novartis		
Dirani, Riad		Johnson & Johnson				
Doghramji, Karl	Ortho McNeil, Sepracor, Takeda, BMS, GSK, Sanofi			Jazz, GSK, Sepracor, Takeda, Boehringer	Merck	
Dougherty, Darin D			Cephalon, Cyberonics, Eli Lilly, Forest Labs., McNeil, Medtronic	Ingelheim, Sanofi Cyberonics, McNeil		
Doyle, Robert L	Shire, Novartis			Janssen, McNeil, Novartis, Shire		
Duffy, Farifeh F		APIRE				
Edinger, Jack D.	Philips		NIMH, NIH, Philips	Eli Lilly, Pfizer, Wyeth-		
Ellison, James M			GSK	Ayerst, Forest Labs.		
Faison, Warachal			Organon, Myriad			GSK (1st degree relative is full-time employee), Pfizer (employed); Alzheimers Foundation of America and Advanstar Communications (honoraria)
Farabaugh, Amy						
Farrow, Martin R	Pfizer, Abbott Labs., Cephalon, GSK, Medivation, Merck, Neurochem, Schering, Takeda		NARSAD Eli Lilly, Novartis, Ono Pharma	Eisai, Novartis, Forest Labs., Pfizer		

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Fava, Maurizio	Amarin, Auspex, Trascrypt, Compellis, EPIX, MedAvante, Somaxon, Vanda, Synthelabo, Teragenex, Cephalon, Cypress, Eli Lilly, Forest Labs., GSK, Janssen, Jazz, Johnson & Johnson PRD, Knoll, Lundbeck, Merck, Neuronetics, Novartis, Nutrition, Organon, Pfizer, Pharmastar, Pharmavite, Roche Biosciences, Aspect Medical Systems, AZ, Bayer AG, Biovail Labs., BMS, Sanofi-Synthelabo, Sepracor, Solvay, Somerset, Takeda, Wyeth-Ayerst Labs., BrainCells, Fabre-Kramer Phar, Grunenthal GmbH, Precision Human Biolaboratory, Pam Lab, Lorex		Synthelabo, BMS, Johnson & Johnson PRD, Abbott Labs., Alkermes, Aspect Medical Systems, AZ, Cephalon, Eli Lilly, Forest Labs., GSK, Lichtwer Pharma GmbH, Lorex, Novartis, Organon, Pfizer, Pharmavite, Roche Biosciences, Sanofi-Synthelabo, Solvay, Wyeth-Ayerst Labs., Abbott Labs., BMS, Pam Lab	AZ, Boehringer Ingelheim, BMS, Cephalon, Eli Lilly, Forest Labs., GSK, Novartis, Organon, Pharmastar, Wyeth-Ayerst Labs.	Financial Options MedAvante, Compellis	
Fava, Maurizio (cont'd.)						
Ferrando, Stephen J	Abbott		AZ	AZ, Pfizer		Pediatric Behavioral Health (owner)
Fisher, Caroline				Pfizer, Cephalon, Reckitt Benckiser, Somaxon, Forest Labs.		
Fong, Timothy W			Pfizer, GSK	Abbott Labs., Eli Lilly, AZ, Pfizer, Novartis, Janssen		
Forester, Brent P			NIMH			Servier (advisory board), Guilford Publ. (royalties)
Frank, Ellen			Eli Lilly, Organon, AZ, BMS, Organon, Otsuka, GSK			AZ, BMS, Organon, and Otsuka (travel funds to attend research or educational meeting with no honoraria)
Frye, Mark	BMS, Abbott Labs., BMS		Pfizer, GSK			Eli Lilly, Pfizer, GSK, Otsuka (speaking fees)
Furukawa, Toshiaki A.						

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Gaebel, Wolfgang						AZ, Eli Lilly, Janssen Cilag (symposium speaker); Wyeth-Ayerst, Eli Lilly, Janssen Cilag (advisory boards)
Gaynes, Bradley N. George, Mark S.	BMS Cyberonics, Aspect Medical Systems, Neurogenetics		Novartis Cortex, GSK, Stanley Medical Research Institute, NIMH			
George, Tony P	Pfizer, Prempharm, Janssen		Pfizer, Sanofi Aventis, Targasept, Sepracor Pfizer	Pfizer, Prempharm, Janssen AZ, Pfizer		
Ghaemi, S. Nassir Glassman, Alexander Glick, Ira	Pfizer		BMS, Glaxo, Solvay, Shire Pharm. Dev. Janssen, Pfizer	Janssen Cilag, Pfizer, BMS, AZ	Johnson & Johnson PRD, Forest Labs.	
Goff, Donald C	Xenoport, Eli Lilly					Pfizer (Clinical Trial Safety Adjudication Board), Wyeth-Ayerst Labs. (Data Safety Monitoring Board)
Goldfinger, Stephen M. Gonzalez, Gerardo Goodkin, Karl Goodwin, Frederick	Teva Pfizer, AZ, Eli Lilly, Wyeth-Ayerst, GSK		Janssen, Pfizer UCB Pharma, BMS GSK, Janssen, Merck GSK	Reckitt Benckiser GSK, Pfizer, Eli Lilly		
Greco IV, Nicholas Green, Alan I.	Eli Lilly, Janssen	Abbott Labs.	Janssen, Lundbeck, AZ, Cyberonics, Eli Lilly Medtronic		Abbott Labs. Johnson & Johnson PRD	
Greenberg, Benjamin D. Grossberg, George T	Medtronic, Jazz Abbott Labs., Myriad Genetics, Novartis, Pfizer, Organon USA, Wyeth-Ayerst, Janssen-Ortho, Research, BMS, Forest Labs., Takeda		Abbott Labs., Elan, Forest Research Institute, Myriad Genetics, Novartis, Eisai, Pfizer, Wyeth-Ayerst Research, Ono, Forest Labs.	Jazz		
Gupta, Nitin Hammerness, Paul G			Shire	AZ Shire		Shire, McNeil, Abbott Labs. (CME activities/ sponsored talks)
Harvey, Philip	Abbott Labs., AZ, BMS, Janssen, Eli Lilly, Solvay, Novartis		Pfizer, BMS, AZ			
Hauser, Peter Healy, David T Henderson, David C	Servier BMS, Pfizer, Solvay, Wyeth-Ayerst		Janssen Takeda, Solvay, NIMH	AZ, Jazz AZ Janssen, Pfizer		Teva (legal expert)
Hendren, Robert L Herman, Barry K Hermann, Richard C Hines, John K	AZ	Pfizer	Forest Labs., BMS, Janssen		Pfizer	
				NMHAC		

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Hirshkowitz, Max	Sanofi-Synthelabo		Vanda, Merck, Cephalon, Sanofi Aventis, Sepracor, Takeda Abbott, Organon	Sanofi Aventis, Takeda, Cephalon		
Hodgkins, Paul Hollander, Eric		Shire	Abbott Labs., Ortho McNeil, Solvay, Somaxon		Shire	
Hoschl, Cyril	Servier			Lundbeck, Eli Lilly, BMS		Janssen Cilag Advisory Board, Czech Republic
Hudson, James I	Eli Lilly, Pfizer		Eli Lilly, Forest Labs., Ortho McNeil			
Janicak, Philip G	BMS, AZ, Janssen, Neuronetics		Ortho, Neuronetics, BMS	Abbott Labs., AZ, BMS, Janssen, Pfizer		
Jayaram, Geetha Jibson, Michael D Johnson, Bankole A				GSK, Janssen AZ		
Kahan, Kara L Kane, John M	Ortho-McNeil Janssen Scientific Affairs, LLC BMS, Janssen, Abbott Labs., Eli Lilly, Pfizer, Wyeth-Ayerst			Novartis BMS, Janssen		
Kaplan, Gabriel Ketter, Terence A	AZ, BMS, Eli Lilly, Abbott Labs., GSK, Janssen, Jazz, Novartis, Solvay, Wyeth-Ayerst		Abbott Labs., AZ, BMS, Cephalon, Eli Lilly, Wyeth-Ayerst, Pfizer, GSK	Shire Pharm. Dev. Abbott Labs., AZ, Eli Lilly, GSK, Pfizer		Johnson & Johnson PRD (spouse employee)
Kingdon, David G Kleber, Herbert D Kocsis, James	Alkermes		Reckitt Benckiser NIDA, Forest Labs., AZ, Nancy Pritzker Network, Novartis, Sanofi Aventis, NIMH NIH	AZ, Wyeth-Ayerst Labs. Forest Labs.		
Kohn, Robert Kollins, Scott	Addrenex, CoMentis, NIEHS, NIND, EPA Ortho McNeil, Sanofi		Ortho McNeil, BMS	Alkermes (Cambridge, MA), Forest Labs.		
Kranzler, Henry R.	Aventis, Solvay, Alkermes (Cambridge, MA), BMS, Forest Labs., Lundbeck					

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Krystal, Andrew D	Arena, AZ, BMS, Cephalon, Eli Lilly, GSK, Jazz, Johnson & Johnson PRD, King, Merck, Neurocrine Biosciences, Novartis, Organon, Pfizer, Research Institute, Roche Biosciences, Sanofi Aventis, Sanofi, Sepracor, Somaxon, Takeda Servier		Cephalon, GSK, Merck, Neurocrine Biosciences, Neurocrine, NIH, Pfizer, Sanofi Aventis, Sepracor, Somaxon, Takeda			
Kupfer, David J			Forest Research Institute, NIMH			Guilford Publ. (royalties/patient, other income)
Lazarus, Arthur L		AZ			AZ	
Lerman, Caryn	GSK, Pfizer, AZ		AZ, GSK, Pfizer			
Leucht, Stefan	Sanofi Aventis, BMS, Eli Lilly, Janssen, Johnson & Johnson PRD, Lundbeck, Pfizer		Sanofi Aventis, Eli Lilly			
Leuchter, Andrew F	Aspect Medical Systems, Eli Lilly, Novartis		Aspect Medical Systems, Eli Lilly, MedAvante, Novartis, Pfizer	Eli Lilly, Wyeth-Ayerst	Aspect Medical Systems	
Levounis, Petros				Pfizer, AZ, Cephalon, Forest Labs., Takeda		
Licinio, Julio	Eli Lilly		Vanda			
Lim, Russell F				AZ		
Lisanby, Sarah H			Neurocrine, Advanced Neuromodulation Systems, Cyberonics, NIH, NARSAD, Stanley Foundation			
Llorente, Maria				Eli Lilly, Pfizer, Wyeth-Ayerst, Wyeth-Ayerst Labs, BMS		
Lusskin, Shari I			GSK, Eli Lilly, NARSAD, AZ, Forest Research Institute			
Mago, Rajnish						
Mao, Alice	Eli Lilly, Novartis			AZ, BMS, Eli Lilly, McNeil Consumer Healthcare, Novartis, Sepracor, Shire		
Marder, Stephen R.	BMS, Otsuka, Pfizer, Solvay, Roche Labs., Wyeth-Ayerst, GSK, Sanofi Aventis		Janssen, BMS, AZ, Sanofi Aventis, Merck, Pfizer, Wyeth-Ayerst, Lundbeck			BMS, Otsuka (honoraria)
Markowitz, John C			NIMH			Basic Books, American Psychiatric Press, Oxford U Press, Elsevier

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Marks, Glenn GM					Financial Options EEG Spectrum International	
Mason, Barbara J	Forest Labs.					
McCarthy, Malia	Forest Labs.					Elsevier (author)
McDonald, William M.	Myriad Genetics, Janssen		Neuronetics, Boehringer Ingelheim, GSK, Wyeth-Ayerst	Janssen		
McKay, James R	Alkermes (Cambridge, MA), Eli Lilly			AZ, Eli Lilly, Janssen, Pfizer		
McLean, Andrew J	BMS, Pam Lab	PRMS		Pam Lab	Johnson & Johnson	
Melonas, Jacqueline M						
Mischoulon, David	BMS, Pam Lab					
Motto, Jerome A	Forest Labs.			Jazz, AZ, BMS, Eli Lilly, Wyeth-Ayerst		
Musklin, Philip R	Forest Labs.					
Mustafa, Husain	AZ, Abbott Labs., BMS, Janssen		Advanced Neuromodulation Systems, Stanley Medical Research Institute, NIMH, Neuronetics, Cyberonics, Abbott, Forest			
Myrick, Hugh				Alkermes, Cephalon, BMS, Forest		
Narasimhan, Meera	BMS		AZ, BMS, Janssen, Forest Labs	Janssen, AZ, Eli Lilly		
Nemeroff, Charles B			NIH		Concept Therapeutics	NARSAD, AZ, Forest Labs., Quintiles, Janssen-Ortho (scientific advisory boards) Tikvah Therapeutics, Vivus
Newcomer, John						
Newcorn, Jeffrey H.	McNeil, Eli Lilly, Shire, Novartis, Cortex, Pfizer		McNeil, Eli Lilly, Shire, Novartis	Novartis, Shire		
Nolen, Willem WA	AZ, Cyberonics, Eli Lilly, GSK, Pfizer, Servier		AZ, Eli Lilly, GSK, Wyeth-Ayerst Labs., Stanley Medical Research Institute	AZ, Eli Lilly, Pfizer, Servier, Wyeth-Ayerst		
Nunes, Edward V				Alkermes	Alkermes	
Ochs, Len	Ochs Labs, Inc			Ochs Labs, Inc		
Ostacher, Michael J			Pfizer	AZ, BMS, Eli Lilly, Forest Labs., GSK, Pfizer		
Papakostas, George I	GSK, Pfizer, Wyeth-Ayerst, BMS, Eli Lilly, Jazz, Pam Lab, Shire		Pfizer, BMS, NIMH, Pam Lab	BMS, Pfizer		Lundbeck (honorarium)
Parks, Joseph J	Eli Lilly, Ortho-McNeil Janssen Scientific Affairs					
Patkar, Ashwin A.			Pfizer, BMS, GSK, Forest Labs., Titan, Organon, Merck, Cephalon	Cephalon, BMS, Pfizer, Reckitt Benckiser		
Perlis, Roy H	AZ, BMS, Eli Lilly, GSK, Pfizer			AZ, BMS, Eli Lilly, GSK, Pfizer		

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Peselow, Eric D						
Petrinati, Helen M	Eli Lilly, Merck		Alkermes, Cephalon, Forest Labs., Eli Lilly, Merck	Pfizer, Forest Labs.		
Pi, Edmond HT						
Pollack, Mark H	AZ, BMS, Cephalon, Forest Labs., GSK, Janssen, Jazz, Eli Lilly, MedAvante, Neurocrine, Novartis, Otsuka		AZ, BMS, Cephalon, Cyberonics, Forest Labs., GSK, Janssen, Eli Lilly, NARSAD, NIDA, NIMH	Pfizer BMS, Forest Labs., GSK, Janssen, Eli Lilly, Pfizer, Solvay, Wyeth-Ayerst	MedAvante	
Potenza, Marc N	Boehringer Ingelheim, Somaxon		Forest Labs., NIH			Somaxon (financial interest)
Portkin, Steven G	Acadia, Arena, AZ, BMS, Janssen, Novartis, Organon, Otsuka, Pfizer, Roche Labs.		Sanofi-Synthelabo, Solvay, Allergan, AZ, BMS, Lilly Research Labs., Forest Labs., Janssen, Mitsubishi Pharma, Novartis, Ono, Organon, Otsuka, Pfizer	AZ, Pfizer, BMS, Novartis		
Primm, Annette B	Eli Lilly					
Prince, Jefferson B	Novartis, Shire, Abbott Labs., McNeil			Alza/McNeil, Janssen		
Pumariega, Andres J	Abbott Labs., Eli Lilly					
Rathod, Shanaya				AZ		
Rathore, Varinder				Reckitt Benckiser		
Redden, Wm Maurice				Novartis		
Regier, Darrel A						
Robb, Adelaide	Otsuka, Eli Lilly, BMS, Forest, Lundbeck, Merck	APIRE	GSK, Otsuka, Pfizer, BMS, Forest, Supernus, Sepracor, Janssen, NIMH, NICH0	McNeil Pediatrics, Eli Lilly, BMS		Epocrates (wrote column on ADHD)
Romberg, Barbara V						GSK
Romeo, Sarah						MGH Psychiatry Academy (CME program support)
Roth, Thomas	Abbott Labs., Cephalon, Cypress Bioscience, Elan, Eli Lilly, Purdue Pharma, Roche Labs., Sanofi, Schering, Sepracor, Servier, Shire, Somaxon, Takeda Abbott, Wyeth-Ayerst Labs., Xenoport, Acadia, Alza, Ancile, Alkermes, AZ, Aventis, BMS		Aventis, Cephalon, GSK, Neurocrine, Pfizer, Sanofi, Sepracor, Somaxon, Takeda Abbott, Wyeth-Ayerst Labs., Xenoport	Cephalon, Sanofi, Takeda Abbott		

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Rothschild, Anthony J	Pfizer, GSK, Eli Lilly, Forest Labs.		Cyberonics, Takeda			
Ruano, Gualberto		Genomas				
Rubik, Beverly A						
Sachs, Gary	Johnson & Johnson PRD, Abbott Labs., AZ, BMS, Eli Lilly, GSK, Janssen, Memory Pharmaceuticals, Novartis, Sanofi, Shire, Wyeth-Ayerst P2D Inc.		Abbott Labs., GSK, Janssen, Memory Pharmaceuticals, Wyeth-Ayerst Labs.	AZ, BMS, GSK, Eli Lilly, Wyeth-Ayerst		NeuroTek (distributor)
Sallee, Floyd						Satiety Solutions (founder and principal)
Salloum, Ihsan M	Abbott Labs., Forest Labs., Cephalon, AZ		AZ, Abbott Labs., Drug Abuse Sciences, LIPHA Pharmaceuticals, OyContral, Alkermes, Ortho McNeil	Sanofi Aventis, Abbott Labs.		
Sampson, Shirlene M	Neuronetics		Neuronetics	Sanofi Aventis		
Sawa, Akira			Eisai America, Mitsubishi Pharma, Stanley Foundation, Wyeth-Ayerst, NIMH, NIDA, NARSAD, Fujisawa Institute of America			
Saxon, Andrew J			Janssen-Ortho	Cephalon, Alkermes, Forest Labs., Schering Corp.		
Schäfer, Ingo			Eli Lilly, BMS	Pfizer, Novartis		
Schatzberg, Alan F	Corcept Therapeutics, Eli Lilly, Neuronetics, Wyeth-Ayerst, GSK				Merck, Corcept Therapeutics, Forest Labs., Neurocrine, Pfizer	Forest Labs., Merck (advisory boards)
Schooler, Nina	Ortho McNeil, Organon USA, Janssen, Schering-Plough, France		AZ, BMS, Ortho McNeil, Eli Lilly			
Shea, Shawn C						
Sheehan, David V	Eli Lilly		AZ, BMS, Eli Lilly, Forest Labs., GSK, Jazz, Pfizer, Quintiles			
Shen, Hong			BMS, Forest Labs., Johnson & Johnson			
Shrivastava, Amresh K.A			Janssen Cilag, Roche Labs.	AZ Canada, AZ, Eli Lilly, Janssen Cilag, Janssen Canada, Roche Labs.		Neuropharm
Sikich, Linmarie			Seaside			
Simon, Robert I						
Sivrioglu, Yusuf	Novartis		Novartis	Novartis		

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Skodol, Andrew E Small, Gary W	Abbott Labs., Eisai, Forest Labs., Myriad Genetics, Novartis, Ortho-McNeil, Pfizer Organon, Shire		NIMH			
Soares, Jair C Srinivasan, Shilpa Stewart, Donna E	Wyeth-Ayerst, Eli Lilly		GSK, Pfizer	AZ, Eli Lilly BMS, Pfizer, Forest Labs.		
Stigler, Kimberly A			BMS, Eli Lilly, Janssen, NIMH Reckitt Benckiser	Reckitt Benckiser		
Strain, Eric C	Grunenthal GmbH, Reckitt Benckiser, Shire Pharm. Dev., Schering Corp., Titan, GSK Eli Lilly, Pfizer		Eli Lilly, Janssen Research Foundation, Forest Labs., AZ, BMS, Shire Pharm. Dev., Johnson & Johnson PRD, NIMH	GSK, AZ		MGH Psychiatry Academy (CME program support) Eli Lilly, AZ, Servier (CME-honoraria)
Suo, Shannon Sutton-Skinner, Kelly						
Swartz, Marvin S. Swartz, Holly A	Eli Lilly BMS		Eli Lilly BMS			
Swift, Robert M	Alkermes, TransOral, Forest Labs.		Eli Lilly, NIH			
Thase, Michael E	AZ, BMS, Cephalon, Cyberonics, Eli Lilly, Forest Research Institute, GSK, Janssen, MedAvante, Neuronetics, Novartis, Organon, Sepracor, Shire, Supernus, Wyeth-Ayerst Labs. AZ, Jazz		Eli Lilly, Sepracor	AZ, BMS, Eli Lilly, Cyberonics, GSK, Sanofi Aventis, Wyeth-Ayerst Labs., Schering-Plough, France	MedAvante, Guilford Publications	
Townsend, Mark H			Eli Lilly, Janssen, Otsuka, BMS, AZ			
Tracy, Martin G		PRMS				

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Trivedi, Madhukar H	Abbott Labs., Akzo-Nobel, AZ, Bayer Corp., BMS, Cephalon, Cyberonics, Eli Lilly, Forest Labs., GSK, Janssen, Johnson & Johnson PRD, Solvay, Neuronetics, Parke-Davis, Pfizer, Pharmacia & Upjohn, Sepracor, Wyeth-Ayerst Labs., Novartis		NIMH, NIDA, BMS, Cephalon, Corcept Therapeutics, GSK, Cyberonics, Eli Lilly, Forest Labs., Janssen, Merck, Pfizer, NIH, Pharmacia & Upjohn, Solvay, Wyeth-Ayerst Labs., NIMH, National Alliance for Research in Schizophrenia and Affective Disorders, Novartis	AZ, Johnson & Johnson PRD, Neuronetics, Pfizer, Akzo-Nobel, BMS, Cephalon, Janssen, Cyberonics, Eli Lilly, Forest Labs., GSK, Pharmacia & Upjohn, Solvay, Wyeth-Ayerst Labs.		
Trzepacz, Paula	Ayerst Labs., Novartis	Lilly Research Labs.	Lilly Research Labs.			
Tsuang, John W				Lilly Research Labs., Janssen, Reckitt Benckiser		
Tyrka, Audrey R			Cyberonics, Pfizer, UCB Pharma, Sepracor, Medtronic			
Unwalla, Khushro				Pfizer, Wyeth-Ayerst, Eli Lilly		
Van der Gaag, Ruiger J	Eli Lilly			Janssen Cilag		
van Wijngaarden-Cremers, Patricia J	Eli Lilly			Janssen Cilag		
Vanderpool, Donna		PRMS				
Várma, Vijay				Pfizer		
Vickar, Garry M				Pfizer		
Viguera, Adele			NARSAD, Stanley Medical Research Institute, Pfizer, Sepracor, Wyeth-Ayerst, Forest Research Institute, AZ, Berlex Laboratories, Eli Lilly, GSK Beechum Pharmaceuticals, Janssen, NIMH	AZ, Eli Lilly, Forest Labs., GSK, Novartis, Wyeth-Ayerst, Forest Labs.		
Wancata, Johannes	Janssen					
Weiner, Elyse D				Pfizer, Wyeth-Ayerst		

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Weisler, Richard	BMS, Biovail Laboratories, Eli Lilly, Forest Labs., Wyeth-Ayerst, Shire Pharm. Dev., Solvay, Pfizer, GSK, Organon, Sanofi-Synthelabo, Johnson & Johnson PRD, Novartis, Otsuka, Corcept Therapeutics, Abbott Labs.		Pfizer, Eli Lilly, GSK, Abbott Labs., Merck, Organon, Wyeth-Ayerst, Upjohn, SmithKline Beecham, Shire Pharm. Dev., AZ, Janssen, Solvay, Novartis, Schwabe, BMS, TAP Pharm., Synaptic, Eisai, UCB Pharma, Cephalon, Lundbeck, Forest Labs., Pharmacia & Upjohn, Neurochem, Ciba Geigy Corp., Pharmaceutical Division, Sanofi-Synthelabo, NIMH, Biovail Labs., Sandoz, Vela, Parke-Davis, Corcept Therapeutics, McNeil, Burroughs-Wellcome, Johnson & Johnson PRD	Solvay, Wyeth-Ayerst, GSK, Eli Lilly, AZ, Cephalon, Biovail Labs., Abbott Labs., Forest Labs., BMS, Shire Pharm. Dev., Pfizer, Organon, Sanofi	Merck, Pfizer, BMS, Cortex	
Weisler, Richard (cont'd.)						
Westgate, Harland		PRMS				
Wilens, Timothy E	Shire, Abbott Labs., Ortho McNeil, Eli Lilly, Merck, NIDA, Novartis		Abbott Labs., Merck, Ortho McNeil, Eli Lilly, NIDA, Shire	Eli Lilly, Ortho McNeil, Novartis, Shire		
Williams, Jill M				Pfizer		
Wirte, Janet M			Abbott Labs., Alkermes, Aspect Medical Systems, AZ, BMS, Cephalon, Forest Labs., GSK, NARSAD, Lichtner, Eli Lilly, Lorex, Roche Bioscience			
Wright, Jesse H			Janssen	AZ, Pfizer	Mindstreet	
Xiang, Yingqiang					Johnson & Johnson PRD	
Yohanan, Monique			Eli Lilly			Pfizer (study medication for NIMH trial)
Yonkers, Kimberly					Noven	
Zablorny, Raymond			AZ, BMS, Cephalon, Cyberonics, Eli Lilly, Forest Labs., GSK, NIMH, McNeil, Novartis, Pam Lab, Pfizer, Sanofi Aventis, Takeda	Abbott Labs., AZ, BMS, Cyberonics, Eli Lilly, GSK, Pam Lab, Pfizer, Wyeth-Ayerst Labs.		
Zajacka, John	Wyeth-Ayerst Labs., Abbott Labs., Biovail Labs., BMS, Eli Lilly, Novartis, Otsuka, Pam Lab, Pfizer, Takeda					

NOTES

DISCLOSURE INDEX

PRESENTERS WITH NOTHING TO DISCLOSE

Abbasi, Farha Z
Abdel-Wahab, Nancy
Abel, Gene G
Abouallaban, Yousef
Aboul-Fotouh, Frieda
Abrams, Karen M
Adams, Jr., Curtis N.
Adelson, Stewart L
Ahmed, Sadaf
Ahmed, Iqbal
Akil, Huda
Akiyama, Tsuyoshi
Albrecht, Suzanne A
Alfonso, Cesar A
Ali, Shirin
Alkhouri, Iyad
Allison, Rebecca
Andermann, Lisa F
Anderson III, Otis
Andrea, Helene
Anglin, Rebecca
Anzia, Joan M
Appelbaum, Paul S
Arboleda-Florez, Julio E
Areal, Patricia A
Armstead, Ron E
Armstrong, Scott C
Aron, Laudan Y
Arroyo, William
Astruc, Bernard
Atkins, Robert
Auger, R. Robert
Austin, Jehannine C
Baker, Allison S
Ballon, Jacob S.
Barak, Yoram
Bark, Nigel
Barnes, Donna H
Bartlett, Selena E
Bassuk, Ellen
Bateman, Anthony W
Batki, Steven
Batten, Sonja V
Baum, Antonia L
Beck, Judith S
Becker, Judith V
Becker, Daniel F
Bedregal, Luis E
Beeber, Alan R
Beer, Jennifer
Begum, Millia Ms
Benedek, David M
Benedek, Elissa P.
Benjelloun, Hind
Bergman, Gretchen
Berkowitz, Ellen
Berman, Karen Faith
Bhandari, Tarun
Bialer, Philip A
Bienenfeld, David
Binder, Renee L.
Birkholm, Molly
Bisaga, Adam
Bittner, Stephen J
Bjork, James M
Blaise, Aguirre A
Blaustein, Mel I
Blendy, Julie Phd
Blum, Nancee S
Blumenfield, Michael
Bocking, Claudi CLH
Boehnlein, James K
Bohus, Martin
Bokarius, Vladimir
Book, Howard E
Booty, Andrew
Bostwick, John M
Boust, Susan J
Brada, Kay
Breiling, James P
Breitbart, Willaim
Brendel, David H.
Brod, Thomas M.
Brodkey, Amy C
Brooks, Kristen
Brooks, Beth Ann
Broquet, Karen
Brown, Sandra A.
Brown, Richard A
Brown, Richard P
Bruce, Travis O
Buchanan, Alec W
Buckley, Peter
Bullock, Karen
Bunt, Gregory C
Burd, Ronald M
Burke, Mary G
Burpee, Stacey
Cabaj, Robert P
Cabrejos, Claudio
Cahill, Larry F
Caligor, Eve
Campbell, Jamae C
Campbell, Nioaka N
Campbell, Frank R
Capitanio, John P.
Caring, Joanne
Carino, Anthony
Carlson, Stephan
Carney, Colleen E
Caselli, Monica T
Casey, Patricia P
Castellanos, Daniel
Castro, Anthony M
Ceccherini-Nelli, Alfonso A
Cefalu, Charles A
Chaffin, Jennifer A
Chaisson, Anne-Marie
Chamberlain, Samuel R
Chan, Carlyle H
Chanen, Andrew M
Chang, Jacquelyn
Chase-Eldridge, Warene
Chaudhry, Haroon
Chen, Chiao-Chicy
Chien, Peter L
Christianson, Amy L
Ciccocioppo, Roberto RC
Clarkin, John F
Cobb, Robert
Coconcea, Cristinel M
Coffey, M. Justin
Cohen, Mitchell JM
Cohen, Michael
Cohen, Carl I.
Collins, Pamela
Compton III, Wilson M
Condon, Timothy P
Coopey, Adrienne
Courchesne, Eric
Cournos, Francine
Critchfield, Kenneth L.
Cureton, Janetta
Cutler, Janis
Cyr, Alan A
D'Souza, Russell
Daley, Christopher T
Dallam, Deborah
Dannon, Pinhas N
Daroff, Robert Jr
Dauenhauer, Laura E
Davae, Umee A
David, Anthony
David, Daniella
Davidoff, Donald A
Davidson, Kate M
Davies, Emily
Davis, Jeri
Daviss, Steven R

DISCLOSURE INDEX

De Blécourt, Carel C.V.
De Jonghe, Frans F
De Maat, Saskia S
De Wit, Harriet
Defrancisci Lis, Lea
Dekker, Jack J
Del Rosario, Salvador R
Demaso, David R.
Desmeules, Marie
Devlin, Michael J
Dewan, Mantosh J
Diamond, Milton Ph.D.
Díaz-Granados, Natalia
Dickstein, Leah J.
Dimaggio, Giuseppe, Giancarlo
Dimeff, Linda A
Donatilla, Mukamana
Dooley-Sammuli, Margaret
Douaihy, Antoine
Dowling, Gayathri
Downey, Jennifer I
Drescher, Jack
Dunn, Jeffrey
Dunn, Laura B
Ecker, Sidney W
Edelheit, Phyllis B
Edenberg, Howard J
Ehrensaft, Diane
Ehret, Megan J
Elliott, Glen R
Elsayed, Yasser A
Esguerra, Chris E
Essex, Marilyn J
Everett, Anita S
Fahrer, Rodolfo
Fairweather, Amy
Falzone, Richard L
Farkas, Marianne D
Fartacek, Reinhold
Faulkner, Larry R
Fauman, Susan
Fauman, Beverly
Fawcett, Jan
Feenstra, Dineke
Feijen, Rudolf R.A.M.
Fernandez, Antony
Ferranti, Jessica
Fewer, Sandra L
Fine, Carla
Finlayson, Reid
Finn, Christine T
Fishel, Tobi
Fishkind, Avrim B
Fitelson, Elizabeth M
Fochtman, Laura
Foelsch, Pamela
Fonagy, Peter
Forstein, Marshall
Francis, Andrew J
Frank, Julia B
Frankel, Debra MS
Franklin, Teresa
Fung, Kenneth Dr.
Gabbard, Glen O
Galanter, Marc
Galynker, Igor
Ganzini, Linda
Garcia, Mai-Ling J
Garrett, Michael
Gask, Linda
Gaudiano, Brandon A
Gelernter, Joel
Geller, Ruth E.
Geller, Jeffrey
George, David T
Gerbarg, Patricia L
Germain, Anne
Gers, Seymour
Gers, Glenn
Gessesse, Hiruy
Ghadiali, Nafisa
Ghitza, Udi E
Glantz, Meyer D.
Gleason, Ondria OG
Glover, Karinn
Goethe, John W
Goin, Marcia K.
Goldman, Marina
Goldman, Howard H
Goldman, Morris B.
Goldstein, Rita
Goodman, Marianne S
Gopal, Arun
Gordon, Harold W
Gordy, Tracy R
Gorelick, David A
Grady-Weliky, Tana A
Granacher, Robert P
Grant, Steven
Grant, Jon E
Green, Stephen
Greenwald, Phyllis
Gregory, Simon
Gregory, Robert J
Grewal, Arvinder K
Greydanus, Donald E
Groen, Wouter
Guarino, Kathleen
Gunderson, John G
Gutheil, Thomas G
Gynn, Robert E.
Hafters Gray, Sheila
Hales, Deborah
Hales, Robert E
Hall, Ryan C
Haller, Ellen
Halmi, Katherine A
Hameed, Noumana
Harlow, Michael
Harrow, Martin
Harvey, Steven
Hasan, Nidal NH
Hatti, Shivkumar S
Healy, David T
Hendriksen, Mariëlle
Herbert, Sarah E
Hercher, Laura S
Herie, Marilyn
Herrman, Helen E
Hersh, Richard G.
Heru, Alison M.
Hickson, Gerald
Hien, Denise
Higgins, Brian D.
Hilty, Don
Hines, Kevin
Hinterhuber, Hartman
Hippman, Catriona
Hira-Brar, Shabneet
Hoffman, Perry D
Hoge, Steven K
Hoglund, Per
Hollon, Steven
Hommer, Rebecca E
Hoop, Jinger G
Hopkinson, Marta J
Horgan, Constance M
Horowitz, Mardi J.
Houston, Michael
Hsiung, Robert C
Huebner, Robert
Huffine, Charles W
Huguelet, Philippe
Hung, Erick
Huremovic, Damir
Hurley, Robin A
Hurwitz, Thomas D
Husain, Arshad
Hutsebaut, Joost
Ibe, Aloysius C
Ignacio, Luis Faustino
Indest, David W
Iren Akbiyik, Derya
Irigoyen, Fructuoso R
Irwin, Michael R

DISCLOSURE INDEX

Isaacs, Julian JI
Ivanov, Iliyan
Jabbarpour, Yad M
Janofsky, Jeffrey
Javed, Afzal
Jenkins, Rachel
Jensen, Peter
Jimerson, David C
Johnson, Bradley R
Johnson, Jeffrey
Joiner, Lasa
Jorgenson, Linda M
Kaitin, Kenneth
Kang, Shimi
Kaplan, Sandra J
Katherine , Shear
Katz, Craig I
Katz-Bearnot, Sherry P.
Kay, Jerald
Kaye, Walter H
Kazim, Batool
Keitner, Gabor I
Kellner, Charles
Kennedy, Robert S
Kent, Laura K
Kernberg, Otto F.
Kertzner, Robert M
Khan, Sarah
Kim, Borah
Kim, Eugene
Kirsch, Andrew
Klein, Carolina A
Klin, Ami
Knight, Sara J
Koivukangas, Jenni
Koob, George F.
Kool, Simone S
Koopman, Cheryl
Kosten, Thomas R
Koyanagi, Chad Y
Kraemer, Helena C.
Krakowski, Menahem I.
Kramer, Milton
Kramer, Elizabeth J
Krueger, Robert
Kua, Ee-Heok Ehk
Kung, Simon
Kuo, Felicia Y
Kuo, Irving
Kuzenko, Nina
Laboy, Phd , Felicity L.
Laje, Gonzalo
Lamb, William K
Landau, Judith
Lane, Richard
Larson, Justine
Lee, Eugene
Lee, Allison M.R.
Lee, Elliott K.
Leigh, Hoyle
Levander, Eric
Levav, Itzhak
Levenson, Hanna
Levin , Edmund C
Levin, Frances R
Levine, Stephen B
Levy, Matthew D
Levy, Norman B
Lewis, Jerry L
Lewis, Stephen
Lewis Harris, Treniece
Lewy, Alfred J
Lieberman, Robert P
Lieberman, Alicia F
Lin, Chieh-Hsin
Linden, Michael
Lipsitt, Don R
Litten, Raye Z.
Liu, Shirley
Livesley, John
Llorca , Pierre Michel
Llorente, Maria
Lo, Ted
Loo, Colleen K
Lowenkopf, Eugene L
Loza, Nasser N
Lu, Francis G
Luby, Joan L.
Luce, John M
Lukas, Scott E
Luo, John
Lynch, Wendy J
Lynch, Minda R
Lynch, Katherine L
Madaan, Vishal
Maercker, Andreas
Maj, Mario
Maki, Pirjo H.
Malaspina, Dolores
Malison, Robert T
Malmquist, Carl P.
Malphurs, Julie E
Mangurian, Christina V
Manring, John
Marazziti, Donatella
Marchionni, Christine
Markov, Dimitri D
Marks, Tracey I
Marks, Saul I
Martens, Elisabeth J
Martinez, Humberto L.
Marumoto, Megan
Marzani-Nissen, Gabrielle
Massie, Mary Jane
Matharu, Yogi
Matorin, Anu A.
May, Alison C.
May, Catherine S
McCabe, Sean E
McCann, Una D
McCarthy, Richard H
McClung, Colleen A
McCormick, Laurie M
McDonald, Scott
McFarland, Bentson H
McFarr, Lynn
McGee, Michael D
McGlashan, Thomas H
McHugh, Paul R
McIntyre, Kathryn
McNicholas, Laura F
McVoy, Molly K
Medina Mora, Maria. Elena
Mee-Lee, David
Mehl-Madrona, Lewis
Melissa, Brymer J
Menezes, Paulo
Menvielle, Edgardo J
Merikangas, James R
Messing, Robert O
Meyerson, David A
Micevski, Aleksandar
Michaels, M
Michaels, Laura
Miettunen, Jouko
Mikalac, Cecilia M
Minoletti, Alberto
Minter, Shannon P
Mintz, David L
Miotto, Karen A
Mishra, Asha S
Mitchell, James E.
Mittal, Sukriti
Moeller, Kristen
Mohamed, Zahurin
Mohandessi, Soroush
Moncrieff, Joanna
Montenegro , Roger M
Morairty, Zach
Morciglio, April H
Morey, Leslie C
Mrazek, David A
Mucic, Davor MD

DISCLOSURE INDEX

Munoz, Rodrigo A.
Munyandamutsa, Naasson MN
Musher, Jeremy S
Myers, Wade
Myers, Michael F
Nace, David K
Nadelson, Carol
Nader, Michael A
Najavits, Lisa M.
Nand, Surinder S
Napoli, Joseph C
Nardi, Antonio E
Narrow, William E
Nash, Sara S
Nasky, Kevin M
Nau, Melissa
Navin, Natarajan A
Nelson, Charles G
Nemat, Ali
Neufeld, Ronald E
Newmark, Thomas S
Ng, Anthony T
Norko, Michael
Northcott, Colleen J.
Notman, Malkah T
Nyhus, Nadine J
O'Brien, Charles
O'Brien, Moira P
O'Leary, Paul J
Obatusin, Tayo
Oele, Bastiaan B.
Ogundipe, Kehinde A
Okasha, Ahmed
Okpaku, Samuel O
Oldham, John M
Oms, Juan D
Ong, Jason C
Ongur, Dost
Ortiz Fragola, Alfredo A
Osinski, Alphonse D
Oslin, David
Osofsky, Howard J
Osofsky, Joy D
Palmer, Christina G
Pandya, Anand
Parikh, Rajesh M
Paris, Joel
Parish, Brooke
Parnham, George J.
Parry, Peter I
Pato, Michele T
Payne, James O.
Peay, Holly L
Pecora, Peter
Peele, Roger
Peeters, Frenk
Perry, Christopher T
Pessar, Linda F
Peteet, John R
Petrakis, Ismene L
Pflanz, Steven E
Phillips, James
Phillips, Robert
Pilotte, Nancy S
Pini, Stefano SP
Plakun, Eric M
Pleak, Richard R
Pollack, David A
Pontius, Edward
Ponton, Lynn
Pope, Kayla
Postlethwaite, Alejandra
Powsner, Seth
Prabhakar, Deepak DP
Preda, Adrian
Preven, David
Price, Marilyn
Puchalski, Christina
Qian, Yifang
Quadrio, Carolyn
Rabow, Michael W
Radke, Alan Q
Ragins, Mark
Ramani, Meena
Ramchandani, Vijay A
Ramirez, Luis F
Randall, Carrie L
Ranz, Jules
Rao, Nyapati R
Rasic, Daniel T
Ratliff, Brenda M
Ravindranath, Divy
Raynor, Jeffrey D
Reardon, Claudia L
Recupero, Patricia R
Rego, Mark D
Reich, James H
Reid, William H
Reifler, Burton V
Reliford, Aaron
Resnick, Phillip J
Reus, Victor I
Reyes, Raymond M
Riba, Michelle B.
Richeimer, Steven
Richman, Jennifer
Rifai, Muhamad Aly
Rigaud, Marie-Claude
Ritchie, Elspeth C
Robinowitz, Carolyn B.
Robinson, Robert G.
Robinson, Gail E
Robinson, David
Rodriguez-Suarez, Mercedes M
Roessel, Mary H
Roman, Brenda J.B.
Romanoski, Alan J
Rondon, Marta B.
Rone, Lisa A.
Rose, Diana
Rosenberg, Stanley D.
Rosenburg, Zack
Rosenquist, Peter B.
Rosenstock, Jason B
Roskes, Erik
Ross, Stephen
Rube, David M
Ruiz, Pedro
Russakoff, L. Mark
Rutter, Joni L
Ryan, Elizabeth
Ryan, Caitlin
Ryan, Deirdre
Rychik, Abe M
Saavedra, Javier E
Sadre-Chirazi-Stark, Michael F
Saeed, Sy A
Sahler, Olle Jane
Samenow, Charles
Sanchez, Francis
Sanders, Kathy M
Santiago, Patcho
Sareen, Jitender
Sartorius, Norman
Sattar, Syed
Saucedo, Catherine J
Saxena, Shekhar
Schnaas, Francisco J
Schneidman, Barbara S
Schoener, Gary R
Schroeder, Steve A
Schubmehl, James Q
Schummer, Gary J
Scimeca, Michael M
Scott, Charles
Scott, Marcia
Seritan, Andreea L
Sevilla, Brett J
Sexson, Sandra B
Shanfield, Stephen B
Shapiro, Edward Robert
Sharfstein, Steven S
Shaw, Kailie
Shea, Tracie
Shihabuddin, Lina

DISCLOSURE INDEX

Shinfuku , Naotaka
Shumay, Dianne M.
Siever, Larry J
Silberman, Edward K
Silberschatz, George
Silk, Kenneth R.
Silver, Jonathan
Simmons, Chantelle M
Simon, Witold
Sinclair, Beryle D
Sitzer, Lauren
Sizoo, Bram B
Slattery, Marcia J
Smith, Eric G
Sonawalla, Shamsah B.
Song, Suzan
Sorel, Eliot
Spack, Norman
Speller, Heather K
Spencer, C. Edgar
Sperber, Jacob E
Srabstein, Jorge C
Srivastava, Shefali
Stahle, Galen W
Stanley, Barbara H
Starcevic, Vladan
Steele, Annie K
Steinglass, Peter
Stevens, Michael C
Stewart, Caroline
Stolar, Andrea
Stone, Michael
Stone, Walter N
Stotland, Eve
Stotland, Nada L.
Strain, James J
Strauss, David H
Streltzer, Jon
Stroeh, Oliver
Sudak, Donna M
Sukumaran, Anand
Sullivan, Maria
Summers, Richard F
Susman, Virginia L.
Sutcliffe, James
Swiggart, William H
Szarek, Bonnie L
Szigethy, Eva
Taintor, Zebulon
Talbot, John A
Tandon, Rajiv
Temporini, Humberto D
Terhakopian, Artin
Terilli, Dale
Tiainen, Anne AT

Tillman, Jane G
Tong, Lowell D
Toomey, R.P.N., Jennifer
Torres, Michael A.
Treisman, Glenn J
Tschan, Werner
Tse, Wing
Tsuang, Ming T
Tuerk, Catherine L.
Turkington, Douglas
Turner, Erick H
Tyrer, Peter
Tzuang, Dan
Udomratn, Pichet
Un, Hyong
Unutzer, Jurgen
Ursano, Amy M
Ursano, Robert J
Vaillant, George
Van, Henricus
Van Horn, Patricia J
Van Nieuwenhuizen, Adrienne O
Varma, Sudepta V
Veijola, Juha M.
Vela, Ricardo M
Verhalen, Nisha
Vianin, Pascal
Victor, Lisa
Vincent, Kathy M.
Viron, Mark
Vogel-Scibilia, Suzanne E.
Volberding, Paul
Volkow, Nora D
Wagner, Eric F
Walker, Sandra C
Warshaw, Carole L.
Webb, Roger T
Weerasekera, Priyanthy
Weiner, Richard
Weinstock, Robert
Weisner, Constance M
Weissman, Sidney
Welch, Kristen U
Wetherington, Cora Lee
Whelan, Gerald P
White, Stephen G
White, Leigh Anne
White-Labora, Deborah
Whyte, Doug DW
Willenbring, Mark
Williams, Eric R
Wills, Marketa
Windle, Michael
Winick, Bruce J
Winters, Kelley

Wise, Robert
Wise, Michael Jan
Wolf, Robert
Wood, William C
Woolley, Stephen B
Worley, Jena
Wynn, Gary
Xie, Yuhuan
Yager, Joel
Yellowlees, Peter M
Yen, Jennifer L
Yen, Shirley
Yeomans, Frank E
Yeung, Albert
Yoo, Tai P
Young, Tina
Young, Jeffrey E
Young, John Q
Yudofsky, Stuart C
Zainal, Nor Z
Zanarini, Mary C
Zangen, Abraham
Zaretsky, Ari E
Zatzick, Douglas F
Zeller, Scott L
Zhu, Ziqing
Ziedonis, Douglas M
Ziegler, Penelope P
Zubieta, Jon-Kar
Zucker, Robert A
Zurowski, Mateusz
Zweben ,Allen

NOTES

IMPORTANT REMINDER:

PROGRAM CHANGES ARE PRINTED EACH DAY IN THE *DAILY BULLETIN* - A COPY MAY BE OBTAINED BY ATTENDEES THROUGHOUT THE MOSCONE CONVENTION CENTER

Special Course Event

BOARD REVIEW: ABPN PART 1

BDRV 9:00 AM- 4:00PM

Gateway Ballroom 104, Exhibit Level, Moscone Center

DIRECTOR: JAMES BOURGEOIS, O.D., M.D.

Faculty: Jaesu Han, M.D., Cameron Quanbeck, M.D., Glen Xiong, M.D., Martin Leamon, M.D., Andreea Seritan, M.D., Alan Koike, M.D., Mark Servis, M.D., Charles Scott, M.D., Humberto Temporini, M.D., Robert McCarron, D.O.
Seperate Fee Required - Textbook included

NEW CLINICAL KNOWLEDGE AND SKILLS (CKS) MASTER COURSE SERIES

**MASTER COURSE:
PRACTICAL COGNITIVE
BEHAVIOR THERAPY**

CKS01 9:00 AM- 4:00PM

Gateway Ballroom 103, Exhibit Level, Moscone Center

DIRECTOR: JESSE WRIGHT, M.D., PH.D.

Faculty: Judith Beck, M.D., Robert Goisman, M.D., Donna Sudak, M.D.
Seperate Fee Required - Textbook included

Course descriptions are available in the *Course Brochure* included in your registration materials. Admission to all courses is by ticket only.

8:00 A.M. SESSIONS

COURSE 1 8:00 A.M. -12 NOON

Room 111, Exhibit Level, Moscone Center

BRAIN STIMULATION THERAPIES IN PSYCHIATRY

Director: Ziad H. Nahas, M.D.
Faculty: Linda Carpenter, M.D., Darin Dougherty, M.D., Mustafa Hussain, M.D.

COURSE 2 8:00 A.M. -12 NOON

Room 131, Exhibit Level, Moscone Center

INTERPERSONAL PSYCHOTHERAPY

Director: John C. Markowitz, M.D.

COURSE 3 8:00 A.M. -12 NOON

Room 226, Mezzanine Level, Moscone Center

PSYCHIATRIC CONSULTATION IN LONG TERM CARE: BASIC COURSE

Directors: Abhilash K. Desai, M.D., George T. Grossberg, M.D.

9:00 A.M. SESSIONS

COURSES 4-10

COURSE 4 9:00 A.M. - 4:00 P.M.

Room 125, Exhibit Level, Moscone Center

HOPE FOR THE DISTRESSED AND DISRUPTIVE PHYSICIAN: THE GOOD, THE BAD AND THE UGLY

Director: William H. Swiggart, M.S.
Faculty: Charles Samenow, M.D., M.P.H., Tobi Fishel, Ph.D., Gerald Hickson, M.D., Ronald Neufeld, B.S., Reid Finlayson, M.D.

COURSE 5 9:00 A.M. - 4:00 P.M.

Room 112, Exhibit Level, Moscone Center

CHILD AND ADOLESCENT PSYCHIATRY FOR THE GENERAL PSYCHIATRIST

Director: Robert L. Hendren, D.O.
Faculty: Malia McCarthy, M.D., Yuhuan Xie, M.D.

COURSE 6 9:00 A.M. - 4:00 P.M.

Room 130, Exhibit Level, Moscone Center

HOW TO BLOG, FRIEND, AND FLY: 21ST CENTURY INTERNET TECHNOLOGIES FOR BEGINNERS

Director: Robert C. Hsiung, M.D.
Faculty: Jerald Block, M.D., Steven Davis, M.D.

Saturday, May 16, 2009

COURSE 7 9:00 A.M.- 4:00 P.M.

Room 220, Mezzanine Level, Moscone Center

BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY I

Directors: Barry K. Herman, M.D.,
Douglas M. Brandt, M.D.

Faculty: L. Mark Russakoff, M.D.,
Shivkumar Hatti, M.D., M.B.A., David Nace, M.D.,
Sy Saeed, M.D., M.S.

COURSE 8 9:00 A.M.- 4:00 P.M.

Room 222, Mezzanine Level, Moscone Center

SPIRITUALITY IN PSYCHIATRY

Director: Michael D. McGee, M.D.

Faculty: Christina Puchalski, M.D.

COURSE 9 9:00 A.M. - 4:00 P.M.

Room 224, Mezzanine Level, Moscone Center

A PRACTICAL APPROACH TO RISK ASSESSMENT

Director: William H. Campbell, M.D., M.B.A.

COURSE 10 9:00 A.M. - 4:00 P.M.

Room 276, Mezzanine Level, Moscone Center

INTERPERSONAL AND SOCIAL RHYTHM THERAPY

Directors: Ellen Frank, Ph.D., Holly A. Swartz, M.D.

Faculty: Debra Frankel, L.C.S.W.

**NOW OPEN
EXHIBIT HALL
APA MEMBER CENTER
PUBLISHERS' BOOKFAIR
HOURS OF OPERATION
10:00 A.M. - 5:00 P.M.**

1:00 P.M. SESSIONS

COURSES 11-12

COURSE 11 1:00 P.M. - 5:00 P.M.

Room 131, Exhibit Level, Moscone Center

PSYCHOPHARMACOLOGIC, ECT AND PSYCHOTHERAPEUTIC TREATMENT OF PSYCHOTIC (DELUSIONAL) DEPRESSION

Director: Anthony J. Rothschild, M.D.

Faculty: Brandon Gaudiano, Ph.D.

COURSE 12 1:00 P.M. - 5:00 P.M.

Room 309, Esplanade Level, Moscone Center

MANAGING MALPRACTICE RISK FOR PSYCHIATRISTS: THE BASICS AND BEYOND

Directors: Jacqueline M. Melonas, J.D., R.N.,
Donna Vanderpool, J.D., M.B.A.

LECTURE 01

LECTURE 01 1:00 P.M.-2:30 P.M.

Grand Ballroom A, Third Floor, Intercontinental
San Francisco

PREVALENCE, CORRELATES, AND RISK OF POST TRAUMATIC STRESS DISORDER:

HOW LATINOS FARE COMPARED TO NON-LATINO WHITES, ASIANS, AFRICAN-AMERICAN, AND AFRO-CARRIBEAN

Margarita Alegria, Ph.D.

Simon Bolivar Award Lecture

Chp.: Andres J. Pumariega, M.D.

Margarita Alegria, Ph.D., is the Director of the Center for Multicultural Mental Health Research at the Cambridge Health Alliance. She is a professor of psychology in the Department of Psychiatry at Harvard Medical School and currently serves as the Principal Investigator of three National Institutes of Health-funded research studies. Dr. Alegria's published work focuses on how to improve services delivery for diverse racial and ethnic populations; conceptual and methodological issues with multicultural populations; and how to bring the community's perspective in the design and implementation of health services. Dr. Alegria also conducts research that will contribute to an understanding of the factors influencing service disparities, and testing interventions aimed at reducing disparities for ethnic and racial minority groups. Dr. Alegria received the 2003 Mental Health Section Award of the American Public Health Association and the 2006 Greenwood Award for Research Excellence. In 2007, she was honored with the first Latino Mental Health Scientific Leadership Award. She is also recipient of the Carl Taube Award, given by the Mental Health Section of the American Public Health Association. She serves on several boards, including the National Academy of State Health Policy, Health Services Research Journal.

IMPORTANT REMINDER:

PROGRAM CHANGES ARE PRINTED EACH DAY IN THE *DAILY BULLETIN* - A COPY MAY BE OBTAINED BY ATTENDEES THROUGHOUT THE MOSCONE CONVENTION CENTER

Course descriptions are available in the *Course Brochure* included in your registration packet. Admission to all courses is by ticket only.

8:00 A.M. SESSIONS

COURSES 13-17

COURSE 13 **8:00 A.M.-12 NOON**
Room 111, Exhibit Level, Moscone Center

PSYCHIATRIC ROLES IN ASSESSING AND TREATING ADULT AND ADOLESCENT SEX OFFENDERS

Directors: Bradley R. Johnson, M.D.,
Judith V. Becker, Ph.D.

COURSE 14 **8:00 A.M.-12 NOON**
Room 120, Exhibit Level, Moscone Center

MOOD DISORDERS IN LATER LIFE

Directors: James M. Ellison, M.D., M.P.H.,
Yusuf Sivrioglu, M.D.
Faculty: Brent Forester, M.D., James Ellison, M.D.,
M.P.H., Donald Davidoff, Ph.D., Patricia Arian, Ph.D.

COURSE 15 **8:00 A.M.-12 NOON**
Room 125, Exhibit Level, Moscone Center

PSYCHIATRIC INTERVENTIONS IN DISASTERS AND PUBLIC HEALTH EMERGENCIES: THEORY TO PRACTICE

Directors: Anand Pandya, M.D., Craig I. Katz, M.D.
Faculty: Judith Cohen, M.D.

COURSE 16 **8:00 A.M.-12 NOON**
Room 226, Mezzanine Level, Moscone Center

PSYCHIATRIC CONSULTATION IN LONG-TERM CARE: ADVANCED COURSE

Directors: Abhilash K. Desai, M.D.,
George T. Grossberg, M.D.

COURSE 17 **8:00 A.M.-12 NOON**
Room 310, Esplanade Level, Moscone Center

HOW TO GIVE A MORE EFFECTIVE LECTURE: PUNCH, PASSION AND POLISH

Director: Phillip J. Resnick, M.D.

9:00 A.M. SESSIONS

NEW CLINICAL KNOWLEDGE AND SKILLS MASTER COURSE SERIES

PRACTICAL PSYCHODYNAMIC PSYCHOTHERAPY

CKS02 9:00 A.M.- 4:00 P.M.

Gateway Ballroom 103, Exhibit Level, Moscone Center

DIRECTOR: GLEN O. GABBARD, M.D.
Faculty: Barbara Milrod, M.D., John Gunderson, M.D.,
Thomas Gutheil, M.D., Funmilayo Rachal, M.D.

Seperate fee required - textbook included.

COURSES 18-27

COURSE 18 **9:00 A.M.- 4:00 P.M.**
Room 222, Mezzanine Level, Moscone Center

LOVE, INTIMACY, DESIRE AND INFIDELITY

Director: Stephen B. Levine, M.D.

COURSE 19 **9:00 A.M.- 4:00 P.M.**
Room 112, Exhibit Level, Moscone Center

THE IMG INSTITUTE

Directors: Nyapati R. Rao, M.D., M.S., Deborah Hales, M.D.
Faculty: Mantosh Dewan, M.D., Jacob Sperber, M.D.,
Priyanthy Weerasekera, M.D., John Manring, M.D.,
Peter Buckley, Joan Anzia, M.D.

COURSE 20 **9:00 A.M.- 4:00 P.M.**
Room 113, Exhibit Level, Moscone Center

BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY II

Directors: Douglas M. Brandt, M.D., Barry K. Herman, M.D.

Faculty: Alan Axelson, M.D., Robert Atkins, M.D.,
Arthur Lazarus, M.D., M.B.A., Jeri Davis, M.B.A.,
William Reid, M.D., M.P.H.

COURSE 21 **9:00 A.M.- 4:00 P.M.**
Room 114, Exhibit Level, Moscone Center

WHAT IS PSYCHIATRY? PHILOSOPHIES AND PRACTICES

Directors: S. Nassir Ghaemi, M.D., M.P.H.,
David H. Brendel, M.D.

COURSE 22 9:00 A.M.- 4:00 P.M.

Room 121, Exhibit Level, Moscone Center

TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT

Director: Robert P. Granacher, M.D., M.B.A.

COURSE 23 9:00 A.M.- 4:00 P.M.

Room 122, Exhibit Level, Moscone Center

AUTISM SPECTRUM DISORDERS OVER THE LIFESPAN: DIAGNOSTIC CLASSIFICATION, NEUROBIOLOGY, BIOPSYCHOSOCIAL INTERVENTIONS AND PHARMACOLOGIC MANAGEMENT

Directors: Kimberly A. Stigler, M.D., Alice Mao, M.D.

Faculty: James Sutcliffe, Ph.D., Kara Kahan, M.D.,
Jolie Brams, Ph.D., Eric Courchesne, Frieda Aboul-Fotouh,
Robert Doyle, D.D.S, M.D.

COURSE 24 9:00 A.M.- 4:00 P.M.

Room 131, Exhibit Level, Moscone Center

ESSENTIALS OF ASSESSING & TREATING ATTENTION DEFICIT HYPERACTIVITY DISOR- DER IN ADULTS AND CHILDREN

Director: Thomas E. Brown, Ph.D.

Faculty: Jefferson Prince, M.D.

COURSE 25 9:00 A.M.- 4:00 P.M.

Room 133, Exhibit Level, Moscone Center

COGNITIVE-BEHAVIOR THERAPY FOR SEVERE MENTAL ILLNESS

Director: Jesse H. Wright, M.D., Ph.D.

Faculty: Douglas Turkington, M.D., Michael Thase, M.D.,
David Kingdon, M.D.

COURSE 26 9:00 A.M.- 4:00 P.M.

Room 276, Mezzanine Level, Moscone Center

SEEING THE FOREST AND THE TREES: AN AP- PROACH TO BIOPSYCHOSOCIAL FORMULATION

Director: William H. Campbell, M.D., M.B.A.

COURSE 27 9:00 A.M.- 4:00 P.M.

Room 309, Esplanade Level, Moscone Center

PSYCHOTHERAPY FOR BORDERLINE PERSONALITY

Directors: Frank E. Yeomans, M.D., Ph.D.,
Otto F. Kernberg, M.D.

Faculty: Eve Caligor, M.D., John Clarkin, Ph.D.

10:00 A.M. SESSIONS

**NOW OPEN
EXHIBIT HALL
APA MEMBER CENTER
PUBLISHERS' BOOKFAIR
HOURS OF OPERATION:
10:00 A.M. -4:30 P.M.**

12:00 NOON SESSIONS

INDUSTRY-SUPPORTED LUNCHEON SYMPOSIA

ISS 12:30 P.M. -2:30 P.M.

*Grand Ballroom Salon B, Grand Ballroom Level,
Hilton San Francisco*

DEVELOPMENT OF NEW AGENTS FOR THE TREATMENT OF SCHIZOPHRENIA

Supported by Dainippon Sumitomo Pharma America, Inc.

Chp.: Steven Potkin, M.D.

- 1. Unmet Needs in Schizophrenia**
Adrian Preda, M.D.
- 2. Drug Development in Psychiatry: Issues and Trends**
Amir Kalali, M.D.
- 3. New Targets for Drug Development**
Philip Harvey, Ph.D.

ISS 12:30 P.M. -2:30 P.M.

Salons 7 & 8, Lower B-2 Level, Marriott San Francisco

EFFECTIVE TREATMENT OF ALZHEIMER'S DISEASE – TRANSLATING GUIDELINES INTO PRACTICE: AN INTERACTIVE PANEL DISCUSSION

Supported by Forest Laboratories, Inc.

Chp.: George Grossberg, M.D.

- 1. Putting Practice Recommendations for AD Patients
into Practice: Confusion for Clinicians**
Maurice Redden, M.D.
- 2. Practice Recommendations from the American
Association for Geriatric Psychiatry**
Gary Small, M.D.
- 3. Management of Dementia: An Evidence-based
Review from the American Academy of Neurology**
Martin Farlow, M.D.
- 4. Current Pharmacologic Treatment of Dementia:
Practice Guidelines from the American College of
Physicians and the American Academy of Family
Physicians**
Charles Cefalu, M.D.

ISS **12:30 P.M. -2:30 P.M.**
Continental Ballroom 4/5/6, Hilton San Francisco

DELIVERING OPTIMAL CARE FOR COMPLEX BIPOLAR PATIENTS: AN AUDIENCE GUIDED SYMPOSIUM

Supported by AstraZeneca Pharmaceuticals

Chp.: Gary Sachs, M.D.

- 1. What Defines Quality of Care In Bipolar Disorder?**
Richard Hermann, M.D.
- 2. What Does the Payor's Data on Quality of Care Tell Us?**
Phyllis Greenwald, M.D.
- 3. How Do We Know If Medications Are Working?**
Michael Ostacher, M.D.
- 4. How Do We Care For Complex Bipolar Patients?**
Gary Sachs, M.D.

1:00 P.M. SESSIONS

COURSES 28-33

COURSE 28 **1:00 P.M.- 5:00 P.M.**
Room 111, Exhibit Level, Moscone Center

LOSING A PATIENT TO SUICIDE

Director: Michael F. Myers, M.D.

Faculty: Carla Fine, M.S.,
Frank Campbell, Ph.D., L.C.S.W.

COURSE 29 **1:00 P.M.- 5:00 P.M.**
Room 120, Exhibit Level, Moscone Center

MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP AND OTHER BODY CLOCK DISORDERS

Director: Alfred J. Lewy, M.D., Ph.D.

COURSE 30 **1:00 P.M. - 5:00 P.M.**
Room 220, Mezzanine Level, Moscone Center

CREATIVE USE OF BOUNDARY CROSSINGS IN THERAPY

Director: Gail E. Robinson, M.D., D.P.H.

Faculty: Gary Schoener, M.A., Linda Jorgenson, J.D.,
Howard Book, M.D.

COURSE 31 **1:00 P.M. - 5:00 P.M.**
Room 272, Mezzanine Level, Moscone Center

SHORT-TERM PSYCHODYNAMIC SUPPORTIVE PSYCHOTHERAPY FOR DEPRESSION

Director: Henricus Van, M.D.

Faculty: Mariëlle Hendriksen, M.A.,
Annemieke Nooteboom, Ph.D., Jack J. Dekker, Ph.D., Frans de Jonghe, M.D., Ph.D., Simone Kool, Ph.D., M.D.

COURSE 32 **1:00 P.M. - 5:00 P.M.**
Room 300, Esplanade Level, Moscone Center

MANAGEMENT OF PSYCHIATRIC DISORDERS IN PREGNANT AND POSTPARTUM WOMEN

Director: Arvinder K. Grewal, M.A.

Faculty: Shari Lusskin, M.D., Diana Carter, M.D.,
Deirdre Ryan, M.D.

COURSE 33 **1:00 P.M. - 5:00 P.M.**
Room 310, Esplanade Level, Moscone Center

NEUROANATOMY OF EMOTIONS

Director: Ricardo M. Vela, M.D.

2:00 P.M. SESSION

LECTURE 02

LECTURE 02 **2:00 P.M. -3:00 P.M.**
Gateway Ballroom 102, Exhibit Level, Moscone Center

PSYCHOPATHIC DISORDERS WITHOUT BORDERS

Alan R. Felthous, M.D. and Henning Sass, M.D.
Manfred Guttmacher Award Lecture

Chp.: Marilyn Price, M.D.

Alan R. Felthous, M.D., is Professor and Director of Forensic Psychiatry, Department of Neurology and Psychiatry, Saint Louis University School of Medicine. He received his bachelors degree from the University of Washington and his medical doctorate from the University of Louisville; he interned at Roosevelt Hospital (New York) with residency training at McLean Hospital and Harvard Medical School. Previously, Dr. Felthous held positions at the Naval Regional Medical Center in Oakland; the Menninger Foundation; the Department of Psychiatry and Behavioral Sciences at the University of Texas Medical Branch in Galveston, where he was Chief of Forensic Services and the Marie B. Gale Centennial Professor of Psychiatry; and Southern Illinois University, where he was Director of Forensic Psychiatry and Medical Director of Chester Mental Health Center, Illinois' maximum security forensic hospital. Dr. Felthous is a past president of the American Academy of Psychiatry and the Law and the American Board of Forensic Psychiatry, and is the senior editor of *Behavioral Sciences and the Law*. His research, scholarly and teaching interests focus on clinical aggression, the psychopathology of criminal behavior, legal requirements of clinicians in managing potentially violent patients, and jail and prison suicide.

Henning Sass, M.D., is currently Medical Director and Chairman of the Board of Directors at the University Hospital of the University of Technology (RWTH) in Aachen/Aix-la-Chapelle, Germany. He studied medicine at the universities of Kiel, Vienna and Mainz. After passing the state examination in Kiel and re

ceiving his medical doctorate in Mainz, he was a resident in the Department of Psychiatry at the University of Heidelberg. Having completed his training in clinical psychiatry and in psychotherapy, he concentrated on forensic psychiatry, general psychopathology, diagnostic research and personality disorders. His habilitation on Psychopathie, Soziopathie, and Dissozialitat (Psychopathy, Sociopathy and Dissocial Behaviors) was published by Springer (1987). Previously, he was Professor of by Springer (1987). Previously, he was Professor of Forensic Psychiatry at the Ludwig-Maximilians University in Munich, after which he was the Chair of Psychiatry and Psychotherapy at the medical faculty in Aachen for 10 years. His research interest is forensic psychiatry, especially personality disorders. He is past president of the German Society for Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and the Association of European Psychiatrists (AEP). He is editor of several scientific journals and member of numerous boards of scientific organizations including the European Brain Council and the Research Council of the German Ministry for Science, Research and technology.

5:00 P.M. SESSION

OFFICIAL OPENING SESSION 5:00 - 6:30 P.M.
Rm 134/135, Exhibit Hall E, Moscone Center

CALL TO ORDER

Nada L. Stotland, M.D., M.P.H., President

INTRODUCTION OF STAGE GUESTS

INTRODUCTION OF SCIENTIFIC PROGRAM COMMITTEE

Joseph Cheong, M.D., Chairperson

INTRODUCTION OF VISITING DIGNITARIES

(List of Presidents of Allied Organization follows this page)

PRESIDENTIAL ADDRESS

Nada L. Stotland, M.D., M.P.H.

RESPONSE OF THE PRESIDENT ELECT

Alan F. Schatzberg, M.D.

ADJOURNMENT

7:00 P.M. SESSIONS

INDUSTRY-SUPPORTED DINNER SYMPOSIA 4-6

ISS 04 7:00 P.M.-9:00 P.M.

*Continental Ballroom 4/5/6, Ballroom Level, Tower 3,
Hilton San Francisco*

NEUROBIOLOGY, PREDICTION AND MANAGEMENT OF ANTIPSYCHOTIC NON-RESPONSE IN PATIENTS WITH SCHIZOPHRENIA

Supported by Lilly USA, LLC

Chp.: Christoph Correll, M.D.

1. Neurobiology, Correlates and Measurement of Antipsychotic Non-response in Schizophrenia

John Kane, M.D.

2. Early Prediction of Antipsychotic Non-Response in Schizophrenia

Stefan Leucht, M.D.

3. Therapeutic Management of Antipsychotic Non-Response in Patients with Schizophrenia

Christoph Correll, M.D.

ISS 05

7:00 P.M.- 9:00 P.M.

*Grand Ballroom Salon B, Grand Ballroom Level,
Hilton San Francisco*

THE PATHOPHYSIOLOGY OF ADHD: IMPLICATIONS FOR TREATMENT

Supported by Shire US, Inc.

Chp.: Timothy Wilens, M.D.

1. The Neurobiology of ADHD: Overview of the Mechanisms of Efficacious Agents

Paul Hammerness, M.D.

2. Role of Dopamine in ADHD

Darin Dougherty, M.D.

3. Alpha-2A Agonists Strengthen Prefrontal Cortex Function

Amy Arnsten, Ph.D.

4. Nicotinic Receptors and Agonists in ADHD

Timothy Wilens, M.D.

ISS 06

7:00 P.M. -9:00 P.M.

Salon 7/8, Lower B-2 Level, Marriott San Francisco

AUGMENTATION STRATEGIES FOR MAJOR DEPRESSIVE DISORDER: THE EVIDENCE FOR EFFECTIVE CLINICAL DECISION-MAKING IN IMPROVING PATIENT CARE

Supported by Bristol-Myers Squibb

Chp.: Madhukar Trivedi, M.D.

1. Atypical Antipsychotics as Augmentation Agents for Major Depressive Disorder: Efficacy and Tolerability

George Papakostas, M.D.

2. Inadequate Treatment Response in Major Depressive Disorder: Predictors and Strategies for Selecting Next-Step Treatments

Roy Perlis, M.D.

3. Effective Management of Treatment-Resistant Depression: Evidence-Based Approaches Beyond First-Line Antidepressant Monotherapy

Madhukar Trivedi, M.D.

2009 Presidents of Allied Organizations

Albanian Psychiatric Association
Prof. Afrim Dangëllia

Algerian Psychiatric Association
Prof. Farid Kacha

Argentinean Association of Psychiatrists (AAP)
Dr. Nestor F. Marchant

Association of Argentinean Psychiatrists (APSA)
Prof. Juan Carlos Stagnaro

Foundation for Interdisciplinary Investigation of Communication (Argentina)
Prof. Miguel Angel Materazzi

Armenian Association of Psychiatrists and Narcologists
Prof. Marietta Melik-Pashayan

The Royal Australian and New Zealand College of Psychiatrists
Prof. Ken Kirkby

Austrian Association for Psychiatry and Psychotherapy
Prof. Michael Musalek

Azerbaijan Psychiatric Association
Prof. Nadir Ismayilov

Arab Gulf Psychiatric Association
Prof. Mohamed Al-Haddad

Bangladesh Association of Psychiatrists
Prof. Abdus Sobhan

Barbados Association of Psychiatrists
Dr. Sharon Harvey

Byelorussian Psychiatric Association
Prof. Roman A. Evsegneev

Royal Society of Mental Medicine of Belgium
Prof. Jean Bertrand

Society of Flemish Neurologists and Psychiatrists (Belgium)
Prof. Bernard Sabbe

Bolivian Society of Psychiatry
Dr. Maria Rosario Del Carpio O

Psychiatric Association of Bosnia-Herzegovina
Prof. Marija Burgic-Radmanovic

Brazilian Association of Psychiatry
Dr. João Alberto Carvalho

Psychiatric Association of Rio de Janeiro State (Brazil)
Dr. Fatima Vasconcellos

Society of Psychiatry of Rio Grande do Sul (Brazil)
Dr. Fernando Lejderman

Bulgarian Psychiatric Association
Prof. Peter Marinov

Canadian Psychiatric Association
Dr. Susan Abbey

Society of Neurology, Psychiatry and Neurosurgery (Chile)
Dr. Juan Maass

Chinese Society of Psychiatry
Prof. Dongfeng Zhou

Hong Kong College of Psychiatrists
Dr. SF Hung

Colombian Psychiatric Association
Dr. Carlos Alberto Miranda Bastidas

Costa Rican Psychiatric Association
Dra. Yanira Obando Salazar

Croatian Psychiatric Association
Prof. Ljubomir Hotujac

Cuban Society of Psychiatry
Dr. Miguel Valdes Mier

Cyprus Psychiatric Association
Dr. Neophytos Papanephytous

Czech Psychiatric Association
Prof. Mudr Jiri Raboch

Danish Psychiatric Association
Dr. Anders Fink-Jensen

Dominican Society of Psychiatry
Dr. Fior Solis de Mendez

Ecuadorian Association of Psychiatry
Dr. José Cruz Dueñas

Egyptian Psychiatric Association
Prof. Ahmed Okasha

Salvadorean Association of Psychiatry
Dra. Claudia Beatriz Barahona Navarrete

Estonian Psychiatric Association
Dr. Andres Lehtmets

Ethiopian Psychiatric Association
Dr. Mesfin Araya

Finnish Psychiatric Association
Prof. Jyrki Korkeila

French Association of Psychiatrists in Private Practice
Dr. Olivier Schmitt

French Association of Psychiatry
Prof. Bernard Gibello

French Psychiatric Information Society
Dr. Nicole Garret-Gloanec

International Society of Psychopathology of Expression (France)
Prof. J. G. Veyrat

Medical Psychologic Society (France)
Prof. J.D. Guelfi

The Psychiatric Evolution (France)
Dr. Yves Thoret

Society of Georgian Psychiatrists
Prof. George Naneishvili

German Society of Psychiatry, Psychotherapy and Neurology
Prof. Wolfgang Gaebel

Ghana Psychiatric Association
Dr. Sammy Ohene

Hellenic Psychiatric Association (Greece)
Prof. Nikolaos Tzavaras

Hellenic Society of Neurology and Psychiatry (Greece)
Prof. Costas Stefanis

2009 Presidents of Allied Organizations

Guatemalan Psychiatric Association

Dr. See King Emilio Quinto

Honduran Society of Psychiatry

Dr. Mario Mendoza

Hungarian Psychiatric Association

Prof. Janos Harmatta

Icelandic Psychiatric Association

Dr. Magnus Haraldsson

Indian Association for Social Psychiatry

Prof. Roy Abraham Kallivayalil

Indian Psychiatric Society

Prof. Priyavadan Chandrashankar Shastri

Indonesian Psychiatric Association

Prof. HM. Syamsul Hadi

Iranian Psychiatric Association

Dr. S. Ahmad Jalili

Iraqi Society of Psychiatrists

Dr. Muhammed Lafta

Irish College of Psychiatrists

Dr. Consilia Walsh

Israeli Psychiatric Association

Prof. Avi Bleich

Italian Association for Research in Schizophrenia

Prof. Carlo Lorenzo Cazzullo

Italian Psychiatric Association

Dr. Mariano Bassi

Jamaica Psychiatric Association

Dr. Roger Gibson

Japanese Society of Psychiatry and Neurology

Prof. Takuya Kojima

Jordan Association of Psychiatrists

Dr. Tawfik Daradkeh

Kazakh Association of Psychiatrists and Narcologists

Prof. Saltanat A. Nurmagambetova

Kenya Psychiatric Association

Prof. Frank G. Njenga

Korean Neuropsychiatric Association

Dr. Soo-Churl Cho

Kuwait Psychiatric Association

Prof. Essam A. Al-Ansari

Kyrgyz Psychiatric Association

Dr. Abjalal Begmatov

Latvian Psychiatric Association

Prof. Raisa Andrezina

Lebanese Psychiatric Society

Dr. Nabil Mikati

Libyan Association of Psychiatry, Neurology and Neurosurgery

Dr. Aburkes Abduraouf

Lithuanian Psychiatric Association

Prof. Algirdas Dembinskas

Luxembourgese Society of Psychiatry, Neurology and Psychotherapy

Dr. Chretien Jacoby

Psychiatric Association of Macedonia (Republic of Macedonia, FYROM)

Prof. Antoni Novotni

Malaysian Psychiatric Association

Dr. Yen Teck Hoe

Mauritius Psychiatric Association

Dr. Mridula Suresh Naga

Mexican Psychiatric Association

Prof. Martha P. Ontivero Uribe

Mexican Society of Neurology and Psychiatry

Dr. Juan Ignacio Rosales

League for Mental Health from Republic of Moldova

Dr. Mihail Hotineanu

Mongolian Mental Health Association

Dr. Bayankhuu Ayushjav

Montenegrin Psychiatric Association

Dr. Lidija Injac-Stevovic

Moroccan Society of Psychiatry

Prof. M.F. Benchekroun

Myanmar Medico-Psychological Society

Prof. Sao Sai Lon

Psychiatrists' Association of Nepal

Dr. Surendra Sherchan

Netherlands Psychiatric Association

Prof. Rutger Jan van der Gaag

Nicaraguan Psychiatric Association

Dr. Luis Aleman

Association of Psychiatrists in Nigeria

Prof. Oye Gureje

Norwegian Psychiatric Association

Dr. Jan Olav Johannessen

Pakistan Psychiatric Society

Prof. Muhammad Riaz Bhatti

Palestinian Psychiatric Association

Dr. Bassam Ashhab

Panamanian Society of Psychiatry

Dr. Miguel Angel Cedeno Tello

Papua New Guinea Psychiatric Association

Dr. Umadevi Ambihaipahar

Paraguayan Society of Psychiatry

Dr. José Britez Cantero

Peruvian Psychiatric Association

Prof. Jorge Anibal Castro Morales

Philippine Psychiatric Association

Dr. Imelda Batar

Polish Psychiatric Association

Prof. Aleksander Araszkievicz

Portuguese Association of Psychiatry

Prof. Jose C. Dias Cordeiro

Portuguese Society of Psychiatry and Mental Health

Prof. Adriano Vaz-Serra

Association of Free Psychiatrists of Romania

Prof. Aurel Romila

Romanian Psychiatric Association

Prof. Dan Prelipceanu

Independent Psychiatric Association of Russia

Prof. Yury Savenko

Russian Society of Psychiatrists

Prof. Valery N. Krasnov

Saudi Psychiatric Association

Dr. Mahdi S. Abumadini

2009 Presidents of Allied Organizations

**Society of Psychopathology and
Mental Hygiene of Dakar (Senegal)**

Prof. Omar Sylla

**Association of Psychiatric
Institutions of Serbia - UPUS**

Dr. Tanja Voskresenski

Serbian Psychiatric Association

Prof. Miroslava Jasovic Gasic

Singapore Psychiatric Association

Dr. Alex Su

Slovak Psychiatric Association

Prof. Livia Vavrusova

Psychiatric Association of Slovenia

Prof. Slavko Ziherl

**South African Society of
Psychiatrists (SASOP)**

Dr. Jan Chabalala

**Spanish Association of
Neuropsychiatry**

Prof. Alberto Fernandez Liria

Spanish Society of Psychiatry

Prof. Jeronimo Saiz

Sri Lanka College of Psychiatrists

Dr. Balapuwadige Jayan Medis

Sudanese Association of Psychiatrists

Dr. Abdullah Abdelrahman

Swedish Psychiatric Association

Dr. Christina Spjut

Swiss Society of Psychiatry

Dr. Hans Kurt

**Syrian Arab Association of
Psychiatrists**

Prof. Pierre Chiniara

Taiwanese Society of Psychiatry

Prof. Cheng-Chung Chen

Psychiatric Association of Thailand

Prof. Udomratn Pichet

Tunisian Society of Psychiatry

Dr. Essedik Jeddi

Psychiatric Association of Turkey

Prof. Seref Ozer

**Turkish Neuro-Psychiatric
Association**

Prof. Peykan G. Gökalp

Uganda Psychiatric Association

Dr. Fred Kigozi

**Ukraine Scientific Society of
Neurologists, Psychiatrists and
Narcologists**

Prof. Petro V. Voloshyn

Ukrainian Psychiatric Association

Prof. Victor Shumlyansky

The Royal College of Psychiatrists

Prof. Dinesh Bhugra

Society of Psychiatry of Uruguay

Dr. Vicente Pardo

**Association of Psychiatrists of
Uzbekistan**

Prof. Ulugbek Alimov

Venezuelan Society of Psychiatry

Dr. Néstor Macías

**Yemen Psychiatrists and Neurologists
Association**

Prof. Abdelmagid S. Al-Khulaidi

NOTES

IMPORTANT REMINDER:

PROGRAM CHANGES ARE PRINTED EACH DAY IN THE *DAILY BULLETIN* - A COPY MAY BE OBTAINED BY ATTENDEES THROUGHOUT THE MOSCONE CONVENTION CENTER

7:00A.M. SESSIONS

**INDUSTRY-SUPPORTED
BREAKFAST SYMPOSIA 7-8**

ISS 07 **7:00 A.M. -9:00 A.M.**
*Grand Ballroom Salon B, Grand Ballroom Level,
Tower 2, Hilton San Francisco*

**AUGMENTATION STRATEGIES FOR MAJOR
DEPRESSIVE DISORDER: THE EVIDENCE FOR
EFFECTIVE CLINICAL DECISION-MAKING IN
IMPROVING PATIENT CARE**

Supported by: AstraZeneca Pharmaceuticals

Chp.: Madhukar Trivedi, M.D.

- 1. Atypical Antipsychotics as Augmentation Agents
for MDD: Efficacy and Tolerability**
George Papakostas, M.D.
- 2. Inadequate Treatment Response in MDD: Predictors
and Strategies for Selecting Next-Step Treatments**
Roy Perlis, M.D.
- 3. Effective Management of Treatment-Resistant
Depression: Evidence-Based Approaches Beyond
First-Line Antidepressant Monotherapy**
Madhukar Trivedi, M.D.

ISS 08 **7:00 A.M. -9:00 A.M.**
*Yerba Buena Ballrooms 7 & 8, Lower B-2 Level, Marriott
San Francisco*

**ADHD FAQs: PRACTICAL ANSWERS FOR THE
OFFICE-BASED PRACTITIONER**

Supported by Shire US, Inc.

Chp.: Gabriel Kaplan, M.D.

- 1. How Do I Identify and Treat Adult ADHD?**
Gabriel Kaplan, M.D.
- 2. Cardiovascular Effects of Stimulants--Is There Cause
for Concern?**
Donald Greydanus, M.D.
- 3. How Do I Approach the Bipolar vs. ADHD Issue?**
Jeffrey H. Newcorn, M.D.
- 4. How Do I Manage the ADHD/SUD Comorbidity?**
Iliyan Ivanov, M.D.

8:00 A.M. SESSIONS

COURSES 34-41

COURSE 34 **8:00 A.M. -12 NOON**
*Continental Ballroom 8, Ballroom Level, Tower 3,
Hilton San Francisco*

EXPLORING TECHNOLOGIES IN PSYCHIATRY
American Association for Technology in Psychiatry

Directors: Robert S. Kennedy, M.D., John Luo, M.D.
Faculty: Carlyle Chan, M.D.

COURSE 35 **8:00 A.M. - 12 NOON**
*Continental Ballroom 9, Ballroom Level, Tower 3,
Hilton San Francisco*

**TREATING MEDICAL STUDENTS AND
PHYSICIANS**

Directors: Michael F. Myers, M.D.,
Leah J. Dickstein, M.D., M.A.
Faculty: Penelope Ziegler, M.D.

COURSE 36 **8:00 A.M. - 12 NOON**
*Franciscan Room A, Ballroom Level, Tower 1,
Hilton San Francisco*

**TREATING PHYSICIANS INVOLVED IN SEXUAL
MISCONDUCT**

Directors: Tracey I. Marks, M.D., Gene G. Abel, M.D.

COURSE 37 **8:00 A.M. - 12 NOON**
*Imperial Ballroom A, Ballroom Level, Tower 2,
Hilton San Francisco*

**ADVANCED ASSESSMENT AND TREATMENT
OF ADHD**

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson Prince, M.D.

COURSE 38 **8:00 A.M. - 12 NOON**
*Yosemite Room B, Ballroom Level, Tower 2,
Hilton San Francisco*

**THE DETECTION OF MALINGERED MENTAL
ILLNESS**

Director: Phillip J. Resnick, M.D.

COURSE 39 **8:00 A.M. - 12 NOON**
*Union Square Rooms 3/4, Fourth Floor, Tower 3,
Hilton San Francisco*

**IMPROVE YOUR PRESENTATION SKILLS: A
COACHING APPROACH**

Director: Luis F. Ramirez, M.D.

COURSE 40 **8:00 A.M. - 12 NOON**
*Union Square Rooms 17/18, Fourth Floor, Tower 3,
Hilton San Francisco*

RESEARCH AND PUBLISHING ON A SHOESTRING BUDGET

Director: Mantosh J. Dewan, M.D.

Faculty: Michele Pato, M.D., Edward Silberman, M.D.

COURSE 41 **8:00 A.M. - 12 NOON**
*Union Square Room 10, Fourth Floor, Tower 3,
Hilton San Francisco*

APPLIED CULTURAL PSYCHIATRY: HOW THE DSM-IV-TR OUTLINE FOR CULTURAL FORMULATION CAN INFORM THE CLINICAL INTERVIEW

Directors: Russell F. Lim, M.D., Francis G. Lu, M.D.

9:00 A.M. SESSIONS

FOCUS LIVE!

FOCUS LIVE 1 **9:00 A.M. - 10:30 A.M.**
Gateway Ballroom 104, Exhibit Level, Moscone Center

FOCUS LIVE! PSYCHIATRIC DIAGNOSIS AND ASSESSMENT IN OLDER ADULTS

Presented by: Barry D. Lebowitz, Ph.D.

The biological processes of aging are surprisingly not well understood. Aging brings important changes, and some of these changes are often difficult to distinguish from the pathophysiologically-based signs and symptoms of diseases common in older persons. The dynamics that have resulted in the growth of the older population in general have also contributed to the increased prevalence of chronic conditions. Age of onset assumes a greater importance of diagnosis of the older patient. Co-morbidity of psychiatric illness, acute physical illnesses, and other brain disorders represent a second area of clinical significance. This multiple-choice question based presentation will provide participants with an opportunity to test their knowledge about diagnosis and treatment of older patients. In FOCUS Live! sessions, expert clinicians lead lively multiple choice question-based discussions. Participants test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Questions cover existing knowledge on a clinical topic important to practicing general psychiatrists, including diagnosis, treatment, and new developments

LECTURES 3-6

LECTURE 03 **9:00 A.M. - 10:30 A.M.**
Gateway Ballroom 102, Exhibit Level, Moscone Center

PILLS TO TREAT ALCOHOLISM

Bankole A. Johnson, M.D., Ph.D., D.Sc.

Solomon Carter Fuller Award Lecture

Chp.: Michele Reid, M.D.

Bankole A. Johnson, M.D., is Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, where he is also a professor in the Departments of Neuroscience and Medicine. Dr. Johnson graduated from Glasgow University with a degree in medicine and trained in psychiatry at the Royal London and Maudsley and Bethlem Royal Hospitals. He trained in research at the Institute of Psychiatry (University of London) and at Oxford University and earned his doctoral degree in Psychopharmacology from Glasgow University. His primary area of research expertise is the psychopharmacology of medications for treating addictions; his clinical expertise is in addiction, biological, and forensic psychiatry. He was the 2001 recipient of the Dan Anderson Research Award and received the Distinguished Senior Scholar of Distinction Award in 2002 from the National Medical Association. In 2006 he received the American Psychiatric Association's Distinguished Psychiatrist Lecturer Award. In 2007, he was named as a Fellow in the Royal College of Psychiatrists, and in 2008 he was elected to the status of Distinguished Fellow of the American Psychiatric Association. Dr. Johnson is on the editorial board of *The International Journal of Neuropsychopharmacology*, has over 200 publications, and has edited two books.

LECTURE 04 **9:00 A.M. - 10:30 A.M.**
Room 130/131, Exhibit Level North, Moscone Center

PSYCHIATRISTS ROLE IN PREVENTION AND INTERVENTION IN DOMESTIC VIOLENCE AMONG SOUTH ASIANS

Surinder Sucha Nand, M.D.

Alexandra Symonds Award

Chp.: Asha S. Mishra, M.D.

Surinder S. Nand, M.D., is professor of Clinical Psychiatry and Associate Director, Psychiatry Residency Training in the Department of Psychiatry at the University of Illinois at Chicago. She served as the Director of the Mental Health Service Line at the Jesse Brown VA Medical Center until May 2005. In 1991, she was appointed Director, Psychiatry Residency Training Program at University of Illinois. She is a Distinguished Fellow of the American Psychiatric Association (APA). She was elected President of the Illinois Psychiatric Society (IPS) in 2005-2006. She has been active in the American Psychiatric Association and served as the Chair of the Asian-American Psychiatrists Committee of the APA from 2005-2007. She has been appointed as a member of the Scientific Program Committee of the APA from 2007-2011. Dr. Nand became a member of The American College of Psychiatrists in 2001. She is currently President of the Indo American Psychiatrists Association (IAPA). She volunteers her time for issues related to suicide, domestic violence and homelessness. At present, she is Co-Vice President of the Board and Interim Executive Director [volunteer] of Apna Ghar [Our Home], an organization which provides services and programs for victims of domestic violence among South Asian and immigrant communities in Chicago. *The Association of Women Psychiatrists/APA Committee on Women*

LECTURE 05 **9:00 A.M. - 10:30 A.M.**
Room 132/133, Exhibit Level North, Moscone Center

**PSYCHIATRIC GENETICS: A CURRENT
PERSPECTIVE**

Kenneth Kendler, M.D.
Distinguished Psychiatrist Lecture

Chp.: Julio Licino, M.D.
Vice-Chp.: Srijan Sen, M.D., Ph.D.

Kenneth Kendler, M.D., is the Rachel Brown Banks Distinguished Professor of Psychiatry and Professor of Human Genetics at the Medical College of Virginia of Virginia Commonwealth University. He also directs, along with Dr. Lindon Eaves, the Virginia Institute for Psychiatric and Behavioral Genetics. He has received a number of prestigious awards, including: the Lieber Prize for Outstanding Research on Schizophrenia (1995); First Prize from the Anna-Monika-Foundation for outstanding contributions to research on depression (1997); the Stanley R. Dean Award from the American College of Psychiatrists, for major contributions to the understanding of schizophrenic disorders (1998), and the Kurt Schneider Scientific Award for exceptional scientific achievement in schizophrenia (1998). He has received an Honorary Doctor of Science from the University of Birmingham, England, and is a member of the Institute of Medicine of the National Academy of Sciences. He was selected by Science Watch 2000 as the second most frequently cited author of high-impact papers in Psychiatry for the years 1990-98 and was given the Edward Strecker Award (2000) for outstanding contributions to psychiatric care and treatment. In 2001, he received two awards — the Fundacion Castillo del Pino 2001 Award in Spain for achievement in Psychiatry and the Edward J. Sachar 2001 Award for outstanding contributions to psychiatric research. In 2002, he received the Rema Lapouse Award for significant contributions to the scientific understanding of epidemiology and control of mental disorders from the American Public Health Association. In 2003, he was awarded the Erik Stromgren Medal by the Stromgren Foundation in Denmark, in 2006 the Judd Marmor Award from the American Psychiatric Association and in 2007, the 12th Howard P. Rome Lecturer Award from the Mayo Clinic, Mayo Clinic College of Medicine.

LECTURE 06 **9:00 A.M. - 10:30 A.M.**
Room 303/305, Esplanade Level, Moscone Center

**ETIOLOGY IN PSYCHIATRY: PHENOMES,
GENOMES AND EPIGENOMES**

James Potash, M.D., M.P.H.
Frontiers of Science Lecture

Chp.: David A. Mrazek, M.D.

James Potash, M.D., M.P.H., is a graduate of Yale College, where he majored in English and was managing editor of the Yale Daily News. Following graduation he served in the Peace Corps in West Africa, and there decided to become a physician. He received an MPH and MD from Johns Hopkins University. He completed his psychiatry residency training at Hopkins as well, and in 1998 joined the faculty. He is currently the Arlene and Robert Kogod Associate Professor, and Director of Research Programs for the Johns Hop-

kins Mood Disorders Center in the Department of Psychiatry. The primary focus of Dr. Potash's research is the genetic basis of mood disorders. He has received major grants from the National Institute of Mental Health studying the genetics of bipolar disorder and major depression, and the epigenetics of major depression. His two areas of research specialty have been the genetic basis of the psychotic form of bipolar disorder and the epigenetics of mood disorders. The author of numerous scientific papers, he has also collaborated on a revision of the textbook, Manic-Depressive Illness. He received American Psychopathological Association's Robins/Guze Award for Research Excellence in 2003. Dr. Potash has collaborated closely with Dr. Andrew Feinberg, Director of the Epigenetics Center of the Institute for Basic Biomedical Science at Johns Hopkins, and a world leader in epigenetics. Drs. Potash and Feinberg co-direct an Epigenetics Core Facility within the Johns Hopkins Brain Sciences Institute. The Center is currently studying the epigenetics of major depression, bipolar disorder, schizophrenia and autism. Dr. Potash also has an Independent Investigator Award from the National Alliance for Research on Schizophrenia and Depression (NARSAD) to study the epigenetics of antidepressant response in an animal model. In addition to his research efforts, Dr. Potash is also an active clinician who sees patients in the Mood Disorders Consultation Clinic and the Mood Disorders Inpatient Service at Johns Hopkins Hospital.

**POSTER SESSION 1:
NEW RESEARCH/YOUNG INVESTIGATORS**

For information on New Research Poster Sessions, please refer to the *New Research Program* section in the back of this publication.

CASE CONFERENCES 1-2

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. A MEMBER REGISTRATION BADGE OR CURRENT APA MEMBERSHIP CARD IS REQUIRED FOR ADMITTANCE.

CASE CONFERENCE 01 9:00 A.M. - 12:00 P.M.
Room 120, Exhibit Level North, Moscone Center

PSYCHOANALYTIC CASE

Chp.: Deborah Spitz, M.D.
Presented by Melvin Lansky, M.D.

CASE CONFERENCE 02 9:00 A.M. - 10:30 A.M.
Room 121, Exhibit Level North, Moscone Center

**A POPULATION-BASED CASE CONFERENCE
ILLUSTRATING THE IMPLEMENTATION OF AN
EVIDENCED -BASED PREVENTION, INTERVEN-
TION IN A COUNTRY WITH 200,000 PEOPLE**

Presented by Carl C. Bell, M.D.

COMPONENT WORKSHOPS 1-6

CW 1 9:00 A.M. -10:30 A.M.

Room 114, Exhibit Level North, Moscone Center

HIGH-RISK STUDENT POPULATIONS: INNOVATIVE APPROACHES TO TREATMENT AND OUTREACH

Chp.: Jerald Kay, M.D.

Participants: Marta Hopkinson, M.D.,
Leigh Anne White, M.D., Beverly Fauman, M.D.

CW 2 9:00 A.M.-10:30 A.M.

Room 220, Mezzanine Level, Moscone Center

LOST AND NOT FOUND: DEPRESSION AND SUICIDE IN ELDERLY ASIAN AMERICANS *APA Committee of Asian-American Psychiatrists*

Chp.: Jacquelyn Chang, M.D.

Participants: Dan Tzuang, M.D.
Megan Marumoto, M.D., Iqbal Ahmed, M.D.

CW 3 9:00 A.M.-10:30 A.M. **WITHDRAWN**

CW 4 9:00 A.M.-10:30 A.M.

Room 224, Mezzanine Level, Moscone Center

INTERNATIONAL DISASTERS: CHALLENGES AND OPPORTUNITIES TO CONTRIBUTE

APA Committee on Psychiatric Dimensions of Disaster

Co-Chps.: Shirley Liu, M.D.,
Patcho Santiago, M.D., M.P.H.

Participants: Joseph Napoli, M.D., Arshad Husain, M.D.,
Robert Ursano, M.D., Artin Terhakopian, M.D., M.P.H.

CW 5 9:00 A.M.-10:30 A.M.

Room 226, Mezzanine Level, Moscone Center

CAREER ADVANCEMENT IN ADMINISTRATIVE PSYCHIATRY FOR EARLY CAREER PSYCHIATRISTS

APA Assembly Committee of Early Career Psychiatrists

Co-Chps.: Dimitri D. Markov, M.D.,
Marina Goldman, M.D.

Participants: Barry Herman, M.D.,
Thomas Newmark, M.D., Shivkumar Hatti, M.D., M.B.A.

CW 6 9:00 A.M.-10:30 A.M.

Room 310, Esplanade Level, Moscone Center

SHOW ME THE MONEY! SUSTAINABLE FUNDING FOR EDUCATION IN PSYCHIATRY

APA/GlaxoSmithKline Fellows

Chp.: M. Justin Coffey, M.D.

Participants: Kayla Pope, M.D., J.D.,
Mohammad Alsuwaidan, M.D., Claudia Reardon, M.D.,
Stacey Burpee, D.O., M.P.H.

ISSUE WORKSHOPS 1-13

IW 1 9:00 A.M.-10:30 A.M.

Room 111, Exhibit Level, Moscone Center

INCREASING CULTURAL COMPETENCY TO ASSESS AND AMELIORATE DISTRESS OF DIVERSE PATIENTS: EXAMPLE FROM THE CARE OF ASIAN VICTIM OF SPOUSAL ABUSE

Co-Chps.: Jacob E. Sperber, M.D., Nyapati R. Rao, M.D., M.S.

Participant: Sadaf Ahmed, M.D.

IW 2 9:00 A.M.-10:30 A.M.

Room 112, Exhibit Level, Moscone Center

PRACTICAL PHARMACOTHERAPY FOR THE TREATMENT OF ALCOHOL DEPENDENCE

National Institute on Alcohol Abuse and Alcoholism

Co-Chps.: Robert M. Swift, M.D., Ph.D.,
Allen Zweben, D.S.W.

IW 3 9:00 A.M.-10:30 A.M.

Room 113, Exhibit Level, Moscone Center

INCEST - A CULTURAL PERSPECTIVE

APA Council on Global Psychiatry and the APA Council on Children, Adolescents, and Their Families

Co-Chps.: Rodrigo A. Munoz, M.D.

IW 4 9:00 A.M.-10:30 A.M.

Room 122, Exhibit Level, Moscone Center

PLAYING IN THE BIG LEAGUE: RESIDENT LEADERSHIP IN THE APA BOARD OF TRUSTEES

Co-Chps.: Molly K. McVoy, M.D., Lauren Sitzler, M.D.

Participants: Otis Anderson III, M.D.,
Carolyn B. Robinowitz, M.D., Pedro Ruiz, M.D.

IW 5 9:00 A.M.-10:30 A.M.

Room 125, Exhibit Level, Moscone Center

RISK MANAGEMENT ISSUES IN PSYCHIATRIC PRACTICE

Co-Chps.: Martin G. Tracy, J.D.,
Jacqueline M. Melonas, J.D., R.N.

Participant: Harland Westgate, J.D.

IW 6 **9:00 A.M.-10:30 A.M.**
Rooms 272, Mezzanine Level West, Moscone Center

ETHICAL, CLINICAL AND LEGAL CHALLENGES CREATED BY INFORMATION TECHNOLOGY

Co-Chps.: Malkah T. Notman, M.D., Linda M. Jorgenson, J.D.
Participants: Elissa Benedek, M.D., Lea DeFrancisci, M.D.,
Carl Malmquist, M.D.

IW 7 **9:00 A.M.-10:30 A.M.**
Room 300, Esplanade Level, Moscone Center

TECHNOLOGY AND PSYCHIATRY: PRACTICAL AND CLINICAL TIPS FOR USING TELEPSYCHIATRY *(For Residents Only)*

Co-Chps.: Jena Worley, M.D., Michael Houston, M.D.
Participants: Don Hilty, M.D., Chad Koyanagi, M.D.,
Peter Yellowlees, M.D.

IW 8 **9:00 A.M.-10:30 A.M.**
Room 301, Esplanade Level, Moscone Center

MINDFUL PRACTICE: UNDERSTANDING ITS ROLE IN PSYCHIATRY AND PSYCHIATRIC TRAINING

Chp.: Tana A. Grady-Weliky, M.D.
Participants: Scott McDonald, M.D.,
Jennifer Richman, M.D.

IW 9 **9:00 A.M.-10:30 A.M.**
Room 302, Esplanade Level, Moscone Center

NEED TO REFORMULATE "RISK" AND ITS "ASSESSMENT" IN CLINICAL PRACTICE *World Psychiatric Association*

Chp.: Amresh K. A. Shrivastava, M.D., D.P.M.
Participant: Charles Nelson, Ph.D.

IW 10 **9:00 A.M.-10:30 A.M.**
Room 304, Esplanade Level, Moscone Center

IMAGING INSIGHT: BASIC DEFINITIONS, MEASURES, AND RELEVANCE TO PSYCHOPATHOLOGY *National Institute on Drug Abuse*

Co-Chps.: Steven Grant, Ph.D., Rita Goldstein
Participants: Jennifer Beer, Ph.D., Richard Lane, Nora D.
Volkow, M.D.

IW 11 **9:00 A.M.-10:30 A.M.**
Room 306, Esplanade Level, Moscone Center

IMPLEMENTING A TELEPSYCHIATRY PROGRAM IN THE KERN COUNTY MENTAL HEALTH SYSTEM IN RURAL CALIFORNIA: PART 2

Co-Chps.: Salvador R. del Rosario, M.D.,
Tai P. Yoo, M.D., M.B.A., Susan Fauman

IW 12 **9:00 A.M.-10:30 A.M.**
Room 308, Esplanade Level, Moscone Center

USING THE DSM-IV-TR CULTURAL FORMULA- TION FOR CULTURAL COMPETENCE SKILL BUILDING AMONG PSYCHIATRY RESIDENTS

Co-Chps.: Treniece Lewis Harris, Ph.D.,
Marshall Forstein, M.D.

IW 13 **9:00 A.M.-10:30 A.M.**
Room 309, Esplanade Level, Moscone Center

DIVERSION OF PRESCRIPTION STIMULANTS *National Institute on Drug Abuse*

Co-Chps.: Moira P. O'Brien, M.P.H.,
Wilson M. Compton III, M.D.
Participants: Sean McCabe, Ph.D., Timothy Wilens, M.D.

SMALL INTERACTIVE SESSION

SI01 **9:00 A.M. - 10:30 A.M.**
Room 216, Mezzanine Level East, Moscone Center

SAFETY ISSUES IN CHILD PSYCHOPHARMACOLOGY

Chp.: Barbara Coffey, M.D.

ADVANCES IN RESEARCH

ADVANCES IN RESEARCH 01 WITHDRAWN

MEDIA WORKSHOPS 1-2

MW 1 **9:00 A.M.-12:30 P.M.**
Room 123, Exhibit Level, Moscone Center

READY? OK! A FILM ABOUT CHILDHOOD GENDER VARIANCE

American Academy of Child and Adolescent Psychiatry

Chps.: Richard R. Pleak, M.D., Sarah E. Herbert, M.D., M.S.W.
Participant: Edgardo Menvielle, M.D.

MW 2 **9:00 A.M.-12:30 P.M.**
Room 124, Exhibit Level, Moscone Center

SILVER SPURS SEVERE AND CHRONIC MENTAL ILLNESS, AND LIFE IN A RESIDENTIAL CARE FACILITY

Co-Chps.: Steven Harvey, M.D., Doug Whyte, B.S.

NEW CLINICAL KNOWLEDGE AND SKILLS MASTER COURSE SERIES

ADVANCES IN NEUROPSYCHIATRY

CKS03 9:00 AM- 4:00PM

*Grand Ballroom, Salon A Level, Tower 2
Hilton San Francisco*

DIRECTOR: C. EDWARD COFFEY, M.D.

Faculty: Jeffrey L. Cummings, M.D.,
Mark S. George, M.D., Nancy Minshew, M.D.,
Randolph Schiffer, M.D.

Separate fee required: Textbook Included

COURSES 42-49

COURSE 42 9:00 A.M.- 4:00 P.M.

*Continental Ballroom 1, Ballroom Level, Tower 3,
Hilton San Francisco*

UNDERSTANDING THE PERSON BEHIND THE ILLNESS: AN APPROACH TO PSYCHODYNAMIC FORMULATION

Director: William H. Campbell, M.D., M.B.A.

COURSE 43 9:00 A.M.- 4:00 P.M.

*Continental Ballroom 2, Ballroom Level, Tower 3,
Hilton San Francisco*

DAVANLOO'S INTENSIVE SHORT-TERM DYNAM- IC PSYCHOTHERAPY IN CLINICAL PRACTICE

Directors: James Q. Schubmehl, M.D., Alan R. Beeber, M.D.

COURSE 44 9:00 A.M.- 4:00 P.M.

*Imperial Ballroom B, Ballroom Level, Tower 2,
Hilton San Francisco*

DRUG INTERACTION PRINCIPLES COURSE: UPDATE 2009

Academy of Psychosomatic Medicine

Directors: Scott C. Armstrong, M.D., Gary Wynn, M.D.

COURSE 45 9:00 A.M.- 4:00 P.M.

*Yosemite Room A, Ballroom Level, Tower 2,
Hilton San Francisco*

GOING FROM THE BIO-BIO-BIO MODEL FOR- WARD TO BIO-PSYCHO-SOCIAL REASONING

Director: Paul R. McHugh, M.D.

Faculty: Alan Romanoski, M.D., M.P.H.,
Glenn Treisman, M.D., Ph.D.

COURSE 46 9:00 A.M.- 4:00 P.M.

*Union Square Room 14, Fourth Floor, Tower 3,
Hilton San Francisco*

MONEY MATTERS I: USING THEORY IN CLINICAL PRACTICE

Director: Cecilia M. Mikalac, M.D.

COURSE 47 9:00 A.M.- 4:00 P.M.

*Union Square Rooms 15/16 Fourth Floor, Tower 3,
Hilton San Francisco*

TREATING BORDERLINE PERSONALTY DISORDERS WITH THE STEPPS MODEL

Director: Donald W. Black, M.D.

Faculty: Nancee Blum, M.S.W., L.C.S.W.

COURSE 48 9:00 A.M.- 4:00 P.M.

*Union Square Rooms 19/20, Fourth Floor, Tower 3,
Hilton San Francisco*

A DEVELOPMENTAL APPROACH TO CONTEMPORARY ISSUES IN PSYCHOTHERAPY WITH GAY MEN

Directors: Robert M. Kertzner, M.D., Marshall Forstein, M.D.

Faculty: Stewart Adelson, M.D.

COURSE 49 9:00 A.M.- 4:00 P.M.

*Union Square Rooms 23/24, Fourth Floor, Tower 3,
Hilton San Francisco*

THERAPEUTIC INTERVENTIONS IN EATING DISORDERS: BASIC PRINCIPLES

Director: David C. Jimerson, M.D.

Faculty: Joel Yager, M.D., Katherine Halmi, M.D.,
Michael Devlin, M.D., James Mitchell, M.D.

**NOW OPEN
EXHIBIT HALL
APA MEMBER CENTER
PUBLISHER'S BOOK FAIR
HOURS OF OPERATION
10:00 A.M. - 5:00 P.M.**

11:00 A.M. SESSIONS

11:00 A.M. SESSIONS

ADVANCES IN MEDICINE

ADVANCES IN

MEDICINE 01

11:00 A.M. - 12:30 P.M.

Room 300, Esplanade Level, Moscone Center

THE TOP 10 MEDICAL ARTICLES OF 2008: A COMPREHENSIVE AND PRACTICAL REVIEW OF WHAT WE NEED TO KNOW

Chp.: Monique Yohanan, M.D.

FOCUS LIVE!

FOCUS LIVE 2

11:00 A.M. - 12:30 P.M.

Gateway Ballroom 104, Exhibit Level, Moscone Center

FOCUS LIVE! PTSD AND DISASTER PSYCHIATRY

Presented by: Anand Pandya, M.D.

In the seven years since the 9-11 attacks and the four years since Hurricane Katrina, American psychiatry has developed an increased interest in the psychiatric sequelae to disasters. This has helped the field to develop greater sophistication in epidemiology and in the treatment of individuals affected by disasters. Large scale tragedies underscore the increasing role that psychiatrists play in aiding survivors, emergency workers, and broader communities to cope with disaster. The field of disaster psychiatry, itself, needs to be understood in relationship to other areas of psychiatry such as trauma psychiatry and military psychiatry. Reactions to stress occur in stages, each one characterized by a specific psychological mechanism. This multiple-choice question based presentation will provide participants with an opportunity to test their knowledge about diagnosis and treatment of PTSD and about Disaster Psychiatry. In FOCUS Live sessions, expert clinicians lead lively multiple choice question-based discussions. Participants test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Questions cover existing knowledge on a clinical topic important to practicing general psychiatrists, including diagnosis, treatment, and new developments.

FORUMS 1-4

FORUM 01

TIME CHANGED 12-1:30 P.M.

Gateway Ballroom 102, Exhibit Level, Moscone Center

DSM-V: PROGRESS IN RESEARCH AND DEVELOPMENT (DSM Track 01)

Chp.: Darrel Regier, M.D.

Participants: Darrel A. Regier, M.D., David Kupfer, M.D., Norman Sartorius, M.D., Ph.D.

FORUM 02

11:00 A.M. - 12:30 P.M.

Room 301, Esplanade Level, Moscone Center

THE RELATIONSHIP BETWEEN APA AND THE PHARMACEUTICAL INDUSTRY: HISTORICAL AND CURRENT PERSPECTIVES AND ISSUES

Chp.: Kenneth Silk, M.D.

Participants: Don Hilty, M.D., Philip Muskin, M.D., M.A., James Scully, Jr., M.D., Josepha Cheong, M.D., Srijan Sen, M.D., Kelli Harding, M.D., Ken Silk, M.D.

FORUM 03

11:00 A.M. - 12:30 P.M.

Room 306, Esplanade Level, Moscone Center

DEVELOPING THE NEXT GENERATION OF CLINICAL TRANSLATIONAL RESEARCHERS: INNOVATION IN AN ACADEMIC DEPARTMENT OF PSYCHIATRY

Chp.: Renee Binder, M.D.

Participants: Renee Binder, M.D., Daniel Mathalon, Ph.D., M.D., Kristine Yaffe, M.D.

FORUM 04

11:00 A.M. - 12:30 P.M.

Room 307, Esplanade Level, Moscone Center

WOMEN WITH ALCOHOL DISORDERS: RESEARCH UPDATES FOR TREATMENT INNOVATION

Chp.: Grace Chang, M.D.

Participants: Chang Grace, M.D., M.P.H., Nancy Goler, M.D., Shelly F. Greenfield, M.D., M.P.H., Lee Ann Kaskutas, Ph.D.

LECTURES 7-9

LECTURE 07

11:00 A.M. - 12:30 P.M.

Room 130/131, Exhibit Level North, Moscone Center

PSYCHIATRIC EDUCATION ACROSS CIVILIZATIONS: THE SEARCH FOR A GURU AND THE IMG

Nyapati R. Rao, M.D., M.S.

George Tarjan Award Lecture

Chp.: Marie Claude Rigaud, M.D.

Nyapati R. Rao, M.D., is the chair of the Department of Psychiatry and Behavioral Sciences at Nassau University Medical Center in Long Island. He was born and completed his medical education in India. Interested in a career in psychiatry in the United States, Dr. Rao completed his postgraduate training at the Brookdale Hospital Medical Center in Brooklyn. In 1987, he became the Director of Residency Training at Brookdale. In 2000, Dr. Rao accepted the residency training director position at SUNY-Downstate Medical Center, in Brooklyn. He also is the Director of residency Training at NUMC, where he assumed the chair in 2006. He continues to maintain his appointment as Professor of Clinical Psychiatry at SUNY-Downstate. Throughout his career, Dr. Rao has worked to address the issues faced by IMGs a priority of psychiatric education. Dr. Rao chaired the APA Council on Medical Education and Life Long Learning from 2000-2004 and recently completed his term

as the president of Brooklyn Psychiatric Society. He is the founding chair of the Committee on IMGs at GAP, a member of ACP, and a consultant to the AMA- IMG Governing Council. Dr. Rao's contributions for IMGs include creation of the IMG Award and mentorship program at AADPRT, creating an APA-supported Diagnostic Evaluation Program for psychiatrists unable to pass the Oral Board exam, and recently organizing the IMG Resident Institute at the APA Annual Meeting, which helps IMG residents orient to US psychiatry. Dr. Rao is a Distinguished Fellow of the APA, and last year received the Educator of the Year Award from the Association of Academic Psychiatry.

LECTURE 08 **11:00 A.M. - 12:30 P.M.**

Room 132/133, Exhibit Level North, Moscone Center

MENTAL HEALTH IN THE NEW ERA OF COST CONTAINMENT

Richard Frank, Ph.D.

Frontiers of Science Lecture

Chp.: Renato D. Alarcon, M.D., M.P.H.

Richard G. Frank, Ph.D., is the Margaret T. Morris Professor of Health Economics in the Department of Health Care Policy at Harvard Medical School. He is also a Research Associate with the National Bureau of Economic Research. Dr. Frank is engaged in research in three general areas: 1) the economics of mental health care; 2) the economics of the pharmaceutical industry; and 3) payment policy and physician practices. Dr. Frank served on the Congressional Citizen's Working Group on Health Care. He advises several state mental health and substance abuse agencies on issues related to managed care and financing of care. Frank serves as Co-Editor of the Journal of Health Economics. In 1997 He was elected to the Institute of Medicine. Dr. Frank was awarded the Georgescu-Roegen prize from the Southern Economic Association for his collaborative work on drug pricing, the Carl A. Taube Award from the American Public Health Association for outstanding contributions to mental health services and economics research, and the Emily Mumford Medal from Columbia University's Department of Psychiatry. Dr Frank received the John Eisberg Mentorship Award from National Research Service Awards. He and Sherry Glied recently published the book *Better but Not Well* (Johns Hopkins Press.)

LECTURE 09 **11:00 A.M. - 12:30 P.M.**

Room 303/305, Esplanade Level, Moscone Center

THE CENTER CANNOT HOLD: MY JOURNEY THROUGH MADNESS

Elyn Saks, J.D.

Chp.: Dillip Jeste, M.D.

Elyn R. Saks is Orrin B. Evans Professor of Law, Psychology, and Psychiatry and the Behavioral Sciences at the University of Southern California Gould School of Law. She is also Associate Dean for Research at the USC Law School; Adjunct Professor of Psychiatry, University of California, San Diego, School of Medicine; and Research Clinical Associate at the New Center for Psychoanalysis. Professor Saks received her BA from Vanderbilt University; an M.Litt., in philosophy from Oxford University; and a J.D. from Yale Law School. She writes extensively in the area of law and mental

health, having published four books and more than two dozen articles. Current projects include empirical studies on informed consent and competency. Professor Saks is an elected member of the American Law Institute and has been awarded numerous awards, including USC's 2004 Associates Award for Creativity in Research and Scholarship and 2004 and 2007 Phi Kappa Phi Faculty Recognition Award; The Books for a Better Life Inspirational Memoir Award; and Top Ten Nonfiction Book of the Year from Time Magazine. Professor Saks is on the board of several mental health nonprofits, including the Bazelon Center for Mental Health Law in Washington, D.C., and Mental Health Advocacy Services in Los Angeles.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-8

SCR 01 **11:00 A.M. - 12:30 A.M.**

Room 111, Exhibit Level, Moscone Center

FORENSIC PSYCHIATRY

Chp.: Dan Coleman, M.D.

- 1. Characteristics of Mentally Ill Offenders From 100 Psychiatric Court Reports**
Yasser Elsayed, M.D.
- 2. Homicide During the First Episode of Psychotic Illness**
Olav Nielssen, M.B.B.S
- 3. Differences Between Men and Women Found Not Guilty By Reason of Insanity for Homicide Offenses at Napa State Hospital**
Jessica Ferranti, M.D.

SCR 2 **11:00 A.M. - 12:30 A.M.**

Room 112, Exhibit Level, Moscone Center

MEASUREMENT OF PERSONALITY DISORDER SEVERITY

Chp.: Adel Gabriel, M.D.

- 4. The Severity Indices of Personality Problems - A New Dimensional Questionnaire for Measuring (mal) Adaptive Personality Functioning**
Helene Andrea, Ph.D.
- 5. Severity Indices of Personality Problems (SIPP-118) in Adolescents: Factor Structure and Validity**
Joost Hutsebaut, Ph.D.
- 6. The Severity Indices of Personality Problems (SIPP-118) as a Clinical Instrument**
Dineke Feenstra, M.A.

SCR 3 **11:00 A.M. - 12:30 P.M.**

Room 113, Exhibit Level, Moscone Center

GENETIC, NEUROIMAGING, AND NEUROPSYCHOLOGICAL STUDIES IN SCHIZOPHRENIA

Chp.: Anna Molofsky, M.D.

7. **Does Aberrant Stimulus Salience Lead to Psychosis in Schizophrenia? A 20-Year Longitudinal Study**
Martin Harrow, Ph.D.
8. **Association of G-1438A Polymorphism of 5HT2A Receptor With Schizophrenia in Three Ethnic Groups in Malaysia**
Zahurin Mohamed, B.S.C., Ph.D.
9. **MEG Analysis of Early Processing of Facial Expressions in Schizophrenia and Controls**
Stephen Lewis, M.D.

SCR 4 11:00 A.M. - 12:30 P.M.

Room 114, Exhibit Level, Moscone Center

ADJUNCTIVE TREATMENT AND COMORBIDITY IN SCHIZOPHRENIA

Chp.: Susan Stabinsky, M.D.

10. **Effects of Adjunctive Treatment With Armodafinil in Schizophrenia**
Ashwin A. Patkar, M.D.
11. **Prevalence of Alcohol Use Disorders in Schizophrenia: A Systematic Review and Meta-Analysis**
Jouko Miettunen, Ph.D.
12. **Zolpidem in Treatment-Resistant Catatonia: Case Reports and Literature Review**
Cristinel Coconcea, M.D.

SCR 5 11:00 A.M. - 12:30 P.M.

Room 234, Mezzanine Level, Moscone Center

PSYCHOPHARMACOLOGY, PSYCHOSTIMULANTS AND ANTIDEPRESSANT SIDE EFFECTS

Chp.: Merrra Vasawani, M.D.

13. **Linking ADHD Ratings and Clinical Global Impressions Scores in Studies of Lisdexamfetamine Dimesylate in ADHD**
Richard Weisler, M.D.
14. **Antidepressant-Induced Excessive Sweating (ADIES): Measurement and Treatment**
Rajnish Mago, M.D.
15. **Armodafinil Once Daily Sustains Wakefulness Throughout the Day in Patients With Excessive Sleepiness Associated With Narcolepsy**
Thomas Roth, Ph.D.

SCR 6 11:00 A.M. - 12:30 P.M.

Room 121, Exhibit Level, Moscone Center

Bipolar Disorder

Chp.: Vivek Singh, M.D.

16. **Who Receives Guideline-Based Pharmacotherapy for Bipolar Depression?**
Megan Ehret, Pharm.D.
17. **Psychiatric Admissions and Hospitalization Costs in Bipolar Disorder in Sweden**
Anne Tiainen, M.P.H.
18. **Symptoms and Treatment of Bipolar Disorder in Sweden**
Mats Adler, M.D.

SCR 7 11:00 A.M. - 12:30 P.M.

Room 122, Exhibit Level, Moscone Center

THE BROAD REACH OF PSYCHIATRY: STUDYING HISTORY, PEACEKEEPING & THE ROLE OF SPIRITUALITY IN SCHIZOPHRENIA

Chp.: Derya Akibiyik, M.D.

19. **The Modern History of American Psychiatry: Unintended Consequences**
Milton Kramer, M.D.
20. **Is Peacekeeping Peaceful? A Systematic Review**
Jitender Sareen, M.D.
21. **Spiritual and Religious Coping in Schizophrenia: Clinical Implications**
Philippe Huguelet, M.D.

SCR 08 11:00 A.M. - 12:30 P.M.

Rooms 272/274/276, Mezzanine Level West, Moscone Center

STUDIES IN PSYCHOTHERAPY

Chp: Waguih Ishak, M.D.

22. **Follow-Up Psychotherapy Outcome of Patients With Dependent, Avoidant and Obsessive-Compulsive Personality Disorders: A Meta-Analytic Review**
Witold Simon M.D.
23. **The Effectiveness of Evidence-Based Treatments for MDD in a Routine Clinical Setting; Results From an Observational Study**
Frenk Peeters M.D., Ph.D.
24. **The Effectiveness of a Group-Oriented Inpatient CBT Program**
Katherine Lynch, Ph.D.

SMALL INTERACTIVE SESSION

SI 02 11:00 A.M. - 12:30 P.M.

Room 216, Mezzanine Level East, Moscone Center

PSYCHIATRIC ISSUES RELATED TO RETURNING VETERANS FROM IRAQ

Chp.: Charles Hoge, M.D.

COMPONENT WORKSHOP SESSIONS 7-9

CW 7 11:00A.M.-12:30 P.M.

Room 220, Mezzanine Level, Moscone Center

REVITALIZING SERVICE: STRATEGIC PLANNING SUCCESS WITHIN DISTRICT BRANCHES AND STATE ASSOCIATIONS

APA Council on Member and District Branch Relations

Chp.: Nioaka N. Campbell, M.D.

Participants: Lasa Joiner, Laura Michaels, J.D., Warene Chase-Eldridge

CW 8 11:00 A.M.-12:30 P.M.

Room 222, Mezzanine Level, Moscone Center

COMBAT TO COMMUNITY: NEEDS AND RESOURCES FOR POST-SEPTEMBER 11TH VETERANS AND THEIR FAMILIES

APA Alliance

Chp.: Kay Brada

Participants: Mai-Ling Garcia, B.A., Amy Fairweather, J.D.

CW 9 11:00 A.M.-12:30 P.M.

Room 226, Mezzanine Level, Moscone Center

BECOMING A PUBLIC PSYCHIATRY LEADER: MENTORING MODELS FOR EVERYONE, FROM RESIDENTS TO MEDICAL DIRECTORS

APA Council on Social Issues and Public Psychiatry

Chp.: Peter L. Chien, M.D., M.A.

Participants: Susan Boust, M.D., David Pollack, M.D., Anita Everett, M.D., Annelle Primm, M.D., M.P.H.

ISSUE WORKSHOPS 14-20

IW 14 11:00 A.M.-12:30 P.M.

Room 125, Exhibit Level, Moscone Center

CHALLENGING STIGMAS & STEREOTYPES: INTEGRATED THERAPY FOR PATIENTS WITH MULTIDIAGNOSED ADDICTION COMBINING INNOVATIVE WITH TRADITIONAL APPROACHES

Chp.: Michael M. Scimeca, M.D.

Participants: Felicity L. LaBoy, Ph.D., Brian D. Higgins, Ph.D., Beryl D. Sinclair, NP

IW 15 11:00 A.M.-12:30 P.M.

Room 224, Mezzanine Level, Moscone Center

MAN AND NON-MAN MADE DISASTERS IN ASIA: THE ROLE OF RESILIENCE

Chp.: Pedro Ruiz, M.D.

Participants: Tsuyoshi Akiyama, M.D., Haroon Chaudhry, M.B.B.S., Chiao-Chicy Chen, M.D., Russell D'Souza, M.D.

IW 16 WITHDRAWN

IW 17 11:00 A.M.-12:30 P.M.

Room 304, Esplanade Level, Moscone Center

CAN DISCLOSURE OF A DIAGNOSIS OF BPD HELP GUIDE TREATMENT FOR CLINICIANS, PATIENTS AND FAMILIES?

Chp.: Richard G. Hersh, M.D.

Participants: Perry Hoffman, Ph.D., Dale Terilli, B.A.

IW 18 11:00 A.M.-12:30 P.M.

Room 308, Esplanade Level, Moscone Center

APPLICATION OF CULTURAL VARIABLES FOR THE PRACTICE OF EFFECTIVE PSYCHOTHERAPY OF INDIANS SETTLED IN USA

Co-Chps.: Nitin Gupta, M.D., Vijoy Varma, M.D.

IW 19 11:00 A.M.-12:30 P.M.

Room 309, Esplanade Level, Moscone Center

COGNITIVE THERAPY FOR PSYCHOSIS IN PRACTICE BY PSYCHIATRISTS: BASIC TECHNIQUES

Co-Chps.: Shanaya Rathod, M.D.,

Douglas Turkington, M.D.

Participant: David Kingdon, M.D.

IW 20 11:00 A.M.-12:30 P.M.

Room 310, Esplanade Level, Moscone Center

RESIDENT WELLNESS SURVEY RESULTS AND DISCUSSION

Co-Chps.: Paul J. O'Leary, M.D., Hind Benjelloun, M.D.

Participant: Leah Dickstein, M.D.

12:00 NOON SESSION

FORUM 01 12:00 NOON -1:30 P.M.

Gateway Ballroom 102, Exhibit Level, Moscone Center

DSM-V: PROGRESS IN RESEARCH AND DEVELOPMENT (DSM Track 01)

12:30 P.M. SESSION

NEW RESEARCH POSTER SESSION 2: YOUNG INVESTIGATORS

See *New Research Program* section in back of this book.

1:00 P.M. SESSIONS

COURSES 50-54

COURSE 50 1:00 P.M.- 5:00 P.M.

*Continental Ballroom 9, Ballroom Level, Tower 3,
Hilton San Francisco*

DEVELOPMENT OF INTEGRATED CARE MODELS FOR PATIENTS WITH HEPATITIS C AND COMORBID PSYCHIATRIC AND SUBSTANCE USE DISORDERS

Director: Muhamad Aly Rifai, M.D., Peter Hauser, M.D.

Faculty: Ondria Gleason, M.D., David Indest, Psy.D.,
Eric Dieperink, M.D.

COURSE 51 1:00 P.M.- 5:00 P.M.

*Imperial Ballroom A, Ballroom Level, Tower 2,
Hilton San Francisco*

MULTIDISCIPLINARY TREATMENT OF CHRONIC PAIN

Directors: Vladimir Bokarius, M.D., Ph.D.,
Steven Richeimer, M.D.

Faculty: Tina Young, O.T., OTR/L, Lisa Victor, Ph.D.,
Yogi Matharu, D.P.M., Ali Nemat, M.D.

COURSE 52 1:00 P.M.- 5:00 P.M.

*Franciscan Room A, Ballroom Level, Tower 1,
Hilton San Francisco*

CURRENT PROCEDURAL TERMINOLOGY CODING AND DOCUMENTATION

Directors: Chester W. Schmidt, M.D., Tracy R. Gordy, M.D.

Faculty: Ronald Burd, M.D., David Nace, M.D.,
Jeremy Musher, M.D., Allan Anderson, M.D.

COURSE 53 1:00 P.M.- 5:00 P.M.

*Yosemite Room B, Ballroom Level, Tower 2,
Hilton San Francisco*

THE PSYCHIATRIST AS EXPERT WITNESS

Director: Phillip J. Resnick, M.D.

COURSE 54 1:00 P.M.- 5:00 P.M.

*Union Square Rooms 3/4, Fourth Floor, Tower 3,
Hilton San Francisco*

REEL PSYCHIATRY

Directors: Luis F. Ramirez, M.D., David Robinson, M.D.

2:00 P.M. SESSIONS

FOCUS LIVE!

FOCUS LIVE 3

2:00 P.M. - 3:30 P.M.

PANIC AND SOCIAL ANXIETY DISORDER

Moderators: Deborah Hales, M.D.,

Presenter: Mark Rapaport, M.D.

Anxiety disorders are among the most common mental health problems in the United States, affecting 18% of adults in a given year and almost 30% at some point during their lifetime. They are associated with a wide range of distressing psychological and somatic symptomatology, as well as disability across broad domains of work, social and family function. There are a number of effective pharmacological and psychosocial interventions with which to treat individuals affected by social anxiety disorder and panic disorder, although there remains a significant unmet need for more effective, well-tolerated, and readily administered interventions that can move more patients from symptomatic to remitted status. This multiple-choice question based presentation will provide participants with an opportunity to test their knowledge about diagnosis and treatment of these disorders. In FOCUS Live! sessions, expert clinicians lead lively multiple choice question-based discussions. Participants test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Questions cover existing knowledge on a clinical topic important to practicing general psychiatrists, including diagnosis, treatment, and new developments.

LECTURE 10

LECTURE 10

2:00 P.M. - 3:30 P.M.

Room 130/131, Exhibit Level, Moscone Center

SUCCESSFUL AGING AND WISDOM: ARE THESE FOR REAL?

Dilip Jeste, M.D.

Distinguished Psychiatrist Lecture

Chp.: Iqbal Ahmed, M.D.

Vice-Chp.: Josepha Cheong, M.D.

Dilip Jeste, M.D., is Estelle and Edgar Levi Chair in Aging, Director of the Stein Institute for Research on Aging, and Distinguished Professor of Psychiatry and Neurosciences, University of California, San Diego and VA San Diego. He is Director of the NIMH-funded Advanced Center for Innovation in Services and Intervention Research, and of the John A. Hartford Center of Excellence in Geriatric Psychiatry. He has received APA's Award for Research in Psychiatry, Jack Weinberg Memorial Award, and George Tarjan Award, and has been listed in "The Best Doctors in America." He has published nine books and over 500 articles, and received a number of federal grants. He is a member of the Institute of Medicine of the National Academy of Sciences, and Editor of the American Journal of Geriatric Psychiatry. He is in the ISI list of "world's most cited authors" comprising less than 0.5% of all publishing researchers of last two decades.

ADVANCES IN SERIES 1-3

ADVANCES IN 01 2:00 P.M.-5:00 P.M.

Gateway Ballroom 102, Exhibit Level, Moscone Center

ADVANCES IN NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES

Chp.: Stuart Yudofsky, M.D.

Co-Chp.: Robert E. Hales, M.D., M.B.A.

- 1. Windows to the Brain: Clinical and Functional Imaging in Psychiatry**
Robin A. Hurley, M.D.
- 2. Current Controversies and Research Opportunities in the Neuropsychiatric Aspects of Delirium**
Paula Trzepacz, M.D.
- 3. Neuropsychiatry of Traumatic Brain Injury**
Jonathan Silver, M.D.
- 4. Advances in Neuropsychiatric Disorders Associated With Cerebrovascular Disease**
Robert G. Robinson, M.D.

ADVANCES IN 02 2:00 P.M.-5:00 P.M.

Gateway Ballroom 103, Exhibit Level, Moscone Center

ADVANCES IN PSYCHOPHARMACOLOGY

Chp.: Alan Schatzberg, M.D., Charles Nemeroff, M.D.

- 1. Personalized, Quantitative, Evidence-Based Treatment for Bipolar Disorders**
Terence Ketter, M.D.
- 2. ECT and Other Non-Pharmacological Treatments**
William M. McDonald, M.D.
- 3. Pharmacotherapy Options for TRD**
Linda Carpenter, M.D.
- 4. An Update on Pharmacological Treatment of Schizophrenia**
Alan I. Green, M.D.
- 5. Perinatal Mood Disorders: Risk Appraisal & Risk Management**
D. Jeffrey Newport, M.D., M.S., M.Div.

ADVANCES IN 03 2:00 P.M.-5:00 P.M.

Room 303/305, Esplanade Level, Moscone Center

ADVANCES IN SUBSTANCE ABUSE

Chp.: Mark Galanter, M.D., Herbert Kleber, M.D.

- 1. Treating Opioid and Marijuana Addiction**
Mark Kleber, M.D.
- 2. Pharmacologic Treatment of Alcoholism**
Hugh Myrick, M.D.
- 3. Treating Prescription Drug Abuse**

Laura F. McNicholas, M.D., Ph.D.

- 4. Treatment of Tobacco Addiction: Integration with Psychiatric Care for People with Mental Health and Addictive Disorders**

Tony P. George, M.D.

- 5. Treating Addiction with Alcoholics Anonymous**
Marc Galanter, M.D.

DSM TRACK

DSM SYMPOSIUM 2:00 P.M. -5:00 P.M.

Room 132/133, Exhibit Level, Moscone Center

EVOLUTION OF THE DSM-V CONCEPTUAL FRAMEWORK: DEVELOPMENT, DIMENSIONS, DISABILITY, SPECTRA AND GENDER/CULTURE

Chair: Darrel Regier, M.D.

- 1. Incorporating Developmental Variations of Disorder Expression Across the Lifespan: The Significance of Later Life**
Warachal Faison, M.D.
- 2. Diagnostic Parity: Incorporating Gender Issues Parity in the DSM-V Text and Categories**
Kimberly Yonkers, M.D.
- 3. One Way Forward for Psychiatric Nomenclature: The Example of the Spectrum Project**
Ellen Frank, Ph.D.
- 4. Clinical Significance and Disorder Thresholds in DSM-V: The Role of Disability and Distress**
William E. Narrow, M.D.
- 5. Enhancing Research and Treatment of Mental Disorders with Dimensional Concepts: A DSM-V Agenda**
Robert Krueger, Ph.D.

PRESIDENTIAL SYMPOSIA 1-2

PS 1 2:00 P.M. - 5:00 P.M.

Room 300, Esplanade Level, Moscone Center

IS PSYCHIATRY BETTER FOR PATIENTS AND PHYSICIANS IN A REAL HEALTH CARE SYSTEM?

Chair: Gisele Apter, M.D., Ph.D.

- 1. The U.S. Non-System**
Steven Shafestein, M.D.
- 2. National Health Service in the United Kingdom**
Dinesh Bhugra, M.B.B.S
- 3. The Australian Mental Health System: A Complex Mix Moving Forward.**
Beverly Raphael, M.D.
- 4. The Fench National Health System: How Much Care for All and For How Long?**
Gisele Apter, M.D.

PS2 2:00 P.M. - 5:00 P.M.
Room 301, Esplanade Level, Moscone Center

THE PSYCHIATRIST RELATIONSHIP WITH INDUSTRY

Chair: Paul Appelbaum, M.D.

Co-Chair: Laura Roberts, M.D.

- 1. Relationships with Industry: What the Data Say**
Paul S. Appelbaum, M.D.
- 2. Ethics and Overlapping Roles: Safeguarding Conflicts of Interest**
Laura W. Roberts, M.D.
- 3. Industry and the Individual Physician**
Jonathan L. Weker, M.D.
- 4. Medical Education Meets Industry: Moving Ahead**
Joel Yager, M.D.
- 5. Relationships With Industry: Academic Departments of Psychiatry**
David A. Baron, D.O.

Discussant: Nada L. Stotland, M.D., M. P. H.

SYMPOSIA 1-18

SYMPOSIUM 01 2:00 P.M.- 5:00 P.M.
Room 111, Exhibit Level, Moscone Center

SPOTTING THE WOLF IN SHEEP'S CLOTHING: CLINICAL CHALLENGES IDENTIFYING AND TREATING UNPRESENTED CO-MORBIDITY

National Institute on Drug Abuse

Co-Chp.: Wilson M. Compton, M.D., Meyer D. Glantz, Ph.D.

- 1. The Prevalence of Substance Use Disorders Among Populations With Psychiatric Disorders**
Carlos Blanco-Jerez, M.D.
- 2. Screening for Substance Use Disorder Among Individuals With Severe Mental Illness**
Stanley D. Rosenberg, Ph.D.
- 3. Motivational Interviewing for Substance Abuse Among Adolescents With Psychiatric Comorbidity**
Richard A Brown, Ph.D.
- 4. Diagnosis Challenges for Co-Occurring ADHD and Substance Use Disorders**
Frances Levin, M.D.
- 5. The Treatment of Co-Occurring Mood and Anxiety Disorders in Addictions**
Kathleen Brady, M.D.

Discussant: Charles O'Brien, M.D., Ph.D.

SYMPOSIUM 02 2:00 P.M.- 5:00 P.M.
Room 112, Exhibit Level, Moscone Center

ADJUSTMENT DISORDERS: PROBLEMS IN CONCEPTUALIZATION, CONUNDRUMS IN CLASSIFICATION

Co-Chp.: Patricia P Casey, M.D., M.Psy.,
Andreas Maercker, M.D., Ph.D.

- 1. Adjustment Disorders and the DSM-V: Considerations for Dimensional (Spectrum Diagnoses) Versus Categorical**
James J. Strain, M.D.
- 2. Recent Advances in the Study of Adjustment Disorders**
Andreas Maercker, M.D.
- 3. Can Adjustment Disorder and Depressive Episode Be Distinguished? Results From the ODIN Study**
Patricia P. Casey, M.D.
- 4. Post-Traumatic Embitterment Disorder**
Michael Linden, M.D.

Discussant: Katherine Shear, M.D.

SYMPOSIUM 03 2:00 P.M.- 5:00 P.M.
Room 113, Exhibit Level, Moscone Center

DELIVERING PSYCHIATRY IN RURAL PERU: THE AYACUCHO MENTAL HEALTH PROJECT

Chp.: James Phillips, M.D.

- 1. The Ayacucho Mental Health Project**
James Phillips, M.D.
- 2. Constructing a Formulary for a Psychiatric Clinic in the Developing World**
Mark D. Rego, M.D.
- 3. Psychiatric Treatment in a Trilingual Setting**
Stephen J. Bittner, M.D.
- 4. The Use of Skype by the Ayacucho Team in Follow-up, Supervision and Other Contacts with Patients and Staff**
Galen W. Stahle, M.D.
- 5. Evaluation of Change in Indicators of Mental Health in an Andean Region of Peru**
Luis E. Bedregal, Ph.D.

SYMPOSIUM 04 2:00 P.M.- 5:00 P.M.
Room 114, Exhibit Level, Moscone Center

STALKING: RISK MANAGEMENT AND TREATMENT OF OFFENDERS AND VICTIMS

Chp.: Gail E. Robinson, M.D.

1. A Comprehensive Approach to the Treatment of Stalking Victims

Gail E. Robinson, M.D.

2. Stalking of Healthcare Professionals

Karen M. Abrams, M.D.

3. Treatment of Stalking-Offenders

Werner Tschan, M.D.

4. Workplace Assessment of Violence Risk

Stephen G. White, Ph.D.

5. Stalking Threat Management

Jeffrey Dunn, M.D.

SYMPOSIUM 05 2:00 P.M.- 5:00 P.M.

Room 120, Exhibit Level, Moscone Center

UNDERSTANDING AND ADDRESSING ADOLESCENT ALCOHOL CONSUMPTION AND ALCOHOL USE DISORDERS IN THE CONTEXT OF OVERALL DEVELOPMENT

National Institute on Alcohol Abuse and Alcoholism

Chp.: Vivian B Faden, Ph.D.

1. Early Development and Continuity of Risk for Early Drinking, Problem Drinking, and Alcoholism from Early Childhood to Adulthood

Robert A. Zucker, Ph.D.

2. Applying a Developmental Framework to Alcohol-Related Behaviors: Ages 10 – 15

Michael Windle, Ph.D.

3. Applying a Developmental Framework to Alcohol-Related Behaviors from Middle to Late Adolescence

Sandra A. Brown, Ph.D.

4. Developmentally Informed Research on the Effectiveness of Clinical Trials (DIRECT) in Adolescents With Alcohol Addiction Problems

Eric F. Wagner, Ph.D.

5. Evidenced-Based Treatments for Adolescents With Alcohol Use Disorders

Deborah Deas, M.D., M.P.H.

SYMPOSIUM 06 2:00 P.M.- 5:00 P.M.

Room 121, Exhibit Level, Moscone Center

“IN OR OUT?”: A DISCUSSION ABOUT GENDER IDENTITY DIAGNOSES AND THE DSM

Co-Chp.: Jack Drescher, M.D., William E. Narrow, M.D., M.P.H.

1. The DSM-V Revision Process: Principles and Progress

William E. Narrow, M.D.

2. Beyond Conundrum: Strategies for Diagnostic Harm Reduction

Kelley Winters, Ph.D.

3. Aligning Bodies With Minds: The Case For Medical and Surgical Treatment of Gender Dysphoria

Rebecca Allison, M.D.

4. The Role of Medical and Psychological Discourse in Legal and Policy Advocacy for Transgender Persons in the U.S.

Shannon P. Minter, J.D.

SYMPOSIUM 07 2:00 P.M.- 5:00 P.M.

Room 122, Exhibit Level, Moscone Center

RELATIONSHIP OF SUBTHRESHOLD PSYCHIATRY TO AXIS II PERSONALITY DISORDERS

Chp.: Ahmed Okasha, M.D., Ph.D.

1. Relationship of Subthreshold Psychiatry To Personality Disorders

Ahmed Okasha, M.D.

2. Personality Disorders, Their Thresholds and Public Health

Norman Sartorius, M.D.

3. Schizophrenia /Schizotaxia: A Genetic Predisposition of Schizophrenia

Ming T. Tsuang, M.D.

4. On the Shared Diathesis of Borderline Personality Disorder And Bipolar Disorder

Hagop S. Akiskal, M.D.

5. Generalized Anxiety Disorder and Avoidant Personality Disorder

Juan J. Lopez-Ibor, M.D.

Discussant: Mario Maj, M.D., Ph.D.

SYMPOSIUM 08 2:00 P.M.- 5:00 P.M.

Room 123, Exhibit Level, Moscone Center

EDUCATING A NEW GENERATION OF PHYSICIANS IN PSYCHIATRY: REPORTS FROM WINNERS OF APA INNOVATIVE TEACHING GRANTS
APA Corresponding Committee on Medical Student Education

Co-Chp.: Linda F. Pessar, M.D., Amy C. Brodkey, M.D.

1. Changing Perspectives: Reducing the Stigma of Mental Illness in Medical Students Through the Living Museum Project

Janis Cutler, M.D.

2. A School-Based Medical Student Curriculum for Education in Child and Adolescent Psychiatry

Justine Larson, M.D.

3. Teaching Third Year Medical Students Brief

Motivational Interviewing Skills to Use in Counseling

Patients With Mental Illness on Smoking Cessation
Brenda J.B. Roman, M.D.

- 4. Preventing and Managing Metabolic Syndrome Among the Seriously Mentally Ill: Teaching Behavioral Medicine to Medical Students**
Jason B. Rosenstock, M.D.

SYMPOSIUM 09 **2:00 P.M.- 5:00 P.M.**
Room 124, Exhibit Level, Moscone Center

EFFECTIVE ASSESSMENT AND TREATMENT OF SEXUAL DYSFUNCTION IN ADULTS AND THE ELDERLY

Co-Chp.: Travis O. Bruce, M.D., Meera Narasimhan, M.D.

- 1. Clinical Presentation and Assessment of Sexual Dysfunction in Patients with Psychiatric Illness**
Jeffrey D. Raynor, M.D.
- 2. Treatment of Psychotropic-Induced Sexual Dysfunction**
Travis O. Bruce, M.D.
- 3. Sexual Dysfunction in Late-Life: Beyond “Vitamin V”**
Shilpa Srinivasan, M.D.

SYMPOSIUM 10 **2:00 P.M.- 5:00 P.M.**
Room 125, Exhibit Level, Moscone Center

THE NEUROBIOLOGICAL EVIDENCE FOR TRANSGENDERISM

Chp.: Sidney W. Ecker, M.D.

- 1. Brain Gender Identity**
Sidney W. Ecker, M.D.
- 2. Transsexuality as an Intersex Condition**
Milton Diamond, Ph.D.
- 3. Novel Approaches to Endocrine Treatment of Transgender Adolescents and Adults**
Norman Spack, M.D.

SYMPOSIUM 11 **2:00 P.M.- 5:00 P.M.**
Rooms 272/274/276, Mezzanine Level West, Moscone Center

COMPREHENSIVE HIV PSYCHIATRY UPDATE

Chp.: Marshall Forstein, M.D.

- 1. HIV/AIDS Medical Update**
Paul Volberding, M.D.
- 2. Neuropsychiatric Overview of HIV/AIDS**
Robert Daroff, Jr., M.D.
- 3. Neurocognitive Decline**
Karl Goodkin, M.D.

- 4. Psychopharmacology**
Gabrielle Marzani-Nissen, M.D.

SYMPOSIUM 12 **2:00 P.M.- 5:00 P.M.**
Room 302, Esplanade Level, Moscone Center

THE OBSESSIVE COMPULSIVE SPECTRUM IN THE ATHLETE: PSYCHOPATHOLOGY OR COMPETITIVE EDGE?

International Society for Sport Psychiatry

Chp.: Antonia L. Baum, M.D., M.D.

- 1. An International Level Athlete’s Struggle With Obsessive Compulsive Disorder**
David O. Conant-Norville, M.D.
- 2. Athletes and Superstition**
Thomas S. Newmark, M.D.
- 3. The Obsessive Compulsive Spectrum in the Athlete: Psychopathology or Competitive Edge**
Saul I. Marks, M.D.

SYMPOSIUM 13
WITHDRAWN

SYMPOSIUM 14 **2:00 P.M.- 5:00 P.M.**
Room 306, Esplanade Level, Moscone Center

INCREASING THE LIKELIHOOD OF ACHIEVING REMISSION IN DEPRESSION

Co-Chp.: Andrew F. Leuchter, M.D., Maurizio Fava, M.D.

- 1. Medication Algorithms for Antidepressant Treatment: Lessons Learned from STAR*D and Other Practical Clinical Trials**
Madhukar H. Trivedi, M.D.
- 2. Strategies for Medication Management of Treatment Resistance: Lessons from STAR*D**
Maurizio Fava, M.D.
- 3. Use of EEG Biomarkers to Direct Selection of Antidepressant Medication**
Andrew F. Leuchter, M.D.
- 4. Collaborative Care Approaches to Depression**
Jurgen Unutzer, M.D.
- 5. Can Genetic Biomarkers Help Direct Treatment for Depression?**
Gonzalo Laje, M.D.

SYMPOSIUM 15 **2:00 P.M. - 5:00 P.M.**
Room 307, Esplanade Level, Moscone Center

THE TRANSMISSION OF BORDERLINE PERSONALITY DISORDER

Chp.: John G. Gunderson, M.D.

- 1. The Aggregation of DIB-R and DSM-IV BPD**

Mary C. Zanarini, Ed.D.

- 2. Familial Coaggregation of BPD with Axis I Disorders**
James I. Hudson, M.D.
- 3. Familial Aggregation of Attachment in BPD**
Lois W. Choi-Kain, M.D.
- 4. Familiarity of BPD's Component Phenotypes**
John G. Gunderson, M.D.
- 5. An Endophenotypic Approach to BPD**
Larry J. Siever, M.D.

SYMPOSIUM 16 **2:00 P.M.- 5:00 P.M.**

Room 308, Esplanade Level, Moscone Center

CONTRIBUTIONS OF NEUROSCIENCE TO MEDICATION DEVELOPMENT FOR ALCOHOL USE DISORDER

National Institute on Alcohol Abuse and Alcoholism

Chp.: Vijay A. Ramchandani, Ph.D.

- 1. Novel Targets From The Dark Side of Dependence on Alcohol: Focus on CRF, Norepinephrine and Vasopressin**
George F. Koob, Ph.D.
- 2. Activation of the Nociceptin/Orphanin FQ System Reduces Alcohol Abuse Related Behaviors in Rats With Innate Predisposition to Excessive Alcohol Intake and Elevated Anxiety**
Roberto RC Ciccocioppo, Ph.D.
- 3. N-Type Calcium Channel Blockers for Alcohol Use Disorders: From Cells to People**
Robert O. Messing, M.D.
- 4. New Array of Potential Treatments for Alcohol Use Disorders: From Drosophila to Electrophysiology and More Predictive Animal Models**
Selena E. Bartlett, Pharm.D.
- 5. The Emerging Role of Pharmacogenetics in Medications Development for Alcoholism: The Case of the Mu-Opioid Receptor**
Vijay A. Ramchandani, Ph.D.

SYMPOSIUM 17 **2:00 P.M. - 5:00 P.M.**

Room 309, Esplanade Level, Moscone Center

MONITORING EQUITY IN MENTAL HEALTH FROM A CROSS-NATIONAL PERSPECTIVE

Chp.: Donna E. Stewart, M.D.

- 1. Equity in Determinants of Health and Health Policies Influencing Mental Health: A Cross-National Perspective**
Donna E. Stewart, M.D.
- 2. Monitoring Equity in Mental Health In Lower,**

Middle And High Income Countries

Natalia Diaz-Granados, M.S.C.

- 3. Socio-demographic Factors Affect Mental Illness Rates Differently Across Countries**
Marta B. Rondon, M.D.
- 4. Factors Associated With Inequities In Mental Health Care Use in a Developing Country**
Javier E. Saavedra, M.D.
- 5. Income-Related Inequity in Mental Health Service Utilization in Colombia and Canada**
Marie DesMeules, M.S.C.

SYMPOSIUM 18 **2:00 P.M.- 5:00 P.M.**

Room 310, Esplanade Level, Moscone Center

RECOVERY AND REHABILITATION FROM THE PROVIDER AND PATIENTS POINTS OF VIEW IN FRANCE AND THE US: VIVE LA DIFFERENCE!

Chp.: John A. Talbott, M.D.

- 1. Recovery From Disability of Serious Mental Disorders: A Phase-Linked Rehabilitation Process**
Robert P. Liberman, M.D.
- 2. Can We Implement "Recovery" and Rehabilitation?: What Do We Know and What Are the Implications for Services?**
Marianne D. Farkas, Sc.D.
- 3. An Individualized Cognitive Remediation Therapy for Patients With Schizophrenia : The RECOS Program**
Pascal Vianin, Ph.D.
- 4. Functional Remission in Schizophrenia: A Specific Tool for Evaluation**
Pierre Michel Llocra, M.D.

Discussant: Alexandra McLean, M.D.

SPECIAL EVENT **2:00 P.M. -5:00 P.M.**

Room 304, Esplanade Level, Moscone Center

NORTHERN CALIFORNIA PSYCHIATRIC SOCIETY PRESENTS: BREAKING THE BARRIERS

This session focuses on landmark cultural changes in society and the APA from 1970 to 1992

Panelists: Carol Nadelson, M.D.,
Lawrence Hartmann, M.D., Melvin Sabshin, M.D.,
Anne Kronenberg, Michael Blumfield, M.D.
Jeannine Yeoman, Alfred Freeman, M.D.

Closing Remarks: Nada Stotland, M.D., M.P.H.

3:00 P.M. SESSIONS

NEW RESEARCH/YOUNG INVESTIGATORS SESSION 3

For information on New Research sessions, please refer to the *New Research Program* section in the back of this publication.

5:30 P.M. SESSION

CONVOCATION OF DISTINGUISHED FELLOWS 5:30 P.M.-6:30 P.M.

Hall E, Exhibit Level, Moscone Convention Center

**ALL DISTINGUISHED LIFE FELLOWS,
DISTINGUISHED FELLOWS, LIFE FELLOWS,
INTERNATIONAL FELLOWS, MEMBERS, AND
REGISTERED GUESTS ARE INVITED.**

Presiding: Nada L. Stotland, M.D., M.P.H., President

Grand Marshals: Robert L. Okin, M.D.,
Lenore C. Terr, M.D.

Marshals: Helen Haller, M.D., Francis G. Lu, M.D.

INTRODUCTION OF DISTINGUISHED LIFE FELLOWS

Alan F. Schatzberg, M.D., *President-Elect*

INDUCTION OF DISTINGUISHED FELLOWS

Alan F. Schatzberg, M.D.

INTRODUCTION OF FIFTY-YEAR DISTINGUISHED LIFE FELLOWS, FIFTY-YEAR LIFE MEMBERS, AND INTERNATIONAL FELLOWS

Nada L. Stotland, M.D., M.P.H.

INTRODUCTION OF FELLOWS

Nada L. Stotland, M.D., M.P.H.

PRESENTATION OF THE HONORARY FELLOWSHIP MEDALLION

Nada L. Stotland, M.D., M.P.H.

PRESENTATION OF SPECIAL PRESIDENTIAL COMMENDATIONS

Nada L. Stotland, M.D., M.P.H.

PRESENTATION OF DISTINGUISHED SERVICE AWARDS

Nada L. Stotland, M.D., M.P.H.

INTRODUCTION OF THE MEMBERSHIP COMMITTEE CHAIRPERSON AND AWARD BOARD CHAIRPERSONS

Nada L. Stotland, M.D., M.P.H.

PRESENTATION OF AWARDS

Nada L. Stotland, M.D., M.P.H.

APA/Lilly Resident Research Awards

APIRE/Kempf Fund Awards for Research
Development in Psychobiological Psychiatry
Human Rights Awards
Blanche F. Ittleson Award for Research in Child Psychiatry
Agnes Purcell McGavin Awards
Isaac Ray Award
Jack Weinberg Memorial Award for Geriatric Psychiatry

WILLIAM C. MENNINGER MEMORIAL CONVOCATION LECTURE

Abraham Verghese, M.D.

Lecture 10

Abraham Verghese, M.D., attended the Iowa Writers Workshop in 1990 at the University of Iowa, where he obtained a Master of Fine Arts degree, taking a sabbatical from an active AIDS practice. His first book, *My Own Country*, about AIDS in rural Tennessee, was a finalist for the National Book Critics Circle Award for 1994 and was made into a movie. His second book, *The Tennis Partner*, was a New York Times Notable Book and a national bestseller. Dr. Verghese's first novel, *Cutting for Stone*, published by Knopf, appeared in bookstores last February – described as “intensely suspenseful, deeply moving, and unexpectedly funny – it is both an unforgettable journey into one man’s astonishing life, and a story about the power, intimacy, and curious beauty in the work of healing others.” He has published extensively in the medical literature, and his writing has appeared in *The New Yorker*, *Sports Illustrated*, *The Atlantic*, *Esquire*, *Granta*, *The New York Times Magazine*, *The Wall Street Journal*. Dr. Verghese is now Senior Associate Chair and Professor of the Theory and Practice of Medicine in the Department of Medicine at Stanford University. From 2002 to 2007, he was the Director of the Center for Medical Humanities & Ethics at the University of Texas Health Science Center San Antonio (UTHSCSA), where he held the Joaquin Cigarroa Jr. Chair in Medicine and was the Marvin Forland Distinguished Professor of Ethics. He maintains an appointment as an adjunct Professor at UTHSCSA. From 1991 to 2002, he was a professor of medicine at the Texas Tech University Health Sciences Center, El Paso where he held the Grover E. Murray Distinguished Professorship. Board certified in internal medicine, pulmonary diseases, and infectious diseases, he serves on the Board of Directors of the American Board of Internal Medicine. He is acclaimed as a dedicated and inspiring teacher of medicine at the bedside.

7:00 P.M. SESSIONS

INDUSTRY-SUPPORTED DINNER SYMPOSIA 9-10

ISS 09

7:00 P.M. -9:00 P.M.

*Continental Ballroom 4, Ballroom Level, Hilton
San Francisco*

ANXIOUS DEPRESSION: DIAGNOSTIC AND TREATMENT ISSUES

Supported by Takeda Pharmaceuticals

Chp.: Maurizio Fava, M.D.

1. How Do We Define Anxious Depression?

John Zajecka, M.D.

2. Neurobiology of Anxious Depression

Monday, May 18, 2009

Audrey Tyrka, M.D.

3. Pharmacotherapeutic Strategies in the Treatment of Anxious Depression

Maurizio Fava, M.D.

4. Psychotherapeutic Approaches to Anxious Depression

Amy Farabaugh, Ph.D.

**INDUSTRY-SUPPORTED
SYMPOSIUM 10**

**BIPOLAR DISORDER THROUGHOUT THE LIFE
CYCLE: TREATMENTS AND TREATMENT
EXPERIENCE**

Supported by Pfizer

Chp.: Joseph R. Calabrese, M.D.

**1. Understanding the Challenges of Reproductive
Mental Health: Pregnancy and Lactation**

Adele Vignera, M.D., MPH

**2. Treatments and Treatment Experience: From Adult to
Late Life**

Martha Sajatovic, M.D.

**3. Management of Metabolic Syndrome Across the Life
Cycle in Bipolar Disorder**

David Kemp

MOVED TO TUESDAY, MAY 19, 2009

7:00 - 9:00 A.M.

**YERBA BUENA BALLROOM, SALON 7/8
MARRIOTT**

8:00 A.M. SESSIONS

COURSES 55-61

COURSE 55 8:00 A.M.-12 NOON

*Continental Ballroom 1, Ballroom Level, Tower 3,
Hilton San Francisco*

**SYSTEMIC THERAPIES FOR SUBSTANCE ABUSE
DISORDERS**

Directors: Peter Steinglass, M.D., Marc Galanter, M.D.

COURSE 56 8:00 A.M. - 12 NOON

*Yosemite Room B, Ballroom Level, Tower 2, Hilton
San Francisco*

RISK ASSESSMENT FOR VIOLENCE

Director: Phillip J. Resnick, M.D.

COURSE 57 8:00 A.M.-12 NOON

*Union Square Rooms 3/4, Fourth Floor, Tower 3,
Hilton San Francisco*

**TIME-LIMITED DYNAMIC PSYCHOTHERAPY:
A PSYCHODYNAMIC/RELATIONAL/
EXPERIENTIAL APPROACH**

Director: Hanna Levenson, Ph.D.

COURSE 58 8:00 A.M.-12 NOON

*Union Square Room 14, Fourth Floor, Tower 3,
Hilton San Francisco*

**MONEY MATTERS II: ADVANCED CLINICAL AD
HOC SEMINAR**

Director: Cecilia M. Mikalac, M.D.

COURSE 59 8:00 A.M.-12 NOON

*Union Square Rooms 15/16 Fourth Floor, Tower 3,
Hilton San Francisco*

**TREATING THE CHRONICALLY DEPRESSED
PATIENT USING CBASP**

Director: Eric Levander, M.D., M.P.H.

Faculty: Toshiaki A. Furukawa, M.D., Ph.D.,
Lynn McFarr, Ph.D.

COURSE 60 8:00 A.M.-12 NOON

*Union Square Rooms 19/20, Fourth Floor, Tower 3,
Hilton San Francisco*

**IT'S NOT JUST IN YOUR HEAD: MEDICAL
PROBLEMS IN PEOPLE WITH MENTAL HEALTH
CONDITIONS**

Directors: Monique Yohanan, M.D., Michele T. Pato, M.D.

Faculty: Hiruy Gessesse, M.D., Robert Cobb, M.D.,
Amy Christianson, M.D., M.B.A.

COURSE 61

8:00 A.M.-12 NOON

*Union Square Room 22, Fourth Floor, Tower 3,
Hilton San Francisco*

**DISASTER PSYCHIATRY: TERRORISM, TRAUMA
AND THINGS TO DO**

Director: Joseph C. Napoli, M.D.

Faculty: Michael Blumenfeld, M.D.

9:00 A.M. SESSIONS

ADVANCES IN SERIES 4-5

ADVANCES IN SERIES 4 9:00 A.M. -12 NOON

Gateway Ballroom 102, Exhibit Level, Moscone Center

PSYCHOSOMATIC MEDICINE

Chp.: James L. Levenson, M.D.

1. Update on Heart Disease and Psychiatry

Peter A. Shapiro, M.D.

2. Update on Psychopharmacology in GI Disease

Catherine Crone, M.D.

3. Legal Issue for Psychiatrists in Medical Settings

James L Levenson, M.D.

4. Psychopharmacology in the Medically Ill

Stephen J. Ferrando, M.D.

5. Severe Drug Reactions

Stanley N. Caroff, M.D.

ADVANCES IN SERIES 5 9:00 A.M. -12 NOON

Gateway Ballroom 103, Exhibit Level, Moscone Center

PSYCHOTHERAPEUTIC PSYCHIATRY

Chp.: Glen O. Gabbard, M.D.

1. How Does Psychodynamic Psychotherapy Work?

Glen Gabbard, M.D.

2. Neural Circuits of Psychotherapy

Bernard D. Beitman, M.D.

3. Mentalizing: Some Theory and Some Practice

Anthony Bateman, M.D.

4. Cognitive-Behavior Therapy Methods

Jesse Wright, M.D.

5. Interpersonal Psychotherapy

John Markowitz, M.D.

CASE CONFERENCE 3

THIS SESSION IS OPEN TO APA MEMBERS ONLY. A MEMBER REGISTRATION BADGE OR APA MEMBERSHIP CARD IS REQUIRED FOR ADMITTANCE.

CASE CONFERENCE 3 9:00 A.M. - 10:30 A.M.

Room 120, Exhibit Level, Moscone Center

ISSUES IN THE DIFFERENTIAL DIAGNOSIS OF MILD TBI, PCS, AND PTSD IN SERVICE MEMBERS AFTER BLAST EXPOSURE IN COMBAT

Chp.: Marvin Oleshansky, M.D.

CASE CONFERENCE 4 WITHDRAWN

DEBATE/ROUNDTABLE 1-2

DR 01 9:00 A.M. - 10:30 A.M.

Room 303/305 Esplanade Level, Moscone Center

APA-OUR RELATIONSHIPS TO PHARMACEUTICAL COMPANIES: THE PROS AND CONS OF REFORM

Moderator: Paul McHugh, M.D.

Pro-side: Glenn Triesman, M.D. Ph.D.

Con-side: Thomas Finucane, M.D.

DR 02 9:00 A.M. - 10:30 A.M.

Room 307, Esplanade Level, Moscone Center

PSYCHIATRY SHOULD EMBRACE MEASUREMENT BASED CARE

Moderator: John McIntrye, M.D.

Pro-side: Madhukar Trivedi, M.D., David Katzelnick, M.D.

Con-side: Robert Michaels, M.D., Harold Eist, M.D.

LECTURES 12-14

LECTURE 12 WITHDRAWN

LECTURE 13 9:00 A.M. - 10:30 A.M.

Room 130/131, Exhibit Level, Moscone Center

MODULES OF THE MIND: DEVELOPING A POSITIVE PSYCHIATRY OF THE PERSON

C. Robert Cloninger, M.D.

Judd Marmor Award Lecture

Chp.: Stuart Yudofsky, M.D.

C. Robert Cloninger, M.D., is Wallace Renard Professor of Psychiatry, Professor of Psychology and Genetics, and Director of the Sansone Family Center for Well-Being at Washington University School of Medicine in St. Louis. He is also Scientific Director of the Anthropedia Institute, a non-profit organization dedicated

to development of human well-being through initiatives in health care and education. He is widely cited and honored for his innovative biopsychosocial research that spans the genetics, neurobiology, development, psychology, brain imaging, and assessment of personality and psychopathology. His personality inventories have been used in more than 4000 peer-reviewed publications around the world. He received his B.A. with High Honors and Special Honors in Philosophy, Psychology, and Anthropology from the University of Texas at Austin, 1966. He received his M.D. from Washington University in 1970 and an Honorary Doctorate from the University of Umea, Sweden in 1983. Dr. Cloninger has published nine books and 400 articles in psychiatry, psychology, and genetics. His recent books include *Feeling Good: The Science of Well-Being* by Oxford University Press and *Personality and Psychopathology* by American Psychiatric Press. Among his many awards, Dr. Cloninger has received the American Psychiatric Association's Adolf Meyer Award in psychobiology (1993) and lifetime achievement awards from the American Society of Addiction Medicine (2000) and the International Society of Psychiatric Genetics (2003). He is a Distinguished Life Fellow of the APA, a fellow of the American Academy for the Advancement of Science, and a member of the Institute of Medicine of the National Academy of Sciences. The Institute of Scientific Information ranks him among the most highly cited psychiatrists and psychologists in the world. *This award is endowed by the estate of Judd Marmor, M.D.

LECTURE 14 9:00 A.M. - 10:30 A.M.

Room 132/133, Exhibit Level, Moscone Center

BORDERLINE PERSONALITY DISORDER: THE BIRTH PAINS OF THE STILL NEW DIAGNOSIS

John G. Gunderson, M.D.

Distinguished Psychiatrist Lecture

Chp.: Kenneth Silk, M.D.

John G. Gunderson, M.D., is Professor of Psychiatry at Harvard Medical School, Boston, Massachusetts. At McLean Hospital in Belmont, Massachusetts, he serves as Director of Psychosocial and Personality Research and of the Borderline Personality Disorder Center. Dr. Gunderson has been integrally involved in the diagnosis and treatment of borderline personality disorder since 1969. His studies helped to define the diagnosis of borderline personality disorder and established an empirical standard for evaluating treatment of this disorder.

MEDICAL UPDATE 1

MEDICAL UPDATE 1 9:00 A.M. - 10:30 A.M.

Room 300, Esplanade Level, Moscone Center

21ST CENTURY ECT – UPDATING THE APA RECOMMENDATIONS ON ECT

Task Force to Revise the Practice of ECT Therapy

Co-Chps.: Sarah H. Lisanby, M.D., Richard Weiner, M.D., Ph.D.

Participants: William M. McDonald, M.D., Pamela Sullivan, M.D., Andrew Krystal, M.D., Husain Mustafa, M.D., Charles Kellner, M.D.

SMALL INTERACTIVE SESSIONS 3-5

SI 03 9:00 A.M. -10:30 A.M.

Room 216, Mezzanine Level East, Moscone Center

A DISCUSSION ABOUT DRUG INTERACTIONS

Chp.: Gary H. Wynn, M.D.

SI 04 9:00 A.M. -10:30 A.M.

Room 218, Mezzanine Level East, Moscone Center

NEUROPSYCHIATRIC ASSESSMENT FOR GENERAL PSYCHIATRISTS

Chp.: Sheldon Benjamin, M.D.

SI 05 9:00 A.M. -10:30 A.M.

Room 266, Mezzanine Level West, Moscone Center

PALLIATIVE CARE AND PSYCHIATRIC ISSUES AT THE END OF LIFE

Chp.: William Breitbart, M.D.

COMPONENT WORKSHOPS 10-14

CW 10 9:00 A.M.-10:30 A.M.

Room 111, Exhibit Level, Moscone Center

BIRACIAL AMERICANS: "CHECK ONE BOX ONLY" AND THE DEVELOPMENT OF MULTIRACIAL IDENTITY

APA Council on Minority Mental Health and Health Disparities

Co-Chps.: Jacquelyn Chang, M.D., Kehinde A. Ogundipe, M.D.

Participants: Brett Sevilla, M.D., Sandra Walker, M.D., U. Diane Buckingham, M.D., B.S.N.

CW 11 9:00 A.M.-10:30 A.M.

Room 113, Exhibit Level, Moscone Center

RECOGNITION AND TREATMENT OF DEMENTIA IN A CHANGING AMERICA

APA Committee on Ethnic Minority Elderly

Co-Chps.: Maria Ilorente, M.D., Khushro Unwalla, M.D.

Participants: Khushro Unwalla, M.D., Irving Kuo, M.D., Deborah Dallam, M.D., Carl I. Cohen, M.D., Maria Ilorente, M.D.

CW 12 9:00 A.M.-10:30 A.M.

Room 224, Mezzanine Level, Moscone Center

HOW GENERAL PSYCHIATRISTS CAN EFFECTIVELY SCREEN & TREAT SUBSTANCE USE DISORDERS

APA Corresponding Committee on Treatment Services for Patients with Addictive Disorders

Co-Chps.: Varinder Rathore, M.D., Petros Levounis, M.D., M.A.

CW 13 9:00 A.M.-10:30 A.M.

Room 226, Mezzanine Level, Moscone Center

OUTPATIENT FORENSIC SERVICES AND INTERVENTIONS TO IMPROVE CLINICAL OUTCOMES AND REDUCE RECIDIVISM

APA Task Force on Forensic Outpatient Services

Co-Chps.: Steven K. Hoge, M.D., M.B.A., Alec W. Buchanan, Ph.D., M.D.

Participants: Erik Roskes, M.D.

CW 14 9:00 A.M.-10:30 A.M.

Room 306, Esplanade Level, Moscone Center

NATIONAL SECURITY, THE HIPPOCRATIC OATH, AND THE WAR ON TERROR

APA Council on Global Psychiatry

Co-Chps.: Shirin Ali, M.D., Karinn Glover, M.D., M.P.H.

Participants: Alan Cyr, M.D., Jeffrey Janofsky, M.D., Eliot Sorel, M.D., Elspeth Ritchie, M.D., M.P.H.

ISSUE WORKSHOPS 21-32

IW 21 9:00 A.M.-10:30 A.M.

Room 112, Exhibit Level, Moscone Center

TIPS FOR EFFECTIVE COMMUNICATION ABOUT GENETICS AND MENTAL ILLNESS WITH PATIENTS AND THEIR FAMILIES

Co-Chps.: Jehannine C. Austin, Ph.D., M.S.C., Holly L. Peay, M.S.

Participants: Christine Finn, M.D., Laura Hercher, M.S., Catriona Hippman, M.S.C., Christina Palmer, M.S.

IW 22 9:00 A.M.-10:30 A.M.

Room 114, Exhibit Level, Moscone Center

CLINICAL AND FORENSIC ISSUES CONCERNING INFANTICIDE, THE MURDER OF A CHILD IN THE FIRST YEAR OF LIFE BY ITS MOTHER

Co-Chps.: Malkah T. Notman, M.D., Carl P. Malmquist, M.D.

Participants: Elissa Benedek, M.D., George Parnham, J.D., Margaret Spinelli, M.D.

IW 23 9:00 A.M.-10:30 A.M.

Room 122, Exhibit Level, Moscone Center

EXTENDED TREATMENTS FOR ALCOHOL USE DISORDERS

National Institute on Alcohol Abuse and Alcoholism

Chp.: James R. McKay, Ph.D.

Participant: David Oslin, M.D.

IW 24 9:00 A.M.-10:30 A.M.

Room 125, Exhibit Level, Moscone Center

COGNITIVE THERAPY FOR PERSONALITY DISORDERS

Chp.: Judith S. Beck, Ph.D.

IW 25 **9:00 A.M.-10:30 A.M.**

Room 220, Mezzanine Level, Moscone Center

THE IMPACT OF MEDITATION AS A NON-PHARMACOLOGICAL INTERVENTION FOR VETERANS WITH MENTAL HEALTH DISORDERS

Co-Chps.: Julie E. Malphurs, Ph.D.,
Daniella David, M.D., M.S.C.

Participant: Molly Birkholm, M.D.

IW 26 **9:00 A.M.-10:30 A.M.**

Room 222, Mezzanine Level, Moscone Center

ASSESSMENT OF CAPACITY: DEVELOPMENTS, DOCUMENTATION & DEFENDABILITY

Co-Chps.: Michael Jan Wise, M.B.B.S, M.S.C., Julian Beezhold, M.D.

IW 27 **9:00 A.M.-10:30 A.M.**

Room 301, Esplanade Level, Moscone Center

LESSONS LEARNED ABOUT RESILIENCE AND RECOVERY FOLLOWING DISASTERS

Chp.: Howard J. Osofsky, M.D., Ph.D.

Participants: Melissa Brymer, Ph.D.,
Jose Calderon-Abbo, M.D., Alicia Lieberman, Ph.D.,
Joy Osofsky, Ph.D., Zack Rosenburg

IW 28 **9:00 A.M.-10:30 A.M.**

Room 302, Esplanade Level, Moscone Center

WHEN PSYCHIATRY RESIDENTS TREAT MEDICAL STUDENTS: SOME CHALLENGES

Chp.: Michael F. Myers, M.D.

Participants: Michael Garrett, M.D., Carolina Klein, M.D.,
Anand Sukumaran

IW 29 **9:00 A.M.-10:30 A.M.**

Room 304, Esplanade Level, Moscone Center

BOOTCAMP FOR BURNOUT

Association of Women Psychiatrists

Chp.: Tana A. Grady-Weliky, M.D.

Participant: Eva Szigethy, M.D.

IW 30 **9:00 A.M.-10:30 A.M.**

Room 308, Esplanade Level, Moscone Center

LESSONS FROM THE POST-RESIDENCY ROAD: FOUR CAREER JOURNEYS SINCE RESIDENCY GRADUATION IN 2004 WITH INSIGHTS FROM OUR TRAINING DIRECTOR

Co-Chps.: William C. Wood, M.D., Kathy M. Sanders, M.D.

Participants: Richard Falzone, M.D., Dost Ongur, M.D.,
Marketa Wills, M.D.

IW 31 **9:00 A.M.-10:30 A.M.**

Room 309, Esplanade Level, Moscone Center

ASSESSMENT AND TREATMENT OF SLEEP DISORDERS IN ALCOHOL-DEPENDENT PATIENTS WITH ADHD AND OTHER CO-OCCURRING DISORDERS

National Institute on Alcohol Abuse and Alcoholism

Co-Chps.: Kirk J. Brower, M.D., Iyad Alkhouri, M.D.

IW 32 **9:00 A.M.-10:30 A.M.**

Room 310, Esplanade Level, Moscone Center

DOING IT RIGHT THE FIRST TIME: RECOGNIZING, MAINTAINING, AND SUPPORTING WORKPLACE FUNCTION

APA Corresponding Committee on Psychiatry in the Workplace

Chp.: Andrea Stolar, M.D.

Participants: Marilyn Price, M.D.,

Marie-Claude Rigaud, M.D., Marcia Scott, M.D.

MEDIA WORKSHOPS 3-4

MEDIA WORKSHOP 3 **9:00 A.M.-12:30 P.M.**

Room 123, Exhibit Level, Moscone Center

THE JOY LUCK CLUB: UNIVERSAL STORIES ABOUT MOTHERS AND DAUGHTERS FROM CHINA

Chp.: Francis G. Lu, M.D.

MEDIA WORKSHOP 4 **9:00 A.M.-12:30 P.M.**

Room 124, Exhibit Level, Moscone Center

PROVOKED: COMBATING DOMESTIC VIOLENCE

Indo-American Psychiatric Association

Co-Chps.: Vishal Madaan, M.D., M.B.B.S.,

Surinder S. Nand, M.D.

Participants: Sarah Khan

COURSES 62-66

COURSE 62 **9:00 A.M.- 4:00 P.M.**

Continental Ballroom 9, Ballroom Level, Tower 3,

Hilton San Francisco

A PSYCHODYNAMIC APPROACH TO TREATMENT RESISTANT MOOD DISORDERS: BREAKING THROUGH COMPLEX COMORBID TREATMENT RESISTANCE BY FOCUSING ON AXIS II

Director: Eric M. Plakun, M.D.

Faculty: Edward Shapiro, M.A., M.D., David Mintz, M.D.

COURSE 63 9:00 A.M.- 4:00 P.M.

*Imperial Ballroom A, Ballroom Level, Tower 2,
Hilton San Francisco*

**HERBS, NUTRIENTS, AND YOGA FOR ANXIETY,
PTSD, DEPRESSION, BIPOLAR, COGNITIVE
ENHANCEMENT, BRAIN INJURY, ADD, SCHIZO-
PHRENIA, AND SEXUAL ENHANCEMENT**

Directors: Patricia L. Gerberg, M.D., Richard P. Brown, M.D.
Faculty: Monica Vermani, M.A., Psy.D., Martin Katzman, M.D.

COURSE 64 9:00 A.M.- 4:00 P.M.

*Yosemite Room A, Ballroom Level, Tower 2,
Hilton San Francisco*

ADVANCED INTERVIEWING TECHNIQUES

Director: Shawn C. Shea, M.D.

COURSE 65 9:00 A.M.- 4:00 P.M.

*Yosemite Room C, Ballroom Level, Tower 2,
Hilton San Francisco*

TREATMENT OF SCHIZOPHRENIA

Director: Philip G. Janicak, M.D.
Faculty: Morris B. Goldman, M.D., Stephen R. Marder, M.D.,
Rajiv Tandon, M.D., Philip Janicak, M.D.

COURSE 66 9:00 A.M.- 4:00 P.M.

*Imperial Ballroom B, Ballroom Level, Tower 2,
Hilton San Francisco*

**AN OVERVIEW OF SLEEP MEDICINE FOR THE
MENTAL HEALTH PROVIDER**

Directors: R. Robert Auger, M.D., Thomas D. Hurwitz, M.D.
Faculty: Elliott Lee, M.D., Max Hirshkowitz, Ph.D.

11:00 A.M. SESSIONS

**NOW OPEN!
EXHIBIT HALL
APA MEMBER CENTER
PUBLISHERS' BOOKFAIR
HOURS OF OPERATION
10:00 A.M. -3:00 P.M.**

ADVANCES IN MEDICINE 2

ADV IN MEDICINE 2 11:00 A.M.-12:30 P.M.

Room 300, Esplanade Level, Moscone Center

**CURRENT ETHICAL CHALLENGES IN ASSISTED
REPRODUCTIVE TECHNOLOGY: A PANEL
DISCUSSION**

Chp.: Elena Gates, M.D.

FORUMS 5-7

FORUM 5 11:00 A.M.-12:30 P.M.

Room 301, Esplanade Level, Moscone Center

**ANXIETY IN PATIENTS WITH HIV: IMPORTANCE,
DIAGNOSTIC AND TREATMENT CHALLENGES**

Chair: Ramaswamy Viswanathan, M.D.

Participants: Maria Tiamson-Kassab, M.D., Aparna Dole,
M.D., Philip Bialer, M.D.

FORUM 6 11:00 A.M.-12:30 P.M.

Room 306, Esplanade Level, Moscone Center

**BRIDGES AND BARRIERS TO CARE:
CURRENT STRATEGIES WITH UNDERSERVED
POPULATIONS**

Chair: Mark Townsend, M.D.

Participants: Khushro Unwalla, M.D.,
Jagannathan Srinivasaraghavan, M.D., Rahn Bailey, M.D.

FORUM 7 11:00 A.M.-12:30 P.M.

Room 307, Esplanade Level, Moscone Center

**NEW PERSPECTIVES ON CULTURAL ISSUES IN
ALCOHOL TREATMENT**

Chair: Barbara McCrady, M.D.

LECTURES 15-17

LECTURE 15 11:00 A.M. -12:30 P.M.

Room 130/131, Exhibit Level, Moscone Convention Center

**CROSS-CULTURAL PSYCHOPHARMACOLOGY:
SHAPING OUR FUTURE VIA BRIDGING
SCIENCE AND SERVICE**

Edmond Pi, M.D.

Kun-Po Soo Award

Chp.: Jacquelyn Chang, M.D.

Edmond Hsin-tung Pi, M.D., has taken an active role in ensuring equal psychiatric care for the ethnic minority community. A Professor of Clinical Psychiatry at the University of Southern California (USC) Keck School of Medicine since 1988, he is also Professor of Psychiatry at the Charles R. Drew University of Medicine and Science, Clinical Professor of Psychiatry at the University of California Los Angeles (UCLA) David Geffen School of Medicine, and a Visiting Professor of Psychiatry at the Tsinghua University in Beijing, China. An accomplished researcher in the field of cross-cultural psychiatry, psychopharmacology, and movement disorders, Dr. Pi has more than 100 publications, 23 book chapters, and one book. He served as Chairperson of the Committee of Asian American Psychiatrists of the APA, President of the Association of Chinese American Psychiatrists, a member of the Organizing-Liaison Committee of the First World Congress of Cultural Psychiatry, and a member of the International Advisory Committee of World Psychiatric Association (WPA) Regional Meetings for Seoul, Shanghai, Paris, and Granada. Dr. Pi is a former Visiting Scholar,

Committee on Scholarly Communication with the People's Republic of China (CSCPRC), sponsored by the U.S. National Academy of Sciences, American Council of Learned Societies, and Social Science Research Council. Dr. Pi served as Medical Director of the Department of Mental Health (DMH) of the State of California. Currently, Dr. Pi is Associate Chair for Clinical Affairs, Department of Psychiatry at the USC Keck School of Medicine and Director of Psychiatric Consultation-Liaison Service at Los Angeles County & USC Medical Center. An active contributor to the community and advocate of people with disabilities, he has served on the Board of Directors of China AIDS Fund, the Committee of 100, the American Red Cross, San Gabriel Chapter, the Mental Health Association of Los Angeles County, and the Executive Board of the California Governor's Committee for Employment of People with Disabilities.

LECTURE 16 **11:00 A.M. -12:30 P.M.**
Room 132/133, Exhibit Level, Moscone Center

**HOW ALCOHOLISM DEVELOPS:
IDENTIFICATION
OF GENETIC AND ENVIRONMENTAL
INFLUENCES IN 25 YEAR LONGITUDINAL STUDY**

Marc Shuckit, M.D.
Adolf Meyer Award

Chp.: Marian Fireman, M.D.

Dr. Schuckit's research has focused on evaluating the importance of genetic influences in alcoholism, and the biological factors that interact with the environment to produce a vulnerability toward heavy drinking and alcohol problems. Other research efforts include a search for the optimal diagnostic criteria for substance abuse or dependence, which lead to his contributions to the *DSM-IV* and *DSM-V* process. He has also studied the relationship between alcoholism or drug use disorders and psychiatric syndromes, especially depression, states of anxiety, or psychoses. He has published almost 600 papers and written over 10 books, including the recent sixth edition of *Drug and Alcohol Abuse*. Dr. Schuckit is a Distinguished Professor of Psychiatry at the University of California, San Diego School of Medicine, and serves as the Director of the Alcohol and Drug Treatment Program and of the Alcohol Research Center at the Veterans Affairs San Diego Healthcare System. He is Editor of the *Journal of Studies on Alcohol and Drugs*, and has been a member of the editorial boards of many major alcohol and drug journals in the United States and Europe. In addition, he is Director of the Alcohol Medical Scholars Program. He has received a number of awards in the alcoholism field including the Middleton Award for the best research within the VA system, the American Psychiatric Association's Hoffheimer Award for Research in Psychiatry (now the President's Prize), the Gold Medal Award for lifetime achievement from the Society of Biological Psychiatry, the Distinguished Scientist Award, as well as the Seixas Award from the Research Society on Alcoholism and the Jellinek Award.

LECTURE 17 **11:00 A.M. -12:30 P.M.**
Room 303/305, Esplanade Level, Moscone Center

**WHEN POLITICS DISTORTS SCIENCE:
A PSYCHIATRIST REPORTS FROM THE
TRENCHES OF THE CULTURE WARS**

Jack Drescher, M.D.
Distinguished Psychiatrist

Chp.: Annette Matthews, M.D.

Jack Drescher, M.D., is a psychiatrist and psychoanalyst in private practice in New York City. He is a Distinguished Fellow of the American Psychiatric Association, and currently serves as a consultant to the APA Committee on Public Affairs. A member of the *DSM-V* Workgroup on Sexual and Gender Identity Disorders, past chair of APA's Committee on GLB Issues, he is also a past president of APA's New York County District Branch, where he is presently the editor of their newsletter "AppleSource". Dr. Drescher is on the Board of the Group for the Advancement of Psychiatry and a past trustee of both the Accreditation Council for Psychoanalytic Education and the American Academy of Psychoanalysis and Dynamic Psychiatry. He is a member of the American College of Psychiatrists and the New York Academy of Medicine. A teacher and educator, he is a Training and Supervising Analyst at the William Alanson White Institute in New York, Adjunct Clinical Assistant Professor at NYU's Postdoctoral Program in Psychotherapy and Psychoanalysis, and Clinical Assistant Professor of Psychiatry at New York Medical College and SUNY Downstate. The author of *Psychoanalytic Therapy and the Gay Man* (the Analytic Press), Dr. Drescher has edited twenty books dealing with gender, sexuality and the health and mental health of LGBT communities. Emeritus editor of the *Journal of Gay and Lesbian Mental Health*, he has authored numerous articles and book chapters, including the chapter "Homosexuality, Gay and Lesbian Identities and Homosexual Behavior" in the 8th and forthcoming 9th edition of Kaplan and Sadock's *Comprehensive Textbook of Psychiatry*. His media appearances include *Good Morning America*, *20/20*, *Nightline*, *CBS Sunday Morning*, *In the Life* (PBS), the *O'Reilly Factor*, NPR and interviews with Wolf Blitzer, Paula Zahn, and Anderson Cooper. He is often quoted in national print media, including the *New York Times*, the *Washington Post*, *Time*, *Newsweek* and many others.

SMALL INTERACTIVE SESSIONS 6-8

SI 6 **11:00 A.M.-12:30 P.M.**
Room 216, Mezzanine Level, Moscone Center

THE PHYSICIAN AS PATIENT: A CLINICAL HANDBOOK FOR MENTAL HEALTH PROFESSIONALS

Chp.: Michael Myers, M.D.

SI 7 **11:00 A.M.-12:30 P.M.**
Room 218, Mezzanine Level, Moscone Center

APPROACH TO THE PSYCHIATRIC PATIENT

Chp.: John W. Barnhill, M.D.

SI 8 WITHDRAWN **11:00 A.M.-12:30 P.M.**

SCIENTIFIC AND CLINICAL REPORT

SCR 09 11:00 A.M. - 12:30 P.M.

Room 111, Exhibit Level, Moscone Center

CHILD AND ADOLESCENT PSYCHIATRY

Chp.: Vishal Madaan, M.D.

25. Medication Trends in New-Onset Pediatric Bipolar Disorder among Medicaid-Insured Youth

Aloysius Ibe, B.S.

26. Physical Activity and Fitness in Adolescents at Risk for Psychosis

Jenni Koivukangas, B.Med.

27. Metabolic Symptoms in Adolescent Psychiatric Inpatients

Michael Stevens, Ph.D.

SCIENTIFIC AND CLINICAL REPORTS

SCR 10 11:00 A.M. - 12:30 P.M.

Room 112, Exhibit Level, Moscone Center

CROSS-CULTURAL PSYCHIATRY

Chp.: Derya Akibiyik, M.D.

28. Genes, Memes, Migration, and Mental Illness

Hoyle Leigh, M.D.

29. One-Year Follow-Up Study of the Culturally Sensitive Collaborative Treatment (CSCT) for Chinese Americans with Depression

Adrienne van Nieuwenhuizen, B.A.

30. Prevalence of Childhood Trauma in Psychiatric and Primary Care Clinics in Cities Along the U.S.-Mexico Border

Alejandra Postlethwaite, M.D.

SCIENTIFIC AND CLINICAL REPORTS

SCR 11 11:00 A.M. - 12:30 P.M.

Room 113, Exhibit Level, Moscone Center

DIAGNOSTIC ISSUES

Chp.: Sanjay Yaswani, M.D.

31. Heterogeneity of the Jealousy Phenomenon in the General Population An Italian Study

Donatella Marazziti, M.D.

32. Olfactory Reference Syndrome (ORS): A Systematic Review of the World Literature

Millia Begum, M.B.B.S.

33. Dimensionality and Etiology in Psychiatric Research

Stephen Shanfield, M.D.

SCR 12 11:00 A.M. - 12:30 P.M.

Room 114, Exhibit Level, Moscone Center

METABOLISM, METABOLIC SYNDROME, AND CARDIOVASCULAR DISEASE IN SCHIZOPHRENIA

Chp.: Merrra Vaswani, M.D.

34. Schizophrenia-Spectrum Disorders Were Associated With Cardiovascular Disease Symptoms, Independent of Known Risk Factors for Symptoms

Stephen Woolley, D.Sc.

35. Ultra Rapid Metabolizers Are in a Pilot Study in Two Different Clinics Overrepresented in Court-Ordered Psychotic Patients

Carel de Blécourt, M.D.

36. Oatmeal vs. Donuts: Treating Metabolic Syndrome/Obesity Using CBT/DBT in an Inner City SPMI Population

Joanne Caring, M.D.

SCIENTIFIC AND CLINICAL REPORTS

SCR 13 11:00 A.M. - 12:30 P.M.

Room 120, Exhibit Level, Moscone Center

DIAGNOSTIC ISSUES IN THE SCHIZOPHRENIA SPECTRUM

Chp.: Adel Gabriel, M.D.

37. Is Schizoaffective Disorder a Distinct Clinical Entity?

John Goethe, M.D.

38. Diagnostic Stability in Patients with Schizoaffective Disorder Compared to Schizophrenia and Bipolar Disorder

Bonnie Szarek, R.N.

39. Depression and Its Treatment in Patients Presenting With Late-Onset Delusional Disorder (LODD)

Rebecca Anglin, M.D.

SCIENTIFIC AND CLINICAL REPORTS

SCR 14 11:00 A.M. - 12:30 P.M.

Room 121, Exhibit Level, Moscone Center

PSYCHIATRIC ISSUES RELATED TO PREGNANCY AND BREAST FEEDING

Chp.: Alison May, M.D.

40. Postpartum Depression and Breast Feeding in an Urban Population of Women in Malaysia

Nor Zainal, M.B.B.S.

41. Psychotic Denial of Pregnancy: Ethical and Legal Considerations for Treating Physicians

Melissa Nau, M.D.

42. Posttraumatic Growth and Quality of Life in Breast Cancer Patients

Derya Iren Akbiyik, M.D.

SCIENTIFIC AND CLINICAL REPORTS

SCR 15 11:00 A.M. - 12:30 P.M.

Room 122, Exhibit Level, Moscone Center

EXPLORING SUICIDALITY: ASSESSMENT AND THE IMPACT OF SPIRITUALITY AND ECONOMIC CONDITIONS

Chp.: Nitin Gupta, M.D.

43. Meeting the Challenge of Risk Assessment: Towards a New Scale of Suicide Assessment: The Scale for Impact of Suicidality: Management and Assessment
Amresh K. Shrivastava, M.D.

44. Economic Factors and Suicide Rates - Associations Over Time in Four Countries
Alfonso Ceccherini-Nelli, M.D.

45. Religion, Spirituality and Suicide in a Large Community Sample
Daniel Rasic, B.S.

SCIENTIFIC AND CLINICAL REPORTS

SCR 16 11:00 A.M. - 12:30 P.M.

Rooms 272/274/276, Mezzanine Level West, Moscone Center

PANIC AND ANXIETY DISORDER

Chp.: Britta Ostermeyer, M.D.

46. Frequency and Clinical Correlates of Adult Separation Anxiety Disorder in 508 Outpatients With Mood and Anxiety Disorders
Stefano Pini, M.D.

47. Long-Term Treatment of Panic Disorder with Clonazepam or Paroxetine: a Randomized Naturalistic Open Study
Antonio Nardi, M.D.

48. Effectiveness of a Mindfulness-Based Cognitive Therapy Program as an Adjunct to Pharmacotherapy in Patients With Panic Disorder
Borah Kim, M.D.

COMPONENT WORKSHOPS 15-18

CW 15 11:00 A.M.-12:30 P.M.

Room 222, Mezzanine Level, Moscone Center

CURRENT TOPICS IN FORENSIC PSYCHIATRY: UPDATE FROM THE COUNCIL ON PSYCHIATRY AND LAW AND THE COMMITTEE ON JUDICIAL ACTION

APA Council on Psychiatry and Law and APA Committee on Judicial Action

Co-Chps.: Patricia R. Recupero, M.D., J.D., Jeffrey Janofsky, M.D.

Participants: Robert Weinstock, M.D., Steven Hoge, M.D., M.B.A.

CW 16 11:00 A.M.-12:30 P.M.

Room 224, Mezzanine Level, Moscone Center

INDICATIONS FOR THE USE OF COMBINED TALKING THERAPY AND PHARMACOTHERAPY AND HOW TO TEACH IN RESIDENCY

Corresponding Committee on Graduate Education

Chp.: Sidney Weissman, M.D.

Participants: Edward Silberman, M.D., David Preven, Ryan Hall, M.D.

CW 17 11:00 A.M.-12:30 P.M.

Room 302, Esplanade Level, Moscone Center

MEDICAL ISSUES FOR PSYCHIATRISTS IN DISASTERS

APA Committee on Psychiatric Dimensions of Disaster

Co-Chps.: Mark Viron, M.D., Nidal NH. Hasan, M.D., M.P.H.

Participants: Brooke Parish, M.D., Catherine May, M.D., Elspeth Ritchie, M.D., M.P.H.

CW 18 11:00 A.M.-12:30 P.M.

Room 304, Esplanade Level, Moscone Center

ETHICAL DILEMMAS IN PSYCHIATRIC PRACTICE

APA Ethics Committee

Chp.: Wade Myers, M.D.

Participants: Burton V. Reifler, M.D., Stephen Green, M.D., Lea DeFrancisci Lis, M.D., Elissa Benedek, M.D.

ISSUE WORKSHOPS 33-38

IW 33 11:00 A.M.-12:30 P.M.

Room 125, Exhibit Level, Moscone Center

THE USE OF RESEARCH MEASURES IN CLINICAL PRACTICE

Chp.: Joan Busner, Ph.D.

Participants: Nicholas Greco IV, M.S., Stuart Kaplan, M.D.

IW 34 11:00 A.M.-12:30 P.M.

Room 220, Mezzanine Level, Moscone Center

FFT-HPI AND FIT: TWO DIFFERENT APPROACHES TO FAMILY-INVOLVED TREATMENT FOR BIPOLAR DISORDER

Chp.: Igor Galynker, M.D., Ph.D.

Participants: Lisa Cohen, Ph.D., Allison Lee, M.D., Annie Steele, B.A., Nisha VerHalen, M.A.

IW 35 **11:00 A.M.-12:30 P.M.**
Room 226, Mezzanine Level, Moscone Center

OUTPATIENT MASTECTOMIES: OVERVIEW OF PSYCHOSOCIAL ISSUES

Co-Chps.: Zach Morairty, M.D., Michelle B. Riba, M.D.
Participant: Mary Jane Massie, M.D.

IW 36 **11:00 A.M.-12:30 P.M.**
Room 308, Esplanade Level, Moscone Center

EVALUATION AND MANAGEMENT OF PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS IN PSYCHIATRIC PRACTICE

Chp.: Dimitri D. Markov, M.D.
Participants: Karl Doghramji, M.D.,
Christine Marchionni, M.D.

IW 37 **11:00 A.M.-12:30 P.M.**
Room 309, Esplanade Level, Moscone Center

THE PORTRAYAL OF PSYCHIATRY IN RECENT AMERICAN FILM

Chp.: Steven E. Pflanz, M.D.

IW 38 **11:00 A.M.-12:30 P.M.**
Room 310, Esplanade Level, Moscone Center

THE CHANGING MANAGED CARE LANDSCAPE FOR BEHAVIORAL HEALTH SERVICES

National Institute on Alcohol Abuse and Alcoholism

Co-Chps.: Constance M. Horgan, Sc.D.,
Mark Willenbring, M.D.
Participants: Hyong Un, M.D., Constance Weisner, D.P.H.

12:00 NOON SESSIONS

NEW RESEARCH POSTER SESSION 4:

For further information on New Research submissions, please refer to the *New Research Program* section in the back of this publication.

1:00 P.M. SESSIONS

COURSES 67-70

COURSE 67 **1:00 P.M.- 5:00 P.M.**
*Continental Ballroom 1, Ballroom Level, Tower 3,
Hilton San Francisco*

ENGAGING RESISTANT AND DIFFICULT-TO-TREAT PATIENTS IN COLLABORATIVE TREATMENT

Director: David Mee-Lee, M.D.

COURSE 68 **1:00 P.M.- 5:00 P.M.**
Yosemite Room B, Ballroom Level, T2, Hilton San Francisco

A PRIMER ON ACCEPTANCE AND COMMITMENT THERAPY

Directors: Kenneth Dr. Fung, M.D., M.S., Mateusz Zurowski, M.D., M.S.

COURSE 69 **1:00 P.M.- 5:00 P.M.**
*Union Square Rooms 19/20, Fourth Floor, Tower 3,
Hilton San Francisco*

STREET DRUGS AND MENTAL DISORDERS: OVERVIEW AND TREATMENT

Director: John W. Tsuang, M.D.
Faculty: Timothy Fong, M.D., Stephen Ross, M.D., Karen Miotto, M.D.

COURSE 70 **1:00 P.M.- 5:00 P.M.**
*Union Square Room 22, Fourth Floor, Tower 3,
Hilton San Francisco*

MOTIVATIONAL THERAPY FOR INDIVIDUALS WITH CONCURRENT DISORDERS

Director: Shimi Kang, M.D.
Faculty: Marilyn Herie, Ph.D., Jennifer Toomey, R.P.N.

2:00 P.M. SESSIONS

ADVANCES IN SERIES 6-7

ADVANCES IN 06 **2:00 P.M. -5:00 P.M.**
Gateway Ballroom 103, Moscone Center

PERSONALITY DISORDER

Chp.: John Oldham, M.D.

1. How Neurobiology Informs Psychotherapy of Personality Disorders

Glen O. Gabbard, M.D.

2. Neurobiology of Personality Disorders

Larry J. Siever, M.D.

3. Attachment and Personality Disorder: A Mentalization Based Approach

Peter Fonagy, Ph.D.

4. Levels of Care

John G. Gunderson, M.D.

5. Essentials of Pharmacotherapy in the PD Patient: An Update

Paul H. Soloff, M.D.

6. Future Directions: Toward DSM-V

Andrew E. Skodol, M.D.

ADVANCES IN 07 2:00 P.M. -5:00 P.M.

Room 132/133 Exhibit Level North, Moscone Center

FORENSIC PSYCHIATRY

Chp.: Robert I. Simon, M.D., Lisa Gold, M.D.

- 1. Managing of Clinical Legal Dilemmas**
Robert Simon, M.D.
- 2. Disability Evaluations**
Lisa Gold, M.D., DFAPA
- 3. Assessment and Management of Students at Risk for Violence at School**
Peter Ash, M.D.
- 4. Standards of Care in Correctional Settings**
Jeffery Matenik, M.D.
- 5. The Changing Law of Family Dissolution**
Daniel Shuman, M.D.

LECTURES 18-19

LECTURE 18 2:00 P.M. -3:30 P.M.

Room 130/131, Exhibit Level, Moscone Center

THE MOVEMENT FOR GLOBAL MENTAL HEALTH: WHY YOU SHOULD JOIN

Vikram Patel M.SC., M.R.C.Psych, Ph.D.
International Lecture

Chp.: Geetha Jayaram, M.D.

Vikram Patel is a Professor of International Mental Health and Wellcome Trust Senior Clinical Research Fellow at the London School of Hygiene & Tropical Medicine, London. He serves on a number of international and national committees including the WHO Expert Advisory Group for Mental Health. His recent books include *Where There Is No Psychiatrist* (Gaskell, 2003) which has become a widely used manual for community mental health in developing countries. He was an editor of the recent *Lancet Series on Global Mental Health* (2007). He led the efforts to set up the Movement for Global Mental Health which was launched on October 10th, 2008 (www.globalmentalhealth.org). He is based in Goa, India, where he serves on the boards of three community based NGOs including Sangath, a community mental health NGO (www.sangath.com) which he founded and which won the MacArthur Foundation's International Prize for Creative and Effective Institutions in 2008.

LECTURE 19 2:00 P.M. -3:30 P.M.

Room 303/305, Esplanade Level, Moscone Center

TRANSLATIONAL NEUROSCIENCE FOR SCHIZOPHRENIA

Akira Sawa, M.D., Ph.D.
Frontiers of Science

Chp.: Julio Licinio, M.D.

Akira Sawa, M.D., Ph.D., received his medical degree from the University of Tokyo in 1990. He completed residency in psychiatry in Japan and also received Ph.D. from University of Tokyo. He enjoys working at Johns Hopkins University in Maryland, where he is the Director of the Program in Molecular Psychiatry. His program is directed translational neuroscience in which both basic and clinical researches are synergistically combined, towards understanding the pathogenesis of neuropsychiatric illnesses at the molecular level. Since 2007, Dr. Sawa is the director of Silvio O. Conte Center grant for translational neuroscience at Johns Hopkins University to study molecular pathogenesis of schizophrenia. His awards and honors include in 1998 Brain Science Research Award (Japan); he was the 2002 and 2004 NARSAD Young Investigator Award recipient. An award presented to provide support for the most promising young scientists conducting neurobiological research; in 2007 he was awarded the NARSAD and Staglin Family Award and the Efron Award from American College of Neuropsychopharmacology; in 2008 he received the NARSAD Freedman Award honorable mention. Dr. Sawa is a widely published researcher having been published in over 130 peer reviewed journals either as lead or corresponding author.

DSM TRACK

DSM TRACK 2:00 P.M. -5:00 P.M.

Room 301, Esplanade Level, Moscone Center

PUBLIC HEALTH ASPECTS OF DIAGNOSIS AND CLASSIFICATION OF MENTAL DISORDERS: A DSM-V RESEARCH AGENDA

Chp.: Norman Sartorius, M.D.

- 1. Public Health Aspects of Mental Disorders Classifications: The WHO-APIRE Conference and Further Thoughts**
Shekhar Saxena, M.D.
- 2. Economic Consequences Revising the Diagnostic Nomenclature for Mental Disorders**
Howard Goldman, M.D.
- 3. Capturing Complexity: The Case for a New Classification System for Mental Disorders in Primary Care**
Linda Gask, Ph.D.

4. What are Consumers' Views on Diagnosis and Can They be Involved in the Development Classifications?
Diana Rose, Ph.D.

5. Translating Psychiatric Diagnostic and Classification into Public Health Usage
Alberto Minoletti, M.D.

PRESIDENTIAL SYMPOSIUM 3

PS 3 **2:00 P.M.-5:00 P.M.**
Room 300, Esplanade Level, Moscone Center

PSYCHIATRY AND THE CONTROL OF FERTILITY

Chp.: Nada Stotland, M.D.

Co-Chps.: Nancy Adler, Ph.D., Gail E. Robinson, M.D.,
Gisele Apter, M.D., Carole E. Joffe, Ph.D.,
Michael F. Myers, M.D.

1. Is There an Abortion Trauma Syndrome?
Nancy Adler, Ph.D.

2. Critiquing the Evidence
Gail E. Robinson, M.D.

3. The Marginality of the Abortion Provider in the United States
Carole E. Joffe, Ph.D.

4. Contraception, Abortion and Men
Michael F. Myers, M.D.

5. Abortion in France: High Availability Best European Fecundity
Gisele Apter, M.D.

SYMPOSIA 19-36

SYMPOSIUM 19 **2:00 P.M.- 5:00 P.M.**
Gateway Ballroom 102, Exhibit Level, Moscone Center

SUICIDE WITHOUT A PSYCHIATRIC DISORDER

Chp.: Norman B. Levy, M.D.

1. Had Gary Powers Killed Himself
Norman B. Levy, M.D.

2. Differentiating Suicide from Other Life-Ending Acts: A Model Illustrated with Chronic Kidney Disease and Dialysis
John M. Bostwick, M.D.

3. Oregon's Death with Dignity Act: Who Chooses Physician Assisted Suicide
Linda Ganzini, M.D.

4. Desire for Death in Terminally Ill Cancer and AIDS Patients: Hopelessness and Loss of Meaning as Contributing Factors, Independent of Depression
William Breitbart, M.D.

5. Ethics in Suicide Which Is not Associated with Psychiatric Illness
James J. Strain, M.D.

SYMPOSIUM 20 **2:00 P.M.- 5:00 P.M.**
Room 111, Exhibit Level, Moscone Center

BIOLOGICAL BASIS OF SEX DIFFERENCES IN DRUG ADDICTION: TRANSLATIONAL PERSPECTIVES

National Institute on Drug Abuse

Co-Chp.: Cora Lee Wetherington, Ph.D.,
Wendy J. Lynch, Ph.D.

1. Sex Differences in Biological Sensitivity to the Reinforcing Effects of Drugs of Abuse in Preclinical Models of Acquisition, Escalation, and Relapse
Wendy J. Lynch, Ph.D.

2. The Role of Dopamine in Sex Differences in Drug Abuse
Jill B. Becker, Ph.D.

3. Gonadal Steroid Hormones and Neural Mechanisms of Cognition and Emotion in Women
Karen Faith Berman, M.D.

4. Sex Differences in MRI Correlates of Stress and Drug Cues in Cocaine Dependence
Marc N. Potenza, M.D.

5. Sex Differences in Amygdala-Based Emotional Memory Processes: Relevance for Addiction
Larry F. Cahill, Ph.D.

SYMPOSIUM 21 **2:00 P.M.- 5:00 P.M.**
Room 112, Exhibit Level, Moscone Center

CO-OCCURRING DISORDERS IN HIV POSITIVE PATIENTS

Chp.: Marshall Forstein, M.D.

1. HIV and Hepatitis C Co-Infection
Elizabeth Ryan, M.D.

2. Metabolic Disease and HIV
Marshall Forstein, M.D.

3. PTSD and HIV
Antoine Douaihy, M.D.

4. Update on Severe Mental Illness and HIV
Francine Cournos, M.D.

5. Substance Use Disorders and HIV
Steven Batki, M.D.

SYMPOSIUM 22 2:00 P.M.- 5:00 P.M.

Room 113, Exhibit Level, Moscone Center

STARTING OUT ON THE RIGHT FOOT: SECURING YOUR FIRST JOB AND ESTABLISHING A PSYCHIATRIC PRACTICE

APA Committee of Residents and Fellows

Co-Chp.: Molly K. McVoy, M.D.,
William H. Campbell, M.D., M.B.A.

SYMPOSIUM 23 2:00 P.M.- 5:00 P.M.

Room 114, Exhibit Level, Moscone Center

SOCIAL STRESS INCREASES VULNERABILITY TO DRUG ABUSE AND DISEASE

National Institute on Drug Abuse

Chp.: Nancy S. Pilotte, Ph.D.

- 1. Adverse Effects of Stress on Drug Addiction**
Julie Blendy, Ph.D.
- 2. Social Stress and Vulnerability to Substance Abuse: Genes, Environment and Neural Correlates**
Huda Akil, Ph.D.
- 3. Interactions of Social Stressors and Enrichment With Social Rank on Dopamine D2 Receptors and the Reinforcing Strength of Cocaine in Monkeys**
Michael A. Nader, Ph.D.
- 4. Social Stress and Simian Immunodeficiency Virus Disease: Behavioral and Physiological Mechanisms That Affect Disease Progression**
John P. Capitanio, Ph.D.

SYMPOSIUM 24 2:00 P.M.-5:00 P.M.

Room 120, Exhibit Level, Moscone Center

WHAT'S NEW IN PHARMACOTHERAPY FOR ALCOHOL DEPENDENCE?

National Institute on Alcohol Abuse and Alcoholism

Chp.: David T. George, M.D.

- 1. Neurokinin 1 Receptor (NK1R) Antagonism: A Novel Anti-Stress Mechanism for the Treatment of Alcoholism**
David T. George, M.D.
- 2. Human Laboratory and Clinical Trial Evidence for Gabapentin Treatment of Alcohol Dependence**
Barbara J. Mason, Ph.D.
- 3. Update on New Clinical Trials for Alcohol Dependence: Opiate, Dopamine and GABA/ Glutamate Acting Medications**
Raymond F. Anton, M.D.

4. An Analysis of Two Promising Medications, Topiramate and Ondansetron, for Treating Alcohol Dependence: Results from Recent Large-Scale Clinical Trials

Bankole A. Johnson, M.D., Ph.D., DSc

5. Pharmacogenetics and Alcohol Dependence

Henry R. Kranzler, M.A.

SYMPOSIUM 25 2:00 P.M.-5:00 P.M.

Room 121, Exhibit Level, Moscone Center

AUTISM IN ADULTS TOWARDS A BETTER CLINICAL APPROACH THROUGH UNDERSTANDING: RECENT INSIGHTS FROM RESEARCH

Chp.: Rutger J. Van der Gaag, M.D., Ph.D.

- 1. Neurodevelopmental Correlates of Social Impairment in Autism: From Infancy to Adulthood**
Ami Klin, Ph.D.
- 2. Diffusion Tensor Imaging in Autism and Asperger Syndrome: Evidence for Impairment of Long Range White Matter Integrity**
Wouter Groen, M.D.
- 3. Neurocognitive Correlates of Substance Use Disorder in Adults With Autism Spectrum Disorder or ADHD**
Bram B. Sizoo, M.D.
- 4. Comorbidity in Adults with ASD Evidence From Data From Cross-Sectional and Prospective Case Controlled Cohort Samples**
Patricia J. van Wijngaarden-Cremers, M.D.
- 5. ASD in Parents and Siblings of Early Diagnosed Infants With ASD**
Rutger J. Van der Gaag, M.D.

SYMPOSIUM 26 2:00 P.M.-5:00 P.M.

Room 122, Exhibit Level, Moscone Center

THE EFFECTS OF CITY LIFE ON MENTAL HEALTH AROUND THE WORLD

The Royal College of Psychiatrists

Co-Chp.: Nigel Bark, M.D., Rachel Jenkins, M.D.

- 1. The Impact of Urban Living on Mental Health and Illness in Egypt**
Nasser N. Loza, M.D.
- 2. Mental Disorders and Quality of Life in Large Metropolitan Areas in Mexico**
Maria Elena Medina Mora, Psy.D., Ph.D.
- 3. Metro-Urban Mental Health in Developing Countries: From Origins to Outcome: An Indian Experience**
Amresh K. A. Shrivastava, M.D.

4. **A Population-Based Study of First Episode Psychosis in São Paulo, Brazil**
Paulo Menezes, M.D.

5. **Chinese Elderly in Singapore : Comparing the Mental Health of an Urban and a Suburban Population**
Ee-Heok Ekh Kua, M.B.B.S.

6. **The Practice of Mental Health Promotion in Urban Planning and City Administration**
Helen E. Herrman, M.B., M.D.

Discussant: Rachel Jenkins, M.D.

SYMPOSIUM 27 **2:00 P.M.-5:00 P.M.**
Room 124, Exhibit Level, Moscone Center

RECENT RESEARCH IN EATING DISORDERS

Chp.: James E. Mitchell, M.D.

1. **Psychopathology and Eating Pathology in Bariatric Surgery Candidates**
James E. Mitchell, M.D.

2. **Disordered Eating and Psychiatric Symptoms in Adolescents Presenting for Bariatric Surgery**
Michael J. Devlin, M.D.

3. **Recent Mortality Studies in Eating Disorders**
Scott J. Crow, M.D.

4. **A Model of Allostasis for Conceptualizing Eating Disorders**
Katherine A. Halmi, M.D.

5. **Are Anorexia Nervosa and Bulimia Nervosa Really Eating Disorders: New Understanding of Puzzling Symptoms**
Walter H. Kaye, M.D.

SYMPOSIUM 28 **2:00 P.M.-5:00 P.M.**
Room 125, Exhibit Level, Moscone Center

PUBLICATION BIAS AND THE EFFECTIVENESS OF ANTIDEPRESSANT TREATMENT AND PSYCHOLOGICAL INTERVENTIONS IN DEPRESSION: SHOULD WE CARE?

Co-Chp.: Claudi C.L.H. Bockting, Ph.D., M.S.C.,
Steven Hollon, Ph.D.

1. **Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy**
Erick H. Turner, M.D.

2. **Publication Bias Is Not Restricted to Reporting Outcomes of Pharmacotherapy Trials**
Willem W.A.Nolen, M.D.

3. **Nonresponse to CBT and Antidepressants in the Treatment of Depression in Myocardial Infarction Patients**
Elizabeth Martens, M.D.

4. **How Well Do We Treat MDD?**
Claudi CLH Bockting, Ph.D., M.S.C.

Discussant: Steven Hollon, Ph.D.

SYMPOSIUM 29 **2:00 P.M.-5:00 P.M.**
Rooms 272/274/276, Mezzanine Level West, Moscone Center

BORDERLINE PERSONALITY DISORDER: THE ROLE OF NEUROBIOLOGY AND GENES

Co-Chp.: Barbara H. Stanley, Ph.D., Larry J. Siever, M.D.

1. **Opioid Receptor and Oxytocin Genotypes in BPD**
Larry J. Siever, M.D.

2. **Dysregulation of Endogenous Opioid System Function in Borderline Personality Disorder**
Jon-Kar Zubieta, M.D.

3. **Pain Processing in Borderline Personality Disorder: Functional and Genetic Approach**
Martin Bohus, M.D.

4. **Neurobiology of Self Injury in Borderline Personality Disorder**
Barbara H. Stanley, Ph.D.

Discussant: Peter Fonagy, Ph.D.

SYMPOSIUM 30 **2:00 P.M.-5:00 P.M.**
Room 302, Esplanade Level, Moscone Center

CURRENT AND FUTURE OF THE EMERGENT FIELD OF THERAPEUTIC BRAIN STIMULATION AND NEUROMODULATION IN PSYCHIATRY

Co-Chp.: Alexander Bystritsky, M.D., Ph.D.,
Mark S. George, M.D.

1. **Neurosurgery for OCD: Focus on Deep Brain Stimulation**
Benjamin D. Greenberg, M.D.

2. **Feasibility Study of an Implantable Cortical Stimulation System for Patients With Major Depressive Disorder**
Darin D. Dougherty, M.D.

3. **Deep Transcranial Magnetic Stimulation: Comparison Between Effects of Unilateral and Bilateral Prefrontal Cortex Stimulation in Depressive Patients**
Abraham Zangen, Ph.D.

4. **Current and Future Therapeutic Uses of TMS**
Mark S. George, M.D.

5. Current and Future of Other Brain Stimulating Techniques

Alexander Bystritsky, M.D.

Discussant: Laura B. Dunn, M.D.

SYMPOSIUM 31 **2:00 P.M.-5:00 P.M.**

Room 304, Esplanade Level, Moscone Center

PEDIATRIC BIPOLAR DISORDER: A CRITICAL LOOK AT AN AMERICAN PHENOMENON.

Chp.: Peter I. Parry, M.B.B.S.

1. Australian and New Zealand's Child & Adolescent Psychiatrists' Views on Bipolar Disorder Prevalence and on Rates of Pediatric Bipolar Disorder in the USA.

Peter I. Parry, M.B.B.S.

2. Changing the Treatment Culture in a Residential Agency for Youth: Broadening the Role of Psychiatry

Edmund C. Levin, M.D.

3. Pediatric Bipolar Disorder: A Dispassionate Review of the Literature

Glen R. Elliott, M.D.

4. Bioethics and "Pediatric Bipolar Disorder"

Mary G. Burke, M.D.

SYMPOSIUM 32 **2:00 P.M.-5:00 P.M.**

Room 306, Esplanade Level, Moscone Center

WORKING WITH LAWYERS

Co-Chp.: Lawrence K. Richards, M.D., Roger Peele, M.D.

1. Values of Medicine and the Law

Roger Peele, M.D.

2. Brownlee Versus Me: A Good Lawyer Directs the Process and Gets a Favorable Summary Judgement

Lawrence K. Richards, M.D.

3. New Opportunities for Attorney/Psychiatrist Collaborations

Bruce J. Winick, J.D.

4. Beyond "Get the Money up Front"

Thomas G. Gutheil, M.D.

5. Working With Lawyers

Harold I. Eist, M.D.

SYMPOSIUM 33 **2:00 P.M.-5:00 P.M.**

Room 307, Esplanade Level, Moscone Center

EMPIRICALLY VALIDATED AND EFFECTIVE PSYCHOTHERAPIES FOR BORDERLINE PERSONALITY DISORDER

Co-Chp.: Kenneth R. Silk, M.D., John G. Gunderson, M.D.

1. Evidence-Based Versus Effectiveness Studies: The Randomized Controlled Trial and Psychotherapy Research

Kenneth R. Silk, M.D.

2. Mentalization Based Treatment: a Discussion of Theory and Evidence.

Anthony W. Bateman, M.R.C.

3. Transference-Focused Psychotherapy for BPD: Aiming for Change in Personality Structure

Frank E. Yeomans, M.D.

4. Dialectical Behavior Therapy for Complex, Multi-Diagnostic Patients – A Review of DBT's Evidence Base to Date

Linda A. Dimeff, Ph.D.

5. CBT for Personality Disorders (CBT-PD)

Kate M. Davidson, Ph.D.

6. Schema Therapy for Borderline Personality Disorder

Jeffrey E. Young, Ph.D.

Discussant: John G. Gunderson, M.D.

SYMPOSIUM 34

WITHDRAWN

SYMPOSIUM 35 **2:00 P.M.-5:00 P.M.**

Room 309, Esplanade Level, Moscone Center

PTSD AND ALCOHOL USE DISORDER (WITH SPECIAL EMPHASIS ON RETURNING VETERANS)

National Institute on Alcohol Abuse and Alcoholism

Chp.: Lisa M. Najavits, Ph.D.

1. Psychotherapy Treatments for PTSD and Alcohol Use Disorder

Lisa M. Najavits, Ph.D.

2. Neurobiological Determinants of the Comorbidity of PTSD and Substance Abuse

Thomas R. Kosten, M.D.

3. Pharmacotherapeutic Treatment of PTSD and Co-Occurring Alcohol Use Disorders

Kathleen Brady, M.D.

4. Outcomes for Alcohol Misusing Women with PTSD in the Women and Trauma Multisite Study in NIDA's Clinical Trials Network

Denise Hien, Ph.D.

5. Impact of Childhood Trauma on Hypothalamic-Pituitary-Adrenocortical (HPA) Activity in Alcohol Dependent Patients

Ingo Schäfer, M.D.

SYMPOSIUM 36 **2:00 P.M.-5:00 P.M.**

Room 310, Esplanade Level, Moscone Center

**PSYCHIATRIC PATIENTS OVERCROWDING
IN EMERGENCY DEPARTMENTS: A CALL FOR
ACTIONS**

APA Council on Healthcare Systems and Financing

Chp.: Anthony T. Ng, M.D.

- 1. Overview of Psychiatric Patient Overcrowding in
Emergency Departments**
Scott L. Zeller, M.D.
- 2. HealthCare Delivery System Influences and Impacts
Strategies for Improvement**
Joseph J. Parks, M.D.
- 3. Innovative Methods To Decrease Psychiatric Patient
Overcrowding of Medical Emergency Departments**
Avrim B. Fishkind, M.D.
- 4. Behavioral Health Service Gaps and the Role of
Emergency Departments**
Alan Q. Radke, M.D.

Discussant: Anita S. Everett, M.D.

3:00 P.M. SESSION

NEW RESEARCH POSTER SESSION 5:

For further information on New Research Poster sessions, please refer to the *New Research Program* section in the back of this publication.

5:00 P.M. SESSION

MIND GAMES **5:00 P.M. -6:00 P.M.**

Gateway Ballroom 104, Moscone Center

Our Host and Moderator: **Glen O. Gabbard, M.D.**

Mind Games is a national team competition for residents at the APA Annual Meeting. The game pits top game scoring residency programs against each other in a final competition testing the depth and breadth of their knowledge of psychiatry.

FINALISTS FOR THE 2009 CHAMPIONSHIP ARE:

Albert Einstein Healthcare Network
University of Pennsylvania
University of Texas at Houston

7:00 P.M. SESSION

INDUSTRY-SUPPORTED SYMPOSIA 11

ISS 11 **7:00 P.M. - 9:00 P.M.**

Continental Ballroom 4/5/6, Ballroom Level, Hilton S.F.

**NOVEL APPROACHES TO ASSESSING AND
TREATING DEPRESSION IN THE MEDICALLY ILL**

Supported by Lilly USA, LLC

Chp.: Bradley Gaynes, M.D.

- 1. Assessing Mood and Somatic Symptoms in the
Medically-Ill, Depressed Patient**
Simon Gregory, M.D.
- 2. Pathophysiology of Somatic Symptoms and
Medical Illness in Major Depressive Disorder**
Janet Witte, M.D.
- 3. An Evidence-Based Guide for Treating
Depression in the Medically Ill**
Bradley N. Gaynes, M.D.
- 4. Management of Treatment-Resistant Patients
With Somatic Symptoms and Medical Illness**
Maurizio Fava, M.D.

Wednesday, May 20, 2009

8:00 A.M. SESSIONS

COURSES 71-76 AND 80

COURSE 71 8:00 A.M. -12 NOON

Continental Ballroom 1, Ballroom Level, Tower 3, Hilton San Francisco

MENTALIZATION BASED TREATMENT (MBT) FOR BORDERLINE PERSONALITY DISORDER (BPD): INTRODUCTION TO CLINICAL PRACTICE

Directors: Anthony W. Bateman, M.R.C., Peter Fonagy, Ph.D.

COURSE 72 8:00 A.M.-12 NOON

Continental Ballroom 2, Ballroom Level, Tower 3, Hilton San Francisco

FROM TRAUMATIC STRESS TO TRAUMA-INFORMED CARE: STRATEGIES FOR PROVIDING SERVICES TO PEOPLE WHO ARE HOMELESS

Director: Kathleen Guarino, B.A., M.A.

Faculty: Ellen K. Bassu, M.D.

COURSE 73 8:00 A.M.-12 NOON

Continental Ballroom 9, Ballroom Level, Tower 3, Hilton San Francisco

COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA CO-MORBID WITH DEPRESSIVE AND ANXIETY DISORDERS

Director: Rachel Manber, Ph.D.

Faculty: Anne Germain, Ph.D., Jack Edinger, Ph.D., Colleen Carney, Ph.D., Rachel Manber, Ph.D., Jason Ong, Ph.D.

COURSE 74 8:00 A.M.-12 NOON

Imperial Ballroom A, Ballroom Level, Tower 2, Hilton San Francisco

INTRODUCING CULTURE INTO PSYCHIATRIC PRACTICE

Directors: Kenneth Fung, M.D., M.S., Lisa F. Andermann, M.D.

Faculty: Ari Zaretsky, M.D., Ted Lo, M.B.B.S, M.R.C.

COURSE 75 8:00 A.M.-12 NOON

Yosemite Room B, Ballroom Level, Tower 2, Hilton San Francisco

ECT PRACTICE UPDATE FOR THE GENERAL PSYCHIATRIST

APA Corresponding Committee on ECT and Other Electro-magnetic Therapies

Director: Jerry L. Lewis, M.D., M.S.

Faculty: Laurie McCormick, M.D., Peter Rosenquist, M.D., Andrew Krystal, M.D., Charles Kellner, M.D.

COURSE 76 8:00 A.M.-12 NOON

Union Square Rooms 15/16 Fourth Floor, Tower 3, Hilton San Francisco

A MODEL OF GROUP PSYCHOTHERAPY FOR PERSONS WITH CHRONIC MENTAL ILLNESS

American Group Psychotherapy Association

Director: Walter N. Stone, B.A., M.D.

COURSE 80 8:00 A.M.- 5:00 P.M.

Yosemite Room C, Ballroom Level, Tower 2, Hilton San Francisco

OFFICE-BASED BUPRENORPHINE TREATMENT OF OPIOID-DEPENDENT PATIENTS

Director: Gerardo Gonzalez, M.D.

Faculty: Andrew Saxon, M.D., Eric Strain, M.D., Laura McNicholas, M.D., Ph.D.

9:00 A.M. SESSIONS

LECTURE 20 9:00 A.M. -10:30 A.M.

Room 130/131, Exhibit Level, Moscone Center

OVERCOMING THE TERROR OF DEATH

Irvin D. Yalom, M.D.

Distinguished Psychiatrist

Chp.: Cathy Crone, M.D.

Vice-Chair: Josepha A. Cheong, M.D.

Irvin Yalom was born in Washington DC, attended Boston University Medical School, interned at Mount Sinai Hospital in NY, and took his psychiatric residency training at Johns Hopkins. His textbooks include: *The Theory and Practice of Group Psychotherapy*, *Existential Psychotherapy*, and *Inpatient Group Psychotherapy*. Books of stories and novels that teach psychotherapy include *Love's Executioner*, *Momma and the Meaning of Life*, *When Nietzsche Wept*, *Lying on the Couch*, *The Schopenhauer Cure*. His most recent book is *Staring at the Sun: Overcoming the Terror of Death*.

SMALL INTERACTIVE SESSION 9

SI 9 9:00 A.M.-10:30 A.M.

Room 218, Mezzanine Level, Moscone Center

CLINICAL MANUAL FOR THE DIAGNOSIS AND TREATMENT OF PSYCHOTIC DEPRESSION

Chp.: Anthony Rothschild, M.D. (*Meet the Author*)

COMPONENT WORKSHOPS 19-23

CW 19 9:00 A.M.-10:30 A.M.

Room 111, Exhibit Level, Moscone Center

IMMIGRANT MENTAL HEALTH: CHALLENGES AND CONSIDERATIONS

APA/SAMHSA and APA/AstraZeneca Minority Fellowships
Co-Chps.: Shirin Ali, M.D., Felicia Y. Kuo, B.A., M.D.
Participants: Chris Esguerra, M.D., Farha Abbasi, M.D.,
Arun Gopal, M.D., Suzan Song, M.D., M.P.H.,
Batool Kazim, M.D.

CW 20 **9:00 A.M.-10:30 A.M.**
Room 125, Exhibit Level, Moscone Center

NATIONAL TRENDS IN PSYCHOTHERAPY BY PSYCHIATRISTS

APA Committee on Psychotherapy by Psychiatrists

Chp.: Eric M. Plakun, M.D.
Participants: Ramin Mojtabai, M.D., Ph.D.,
Glen Gabbard, M.D., Nada L. Stotland, M.D., M.P.H.

CW 21 **9:00 A.M.-10:30 A.M.**
Room 222, Mezzanine Level, Moscone Center

TRADITIONAL AND PSYCHIATRIC HEALERS IN NORTH AMERICA

*APA Committee of American Indian, Alaska Native,
and Native Hawaiian Psychiatrists*

Chp.: Mary H. Roessel, M.D.

CW 22 **9:00 A.M.-10:30 A.M.**
Room 302, Esplanade Level, Moscone Center

SCHOOL BULLYING: PSYCHIATRIC AND PHYSICAL HEALTH RISKS, AND TREATMENT INTERVENTIONS

APA Corresponding Committee on Mental Health and Schools

Chp.: Marcia J. Slattery, M.D.
Participants: Jorge Srabstein, M.D., Hong Shen, M.D.

CW 23 **9:00 A.M.-10:30 A.M.**
Room 304, Esplanade Level, Moscone Center

BREAKING THROUGH A SHATTER-PROOF GLASS CEILING: WHAT KEEPS WOMEN PSYCHIATRISTS FROM REACHING THEIR LEADERSHIP GOALS?

APA Committee on Women

Co-Chps.: Claudia L. Reardon, M.D.,
Stacey Burpee, D.O., M.P.H.
Participants: Dolores Malaspina, M.D.,
Carol Nadelson, M.D., Gail Robinson, M.D.

ISSUE WORKSHOPS 39-50

IW 39 **9:00 A.M.-10:30 A.M.**
Room 113, Exhibit Level, Moscone Center

SUPERVISION IN THE PSYCHIATRIC EMERGENCY DEPARTMENT: TECHNIQUES FOR MAXIMIZING THE SUPERVISOR-TRAINEE

INTERACTION

Co-Chps.: Divy Ravindranath, M.D., M.S.,
Erick Hung, M.D.
Participant: Michelle Riba, M.D., Kristen Brooks, M.D.,
Jewel Shim, M.D.

IW 40 **9:00 A.M.-10:30 A.M.**
Room 114, Exhibit Level, Moscone Center

PATIENT SUICIDE DURING PSYCHIATRY RESIDENCY: A WORKSHOP DISCUSSION

Co-Chps.: Christina V. Mangurian, M.D.,
Andrew Booty, M.D.
Participants: Emily Davies, M.D., Kristen Brooks, M.D.,
Aaron Reliford, M.D., Laura Dauenhauer, M.D.,
Francine Cournos, M.D.

IW 41 **9:00 A.M.-10:30 A.M.**
Room 122, Exhibit Level, Moscone Center

PEDIATRIC GRIEF AND BEREAVEMENT: STRATEGIES TO HELP KIDS AND PARENTS COPE

Co-Chps.: Ruth E. Geller, M.D., M.Ed.,
Eva Szigethy, M.D., Ph.D.
Participants: Ruth Geller, M.D., M.Ed.,
Olle Jane Sahler, M.D., David R. DeMaso, M.D.

IW 42 **9:00 A.M.-10:30 A.M.**
Room 224, Mezzanine Level, Moscone Center

PRACTICAL MODELS FOR INCORPORATING EBM INTO ACADEMIC CLINICAL PRACTICES

Chp.: John Q. Young, M.D., M.P.P.
Participants: Melissa Nau, M.D., Alison May, M.D.,
Christopher Daley, M.D., Monica Caselli, M.D.,
Lowell Tong, M.D.

IW 43 **9:00 A.M.-10:30 A.M.**
Room 226, Mezzanine Level, Moscone Center

PROMOTING SCHOLARSHIP & LEADERSHIP DURING RESIDENCY TRAINING

Co-Chps.: Anu A. Matorin, M.D., Sandra B Sexson, M.D.
Participants: Jennifer Yen, M.D., Deborah Hales, M.D.,
Pedro Ruiz, M.D.

IW 44 **9:00 A.M.-10:30 A.M.**
Rooms 272-276, Mezzanine Level W, Moscone Center

BEYOND DOCTOR-PATIENT RELATIONSHIP IN CYBERSPACE: PITFALLS, TRANSGRESSIONS, AND GUIDELINES (WHEN THERAPISTS AND PATIENTS GOOGLE EACH OTHER)

Co-Chps.: Damir Huremovic, M.D., M.P.P.,
Nyapati R. Rao, M.D., M.S.
Participants: Shabneet Hira-Brar, M.D., Jacob Sperber, M.D.

IW 45 **9:00 A.M.-10:30 A.M.**
Room 300, Esplanade Level, Moscone Center

**OLDER ADULTS AND THE NEUROBIOLOGY OF
SUBSTANCE ABUSE**

National Institute on Drug Abuse

Chp.: Timothy P. Condon, Ph.D.

Participants: David Oslin, M.D., Gayathri Dowling, Ph.D.

IW 46 **9:00 A.M.-10:30 A.M.**
Room 301, Esplanade Level, Moscone Center

**AMERICAN BOARD OF PSYCHIATRY AND
NEUROLOGY UPDATE: CERTIFICATION IN
PSYCHIATRY AND ITS SUBSPECIALTIES**

Co-Chps.: Larry R. Faulkner, M.D.,

Naleen N. Andrade, M.D.

Participants: Kailie Shaw, M.D., Robert Guynn, B.A.,
M.D., Barbara Schneidman, M.D., M.P.H., Beth Ann
Brooks, M.D., Victor Reus, M.D., David Mrazek, M.D.

IW 47 **9:00 A.M.-10:30 A.M.**
Room 306, Esplanade Level, Moscone Center

**THE COBBLER'S CHILDREN: DEALING WITH
PSYCHIATRIC PROBLEMS IN OUR OWN
FAMILIES**

Chp.: Julia B. Frank, M.D.

Participants: Mitchell Cohen, M.D., Kathryn McIntyre, M.D.

IW 48 **9:00 A.M.-10:30 A.M.**
Room 308, Esplanade Level, Moscone Center

ORAL BOARDS BOOT CAMP-2009

Co-Chps.: Elyse D. Weiner, M.D., Eric D. Peselow, M.D.

IW 49 **9:00 A.M.-10:30 A.M.**
Room 309, Esplanade Level, Moscone Center

**HOW TO LAUNCH A SUCCESSFUL PRIVATE
PRACTICE (PART I)**

Chp.: William E. Callahan, M.D.

Participants: Donna Vanderpool, J.D., M.B.A.,
Martin Tracy, J.D.

IW 50 **9:00 A.M.-10:30 A.M.**
Room 310, Esplanade Level, Moscone Center

**PSYCHIATRISTS WHO HAVE HAD A
PSYCHIATRIC ILLNESS: THEIR STORIES**

Co-Chps.: Michael F. Myers, M.D.,

Leah J. Dickstein, M.D., M.A.

Participants: Alphonse Osinski, M.D., Raymond Reyes, M.D.,
Suzanne E. Vogel-Scibilia, M.D., Francine Cournos, M.D.

SPECIAL EVENT **9:00 A.M. - 11:00 A.M.**
Gateway Ballroom 102 Exhibit Level, Moscone Center

**PSYCHOLOGICAL EFFECTS OF THE LONG WAR:
STRATEGIES FOR MITIGATION**

Co-Chairs: Brigadier General Loree Sutton, M.D.,
Colonel Elspeth Ritchie, M.D.

Presenters: Captain Paul Hammer, M.D.,
Captain Ed Simmer, M.D.

1. Updates on the Defense Center of Excellence
Brigadier General Loree Sutton, M.D.

**2. Suicide and Psychological Issues in the United
States Army**
Colonel Elspeth Ritchie, M.D.

3. Psychological Issues for the United States Navy
Captain Paul Hammer, M.D.

4. Best Practice: Update from DCOE
Captain Ed Simmer, M.D.

Discussant: Robert Ursano, M.D.

ADVANCES IN SERIES

ADVANCES IN SERIES 8 **9:00 A.M.-12 NOON**
Gateway Ballroom 103, Exhibit Level, Moscone Center

HOSPITAL PSYCHIATRY

Chp.: Steven Sharfstein, M.D.

1. A New Model for Acute Psychiatric Hospitalization
Ira D. Glick, M.D., Harold I. Schwartz, M.D.

**2. Core Requirements for an Inpatient Co-Occurring
Disorders Unit**
Patricia R. Recupero, J.D., M.D., John M. Oldham, M.D.

**3. Information Systems and the Electronic Medical
Record**
John J. Boronow, M.D.

4. Financing of Hospital-Based Psychiatry
Benjamin Liptzin, M.D.

**5. Working with Families of Patients with Serious
Mental Illness in the Inpatient Setting**
Lisa B. Dixon, M.D., M.P.H.

MEDIA WORKSHOPS 5-6

MEDIA WORKSHOP 5 **9:00 A.M.-12 NOON**
Room 123, Exhibit Level, Moscone Center

**THE BRIDGE (A DOCUMENTARY FILM ABOUT
SUICIDE FROM THE GOLDEN GATE BRIDGE;
DISCUSSION WITH THE FILM'S DIRECTOR AND A
BRIDGE JUMP SURVIVOR)**

APA Northern California Psychiatric Society

Co-Chps.: Mel I. Blaustein, M.D., Raymond Zablonty, M.D.
Participant: Patrick Hines, Kevin Hines

MEDIA WORKSHOP 6 9:00 A.M.-12:00 NOON

Room 124, Exhibit Level, Moscone Center

disFIGURED – A MOVIE ABOUT WOMEN AND WEIGHT: THE IMPACT OF APPEARANCE ON COPING WITH LIFE

Co-Chps.: Katherine A. Halmi, M.D., Seymour Gers, M.D.

COURSES 77-79

COURSE 77 9:00 A.M.- 4:00 P.M.

*Imperial Ballroom B, Ballroom Level, Tower 2,
Hilton San Francisco*

YOGA OF THE EAST AND WEST: INTEGRATING BREATH WORK AND MEDITATION INTO CLINICAL PRACTICE

Directors: Patricia L. Gerbarg, M.D., Richard P. Brown, M.D.
Faculty: Monica Vermani, M.A., Psy.D.,
Martin Katzman, M.D.

COURSE 78 9:00 A.M.- 4:00 P.M.

*Union Square Room 22, Fourth Floor, Tower 3,
Hilton San Francisco*

EEG FEEDBACK IN PSYCHIATRY: CLINICAL APPLICATIONS

Directors: Thomas M. Brod, M.D., Michael Cohen, M.D.
Faculty: Julian Isaacs, B.A., Ph.D., Gary Schummer, Ph.D.,
Beverly Rubik, B.S., Ph.D., Glenn Marks, Ph.D.,
Len Ochs, M.D.

COURSE 79 9:00 A.M.- 4:00 P.M.

*Union Square Rooms 17/18, Fourth Floor, Tower 3,
Hilton San Francisco*

NARRATIVE PSYCHIATRY: AN INDIGENOUS-FRIENDLY APPROACH FOR CROSS-CULTURAL PSYCHOTHERAPY

Director: Lewis Mehl-Madrona, M.D., Ph.D.
Faculty: Anne-Marie Chaisson, M.D., M.P.H.

10:00 A.M. SESSIONS

**NOW OPEN
EXHIBIT HALL
APA MEMBER CENTER
PUBLISHERS' BOOKFAIR
HOURS OF OPERATION:
10:00 A.M. -5:00 P.M.**

11:00 A.M. SESSIONS

ADVANCES IN MEDICINE 03

ADV IN MEDICINE 11:00 A.M.-12:30 P.M.

Gateway Ballroom 104, Exhibit Level, Moscone Center

MEDICAL UPDATES AND CONTROVERSIES: WHAT PSYCHIATRISTS SHOULD KNOW

Chp.: Robert McCarron, D.O.
Participants: Glen L. Xiong, M.D., John C. Onate, M.D.,
James A. Bourgeois, O.D., M.D.

FORUMS 8-10

FORUM 8 11:30 A.M.-12:30 P.M.

Room 301, Esplanade Level, moscone Center

HOW TO CHOOSE A TOPIC AND SUBMIT SUCCESSFULLY TO THE APA ANNUAL MEETING: UNDERSTANDING MEMBERS' INTERESTS AND DIFFERENT FORMATS

Chairs.: Donald Hilty, M.D., Deborah Spitz, M.D.
Presenters: Robert Boland, M.D., Michele Pato, M.D.,
Ken Silk, M.D., Anand Pandya, M.D., Don Hilty, M.D.

FORUM 9 12:00 A.M.-1:30 P.M.

Room 306, Esplanade Level, Moscone Center

PSYCHIATRY IN AMERICA: AN EUROPEAN PERSPECTIVE

Chair: Pedro Ruiz, M.D.
Presenters: Livia Vaburosa, M.D., Cyril Holsch, M.D.,
Wolfgang Gaebel, M.D., Michael Musaleck, M.D.

FORUM 10 11:00 A.M.-12:30 P.M.

Room 307, Esplanade Level, Moscone Center

THE MILESTONES OF RECOVERY SCALE: TRACKING RECOVERY AND GUIDING SERVICES

Chair: Mark Ragins, M.D.
Participants: Leonard Miller, Ph.D., Dave Pilon, Ph.D.,
Lisa S. Miller, M.D.

LECTURE 21

LECTURE 21 11:00 A.M. -12:30 P.M.

Room 130/131, Exhibit Level, Moscone Center

DEVELOPMENTS IN MENTAL HEALTH SERVICES IN INDIA

Mathew Varghese, M.D.
International Lecture

Chp.: Geetha Jayaram, M.D.
Vice-Chair: Srijan Sen, M.D.

Dr Mathew Varghese is Professor of Psychiatry at the National Institute of Mental Health and NeuroSciences (NIMHANS) at Bangalore, India. He trained in Medicine at the St John's Medical College, Bangalore and specialized in psychiatry at NIMHANS in 1984. For 25 years he has served on the psychiatry faculty at NIMHANS, where he provides clinical service on the adult, geriatric and family psychiatry services as well as postgraduate teaching, research and administration. A visiting faculty and examiner in mental health, he is also on the governing boards of the World Association for Psychosocial Rehabilitation, the Alzheimer's Disease International Association, and the Medical Pastoral Association. Dr Varghese's research interests are in the area of family interventions with psychiatric disorders, social psychiatry and rehabilitation. He does research on dementia and is one of the founding members of the international "10/66 Dementia Research Group". He has developed family intervention manuals for use with caregivers of persons with dementia and schizophrenia. He studies resource needs for mental health care in developing countries. He was a co-investigator and author of the National Human Rights Commission project on "Quality Assurance in Mental Health" in 1999. He was the principle investigator for the Bangalore center on the multi-site World Mental Health Survey in India. Dr. Varghese was the recipient of a Fulbright Alumni Exchange fellowship in geriatric psychiatry at the Robert Wood Johnson Medical School, New Jersey in 2001, and a Fogarty International Center Visiting Fellowship at the ADRC at Washington University School of Medicine, St Louis, in 2008. His research projects supported have been supported by Fogarty International Center (FIRCA & ICOHRTA), the Ministry of Health, the ICMR, the Dept of Science & Technology, the Dept of Biotechnology. He has over 60 publications in journals, books and monographs.

SCIENTIFIC AND CLINICAL REPORTS 17-24 **SCR 17 11:00 A.M.- 12:30 P.M.**

Room 111, Exhibit Level, Moscone Center

BORDERLINE PERSONALITY DISORDER

Chp.: Karla Compton, M.D.

49. Parental Viewpoints of Trajectories to Borderline Personality Disorder

Marianne Goodman, M.D.

50. Lifetime Patterns of Psychotherapy and Medication Utilization in Females with Borderline Personality Disorder- Results of an On-line Parental Survey

Marianne Goodman, M.D.

51. Is Borderline Personality Disorder Underdiagnosed?

David Meyerson, B.A.

SCIENTIFIC AND CLINICAL REPORT **SCR 18 11:00 A.M.- 12:30 P.M.**

Room 112, Exhibit Level, Moscone Center

ALGORITHMS AND OTHER MODELS IN THE TREATMENT OF DEPRESSION

Chp.: Nitin Gupta, M.D.

52. Using the Chronic Care Model to Improve

Depression Care on College Campuses

Henry Chung, M.D.

53. CBASP and Brief Supportive Psychotherapy for Augmentation of Antidepressant Nonresponse in Chronic Depression

James Kocsis, M.D.

54. Can Clinicians Improve Antidepressant Remission Rates With Better Treatment Algorithms?

Richard Metzner, M.D.

SCIENTIFIC AND CLINICAL REPORT

SCR 19 11:00 A.M.- 12:30 P.M.

Room 113, Exhibit Level, Moscone Center

PREMORBID FACTORS AND COURSE IN SCHIZOPHRENIA

Chp.: Haldun Soygur, M.D.

55. Remission in Schizophrenia: A National Survey of Clinical and Psychosocial Aspects

Yoram Barak, M.D.

56. Schizophrenia in the Offspring of Ante-natally Depressed Mothers in the Northern Finland 1966 Birth Cohort – A Gene X Environment Interaction

Pirjo H. Maki, M.D., Ph.D.

57. Child and Adolescent Symptoms Predicting Psychosis

Juha M. Veijola, M.D.

SCIENTIFIC AND CLINICAL REPORTS

SCR 20 11:00 A.M.- 12:30 P.M.

Room 114, Exhibit Level, Moscone Center

TRAUMA AND PTSD

Chp.: Brigitte Apfel, M.D.

58. The USS Cole Bombing: Analysis of Preexisting Factors as Predictors for Development of PTSD

Kevin Nasky, D.O.

59. Emotional Distress and Other Health-Related Dimensions Among Elderly Survivors of the Shoa Living in the Community

Robert Kohn, M.D.

60. Psychopathology Among Holocaust Survivors Sixty Years Thereafter

Itzhak Levav, M.D.

SCIENTIFIC AND CLINICAL REPORTS

SCR 21 11:00 A.M.- 12:30 P.M.

Room 120, Exhibit Level, Moscone Center

SUICIDE IN SPECIALLY DEFINED POPULATIONS

Chp.: Sanjay Vaswani, M.D.

61. Suicide Among Female Veterans During 2005: Findings From the National Violent Death Reporting System
Bentson McFarland, M.D., Ph.D.

62. A Multi-Site Study of the Incidence and Nature of Inpatient Suicide Attempts
Virginia L. Susman, M.D.

63. Association Between Antidepressant Half-Life and the Risk of Suicidal Ideation or Behavior Among Children and Adolescents
Eric Smith M.D.

SCIENTIFIC AND CLINICAL REPORTS

SCR 22 11:00 A.M.- 12:30 P.M.
Room 121, Exhibit Level, Moscone Center

SUBSTANCE USE DISORDER IN PSYCHOSIS AND BIPOLAR DISORDER

Chp.: Merra Vaswani, M.D.

64. Cannabis Withdrawal in People With Schizophrenia
David Gorelick, M.D., Ph.D.

65. Is Use of Illegal Non-Cannabinoid Substances Associated With Psychotic Symptoms?
Nina Kuzenko, M.D.

66. Comorbid Anxiety and Substance Use Disorders Confound the Clinical Diagnosis of Bipolar I But Not II: Implication for Mood Stabilizer Use
Keming Gao, M.D., Ph.D.

SCIENTIFIC AND CLINICAL REPORTS

SCR 23 11:00 A.M.- 12:30 P.M.
Room 122, Exhibit Level, Moscone Center

EPIDEMIOLOGY

Chp.: Derya Akibiyik, M.D.

67. Survey of World Psychiatric Association (WPA) Member Societies on Child Sexual Abuse and Physician-Patient Sexual Relations
Donna Stewart M.D., Ph.D.

68. Parental Mental Illness and Sudden Infant Death Syndrome: The Role of Maternal Smoking, Obstetric Risk Factors and Social Adversity
Roger Webb Ph.D., M.S.C.

69. SMI, SPMI, SED, FMD: Why Can't We Use Only One Mental Health Indicator?
Deepak Prabhakar M.D., M.P.H.

SCIENTIFIC AND CLINICAL REPORTS

SCR 24 11:00 A.M. - 12:30 P.M.
Rooms 272-276, Mezzanine Level W, Moscone Center

METABOLIC EFFECTS OF PSYCHOTROPIC MEDICATION

Chp.: Julio Licinio, M.D.

70. Do Cardiovascular Risk Factors Impede Anti-depressant Treatment Response?
Dale D'Mello M.D.

71. Depressive Symptoms and Risk for 10-Year Cardiovascular Morbidity and Mortality
Hannu Koponen M.D., Ph.D.

72. Weight Gain and Increases in Cholesterol, Triglyceride, and Glucose Levels in Schizophrenic Patients Treated With Clozapine, Olanzapine and Haloperidol
Menahem Krakowski M.D., Ph.D.

SMALL INTERACTIVE SESSIONS 10-11

SI 10 11:00 A.M.-12:30 P.M.
Room 216, Mezzanine Level, Moscone Convention Ctr

HOW TO RESEARCH A CLINICAL QUESTION

Chp.: Ranga Krishnan, M.D.

SI 11 11:00 A.M.-12:30 P.M.
Room 218, Mezzanine Level, Moscone Convention Ctr

HOW TO TREAT BEHAVIORAL SYMPTOMS IN DEMENTIA

Chp.: Marc E. Agronin, M.D.

COMPONENT WORKSHOPS 24-26

CW 24 11:00 A.M.-12:30 P.M.
Room 125, Exhibit Level, Moscone Center

PSYCHIATRIC RESIDENCY TRAINING NEEDS FOR INTERNATIONAL MEDICAL GRADUATES
APA Committee on International Medical Graduates

Co-Chps.: Antony Fernandez, M.D.

Participants: Marie-Claude Rigaud, M.D.,
Fructuoso Irigoyen, Milton Kramer, M.D.

CW 25 11:00 A.M.-12:30 P.M.
Room 222, Mezzanine Level, Moscone Center

MOTIVATING THE MOTIVATORS: MOTIVATIONAL ENHANCEMENT THERAPY MADE EASY
APA Corresponding Committee on Training and Education in Addiction Psychiatry

Chp.: Syed Sattar, M.D.

Participants: Tayo Obatusin, M.D.,
Petros Levounis, M.D., M.A.

CW 26 **11:00 A.M.-12:30 P.M.**

Room 304, Esplanade Level, Moscone Center

THE ASSESSMENT OF VIOLENCE RISK

APA Council on Psychiatry and Law

Chp.: Alec W. Buchanan, Ph.D., M.D.

Participants: Michael Norko, M.D., Renee Binder, M.D.,
Marvin S. Swartz, M.D., Alec Buchanan, Ph.D., M.D.

ISSUE WORKSHOPS 51-56

IW 51 **11:00 A.M.-12:30 P.M.**

Room 224, Mezzanine Level, Moscone Center

THE POST 9-11 ERA: UNDERSTANDING THE CULTURAL ISSUES IN THE PSYCHIATRIC TREATMENT OF MUSLIM PATIENTS

APA Illinois Psychiatric Society

Co-Chps.: Nancy Abdel-Wahab, M.D., Nafisa Ghadiali, M.D.

Participant: Surinder Nand, M.D.

IW 52 **11:00 A.M.-12:30 P.M.**

Room 226, Mezzanine Level, Moscone Center

VISUAL RECOGNITION OF CATATONIA: VIDEO TEACHING SESSION

Chp.: Andrew J. Francis, M.D., Ph.D.

Participants: Gregory Fricchione, M.D.,
Stanley Caroff, M.D.

IW 53 **11:00 A.M.-12:30 P.M.**

Rooms 302, Esplanade Level, Moscone Center

WATCHING THE MOVIES, BEATING THE STIGMAS

Chp.: Rudolf R.A.M. Feijen, M.D.

Participants: Rudolf Feijen, M.D., Bastiaan Oele, M.D.

IW 54 **11:00 A.M.-12:30 P.M.**

Room 308, Esplanade Level, Moscone Center

PSYCHOTHERAPY UPDATE: A REVIEW OF THE CURRENT LITERATURE FOR THE PRACTICING PSYCHIATRIST

Co-Chps.: Priyanthy Weerasekera, M.D., M.Ed.,
John Manring, M.D.

IW 55 **11:00 A.M.-12:30 P.M.**

Room 309, Esplanade Level, Moscone Center

DEVELOPING A M.H.COURT FOR DOMESTIC VIOLENCE PERPETRATORS: A NEW JUDICIAL MODEL

Co-Chps.: Lawrence K. Richards, M.D.,
Bruce J. Winick, J.D.

Participants: Juan Oms, M.D., Bruce Winick, J.D.,

Deborah White-Labora, B.S., J.D., Janetta Cureton,
Anthony Castro, Psy.D., Ph.D.

IW 56 **11:00 A.M.-12:30 P.M.**

Room 310, Esplanade Level, Moscone Center

“DOCTOR, IS THAT A BABY YOU ARE CARRYING?”: IMPACT OF PHYSICIAN PREGNANCY ON THE THERAPEUTIC ALLIANCE

Co-Chps.: Sudeepta SV Varma, M.D.,

Jamae C. Campbell, M.D.

Participants: Kathy Vincent, M.D., M.S.,
Asha Mishra, M.D., Nioaka Campbell, M.D.,
April Morciglio, M.D.

12 NOON SESSIONS

NEW RESEARCH POSTERS SESSION 6:

For further information on New Research sessions, please refer to the *New Research Program* section in the back of this publication.

2:00 P.M. SESSIONS

LECTURE 22

LECTURE 22 **2:00 P.M.-3:30 P.M.**

Room 130/131, Exhibit Level, Moscone Center

WHAT RESEARCH TELLS US ABOUT SUICIDE

Paula J. Clayton, M.D.

Distinguished Psychiatrist Lecture

Chp.: Michael F. Myers, M.D.

Vice-Chair: David Baron, M.S.Ed., D.O.

Dr. Clayton is the Medical Director of the American Foundation for Suicide Prevention in New York City. In this position, she oversees grant funding and educational projects for both professionals and the public. The foundation recently produced *Struggling in Silence: Physician Depression and Suicide*, an educational film that was awarded the 2008 FREDDIE Award in the category of psychiatry. The film was aired on over 300 public television stations nationwide. She graduated AOA from Washington University School of Medicine in St. Louis, Missouri in 1960. She did her psychiatric residency there and joined the staff in 1965. She became a full professor in 1976. In September of 1980, she was appointed Professor and the Head of the Department of Psychiatry at the University of Minnesota School of Medicine, where she served until her retirement in 1999. Later, she was a Professor of Psychiatry at the University of New Mexico School of Medicine from 2001 to 2005. Her first paper, in 1965, defined mania. She received her first clinical grant from NIMH in 1967 to study the recently widowed, to define their responses and compare them to those of psychiatric patients with major depression. She published her first paper on that work in 1968 and multiple manuscripts followed. In 1968 she published a paper, borrowing from European psychiatry, that defined the schizoaffective disorders. In 1969,

she published, with Drs. Winokur and Reich, the first textbook on mania entitled Manic-Depressive Illness. She published three additional books, more than 160 papers and 20 book chapters. Her textbook The Medical Basis of Psychiatry is now in its third revision. Her areas of expertise and research are mood disorders, particularly bipolar and unipolar illness, and bereavement. She is a member of many editorial boards, psychiatric societies, has served on study sections, and has been on many other governmental and nongovernmental committees. In 1985, she received the Athena Award from the University of Michigan as the outstanding woman alumna of the year. She also received a Distinguished Alumnae Award from Washington University in 1985 and in 1993, the First Aphrodite Jannapaula Hofsommer Award from Washington University.

PRESIDENTIAL SYMPOSIA 4-7

PS 4 2:00 P.M.-5:00 P.M.

Rooms 132/133, Exhibit Level North, Moscone Center

WHEN THE TREATMENT FAILS THE PATIENT: PSYCHODYNAMIC CONTRIBUTIONS TO THE TREATMENT OF TREATMENT REFRACTORY PATIENTS

American Academy of Psychoanalysis and Dynamic Psychiatry

Chp.: Sherry P. Katz-Bearnot, M.D.

1. When the Patient Is a Mother: Addressing Parenting Issues in Psychotherapy, Promises and Pitfalls

Jennifer I. Downey, M.D.

2. Challenges Presenting in Transference and Counter-transference in the Psychotherapy of a Military Service Member

Eugene Kim, M.D.

3. Treatment Resistant Patients in Psychotherapy

Michael Stone, M.D.

4. Improving Adherence to Treatment – Contributions of Attachment Theory to our Understanding of Non-Compliance

Cesar A. Alfonso, M.D.

5. Psychodynamic Psychopharmacology: An Approach to Pharmacologic Treatment Resistance

David L. Mintz, M.D.

Discussant: Philip R. Muskin, M.D., M.A.

PS 5 2:00 P.M.-5:00 P.M.

Room 300, Esplanade Level, Moscone Center

THE INVISIBLE WOUNDS OF WAR: MENTAL HEALTH NEEDS OF RETURNING MILITARY AND THEIR FAMILIES

Chp.: Carolyn B. Robinowitz, M.D.

1. Special Needs of Women and Children

Carolyn B. Robinowitz, M.D.

2. Hidden Wounds of War

Barbara Van Dahlen Romberg, Ph.D.

3. Treatment of Post-traumatic Stress Disorder (PTSD)

Robert Ursano, M.D.

4. The Role of VA and the Development of DOD/State and Community Partnerships

Harold Kudler, M.D.

PS 6

2:00 P.M.-5:00 P.M.

Room 301, Esplanade Level, Moscone Center

THE GRANDKIDS OF THE 1967 FLOWER CHILDREN: LESSONS FROM HAIGHT-ASHBURY AND FROM TREATMENT AND RECOVERY

Chp.: Mark S. Gold, M.D.

1. Epidemiology of Drug Use, Abuse, Misuse and Death From the 60s to Today

Bruce A. Goldberger, Ph.D.

2. Lessons from Four Decades of Drug Abuse

Robert L. Dupont, M.D.

3. Summer of Love: 40 Years Later

David E. Smith, M.D.

PS 7

2:00 P.M.-5:00 P.M.

Room 303/305, Esplanade Level, Moscone Center

SUICIDE AND THE GOLDEN GATE BRIDGE

Chp.: Mel I. Blaustein, M.D.

1. A History of Golden Gate Bridge Barrier Campaigns

Eve Meyer, MSW

2. Perspective from a Family Member

John Brooks

3. Suicide Deterrents

Ann Fleming, M.D.

4. The Coroner Reports on Bridge Suicide

Ken Holmes

SYMPOSIA 37-55

SYMPOSIUM 37

2:00 P.M.-5:00 P.M.

Gateway Ballroom 102, Exhibit Level, Moscone Center

DISABILITY REDUCTION AND REHABILITATION OF IRAQI AND AFGHANISTAN WAR VETERANS: THE ROLE OF CIVILIAN MENTAL HEALTH PROVIDERS

Chp.: Samuel O. Okpaku, M.D., Ph.D.

- 1. Suicide Prevention Among Returning Soldiers of War**
Donna H. Barnes, Ph.D.
- 2. Meeting the Needs of Post-Deployment Soldiers: An Interagency Approach**
James K. Boehnlein, M.D.
- 3. Civilian Assessment of Veterans of Iraqi and Afghanistan Wars**
Samuel O. Okpaku, M.D.
- 4. Psychological Effects of Persistent Conflict: Strategies for Mitigation and Collaboration with Civilians**
Elspeth C. Ritchie, M.D.
- 5. Traumatic Brain Injury, Treatment and Rehabilitation**
James R. Merikangas, M.D.
- 6. The War on Terrorism: Rethinking Systems and Services for Iraq and Afghanistan Combat Soldiers and Their Families**
Ron E. Armstead, L.C.S.W.

SYMPOSIUM 38 **2:00 P.M.-5:00 P.M.**

Gateway Ballroom 104, Exhibit Level, Moscone Center

IN-RESIDENCY CLINICAL SKILLS ASSESSMENT: TRAINING FOR FACULTY EVALUATORS

APA Council on Medical Education and Lifelong Learning

Chp.: Michael D. Jibson, M.D., Ph.D.

- 1. Rationale for a Change in the Live-Patient Exam and Program Requirements for the in-Residency Clinical Skills Assessment**
Sandra B. Sexson, M.D.
- 2. What the Research on Direct Observation of Clinical Skills Tells Us**
Joan M. Anzia, M.D.
- 3. Clinical Skills Assessment: Competencies, Skills, Forms, and Anchor Points**
Richard F. Summers, M.D.
- 4. Setting Up a Curriculum for Faculty on Clinical Skills Assessment**
Karen Broquet, M.D.

SYMPOSIUM 39 **2:00 P.M.-5:00 P.M.**

Room 111, Exhibit Level, Moscone Center

INTEGRATING TREATMENT FOR SUBSTANCE USE AND POST-TRAUMATIC STRESS DISORDERS IN PATIENTS WITH CO-OCCURRING CONDITIONS

National Institute on Drug Abuse

Co-Chp.: Udi E. Ghitza, Ph.D., Andrew J. Saxon, M.D.

- 1. Treatment of Co-Occurring PTSD and Substance Use Disorders: Exposure-Based Therapy and Medication Management**
Kathleen Brady, M.D.
- 2. Stepped Collaborative Care Targeting PTSD and Co-Occurring Substance Use Disorders**
Douglas F. Zatzick, M.D.
- 3. Seeking Safety: An Evidence-Based Model for PTSD and/or Substance Abuse**
Lisa M. Najavits, Ph.D.
- 4. Integrating Treatment for Smoking Cessation and PTSD**
Andrew J. Saxon, M.D.
- 5. Pharmacologic Management of PTSD and Comorbid Alcohol Dependence**
Ismene L. Petrakis, M.D.
- 6. Integrated Treatment for PTSD and Substance Use Disorders in Veterans**
Sonja V. Batten, Ph.D.

SYMPOSIUM 40 **2:00 P.M.-5:00 P.M.**

Room 112, Exhibit Level, Moscone Center

IMPULSE CONTROL DISORDERS: RECOGNITION AND CLINICAL MANAGEMENT

Chp.: Jon E. Grant, M.D., J.D.

- 1. Overview of Impulse Control Disorders and Their Neurobiology**
Eric Hollander, M.D.
- 2. Compulsive Shopping Disorder: A Review**
Donald W. Black, M.D.
- 3. Update on the Clinical Features and Treatment of Kleptomania**
Jon E. Grant, M.D.
- 4. Trichotillomania and Skin Picking - Clinical Features and Treatment**
Samuel R. Chamberlain, M.D.
- 5. Etiology, Identification, and Treatment of Pathological Gambling**
Marc N. Potenza, M.D.

SYMPOSIUM 41 **2:00 P.M.-5:00 P.M.**

Room 114, Exhibit Level, Moscone Center

RECENT DEVELOPMENTS IN CROSS-CULTURAL, ETHNIC AND ETHNOPSYCHOPHARMACOLOGICAL ASPECTS OF MOOD DISORDERS: A GLOBAL PERSPECTIVE

Co-Chp.: Rajesh M. Parikh, M.D.,
David Mischoulon, M.D., Ph.D.

1. **Ethnopsychopharmacology Update**
David C. Henderson, M.D.
2. **Psychiatric Management of Hispanic Patients: Cross Cultural Issues and Ethnopsychopharmacology**
David Mischoulon, M.D.
3. **Culturally Sensitive Collaborative Treatment (CSCT) for Chinese Americans with Depression**
Albert Yeung, M.D.
4. **Mood Disorders in the Asian-Indian Population: Effects of Culture, Globalization & Ethnopsychopharmacology**
Rajesh M. Parikh, M.D.
5. **Mood Disorders In Women: The Interaction of Culture and Biopsychosocial Factors**
Shamsah B. Sonawalla, M.D.

Discussant: Shamsah B. Sonawalla, M.D.

SYMPOSIUM 42 **2:00 P.M.-5:00 P.M.**

Room 120, Exhibit Level, Moscone Center

CHOOSING THE RIGHT TREATMENT FOR SUBSTANCE ABUSE

Co-Chp.: Herbert D. Kleber, M.D., Frances R. Levin, M.D.

1. **Choosing the Right Treatment for Cocaine Dependence**
Adam Bisaga, M.D.
2. **Choosing Treatment for Cannabis Dependence**
Frances R. Levin, M.D.
3. **Integrating Psychosocial Interventions with Medications in the Treatment of Substance Dependence**
Edward V. Nunes, M.D.
4. **Pain and Addiction: Implications of Substance Use Disorders for Opioid Therapy**
Maria Sullivan, M.D.
5. **Choosing the Right Treatment for Opioid Dependence**
Herbert D. Kleber, M.D.

SYMPOSIUM 43 **2:00 P.M.-5:00 P.M.**

Room 121, Exhibit Level, Moscone Center

SUICIDE AND AGGRESSION: A PRACTICAL TOOLKIT FROM RISK ASSESSMENT TO JOINT COMMISSION TO THE PATIENT

APA Committee on Patient Safety

Chp.: Yad M. Jabbarpour, M.D.

1. **From Rules to Protocols: Suicide Risk Assessment in Everyday Practice**
Geetha Jayaram, M.D.

2. **Practical Approaches to Violence Risk Assessment**
Marvin S. Swartz, M.D.
3. **SAFE-T Suicide Assessment Five-Step Evaluation and Triage**
Jefferson B. Prince, M.D.
4. **Suicide Risk Management: Research and Practice in an Inpatient Department of Suicide Prevention (Psychiatric University Clinic Salzburg – Austria)**
Reinhold Fartacek, M.D.
5. **The Joint Commission’s View of the Response and Prevention of Suicide and Aggression**
Robert Wise, M.D.

Discussant: Paul S. Appelbaum, M.D.

SYMPOSIUM 44 **2:00 P.M.-5:00 P.M.**

Room 122, Exhibit Level, Moscone Center

THE ROLE OF FORENSIC PSYCHIATRY IN EVALUATING PROBLEMATIC INTERNET BEHAVIORS: UNTANGLING WEBS OF DECEIT FROM MURDER TO MALPRACTICE

Chp.: Charles Scott, M.D.

1. **Forensic Aspects of “Internet Addiction”**
Michael Harlow, M.D.
2. **Psychiatric Evaluations of Defendants Charged with Internet Pornography Possession**
Humberto D. Temporini, M.D.
3. **The Internet and Child and Adolescent Victimization**
Jennifer A. Chaffin, M.D.
4. **The Internet and Cyberstalking**
Soroush Mohandessi, M.D.
5. **Mental Health Treatment via the Internet**
Charles Scott, M.D.

SYMPOSIUM 45 **2:00 P.M.-5:00 P.M.**

Room 123, Exhibit Level, Moscone Center

DROP “SCHIZOPHRENIA”? INTERNATIONAL PERSPECTIVES

World Psychiatric Association’s Section on Rehabilitation and Section for Psychosocial Rehabilitation

Co-Chp.: Zebulon Taintor, M.D., Gregory C. Bunt, M.D.

1. **Should We Abandon the Term Schizophrenia After All These Years?**
John A. Talbott, M.D.
2. **Beyond the Term Schizophrenia**
Afzal Javed, M.B.B.S

3. **Japan: Experience Since Schizophrenia Was Renamed in 2002**
Naotaka Shinfuku, M.D.
4. **Western Pacific Perspectives on Schizophrenia**
Luis Faustino Ignacio, M.D.
5. **Schizophrenia**
Russell D'Souza, M.D.
6. **Subtypes, Electrophysiological Data Point to Several Different Diseases**
Zebulon Taintor, M.D.

Discussant: Michael F. Sadre-Chirazi-Stark, M.D., Ph.D.

SYMPOSIUM 46 **2:00 P.M.-5:00 P.M.**

Room 124, Exhibit Level, Moscone Center

LESBIAN, GAY, BISEXUAL AND TRANSGENDER YOUTH: FAMILY APPROACHES

Chp.: Edgardo J. Menvielle, M.D., M.S., Darryl Hill

1. **Psychopathology and Gender Variance in a Clinical Sample of Children**
Edgardo J. Menvielle, M.D.
3. **Gender Made, Gender Nurtured, Gender Bent: The Child Shapes the Parent as the Parent Shapes the Child in Families with a Gender Variant Child**
Diane Ehrensaft, Ph.D.
4. **Three Integrated Family Interventions for Children With Gender-Variant Behaviors: Face-To-Face Groups, Online Discussions and Multi-Family Gatherings**
Catherine L. Tuerk, M.A.
5. **Raising the Gender-Variant Boy: A Parent's Perspective**
Sarah Hoffman

SYMPOSIUM 47 **2:00 P.M.-5:00 P.M.**

Room 125, Exhibit Level, Moscone Center

PERSONALITY DISORDERS IN THE U.S.A.: RELATIONSHIP TO EARLY EXPERIENCES OCCURRENCE AND COURSE OF AXIS I DISORDERS

National Institute on Alcohol Abuse and Alcoholism

Co-Chp.: Deborah S. Hasin, Ph.D., Andrew E. Skodol, M.D.

1. **Relationship of Personality Disorders to Course of Mood and Anxiety Disorders in a National Sample**
Andrew E. Skodol, M.D.
2. **Personality Disorders: Their Impact on the Course of Alcohol and Drug Dependence in the U.S. General Population**
Deborah S. Hasin, Ph.D.

3. **Childhood Abuse and Neglect Associated with Personality Disorders**
Jeffrey Johnson, Ph.D.
4. **Empirically-Derived Mental Disorder Spectrums and Case Conceptualization: The Role of Personality in Linking Axes I and II**
Robert Krueger, Ph.D.

Discussant: Wilson M. Compton III, M.D.

SYMPOSIUM 48 **2:00 P.M.-5:00 P.M.**

Rooms 272/274/276, Mezzanine Level West, Moscone Center

SPIRITUALLY INTEGRATED TREATMENT

Chp.: John R. Peteet, M.D.

1. **Therapeutic Uses of a Shared Tradition to Address Problematic Faith**
Nadine J. Nyhus, M.D.
2. **Spiritually Integrated Treatment**
Yousef Abouallaban, M.D.
3. **Mental Health Promotion in the African American Faith Community**
Michael A. Torres, M.D.
4. **Spiritual Interventions in the Treatment of Depression**
John R. Peteet, M.D.

SYMPOSIUM 49 **2:00 P.M.-5:00 P.M.**

Room 302, Esplanade Level, Moscone Center

HOW TO APPROACH THE PREGNANT PATIENT FROM A MENTAL HEALTH STANDPOINT

Co-Chp.: Allison S. Baker, M.D., Christina V. Mangurian, M.D.

1. **Diagnosis and Prognosis of Mood Disorders During Pregnancy and the Postpartum Period**
Adele Viguera, M.D.
2. **Prevention and Treatment of Psychiatric Disorders During Pregnancy**
Gail E. Robinson, M.D.
3. **Medicating the Depressed Pregnant Woman: Risk Benefit Discussions and the Informed Consent Process**
Margaret Spinelli, M.D.
4. **Staying Informed and Afloat: The Importance of Evidence-Based Clinical Practice in The Treatment of Mentally ill Patients During and After Pregnancy**
Elizabeth M. Fitelson, M.D.

SYMPOSIUM 50 **2:00 P.M.-5:00 P.M.**

Room 304, Esplanade Level, Moscone Center

ADVANCES IN ELECTROCONVULSIVE THERAPY

APA Corresponding Committee on ECT and Other Electro-magnetic Therapies

Chp.: Shirlene M. Sampson, M.D., M.S.

1. **Ultra-Brief Pulse ECT: Efficacy and Cognitive Impact-Findings From the United States**
Joan Prudic, M.D.
2. **Ultra-brief Pulse ECT: Efficacy and Cognitive Impact Findings From a Larger Clinical Sample (Sydney)**
Colleen K. Loo, M.B.B.S.
3. **Comparing Bifrontal, Bitemporal, and Right Unilateral Electrode Placement in ECT: A Multisite Study From the Consortium for Research in ECT (CORE)**
Charles Kellner, M.D.
4. **An Update on Continuation-ECT**
Mustafa Husain, M.D.

SYMPOSIUM 51 **2:00 P.M.-5:00 P.M.**

Room 306, Esplanade Level, Moscone Center

INTEGRATED TREATMENT OF PERSONALITY DISORDER: PRINCIPLES AND TECHNIQUE

Co-Chp.: John Livesley, M.D., Giuseppe Giancarlo Dimaggio, M.D.

1. **Principles for Organizing Integrated Treatment for Personality Disorder**
John Livesley, M.D.
2. **Tailoring Common Treatment Principles to fit Individual Personalities**
Kenneth L. Critchfield, Ph.D.
3. **An Integrated View of Therapy Techniques for Personality Disorders**
John F. Clarkin, Ph.D.
4. **Integrated Treatment for Personality Disorder with Prominent Inhibited/Constricted Traits**
Giuseppe Giancarlo Dimaggio, M.D.

SYMPOSIUM 52 **2:00 P.M.-5:00 P.M.**

Room 307, Esplanade Level, Moscone Center

“ME-TOO” MEDICATIONS, REALLY?

APA Council on Global Psychiatry and the APA Council on Children, Adolescents

Co-Chp.: Rodrigo A. Munoz, M.D.,
Amy M. Ursano, M.D., A.A.

1. **Barriers to Innovation in Psychopharmacology of Schizophrenia**

William T. Carpenter, M.D.

2. **Diagnosis and Treatment of Bipolar Disorder**
Frederick Goodwin, M.D.
3. **Pharmacology Leading to the Current Debates about Old and New Psychotropics**
Alan F. Schatzberg, M.D.
4. **Concept of “Me-Too” Medications on Public Policies**
Roger Peele, M.D.
5. **Pharmacologic Treatment of Depression**
Jan Fawcett, M.D.

Discussant: M Michaels, M.D.

SYMPOSIUM 53 **2:00 P.M.-5:00 P.M.**

Room 308, Esplanade Level, Moscone Center

END OF LIFE CARE: A MULTIDISCIPLINARY CLINICAL AND RESEARCH UPDATE

Chp.: Laura B. Dunn, M.D.

1. **Psychiatry and Palliative Medicine Collaboration at the End of Life**
Michael W. Rabow, M.D.
2. **Issues Facing Caregivers and Family at the End of Life**
Dianne M. Shumay, Ph.D.
3. **Psychological Adjustment to End of Life Losses: Application of the Reintegration Model to Advanced Cancer**
Sara J. Knight, Ph.D.
4. **End of Life Care in Dementia: A Research Update**
Laura B. Dunn, M.D.
5. **Legal and Ethical Issues at the End of Life in Chronically Mentally Ill Patients with HIV/AIDS**
Jeanne M. St. Pierre, M.D.

SYMPOSIUM 54 **2:00 P.M.-5:00 P.M.**

Room 309, Esplanade Level, Moscone Center

ENGAGING AND TREATING PERSONS WITH RECENT ONSET SCHIZOPHRENIA: PRATICE BASED EVIDENCE FROM THE CLINICAL TRENCHES

American Association of Community Psychiatrists

Chp.: Robert P. Liberman, M.D.

1. **Working in the Trenches with 18 to 25-Year-Olds**
Mark Ragins, M.D.
2. **Assisting the Transition from Child Mobile Treatment to Adult ACT Services for Adolescents with Schizophrenia.**
Curtis N. Adams, Jr., M.D.

3. The Dance of Engagement Connecting with Young Adults in the Pursuit of Mental Health

Andrew J. McLean, M.D.

4. Early Assessment and Support Team: A Community Based Clinical Team Focused on Identifying, Engaging and Treating Youth Who Are Developing Psychosis

Robert Wolf, M.D.

Discussant: Charles W. Huffine, M.D.

SYMPOSIUM 55 **2:00 P.M.-5:00 P.M.**

Room 310, Esplanade Level, Moscone Center

SLEEP DISTURBANCES AND CIRCADIAN DISRUPTIONS AFFECTING, AND AFFECTED BY, ADDICTION TO DRUGS

National Institute on Drug Abuse

Chp.: Harold W. Gordon, Ph.D.

1. Differential Roles for Individual Circadian Genes in Bipolar Disorder and Drug Addiction

Colleen A. McClung, Ph.D.

2. Disordered Sleep and Proinflammatory Cytokines in Cocaine Dependence: Clinical Implications

Michael R. Irwin, M.D.

3. (+/-3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) Use is Associated With Sleep-Disordered Breathing

Una D. McCann, M.D.

4. Impact of Sleep Deprivation and Insomnia on the Development and Maintenance of Drug Addiction

Scott E. Lukas, Ph.D.

5. "Occult insomnia" and Abstinence From Cocaine: Implications for Cognitive Function and the Clinical Treatment of Cocaine Dependence

Robert T. Malison, M.D.

3:00 P.M. SESSIONS

NEW RESEARCH POSTER SESSION 7:

For further information on New Research submissions, please refer to the *New Research Program* section in the back of this publication.

9:00 A.M. SESSIONS

MEDICAL UPDATE

MEDICAL UPDATE 02 9:00 A.M.-10:30 A.M.

Room 122, Exhibit Level, Moscone Center

OPTIMIZING THE DELIVERY OF MENTAL HEALTH AND PRIMARY CARE SERVICES FOR PERSONS LIVING WITH HIV/AIDS

Chp.: David E. Cohn, M.D.

Participants: Saul Perea, Shane Spicer, M.D.

SMALL INTERACTIVE SESSION

SI 12 9:00 A.M. - 10:30 A.M.

Room 218, Mezzanine Level East, Moscone Center

ANTIPSYCHOTIC POLYPHARMACY: AN EVIDENCE BASED PERSPECTIVE

Chp.: Donald Goff, M.D.

COMPONENT WORKSHOPS 27-31

CW 27 9:00 A.M.-10:30 A.M.

Room 113, Exhibit Level, Moscone Center

IDENTIFYING CHILDREN AT RISK FOR MENTAL HEALTH PROBLEMS: EXPLORING HOW RISK FACTORS WORK TOGETHER IN THE EMERGENCE OF CHILDHOOD PSYCHOPATHOLOGY

APA Corresponding Committee on Infancy and Early Childhood

Chp.: William C. Wood, M.D.

Participants: Joan Luby, M.D., Marilyn Essex, Ph.D., Helena Kraemer, Ph.D.

CW 28 9:00 A.M.-10:30 A.M.

Room 114, Exhibit Level, Moscone Center

OUT AND UP IN AGE: MENTAL HEALTH IN LESBIAN, GAY, BISEXUAL AND TRANSGENDER OLDER ADULTS

APA Committee on Gay, Lesbian, and Bisexual Issues

Chp.: Ellen Haller, M.D.

Participants: Stephan Carlson, M.D., Eric Williams, M.D., Umee Davae, D.O., Philip Bialer, M.D.

CW 29 9:00 A.M.-10:30 A.M.

Room 224, Mezzanine Level, Moscone Center

PROMISE AND PERILS OF ELECTRONIC HEALTH RECORD ADOPTION IN PRIVATE PRACTICE PSYCHIATRY

APA Corresponding Committee on Electronic Health Records

Chp.: Laura Fochtmann, M.D.

Participants: Zebulon Taintor, M.D.,

Edward Pontius, M.D., Suzanne Albrecht, M.D.

CW 30 9:00 A.M.-10:30 A.M.

Room 226, Mezzanine Level, Moscone Center

SCHIZOPHRENIA AND AGING: COGNITIVE, MEDICAL, SOCIAL AND PSYCHIATRIC ISSUES *APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly*

Chp.: David A. Casey, M.D.

Participants: Mercedes Rodriguez-Suarez, M.D., Colleen Northcott, Ph.D., M.D., Lina Shihabuddin, M.D., Chantelle Simmons, M.D., Garry Vickar, M.D.

CW 31 9:00 A.M.-10:30 A.M.

Room 310, Esplanade Level, Moscone Center

SCIENCE IN THE CLINIC: DOING RESEARCH AS WE CARE FOR PATIENTS

APA Lifers

Chp.: Sheila Hafter Gray, M.D.

Participants: Christopher Perry, M.D., Pamela Foelsch, Ph.D., Milton Kramer, M.D., Mardi Horowitz, M.D.

ISSUE WORKSHOPS 57-68

IW 57 9:00 A.M.-10:30 A.M.

Room 111, Exhibit Level, Moscone Center

PHANTOMS OF THE MIND: THE ROLE OF NARCISSISM IN THERAPIST BOUNDARY-CROSSING

Chp.: Howard E. Book, M.D.

Participants: Gary Schoener, Psy.D., Carolyn Quadrio, M.D., Ph.D.

IW 58 9:00 A.M.-10:30 A.M.

WITHDRAWN

IW 59 9:00 A.M.-10:30 A.M.

Room 123, Exhibit Level, Moscone Center

RESEARCH WITH SUBJECTS WHO LACK CAPACITY TO CONSENT: SURROGATE CONSENT, ACCEPTABLE RISK, AND OTHER CLINICAL AND ETHICAL CHALLENGES

Chp.: David H. Strauss, M.D.

Participants: Paul Appelbaum, M.D., John Luce, M.D., Jason Karlawish, M.D., David Strauss, M.D., John Oldham, M.D., M.S.

IW 60 9:00 A.M.-10:30 A.M.

Room 124, Exhibit Level, Moscone Center

MAKING THE MOST OF YOUR CHIEF YEAR: CHIEF RESIDENTS' FORUM, PART I

Co-Chps.: Oliver Stroeh, M.D., Shefali Srivastava, M.D.

Participants: Jacob Ballon, M.D., Melissa Nau, M.D.

IW 61 9:00 A.M. -10:30 A.M.
Room 125, Exhibit Level, Moscone Center

MALPRACTICE DEFENSE: WINNING STRATEGIES

Co-Chps.: Abe M. Rychik, J.D., Eugene L. Lowenkopf, M.D.

IW 62 9:00 A.M.-10:30 A.M.
Room 222, Mezzanine Level, Moscone Center

SC PARTNERS IN BEHAVIORAL HEALTH EMERGENCY SERVICES: ACHIEVING TOMORROW, TODAY!

Co-Chps.: Adrienne Coopey, D.O., Brenda M. Ratliff, M.D.
Participants: C. Edgar Spencer, Ed.M., M.S.W.

IW 63 9:00 A.M.-10:30 A.M.
Rooms 272/274/276, Mezzanine Level West, Moscone Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE (PART II)

Chp.: William E. Callahan, M.D.

IW 64 9:00 A.M.-10:30 A.M.
WITHDRAWN

IW 65 9:00 A.M.-10:30 A.M.
Room 301, Esplanade Level, Moscone Center

PSYCHIATRY IN THE AMERICAS: UPDATE FROM THE WORLD PSYCHIATRIC ASSOCIATION

Chp.: Michelle B. Riba, M.D.
Participants: Alfredo Ortiz Fragola, M.D., Francisco Schnaas, M.D., Edgard Belfort, M.D., M.Ed., Rodolfo Fahrer, M.D., Roger Montenegro, M.D., Enrique Camarena, M.D.

IW 66 9:00 A.M.-10:30 A.M.
Room 302, Esplanade Level, Moscone Center

RESPONDING TO THE IMPACT OF SUICIDE ON CLINICIANS

Chp.: Eric M. Plakun, M.D.
Participants: Jane Tillman, Ph.D., Edward Shapiro, M.A., M.D.

IW 67 9:00 A.M.-10:30 A.M.
Room 304, Esplanade Level, Moscone Center

COGNITIVE AND BEHAVIORAL TECHNIQUES TO IMPROVE BRIEF PHARMACOTHERAPY SESSIONS

Chp.: Donna M. Sudak, M.D.
Participants: Judith Beck, Ph.D., Jesse Wright, M.D., Ph.D.

IW 68 9:00 A.M.-10:30 A.M.
Room 309, Esplanade Level, Moscone Center

HELPING PATIENTS WHO DRINK TOO MUCH: USING THE NIAAA CLINICIAN'S GUIDE
National Institute on Alcohol Abuse and Alcoholism

Co-Chps.: Mark Willenbring, M.D., Robert Huebner, Ph.D.

11:00 A.M. SESSIONS

FORUMS 11-13

FORUM 11 11:00 A.M. -12:30 P.M.
Room 301, Esplanade Level, Moscone Center

FROM THE OTHER SIDE OF THE COUCH - A PSYCHIATRIST'S VIEW AS A BREAST CANCER SURVIVOR

Chp.: Ruksana Iftexhar, M.D.
Participants: Lloyd Alcera, M.D.

FORUM 12 11:00 A.M. -12:30 P.M.
Room 306, Esplanade Level, Moscone Center

ACCULTURATION RELATED CHALLENGES IN MENTAL HEALTH

Chp.: Meena Ramani, M.D.
Participants: Tarun Bhandari, M.D., Shivani Mehta, Jovita Crasta, Noumana Hameed, M.D.

FORUM 13 11:00 A.M. -12:30 P.M.
Room 307, Esplanade Level, Moscone Center

NEW TOOLS AND TRENDS: SMOKING CESSATION

Chp.: Steve Schroeder, M.D.

LECTURE 23

LECTURE 23 11:00A.M. -12:30 P.M.
Room 308, Esplanade Level, Moscone Center

THE POWER OF PERSONALIZED LIFESTYLE CHANGES

Dean Ornish, M.D.
Frontiers of Science Lecture

Chp.: Carolyn B. Robinowitz, M. D.

Dean Ornish, M.D., is a pioneer in the medicine of the future. He is the founder and president of the non-profit Preventive Medicine Research Institute in Sausalito, California and a Clinical Professor of Medicine at the University of California, San Francisco. Dr. Ornish received his medical training in internal medicine from the Baylor College of Medicine, Harvard Medical School, and the Massachusetts General Hospital. He received a B.A. in Humanities summa cum laude from the University of Texas in Austin. For over 30 years, Dr.

Ornish has directed clinical research demonstrating, for the first time, that comprehensive lifestyle changes may begin to reverse even severe coronary heart disease, without drugs or surgery. Recently, Medicare agreed to provide coverage for this program, the first time that Medicare has covered a program of comprehensive lifestyle changes. He recently directed the first randomized controlled trial demonstrating that comprehensive lifestyle changes may stop or reverse the progression of prostate cancer. His current research showed that comprehensive lifestyle changes affect gene expression, "turning on" disease-preventing genes and "turning off" genes that promote cancer and heart disease. He is the author of five books, including *The Spectrum: A Scientifically Proven Program to Feel Better, Live Longer, Lose Weight & Gain Health*; *Dr. Dean Ornish's Program for Reversing Heart Disease*; *Eat More, Weigh Less*; *Everyday Cooking with Dr. Dean Ornish*; and *Love & Survival: The Scientific Basis for the Healing Power of Intimacy*.

SCIENTIFIC AND CLINICAL REPORTS 25-27 SCR 25 11:00 A.M.- 12:30 P.M.

Room 113, Exhibit Level, Moscone Center

THE SETTINGS OF PSYCHIATRY: FROM TELE-PSYCHIATRY TO THE EMERGENCY ROOM

Chp.: Derya Akibiyik, M.D.

73. Telepsychiatry – New Approach in Treatment of Cross-Cultural Population: Patient Acceptability Study

Davor Mucic, M.D.

74. Videoconferencing for Delivering Group Intervention to Reduce PTSD and Depression in Women Living in Rural Communities

Cheryl Koopman, Ph.D.

75. Gender Difference of Frequent Visitors in the Psychiatric Emergency Room

Chieh-Hsin Lin, M.D.

SCIENTIFIC AND CLINICAL REPORTS SCR 26 11:00 A.M. - 12:30 P.M.

Room 111, Exhibit Level, Moscone Center

ANTIPSYCHOTIC MEDICATION IN SCHIZOPHRENIA

Chp.: Nitin Gupta, M.D.

76. Long-Term Treatment With Asenapine Versus Olanzapine in Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia

Nina Schooler, Ph.D.

77. Factors Associated With the Use of Atypical Antipsychotics Among the Schizophrenic Population: Generational and Disease Severity Effects

Bernard Astruc, M.D.

78. Ethnic Differences in Length of Stay and Choice of Antipsychotic Medication Among In-Patients Diagnosed With Schizophrenia

Karen Bullock, Ph.D., M.S.W.

SCIENTIFIC AND CLINICAL REPORTS SESSION 27 11:00 A.M. - 12:30 P.M.

Room 112, Exhibit Level, Moscone Center

GAMBLING, ADDICTIONS AND COMPULSIONS

Chp.: Merrra Vaswani, M.D.

79. Pathological Gambling: An Update on Neurophysiology and Pharmacotherapy

Pinhas Dannon, M.D.

80. Psychiatric, Behavioral, and Attitudinal Correlates of Avoidant and Obsessive-Compulsive Personality Pathology in Patients With Binge Eating Disorder

Daniel Becker, M.D.

81. Problem Video Game Use: Assessment and Association With Dimensions of Psychopathology

Vladan Starcevic, M.D., Ph.D.

CWS 32-34

CW 32 11:00 A.M. -12:30 P.M.

Room 120, Exhibit Level, Moscone Center

SAVED BY THE INTERNET? PSYCHIATRIC ADMINISTRATION AND GENERATION X

APA Committee on Psychiatric Administration and Management

Chp.: L. Mark Russakoff, M.D.

Participants: Brian Matthew Hepburn, M.D., James A. Greene, M.D., Susan Stabinsky, M.D., Lydia Weisser, MD

CW 33 11:00 A.M. -12:30 P.M.

Room 122, Exhibit Level, Moscone Center

FORENSIC ISSUES AMONG HISPANICS

APA Committee of Hispanic Psychiatrists

Co-Chps.: Humberto L. Martinez, M.D., Andres J. Pumariega, M.D., Susan Stabinsky, M.D.

Participants: Humberto Martinez, M.D., Roberto Lewis-Fernandez, M.D., Daniel Castellanos, M.D., Andres Pumariega, M.D.

CW 34 11:00 A.M. -12:30 P.M.

Room 222, Mezzanine Level, Moscone Center

NEGOTIATION SKILLS FOR PSYCHIATRISTS

APA Central California Psychiatric Society

Chp.: Andreea L. Seritan, M.D.

Participants: Shannon Suo, M.D.

ISSUE WORKSHOPS 69-80

IW 69 **11:00 A.M. -12:30 P.M.**

Room 114, Exhibit Level, Moscone Center

MAKING THE MOST OF YOUR CHIEF YEAR: CHIEF RESIDENTS FORUM, PART II

Co-Chps.: Oliver Stroeh, M.D., Shefali Srivastava, M.D.

Participants: Jacob Ballon, M.D., Melissa Nau, M.D.

IW 70 **11:00 A.M. -12:30 P.M.**

Room 121, Exhibit Level, Moscone Center

THE NEW PUBLIC PSYCHIATRY: CREATING A FUTURE GENERATION OF PUBLIC PSYCHIATRISTS

Co-Chps.: Eugene Lee, M.D., Jules Ranz, M.D.

Participants: Andrew Kirsch, M.D., M.A.,
Aleksandar Micevski, Matthew Levy, M.D.,
Anthony Carino, M.D.

IW 71 **11:00 A.M. -12:30 P.M.**

Room 123, Exhibit Level, Moscone Center

CROSS-CULTURAL COMPARISONS OF SYSTEM APPROACHES TO PSYCHIATRIC REHABILITATION: EXPERIENCES FROM CHINA AND SAN FRANCISCO

Chp.: Yifang Qian, M.D., Ph.D.

Participants: Robert Cabaj, M.D.,
Yingqiang Xiang, M.D., Ph.D., Ziqing Zhu, Ph.D.

IW 72 **11:00 A.M. -12:30 P.M.**

Room 124, Exhibit Level, Moscone Center

SHOULD HIV TESTING BE ROUTINE FOR PSYCHIATRIC PATIENTS IN INPATIENT AND OUTPATIENT SETTINGS?

Chp.: Robert B. Daroff, M.D.

Participants: Peter Jensen, M.D., Marshall Forstein, M.D.

IW 73 **11:00 A.M. -12:30 P.M.**

Room 125, Exhibit Level, Moscone Center

PSYCHIATRY TRAINING FOR PRIMARY CARE PHYSICIANS, AN ONGOING CHALLENGE

Chp.: Hoyle Leigh, M.D.

Participants: Jon Streltzer, M.D., Seth Powsner, M.D.,
Don Lipsitt, M.D., M.A., Hoyle Leigh, M.D.

IW 74 **11:00 A.M. -12:30 P.M.**

Room 224, Mezzanine Level, Moscone Center

TEEN RISK-TAKING: TRANSLATING NEUROSCI- ENCE INTO REAL LIFE CHOICES

Co-Chps.: Rebecca E. Hommer, M.D.,
William C. Wood, M.D.

Participants: James Bjork, Ph.D., Lynn Ponton, M.D.

IW 75 **11:00 A.M. -12:30 P.M.**

Room 226, Mezzanine Level, Moscone Center

MAKING YOUR PRESENTATION MORE INTERACTIVE: THE BETTER WAY!

Chp.: Jon JD Davine, M.D.

IW 76 **11:00 A.M. -12:30 P.M.**

*Rooms 272/274/276, Mezzanine Level West,
Moscone Center*

PSYCHODYNAMIC THERAPY WITH SELF-DESTRUCTIVE BORDERLINES

Co-Chps.: Eric M. Plakun, M.D.,

Edward Robert Shapiro, M.A., M.D.

IW 77 **11:00 A.M. -12:30 P.M.**

Room 302, Esplanade Level, Moscone Center

CHILDREN OF PSYCHIATRISTS

Co-Chps.: Michelle B. Riba, M.D.,

Leah J. Dickstein, M.D., M.A.

Participants: Eve Stotland, Esq., Naomi Stotland, M.D.,
Heather Speller, Susan Fauman

IW 78 **11:00 A.M. -12:30 P.M.**

Room 304, Esplanade Level, Moscone Center

THE PHYSICIAN AS PATIENT: AN INTERACTIVE WORKSHOP

Co-Chps.: Michael F. Myers, M.D., Glen O. Gabbard, M.D.

IW 79 **11:00 A.M. -12:30 P.M.**

WITHDRAWN

IW 80 **11:00 A.M. -12:30 P.M.**

Room 310, Esplanade Level, Moscone Center

INTEGRATING RESEARCH TRAINING AND EXPERIENCE INTO RESIDENCY TRAINING: A "HOW TO" GUIDE

Chp.: Ellen Berkowitz, M.D.

Participants: Mantosh Dewan, M.D.,
Stephen M. Goldfinger, M.D., Milton Kramer, M.D.,
Michele Pato, M.D., Nina Schooler, Ph.D.

2:00 P.M. SESSIONS

SYMPOSIA 56-72

SYMPOSIUM 56 2:00 P.M. -5:00 P.M.

Room 111, Exhibit Level, Moscone Center

THE ARCHITECTURAL ESSENTIAL BUILDING BLOCKS AND DESIGN ELEMENTS TOWARD A "GOOD ENOUGH" MENTAL HEALTH SYSTEM: NATIONAL AND INTERNATIONAL PERSPECTIVES

American Association of Psychiatric Administrators

Chp.: Yad M. Jabbarpour, M.D.

1. **In the Nirvana Mental Health System We All Pay the Same**
Jeffrey Geller, M.D.
2. **Considering National Mental Healthcare Reform: Report from The APA Task Force on Systems of Care**
Anita S. Everett, M.D.
3. **Grading the States 2009: A Report to the Nation on America's Healthcare System for Serious Mental Illness**
Laudan Y. Aron, M.A.
4. **Canadian Innovations in Mental Health Care: Steps Towards an Optimal System**
Jon JD Davine, M.D.
5. **Unmet Needs Among Schizophrenia Patients and Their Family Caregivers – Selected Results From a European Perspective**
Hartman Hinterhuber, M.D.

Discussant: Steven S. Sharfstein, M.D.

SYMPOSIUM 57 2:00 P.M. -5:00 P.M.

Room 112, Exhibit Level, Moscone Center

PSYCHODYNAMIC PSYCHOTHERAPY: UPDATE ON EMPIRICAL EVIDENCE

Chp.: Mardi J. Horowitz, M.D.

1. **Long Term Effects of Transference Interpretation in Dynamic Psychotherapy**
Per Hoglend, M.D.
2. **Working-Out Traumatic Mourning: a Controlled Evaluation of Psychodynamic Psychotherapy Among Borderline Patients in a Suicidal Crisis**
Antonio Andreoli, M.D.
3. **Transference Formulations by CBT and Dynamic Therapists**
Mardi J. Horowitz, M.D.
4. **Predicting Outcome From Ratings of Therapist Interventions**
George Silberschatz, Ph.D.

5. Evaluating Evidence for the Effectiveness of Psychodynamic Psychotherapy through Meta-Analytic Methods

William K. Lamb, Ph.D.

Discussant: Glen O. Gabbard, M.D.

SYMPOSIUM 58 2:00 P.M. -5:00 P.M.

Room 113, Exhibit Level, Moscone Center

OPTIMIZING TREATMENT OUTCOME IN AXIS 1 DISORDERS: AUGMENTATION WITH FAMILY INTERVENTIONS

Chp.: Gabor I. Keitner, M.D.

1. **Family Intervention to Improve Efficacy and Effectiveness of Medication for Schizophrenia**
Ira Glick, M.D.
2. **Family Systemic Models for Engaging Substance Abusers in Treatment**
Judith Landau, M.D., D.P.M.
3. **The Effectiveness of Adjunctive Family Therapy for Patients with Mood Disorders**
Gabor I. Keitner, M.D.
4. **Adjunctive Family Interventions in Psychosomatic Medicine**
Alison M. Heru, M.D.

Discussant: Michael E. Thase, M.D.

SYMPOSIUM 59 2:00 P.M. -5:00 P.M.

Room 114, Exhibit Level, Moscone Center

HEALING TRAUMATIC WOUNDS IN POST-GENOCIDE RWANDA: PSYCHIATRIC TREATMENT AIDS THE PEACE DIALOGUE

Chp.: Lisa A. Rone, M.D.

1. **Healing Traumatic Wounds in Post-Genocide Rwanda: An Anthropological View of the Rwandan Genocide**
Kristen U. Welch, M.D.
2. **Healing Traumatic Wounds in Post-Genocide Rwanda: Psychiatric Disorders After Genocide**
Lisa A. Rone, M.D.
3. **Healing Traumatic Wounds in Post-Genocide Rwanda: A View from the Inside**
Mukamana Donatilla, M.S.N.
4. **Healing Traumatic Wounds in Post-Genocide Rwanda: The Process of the Dialogue for Peace**
Naasson MN Munyandamutsa, M.D.

SYMPOSIUM 60 **2:00 P.M. -5:00 P.M.**

Room 120, Exhibit Level, Moscone Center

TREATMENT OF ALCOHOL AND CO-OCCURRING PSYCHIATRIC DISORDERS: WHAT DO WE KNOW, AND WHERE DO WE GO FROM HERE?

National Institute on Alcohol Abuse and Alcoholism

Chp.: Carrie L. Randall, Ph.D.

- 1. Treatment of Schizophrenia and Co-Occurring Alcoholism**
Alan I. Green, M.D.
- 2. Treatment of Alcoholism and Other Addictive Disorders with Co-Occurring Bipolar Disorder: Review of the Evidence**
Ihsan M. Salloum, M.D.
- 3. Problems in Assessment and Treatment of Co-Occurring Depression and Alcohol Dependence**
Helen M. Pettinati, Ph.D.
- 4. Co-Occurring Alcohol Use Disorders and Social Anxiety Disorder**
Carrie L. Randall, Ph.D.
- 5. PTSD and Co-Occurring Alcohol Use Disorders**
Kathleen Brady, M.D.

Discussant: Raye Z. Litten, Ph.D.

SYMPOSIUM 61 **2:00 P.M. -5:00 P.M.**

Room 121, Exhibit Level, Moscone Center

UNDER THE BELL JAR: THE LIFE, WORKS, PSYCHOPATHOLOGY AND TREATMENT OF SYLVIA PLATH

Chp.: Laura K. Kent, M.D.

- 1. Sylvia Plath: The Childhood years.**
Allison S. Baker, M.D.
- 2. Sylvia Plath: The College Years**
Laura K. Kent, M.D.
- 3. Sylvia Plath: The Cambridge Years**
Sara S. Nash, M.D.

Discussant: Philip R. Muskin, M.D., M.A.

SYMPOSIUM 62 **2:00 P.M. -5:00 P.M.**

Room 122, Exhibit Level, Moscone Center

BORDERLINE PERSONALITY DISORDER IN ADOLESCENCE: WHAT DOES IT LOOK LIKE AND HOW IS IT TREATED?

Co-Chps.: Marianne S. Goodman, M.D.,
Mary C. Zanarini, Ed.D.

- 1. The Axis I Comorbidity of Adolescent Onset Borderline Personality Disorder**
Mary C. Zanarini, Ed.D.
- 2. Borderline Personality Disorder in Suicidal Adolescents**
Shirley Yen, Ph.D.
- 3. Patterns of Mental Health Treatment Utilization in Adolescent Borderline Personality Disorder (BPD): Does It Differ from Adult BPD?**
Marianne S. Goodman, M.D.
- 4. A Hospital Based Adolescent DBT Program for Adolescent Girls with Borderline Personality Disorder**
Aguirre A. Blaise, M.D.
- 5. Early Intervention for Borderline Personality Disorder in Adolescence: A Randomized Controlled Trial**
Andrew M. Chanen, M.B.B.S.

Discussant: Peter Fonagy, Ph.D.

SYMPOSIUM 63 **2:00 P.M. -5:00 P.M.**

Room 123, Exhibit Level, Moscone Center

DIFFERENT EXPERTS APPROACH A CASE OF BORDERLINE PERSONALITY DISORDER

Association for Research in Personality Disorders

Chp.: James H. Reich, M.D., M.P.H.

- 1. Dealing With Axis I Comorbidity in a Borderline Personality Disorder Case**
James H. Reich, M.D.
- 2. A Dimensional/Vulnerability Approach to Borderline Personality Disorders (BPD)**
Larry J. Siever, M.D.
- 3. Short-term Psychodynamic Supportive Psychotherapy (SPSP) for the Treatment of Borderline Personality Disorder**
Simone Kool, Ph.D.
- 4. Using Nidotherapy to Treat Personality Dysfunction**
Peter Tyrer, M.D.
- 5. An Integrated Perspective on the Treatment of Borderline Personality Disorder**
John Livesley, M.D.
- 6. Treating the Case of "Sam" with STEPPS* (Systems Training for Emotional Predictability & Problem Solving)**
Nancee S. Blum, M.S.W.

SYMPOSIUM 64 2:00 P.M. -5:00 P.M.

Room 124, Exhibit Level, Moscone Center

BAD VERSUS MAD: THE FAILURE OF THE PENAL SYSTEM IN CALIFORNIA

APA Council on Global Psychiatry and the APA Council on Children, Adolescents, and Their Families

Co-Chps.: Rodrigo A. Munoz, M.D.,
Marcia K. Goin, M.D., Ph.D.

- 1. Therapeutic Justice: Family Members Speak out to End Discrimination Against Individuals Struggling to Recover From Addictive Illness**
Gretchen Bergman
- 2. Deconstructing Co-Dependence: Parents Need to Shepherd Their Loved Ones Into Treatment Services and Away From Punitive Policies**
Caroline Stewart
- 3. New Treatments and Better Prognosis**
Claudio Cabrejos, M.D., M.P.H.
- 4. Treat or Shun**
Kenneth A. Khoury, M.D.
- 5. California's Nonviolent Offender Rehabilitation Act: Reducing the Role of Addiction and Mental Illness in Prison Overcrowding**
Margaret Dooley-Sammuli

Discussant: Robert Phillips, M.D., Ph.D.

SYMPOSIUM 65 2:00 P.M. -5:00 P.M.

Room 125, Exhibit Level, Moscone Center

PREVENTION AND TREATMENT OF MENTAL DISORDERS IN CHILDREN IN CARE

APA Committee on Family Violence and Abuse

Co-Chps.: Gail E. Robinson, M.D., D.P.H.,
Carole L. Warshaw, M.D.

- 1. Helping Violence Exposed Children: A Curriculum to Strengthen the Parent-Child Relationship**
Patricia J. Van Horn, Ph.D.
- 2. Increasing Access to Child Welfare and Mental Health Systems by Reducing Stigma**
William Arroyo, M.D.
- 3. The Effects of Enhanced Foster Care on the Long-Term Physical and Mental Health of Foster Care Alumni**
Peter Pecora, Ph.D.
- 4. Youth Empowerment Interventions and Foster Care**
Sandra J. Kaplan, M.D.

SYMPOSIUM 66 2:00 P.M. -5:00 P.M.

Rooms 272-276, Mezzanine Level W, Moscone Center

REASSESSING THE ACTION OF PSYCHIATRIC DRUGS

Chp.: Joanna Moncrieff, M.D.

- 1. What Do Psychiatric Drugs Really Do? Deconstructing Conventional Views of Psychiatric Drug Action**
Joanna Moncrieff, M.D.
- 2. Does Anything Stabilize Moods?**
David T. Healy, M.D.
- 3. Hippocratic Psychopharmacology: A New Approach**
Nassir Ghaemi, M.D.

SYMPOSIUM 67 2:00 P.M. -5:00 P.M.

Room 301, Esplanade Level, Moscone Center

THE SUICIDAL PATIENT WITH BORDERLINE PERSONALITY DISORDER

Chp.: Robert J. Gregory, M.D.

- 1. Risk Factors for Suicidal Behavior in Borderline Personality Disorder**
Paul H. Soloff, M.D.
- 2. The Suicidal Borderline Patient: An Object Relations Approach**
John F. Clarkin, Ph.D.
- 3. Strategies and Interventions for Suicidal Individuals with Borderline Personality Disorder: DBT Techniques and Beyond**
Barbara H. Stanley, Ph.D.
- 4. Dynamic Deconstructive Psychotherapy: A Novel Treatment for Reducing Suicide Risk in Borderline Personality Disorder**
Robert J. Gregory, M.D.

SYMPOSIUM 68 2:00 P.M.-5:00 P.M.

Room 302, Esplanade Level, Moscone Center

EMERGING CLINICAL APPLICATIONS OF GENOTYPE-GUIDED PSYCHOTROPICS FOR DEPRESSIVE DISORDERS

Co-Chp.: Simon Kung, M.D., Gualberto Ruano, M.D., Ph.D.

- 1. Greater Utilization of Psychiatric Services Is Associated With Cyp450 Drug Metabolism Deficiencies**
Gualberto Ruano, M.D.
- 2. Cytochrome P-450 2D6, 2C19, and Serotonin Transporter Genotyping for Depressed Inpatients at the Mayo Clinic Mood Disorders Unit**
Simon Kung, M.D.

3. Pharmacogenetic Testing in Psychiatry: Early Adopters' Attitudes and Practices

Jinger G. Hoop, M.D.

4. The Serotonin Transporter Gene (SLC6A4): Understanding Variability and Enhancing the Clinical Utility of Genotyping

David A. Mrazek, M.D.

SYMPOSIUM 69 **2:00 P.M.-5:00 P.M.**

Room 304, Esplanade Level, Moscone Center

COMBATING STIGMA OF BORDERLINE PERSONALITY DISORDER

Co-Chp.: Stuart C. Yudofsky, M.D., Perry D. Hoffman, Ph.D.

1. The Consequences of Stigma for Patients With Borderline Personality Disorders

George Vaillant, M.D.

2. Medical Care for Borderline Personality Disorder in Germany - A European Perspective

Martin Bohus, M.D.

3. Psychoeducation for Patients With Borderline Personality Disorder and Their Families

Joel Paris, M.D.

4. Family and Consumer Advocacy to Congress: From Stigma to Stability for Borderline Personality Disorder

James O. Payne, J.D.

5. Borderline Personality Disorder Research at NIMH

James P. Breiling, D.Phil.

SYMPOSIUM 70 **2:00 P.M.-5:00 P.M.**

Room 306, Esplanade Level, Moscone Center

GENETIC VULNERABILITIES FOR DRUG ABUSE AND CO-MORBID MENTAL HEALTH DISORDERS

National Institute on Drug Abuse

Co-Chp.: Minda R Lynch, Ph.D., Joni L Rutter, Ph.D.

1. Subjective Drug Effects as Endophenotypes for Vulnerability

Harriet de Wit, Ph.D.

2. The Influence of Genetic Variance in the Dopamine Transporter on Brain and Behavioral Responses to Smoking Cues

Teresa Franklin, Ph.D.

3. Interacting Effects of COMT Genotype and Nicotine Withdrawal on Brain Function and Cognition

Caryn Lerman, Ph.D.

4. Approaching Comorbidity in Addiction Genetics

Joel Gelernter, M.D.

5. Genetics of Alcoholism and Related Endophenotypes

Howard J. Edenberg, Ph.D.

SYMPOSIUM 71

2:00 P.M.-5:00 P.M.

Room 307, Esplanade Level, Moscone Center

THE COLLABORATIVE LONGITUDINAL PERSONALITY DISORDERS STUDY: IMPLICATIONS FOR DSM-V

Co-Chp.: Andrew E. Skodol, M.D., John G. Gunderson, M.D.

1. Associations of Personality Disorders and Axis I Disorders Over Time: Implications for Spectrum Models

Tracie Shea, Ph.D.

2. Traits and Symptomatic Behaviors: A Hybrid Model of Personality Disorders

Thomas H. McGlashan, M.D.

3. Comparative Validity of Diagnostic Models for Personality Disorders

Leslie C. Morey, Ph.D.

4. Impact of Personality Psychopathology on Course and Outcome of Axis I Disorders

Andrew E. Skodol, M.D.

5. Perspectives on BPD: Lessons Learned From CLPS

John G. Gunderson, M.D.

Discussant: Kenneth R. Silk, M.D.

SYMPOSIUM 72

2:00 P.M.-5:00 P.M.

Room 308, Esplanade Level, Moscone Center

MATTERS OF THE HEART: DEPRESSION AND CARDIOVASCULAR DISEASE

Chp.: Carolyn B. Robinowitz, M.D.

Co-Chp.: Charles B Nemeroff, M.D. Ph.D.

1. Autonomic Imbalance, Depression and CAD: Facing Our Scotoma

Lawson Wulsin, M.D.

2. The Relationship Between Depressive Episodes and Acute Coronary Syndrome (ACS)

Alexander Glassman, M.D.

3. The AHA Scientific Perspective: Is Depression an Independent Risk Factor for Cardiovascular Disease?

Erika Froelicher, RN

* * * *

Don't Miss the opportunity to submit Your presentation for the the 2010 APA Annual meeting

May 22-27, 2010 in New Orleans, LA

Watch for Updates and Infomation at www.psych.org

TOPIC INDEX

Addiction Psychiatry

IW10-Imaging insight: Basic Definitions, Measures	11
IW13-Diversion of Prescription Stimulants.....	11
A03-Advances in Substance Abuse	18
S01-Spotting the Wolf in Sheep's Clothing	19
CW12-How General Psychiatrists Can Effectively.....	27
IW31-Assessment and Treatment of Sleep Disorders	28
C70-Motivational Therapy for People	33
S20-Biological Basis of Sex Differences in Drug.....	35
C80-Office-based Buprenorphine: Treatment.....	40
CW25-Motivating the Motivators: Motivational	45
PS6-The Grandkids of the 1967 Flower	47
S42-Choosing the Right Treatment for Substance	49
FO13-New Tools and Trends: Smoking Cessation	54
S60-Treatment of Alcohol and Co-Occurring	58

Aids and HIV Related Disorders

S11-Comprehensive HIV Psychiatry Update	21
FO5-Anxiety in Patients with HIV	29
S21-Co-occurring Disorders in HIV Positive Patient	35
IW72-Should HIV Testing be Routine for Psychiatric	56

Alcohol and Drug-Related Disorders

Lecture 3-Pills to Treat Alcoholism	8
IW02-Practical Pharmacotherapy For The Treatment	10
FO4-Treating Women with Alcohol Use Disorders	13
IW14-Challenging Stigmas & Stereotypes: Integrated	16
S05-Understanding and Addressing Adolescent	20
S16-Contributions of Neuroscience to Medications.....	22
C55-Systemic Therapies for Substance Abuse	25
IW23-Extended Treatments for Alcohol Use	27
FO7-New Perspectives on Cultural Issues.....	29
Lecture 16-How Alcoholism Develops.....	30
C69-Street Drugs & Mental Disorders Overview	33
S23-Social Stress Increases Vulnerability to Drug	35
S24-What's New in Pharmacotherapy for Alcohol	36
S35-PTSD and Alcohol Use Disorder	38
IW45-Older Adults and the Neurobiology of	42
S39-Integrating Treatment for Substance Use	48
IW68-Helping Patients Who Drink Too Much:	54
S70-Genetic Vulnerabilities for Drug Abuse	60

Anxiety Disorders

Lecture 1-Prevalence, Correlates, and Risk of PTSD	2
Focus Live 2-PTSD & Disaster Psychiatry	13
Focus Live 3-Panic & Social Anxiety Disorder	17
S12-The OC Spectrum in the Athlete:	21

FO5-Anxiety in Patients with HIV	29
Lecture 20-Overcoming the Terror of Death	40
S39-Integrating Treatment for Substance Use	48

Attention Spectrum Disorders

C24-Essentials of Assessing & Treating ADHD	4
ISS-05 The Pathophysiology of ADHD	6
C37-Advanced Assessment and Treatment	7
ISS-08 ADHD FAQs: Practical Answers	7

Behavior and Cognitive Therapies

CKS01 Practical Cognitive Behavior Therapy	1
C25-CBT for Severe Mental Illness	4
C33-Neuroanatomy of Emotions	5
IW19-Cognitive Therapy for Psychosis	16
C59-Treating Chronically Depressed Patient with CB	25
IW24-Cognitive Therapy for Personality Disorders	27
C67-Engaging Resistant and Difficult-to-Treat	33
C68-A Primer on Acceptance and Commitment	33
IW67-Cognitive and Behavioral Techniques	54

Biological Psychiatry and Neuroscience

S23-Social Stress Increases Vulnerability to Drug	35
S30-Current and Future of the Emergent Field of	37
S40-Impulse Control Disorders: Recognition	48

Child and Adolescent Psychiatry and Disorders

C05-Child & Adol Psychiatry for General Psychiatrist	1
C23-Autism Spectrum Disorders Over the Lifespan	4
Small Interactive 1-Safety Issues in Child	11
MW1-Ready? OK! A Film About Childhood	11
S05-Understanding and Addressing Adolescent	20
S31-Pediatric Bipolar Disorder: A Critical	37
IW41-Pediatric Grief and Bereavement	41
CW22-School Bullying: Psychiatric and	41
S46-Lesbian, Gay, Bisexual and Transgender 5.....	0
CW27-Identifying Children At Risk for Mental	53
IW74-Teen Risk-Taking: Translating Neuroscience	56
IW77-Children of Psychiatrists	56
S62-Borderline Personality Disorder	58

Cognitive Disorders

ISS-02 Effective Treatment of Alzheimers Disease.....	4
CW11-Recognition and Treatment of Dementia	27
Small Interactive 11-How to Treat Behavioral	45

TOPIC INDEX

Combined Pharmacotherapy and Psychotherapy

C46-Money Matters I: Using Theory in Clinical	12
C58-Money Matters II: Advanced Clinical Ad Hoc	25
CW16-Indications for the Use of Combined Talking	32
PS4 When the Treatment Fails the Patient:	47
IW67-Cognitive and Behavioral Techniques	54

Computers

C34-Exploring Technologies in Psychiatry	7
--	---

Couple and Family Therapies

C18-Love, Intimacy, Desire, and Infidelity	3
--	---

Creativity and the Arts

C54-Reel Psychiatry	17
MW3-The Joy Luck Club: Universal Stories	28
IW37-The Portrayal of Psychiatry in Recent.....	33
IW53-Watching the Movies, Beating the Stigma's	46
S61-Under the Bell Jar: The life, Works	58

Cross-Cultural and Minority Issues

C19-The IMG Institute	3
C41-Applied Cultural Psychiatry: How the DSM-IV	8
CW02-Lost and Not Found: Depression	10
IW01-Increasing Cultural Competency	10
IW03-Incest - a Cultural Perspective	10
IW12-Using the DSM-IV-TR Cultural	11
Lecture 7-Psychiatric Education Across	13
IW18-Application of Cultural Variables	16
S17-Monitoring Equity In Mental Health	22
S18-Recovery and Rehabilitation: From	22
CW10-Biracial Americans: "Check One Box Only"	27
MW3-The Joy Luck Club: Universal Stories	28
FO6-Bridges and Barriers to Care	29
FO7-New Perspectives on Cultural Issues	29
Lecture 15-Cross-cultural Psychopharmacology	29
S26-The Effects of City Life on Mental Health	36
C74-Introducing Culture Into Psychiatric Practice	40
CW19-Immigrant Mental Health: Challenges	40
CW21-Traditional and Psychiatric Healers	41
C79-Narrative Psychiatry An Indigenous Friendly	43
FO9-Psychiatry in America: An European	43
Lecture 21-Developments in Mental Health	43
IW51-The Post 9-11 Era: Understanding	46
PS6-The Grandkids of the 1967 Flower Children	47
S41-Recent Developments in Cross-Cultural	48
FO12-Acculturation Related Challenges	54

IW65-Psychiatry in the Americas: Update	54
IW71-Cross-Cultural Comparisons of System	56

Diagnostic Issues

C26-Seeing the Forest and the Trees	4
C42-Understanding the Person Behind	12
C45-Going From the Bio-Bio-Bio Model	12
FO1-DSM-V: Progress in Research	13
DSM - Evolution of the DSM	18
S06-"In or Out?": A Discussion about DSM	20
CC3-Issues in the Differential Diagnosis	26
Lecture 13-Models of the Mind	26
C64-Advanced Interviewing Techniques	29
IW33-The Use of Research Measures	32
DSM - Public Health Aspects of Diagnosis	33
AM03-Medical Updates and Controversies	43
S45-Drop "Schizophrenia"? International	49
S72-Matters of the Heart: Depression & Cardio	60

Eating Disorders

C49-Therapeutic Interventions in Eating Disorders	12
S27-Recent Research In Eating Disorders	36
MW6-disFIGURED – A Movie About Women	43

Electronic Medical Records

CW29-Promise and Perils of Electronic Health	53
--	----

Epidemiology

Lecture 16-How Alcoholism Develops	30
Lecture 18-The Movement for Global Mental	34

Ethics and Human Rights

IW06-Ethical, Clinical and Legal Challenges	10
FO2-The Relationship Between the APA	13
PS2-Psychiatrist Relationship with Industry	19
DR01-APA: Our Relationships to Pharmaceutical	26
CW14-National Security, the Hippocratic Oath	27
AM02-Current Ethical Challenges in Assisted	29
CW18-Ethical Dilemmas in Psychiatric Practice	32

Forensic Psychiatry

C09-A Practical Approach to Risk Assessment	2
C12-Malpractice Risk for Psychiatrists Basics & Be	2
C13-Psychiatric Roles in Assessing and Treating	3
Lecture 2-Psychopathic Disorders Without Borders	5
C38-The Detection of Malingered Mental Illness	7
IW05-Risk Management Issues in Psychiatric	10
C53-The Psychiatrist as Expert Witness	17

TOPIC INDEX

S04-Stalking: Risk Management and Treatment	19
C56-Risk Assessment for Violence	25
CW13-Outpatient Forensic Services and Intervention	27
IW22-Clinical and Forensic Issues Concerning Infan	27
IW26-Assessment of Capacity: Developments	28
IW32-Doing it Right the First Time: Recognizing	28
CW15-Current Topics in Forensic Psychiatry: Update	32
A07-Advances in Forensic Psychiatry	33
S32-Working With Lawyers	37
CW26-The Assessment of Violence Risk	46
S44-The Role of Forensic Psychiatry in Evaluating	49
IW59-Research With Subjects Who Lack Capacity	53
IW61-Malpractice Defense: Winning Strategies	54
CW33-Forensic Issues Among Hispanics	55
S64-Bad v. Mad. The failure of the Penal System	59

Gender Issues

MW1-Ready? OK! A Film About Childhood	11
---	----

Genetics

Lecture 5-Psychiatric Genetics A Current	9
Lecture 6-Etiology in Psychiatry: Phenomes	9
IW21-Tips for Effective Communication	27
S68-Emerging Clinical Applications of Genotype	59
S70-Genetic Vulnerabilities for Drug Abuse	60

Geriatric Psychiatry

C03-Psychiatric Consultation in Long-term Care.....	1
C14-Mood Disorders in Later Life	3
C16-Psychiatric Consultation in Long-term Care	3
Focus Live 1-Geriatric Psychiatry	8
Lecture 10-Successful Aging and Wisdom	17
CW11-Recognition and Treatment of Dementia	27
Small Interactive 5-Palliative Care and Psychiatric	27
IW45-Older Adults and the Neurobiology of	42
S53-End of Life Care: A Multidisciplinary Clinical	51
CW28-Out and Up in Age: Mental Health in Lesbian.....	53
CW30-Schizophrenia and Aging: Cognitive, Medical	53

Group Therapy

C47-Treating BPD with the STEPPS* Model	12
C76-Model of Group Psychotherapy for Persons	40

Historical Questions

Special Event - NCPS Presents Breaking the Barriers	22
---	----

Individual Psychotherapies

C04-Hope for the Distressed & Disruptive Physician.....	1
C02-Interpersonal Psychotherapy	1
C10-Interpersonal and Social Rhythm Therapy	2
CKS02 Practical Psychodynamic Psychotherapy	3
C31-Short-Term Psychodynamic Supportive	5
C43-Davanloo's Intensive Short-Term Dynamic	12
A05-Advances in Psychotherapeutic Psychiatry	25
C57-Time-Limited Dynamic Psychotherapy	25
C62-A Psychodynamic Approach to Trmt	28
C64-Advanced Interviewing Techniques	29
CW20-National Trends in Psychotherapy	41
IW54-Psychotherapy Update: A Review of	46
IW57-Phantoms of the Mind: The Role Of	53
IW76-Psychodynamic Therapy With Self	56

Internet

C06-How to Blog, Friend, & Fly: 21st Century	1
IW44-Beyond Doctor-Patient Relationship	41
S44-The Role of Forensic Psychiatry in Eval	49
CW32-Saved by the Internet? Psychiatric Admin	55

Lesbian/Gay/Bisexual/Transgender Issues

C48-Developmental Approach to Contemporary	12
Special Event - NCPS Presents Breaking the	22
S46-Lesbian, Gay, Bisexual and Transgender	50
CW28-Out and Up in Age: Mental Health in	53

Managed Care and Health Care Funding

Lecture 8-Mental Health in the New Era of Cost	14
C52-CPT Coding and Documentation	17
PS1-Psychiatry Better for Patients and Physicians	18
IW38-The Changing Managed Care Landscape	33

Mood Disorders

C11-Psychopharmacologic ECT & Therapeutic	2
C14-Mood Disorders in Later Life	3
C29-Melatonin & Light Trtmt of SAD,	5
ISS-03 Delivering Optimal Care for Complex	5
ISS-06 Augmentation Strategies for Major	6
ISS-07 Augmentation Strategies for Major	7
CW02-Lost and Not Found: Depression	10
S02-Adjustment Disorders: Problems in	19
S14-Increasing the Likelihood of Achieving	21
ISS-09 Anxious Depression: Diagnostic and	23
ISS-10 Bipolar Disorder Throughout the Life	24
C62-A Psychodynamic Approach to Trmt	28

TOPIC INDEX

IW34-FFT-HPI and FIT: Two Different Approaches	32
S28-Publication Bias and the Effectiveness	37
S31-Pediatric Bipolar Disorder: A Critical Look	37
ISS-11-Novel Approaches to Assessing and	39
Small Interactive 9-Clinical Manual for the Dx	40
C73-CBT for Insomnia Co-morbid	40
IW41-Pediatric Grief and Bereavement	41
S72-Matters of the Heart: Depression	60

Neuropsychiatry

C22-Traumatic Brain Injury: Neuropsychiatric	3
CKS03 Advances in Neuropsychiatry	12
A01-Advances in Neuropsychiatry	18
S16-Contributions of Neuroscience to Medications	22
Small Interactive 4-Neuropsychiatric Assessment	27
IW52-Visual Recognition of Catatonia: Video	46

Other Somatic Therapies

C01-Brain Stimulation Therapies in Psychiatry	1
C60-It's Not Just in Your Head: Medical Problems	25
MU01-21st Century ECT – Updating the APA	26
C63-Herbs, Nutrients, & Yoga for Anxiety, PTSD	28
IW25-The Impact of Meditation as a Non-Phar	28
Small Interactive 8-Brain Stimulation Therapies	30
C75-ECT Practice Update for the General Psych	40
C78-EEG Feedback in Psychiatry: Clinical App	43
C77-Yoga of the East and West: Integrating	43
S50-Advances in Electroconvulsive Therapy	50
Lecture 23-The Power of Personalized Lifestyle	54

Pain Management

C51-Multidisciplinary Treatment of Chronic Pain	17
---	----

Personality Disorders

C27-Psychotherapy for Borderline Personality	4
C47-Treating BPD with the STEPPS* Model	12
IW17-Can Disclosure of a Diagnosis of Borderline	16
S07-Relationship of Subthreshold Psychiatry	20
S15-The Transmission of Borderline Personality	21
Lecture 14-Borderline Personality Disorder	26
IW24-Cognitive Therapy for Personality Disorders	27
A06-Advances in Personality Disorder	33
S29-Borderline Personality Disorder: The Role	37
S33-Empirically Validated and Effective Psychotherapy	38
C71-Mentalization Based Treatment (MBT) for BPD	40
S47-Personality Disorders in the United States	50
S51-Integrated Treatment of Personality Disorder	51
S62-Borderline Personality Disorder in Adolescence	58

S63-Different Experts Approach a Case of Borderline	58
S67-The Suicidal Patient with Borderline	59
S69-Combating Stigma of Borderline	60
S71-The Collaborative Longitudinal	60

Political Questions

Lecture 17-When Politics Distorts Science	30
---	----

Presidential Theme

CW31-Science in the Clinic: Doing Research	53
--	----

Professional and Personal Issues

BDRV Board Review: ABPN Part 1	1
C04-Hope for the Distressed & Disruptive	1
C12-Malpractice Risk for Psychiatrists Basics	2
C28-Losing a Patient to Suicide	5
C35-Treating Medical Students and Physicians	7
C36-Treating Physicians Involved in Sexual	7
IW05-Risk Management Issues in Psychiatric	10
CW05-Career Advancement in Administrative	10
FO2-The Relationship Between the APA	13
PS2-Psychiatrist Relationship with Industry	19
DR01-APA: Our Relationships to Pharma	26
IW28-When Psychiatry Residents Treat	28
IW29-Bootcamp for Burnout	28
Small Interactive 6-When a Physician	30
Small Interactive 7-Approach to the Psychiatric	30
CW23-Breaking through a Shatter-Proof Glass	41
IW46-American Board of Psychiatry	42
IW47-The Cobbler's Children: Dealing	42
IW50-Psychiatrists Who Have Had	42
FO8-How to Submit to the Annual Meeting	43
IW56-"Doctor, is That a Baby You Are	46
IW57-Phantoms of the Mind: The Role	53
FO11-From the Other Side of the Couch	54
CW34-Negotiation Skills for Psychiatrists	55
IW77-Children of Psychiatrists	56
IW78-The Physician As Patient:	56

Psychiatric Administration and Services: Public, Private, and University

C07-Basic Concepts in Admin Psychiatry	2
C20-Basic Concepts in Administrative	3
CW05-Career Advancement in Administrative	10
CW07-Revitalizing Service: Strategic Planning	16
A08-Advances in Hospital Psychiatry	42
Lecture 21-Developments in Mental Health	43
CW32-Saved by the Internet? Psychiatric	55

TOPIC INDEX

IW70-The New Public Psychiatry: Creating	56
S56-The Architectural Essential Building Blocks	57
S64-Bad v. Mad. The failure of the Penal System	59

Psychiatric Education

C19-The IMG Institute	3
C17-Give a More Effective Lecture Punch Passion	3
C21-What is Psychiatry? Philosophies and Practice	3
C39-Improve Your Presentation Skills	7
CW06-Show Me the Money! Sustainable Funding	10
IW12-Using the DSM-IV-TR Cultural Formulation	11
IW08-Mindful Practice: Understanding its Role	11
Lecture 7-Psychiatric Education Across Civilizations	13
AM01-The Top 10 Medical Articles of 2008	13
C54-Reel Psychiatry	17
S08-Educating a New Generation of Physicians	20
IW21-Tips for Effective Communication	27
Small Interactive 7-Approach to the Psychiatric	30
IW39-Supervision in the Psychiatric Emergency	41
IW42-Practical Models for Incorporating EBM	41
FO8-How to Submit to the Annual Meeting	43
CW24-Psychiatric Residency Training Needs	45
S38- In-Residency Clinical Skills Assessment	48
IW80-Training for All Psychiatric Residents	56
IW75-Making Your Presentation More Interactive	56

Psychoanalysis

CC1-Psychoanalytic Case	9
Lecture 20-Overcoming the Terror of Death	40

Psychopharmacology

Small Interactive 1-Safety Issues in Child	11
C44-Drug Interaction Principles Course: Update 2009	12
A02-Advances in Psychopharmacology	18
S09-Effective Assessment and Treatment of Sexual	21
Small Interactive 3-A Discussion about Drug	27
Lecture 15-Cross-cultural Psychopharmacology	29
S24-What's New in Pharmacotherapy for Alcohol	36
S52-"Me-too" Medications, Really?	51
Small Interactive 12-Antipsychotic Polypharmacy	53
S66-Reassessing the Action of Psychiatric Drugs	59

Psychosomatic Medicine

C44-Drug Interaction Principles Course: Update 2009	12
C50-Dev of Integrated Care Models for Patients	17
A04Advances in Psychosomatic Medicine	25
CW17-Medical Issues for Psychiatrists in Disasters	32

IW35-Outpatient Mastectomies	32
AM03-Medical Updates and Controversies	43
S53-End of Life Care: A Multidisciplinary Clinical	51
IW73-Psychiatry Training for Primary Care	56

Religion, Spirituality, and Psychiatry

C08-Spirituality in Psychiatry	2
IW51-The Post 9-11 Era: Understanding the Cultural	46
S48-Spiritually Integrated Treatment	50

Research Issues

C40-Research & Publishing on a Shoestring Budget	8
C41-Applied Cultural Psychiatry: How the DSM-IV-TR	8
FO3-Developing the Next Generation of Clinical	13
FO1-DSM-V: Progress in Research and Development	13
IW33-The Use of Research Measures In Clinical	32
S25-Autism in Adults Towards a Better Clinical	36
S28-Publication Bias and the Effectiveness	37
Small Interactive 10-How to Research a Clinical	45
IW59-Research With Subjects Who Lack Capacity	53

Resident and Medical Student Concerns

C35-Treating Medical Students and Physicians	7
IW04-Playing in the Big League: Resident	10
IW20-Resident Wellness Survey Results	16
IW30-Lessons from the Post-Residency Road	28
IW28-When Psychiatry Residents Treat Medical	28
S22-Starting Out on the Right Foot: Securing Your	35
IW43-Promoting Scholarship & Leadership During	41
IW40-Patient Suicide During Psychiatry Residency	41
IW48-Oral Boards Boot Camp-2009	42
IW49-How to Launch a Successful Private Practice	42
CW24-Psychiatric Residency Training	45
S38- In-Residency Clinical Skills Assessment	48
IW60-Making the Most of Your Chief Year:	53
IW63-How to Launch a Successful Private Practice	54
IW69-Making the Most of Your Chief Year	56
IW80-Training for All Psychiatric Residents	56

Schizophrenia and Other Psychotic Disorders

ISS-01 Development of New Agents for the	4
ISS-04 Neurobiology: Predication and Manage	6
Lecture 9-The Center Cannot Hold: My Journey	14
IW19-Cognitive Therapy for Psychosis in Practice	16
C65-Treatment of Schizophrenia	29
Lecture 19-Translational Neuroscience	34
S45-Drop "Schizophrenia"? International Perspective	49
S54-Engaging and Treating Persons with Recent	51

TOPIC INDEX

Small Interactive 12-Antipsychotic Polypharmacy	53
CW30-Schizophrenia and Aging: Cognitive, Medical	53

Sexual and Gender Identity Disorders

C13-Psychiatric Roles in Assessing and Treating	3
C36-Treating Physicians Involved in Sexual Misconduct	7
S10-The Neurobiological Evidence for Transgenderis	21
S09-Effective Assessment and Treatment of Sexual	21

Sleep Disorders

C29-Melatonin & Light Trtmt of SAD, Sleep & Other	5
IW31-Assessment and Treatment of Sleep Disorders	28
C66-Overview - Sleep Medicine for Mental Hlth	29
IW36-Evaluation and Management of Patients	33
C73-CBT for Insomnia Co-morbid w/Depressive	40
S55-Sleep Disturbances and Circadian Disruptions	52

Social and Community Psychiatry

Lecture 4-Psychiatrists Role in Prevention	8
CC2-A Population-Based Case Conference	9
CW08-Combat to Community: Needs and Resources	16
CW09-Becoming a Public Psychiatry Leader:	16
S03-Delivering Psychiatry in Rural Peru:	19
Lecture 11- William C. Menninger Convocation	23
IW27-Lessons Learned About Resilience	28
S36-Psychiatric Patients Overcrowding	38
FO10-The Milestones of Recovery Scale	43
S37-Disability Reduction and Rehabilitation	47

Stigma/Advocacy

MW2-Silver Spurs - Severe and Chronic Mental Illness	11
IW14-Challenging Stigmas & Stereotypes: Integrated	16
IW53-Watching the Movies, Beating the Stigma's	46
S65-Prevention and Treatment of Mental Disorders	59
S69-Combating Stigma of Borderline Personality	60

Stress

IW29-Bootcamp for Burnout	28
C77-Yoga of the East and West: Integrating Breath	43

Suicide

C28-Losing a Patient to Suicide	5
IW09-Need to Reformulate 'Risk' and Its	11
S19-Suicide Without a Psychiatric Disorder	35
IW40-Patient Suicide During Psychiatry	41

MW5-The Bridge(a Documentary Film	42
Lecture 22-What Research Tells us About Suicide	46
PS7-Suicide and the Golden Gate Bridge	47
S43-Suicide and Aggression: A Practical Toolkit	49
IW66-Responding to the Impact of Suicide	54
S67-The Suicidal Patient with Borderline Personality	59

Telepsychiatry

IW07-Technology And Psychiatry: Practical	11
IW11-Implementing a Telepsychiatry Program	11
IW62-SC Partners in Behavioral Health Emergency	54

Treatment Techniques and Outcome Studies

C30-Creative Use of Boundary Crossings in Therapy.....	5
CW01-High Risk Student Populations: Innovative	10
DR02-Psychiatry Should Embrace Measurement	26
IW25-The Impact of Meditation as a Non-Pharm	28
FO6-Bridges and Barriers to Care	29
S57-Psychodynamic Psychotherapy: Update	57
S58-Optimizing Treatment Outcome in Axis	57

Violence, Trauma, and Victimization

Lecture 1-Prevalence, Correlates, and Risk of PTSD	2
C15-Psychiatric Interventions in Disasters & Public	3
Lecture 4-Psychiatrists Role in Prevention	8
CW04-International Disasters: Challenges	10
Focus Live 2-PTSD & Disaster Psychiatry	13
IW15-Man and Non-Man Made Disasters in Asia	16
Small Interactive 2-Psychiatric Issues Related	16
CW08-Combat to Community: Needs and Resources	16
S04-Stalking: Risk Management and Treatment of Off	19
C56-Risk Assessment for Violence	25
C61-Disaster Psychiatry Terrorism Trauma & Things	25
CW14-National Security, the Hippocratic Oath	27
MW4-Provoked: Combating Domestic Violence	28
CW17-Medical Issues for Psychiatrists in Disasters	32
C72-From Traumatic Stress to Trauma-Infor	40
CW22-School Bullying: Psychiatric and Physical	41
Special Event - Psychological Effects of the	42
CW26-The Assessment of Violence Risk	46
IW55-Developing a M.H.Court for Domestic	46
PS5-The Invisible Wounds of War	47
S43-Suicide and Aggression: A Practical	49
S59-Healing Traumatic Wounds in Post-Genocide	57

TOPIC INDEX

Women's Health Issues

C32-Management of Psychiatric Disorders	5
AM02-Current Ethical Challenges in Assisted	29
PS3-Psychiatry and the Control of Fertility	34
IW56-"Doctor, is That a Baby You Are Carrying?"	46
S49-How to Approach the Pregnant Patient from	50
FO11-From the Other Side of the Couch	54
FO4-Treating Women with Alcohol Use	13
IW35-Outpatient Mastectomies	32
MW6-disFIGURED – A Movie About Women	43

PRESENTER INDEX

A

Abbasi, Farha	41
Abdel-Wahab, Nancy	46
Abel, Gene G.	7
Abouallaban, Yousef	50
Aboul-Fotouh, Frieda	4
Abrams, Karen M.	20
Adams, Curtis N., Jr.	51
Adelson, Stewart	12
Adler, Mats	15
Adler, Nancy	35
Agronin, Marc E.	45
Ahmed, Iqbal	10, 17
Ahmed, Sadaf	10
Akibiyik, Derya Iren	15, 31, 45, 55
Akil, Huda	36
Akiskal, Hagop S.	20
Akiyama, Tsuyoshi	16
Alarcon, Renato D.	14
Albrecht, Suzanne	53
Alcera, Lloyd	54
Alegría, Margarita	2
Alfonso, Cesar A.	47
Ali, Shirin	27, 41
Alkhouri, Iyad	28
Allison, Rebecca	20
Alsuwaidan, Mohammad	10
Andermann, Lisa F.	40
Anderson, Allan	17
Anderson, Otis, III	10
Andrade, Naleen N.	42
Andrea, Helene	14
Andreoli, Antonio	57
Anglin, Rebecca	31
Anton, Raymond F.	36
Anzia, Joan M.	3, 48
Apfel, Brigitte	44
Appelbaum, Paul S.	19, 49, 53
Apter, Gisele	18, 34, 35
Arean, Patricia	3
Armstead, Ron E.	48
Armstrong, Scott C.	12
Arnsten, Amy	6
Aron, Laudan Y.	57
Arroyo, William	59
Ash, Peter	34
Astruc, Bernard	55
Atkins, Robert	3
Auger, R. Robert	29
Austin, Jehannine C.	27
Axelson, Alan	3

B

Bailey, Rahn	29
Baker, Allison S.	50, 58
Ballon, Jacob	54, 56
Barak, Yoram	44

Bark, Nigel	36
Barnes, Donna H.	48
Barnhill, John W.	30
Baron, David A.	19, 46
Bartlett, Selena E.	22
Bassu, Ellen K.	40
Bateman, Anthony W.	25, 38, 40
Batki, Steven	35
Batten, Sonja V.	48
Baum, Antonia L.	21
Beck, Judith S.	1, 27, 54
Becker, Daniel	55
Becker, Jill B.	35
Becker, Judith V.	3
Bedregal, Luis E.	19
Beeber, Alan R.	12
Beer, Jennifer	11
Beezhold, Julian	28
Begum, Millia	31
Beitman, Bernard D.	25
Belfort, Edgard	54
Bell, Carl C.	9
Benedek, Elissa	11, 27, 32
Benjamin, Sheldon	27
Benjelloun, Hind	16
Bergman, Gretchen	59
Berkowitz, Ellen	56
Berman, Karen Faith	35
Bhandari, Tarun	54
Bhugra, Dinesh	18
Bialer, Philip	29, 53
Binder, Renee	13, 46
Birkholm, Molly	28
Bisaga, Adam	49
Bittner, Stephen J.	19
Bjork, James	56
Black, Donald W.	12, 48
Blaise, Aguirre A.	58
Blanco-Jerez, Carlos	19
Blaustein, Mel I.	42, 47
Blendy, Julie	36
Block, Jerald	1
Blum, Nancee S.	12, 58
Blumenfeld, Michael	25
Blumfield, Michael	22
Bockting, Claudi C.L.H.	37
Boehnlein, James K.	48
Bohus, Martin	37, 60
Bokarius, Vladimir	17
Boland, Robert	43
Book, Howard E.	5, 53
Booty, Andrew	41
Boronow, John J.	42
Bostwick, John M.	35
Bourgeois, James A.	1, 43
Boust, Susan	16
Brada, Kay	16
Brady, Kathleen	19, 38, 48, 58
Brams, Jolie	4
Brandt, Douglas M.	2, 3

PRESENTER INDEX

Breiling, James P.	60
Breitbart, William	27, 35
Brendel, David H.	3
Brod, Thomas M.	43
Brodkey, Amy C.	20
Brooks, Beth Ann	42
Brooks, John	47
Brooks, Kristen	41
Broquet, Karen	48
Brower, Kirk J.	28
Brown, Richard A.	19
Brown, Richard P.	29, 43
Brown, Sandra A.	20
Brown, Thomas E.	4, 7
Bruce, Travis O.	21
Brymer, Melissa	28
Buchanan, Alec W.	27, 46
Buckingham, U. Diane	27
Buckley, Peter	3
Bullock, Karen	55
Bunt, Gregory C.	49
Burd, Ronald	17
Burke, Mary G.	38
Burpee, Stacey	10, 41
Busner, Joan	32
Bystritsky, Alexander	38

C

Cabaj, Robert	56
Cabrejos, Claudio	59
Cahill, Larry F.	35
Calabrese, Joseph R.	24
Calderon-Abbo, Jose	28
Caligor, Eve	4
Callahan, William E.	42, 54
Camarena, Enrique	54
Campbell, Frank	5
Campbell, Jamae C.	46
Campbell, Nioaka N.	16, 46
Campbell, William H.	2, 4, 12, 36
Capitanio, John P.	36
Caring, Joanne	31
Carino, Anthony	56
Carlson, Stephan	53
Carney, Colleen	40
Caroff, Stanley N.	25, 46
Carpenter, Linda	1, 18
Carpenter, William T.	51
Carter, Diana	5
Caselli, Monica	41
Casey, David A.	53
Casey, Patricia P.	19
Castellanos, Daniel	55
Castro, Anthony	46
Ceccherini-Nelli, Alfonso	32
Cefalu, Charles	4
Chaffin, Jennifer	49
Chaisson, Anne-Marie	43
Chamberlain, Samuel R.	48

Chan, Carlyle	7
Chanen, Andrew M.	58
Chang, Grace	13
Chang, Jacquelyn	10, 27, 29
Chase-Eldridge, Warene	16
Chaudhry, Haroon	16
Chen, Chiao-Chicy	16
Cheong, Josepha A.	13, 17, 40
Chien, Peter L.	16
Choi-Kain, Louis W.	22
Christianson, Amy	25
Chung, Henry	44
Ciccocioppo, Roberto R. C.	22
Clarkin, John F.	4, 51, 59
Clayton, Paula J.	46-47
Cloninger, C. Robert	26
Cobb, Robert	25
Coconcea, Cristinel	15
Coffey, Barbara	11
Coffey, C. Edward	12
Coffey, Justin	10
Cohen, Carl I.	27
Cohen, Judith	3
Cohen, Lisa	32
Cohen, Michael	43
Cohen, Mitchell	42
Cohn, David E.	53
Coleman, Dan	14
Compton, Karla	44
Compton, Wilson M., III	11, 19, 50
Conant-Norville, David O.	21
Condon, Timothy P.	42
Coopey, Adrienne	54
Correll, Christoph	6
Courchesne, Eric	4
Cournos, Francine	35, 41, 42
Crasta, Jovita	54
Critchfield, Kenneth L.	51
Crone, Catherine	25, 40
Crow, Scott J.	37
Cummings, Jeffrey L.	12
Cureton, Janetta	46
Cutler, Janis	20
Cyr, Alan	27

D

Daley, Christopher	41
Dallam, Deborah	27
Dannon, Pinhas	55
Daroff, Robert, Jr.	21
Daroff, Robert B.	56
Dauenhauer, Laura	41
Davae, Umee	53
David, Daniella	28
Davidoff, Donald	3
Davidson, Kate M.	38
Davies, Emily	41
Davine, Jon J. D.	56, 57
Davis, Jeri	3

PRESENTER INDEX

Davis, Steven	1
De Blécourt, Carel	31
De Jonghe, Frans	5
De Wit, Harriet	60
Deas, Deborah	20
DeFrancisci, Lea	11, 32
Dekker, Jack J.	5
Del Rosario, Salvador R.	11
DeMaso, David R.	41
Desai, Abhilash K.	1, 3
DesMeules, Marie	22
Devlin, Michael J.	12, 37
Dewan, Mantosh J.	3, 8, 56
Diamond, Milton	21
Diaz-Granados, Natalia	22
Dickstein, Leah J.	7, 16, 42, 56
Dieperink, Eric	17
Dimaggio, Giuseppe Giancarlo	51
Dimeff, Linda A.	38
Dixon, Lisa B.	42
D’Mello, Dale	45
Doghramji, Karl	33
Dole, Aparna	29
Donatilla, Mukamana	57
Dooley-Sammuli, Margaret	59
Douaihy, Antoine	35
Dougherty, Darin D.	1, 6, 37
Dowling, Gayathri	42
Downey, Jennifer I.	47
Doyle, Robert	4
Drescher, Jack	20, 30
D’Souza, Russell	16, 50
Dunn, Jeffrey	20
Dunn, Laura B.	38, 51
Dupont, Robert L.	47

E

Ecker, Sidney W.	21
Edenberg, Howard L.	60
Edinger, Jack	40
Ehrensaft, Diane	50
Ehret, Megan	15
Eist, Harold I.	26, 38
Elliott, Glen R.	38
Ellison, James M.	3
Elsayed, Yasser	14
Esguerra, Chris	41
Essex, Marilyn	53
Everett, Anita S.	16, 39, 57

F

Faden, Vivian B.	20
Fahrer, Rodolfo	54
Fairweather, Amy	16
Faison, Warachal	18
Falzone, Richard	28
Farabaugh, Amy	24

Farkas, Marianne D.	22
Farlow, Martin	4
Fartacek, Reinhold	49
Faulkner, Larry R.	42
Fauman, Beverly	10
Fauman, Susan	11, 56
Fava, Maurizio	21, 23, 24, 39
Fawcett, Jan	51
Feenstra, Dineke	14
Feijen, Rudolf R.A.M.	46
Felthous, Alan R.	5
Fernandez, Antony	45
Ferrando, Stephen J.	25
Ferranti, Jessica	14
Fine, Carla	5
Finlayson, Reid	1
Finn, Christine	27
Finucane, Thomas	26
Fireman, Marian	30
Fishel, Tobi	1
Fishkind, Avrim B.	39
Fitelson, Elizabeth M.	50
Fleming, Ann	47
Fochtman, Laura	53
Foelsch, Pamela	53
Fonagy, Peter	33, 37, 40, 58
Fong, Timothy	33
Forester, Brent	3
Forstein, Marshall	11, 12, 21, 35, 56
Fragola, Alfredo Ortíz	54
Francis, Andrew J.	46
Frank, Ellen	2, 18
Frank, Julia B.	42
Frank, Richard	14
Frankel, Debra	2
Franklin, Teresa	60
Freeman, Alfred	22
Fricchione, Gregory	46
Froelicher, Erika	60
Fung, Kenneth	33, 40
Furukawa, Toshiaki A.	25

G

Gabbard, Glen O.	3, 25, 33, 39, 41, 56, 57
Gabriel, Adel	14, 31
Gaebel, Wolfgang	43
Galanter, Marc	18, 25
Galynker, Igor	32
Ganzini, Linda	35
Gao, Keming	45
Garcia, Mai-Ling	16
Garrett, Michael	28
Gask, Linda	34
Gates, Elena	29
Gaudio, Brandon	2
Gaynes, Bradley N.	39
Gelernter, Joel	60
Geller, Jeffrey	57
Geller, Ruth E.	41

PRESENTER INDEX

George, David T.	36
George, Mark S.	12, 37
George, Tony P.	18
Gerbarg, Patricia L.	29, 43
Germain, Anne	40
Gers, Seymour	43
Gessesse, Hiruy	25
Ghadiali, Nafisa	46
Ghaemi, S. Nassir	3, 59
Ghitza, Udi E.	48
Glantz, Meyer D.	19
Glassman, Alexander	60
Gleason, Ondria	17
Glick, Ira D.	42, 57
Glover, Karinn	27
Goethe, John	31
Goff, Donald	53
Goin, Marcia K.	59
Goisman, Robert	1
Gold, Lisa	34
Gold, Mark S.	47
Goldberger, Bruce A.	47
Goldfinger, Stephen M.	56
Goldman, Howard	34
Goldman, Marina	10
Goldman, Morris B.	29
Goler, Nancy	13
Gonzalez, Gerardo	40
Goodkin, Karl	21
Goodman, Marianne S.	44, 58
Goodwin, Frederick	51
Gopal, Arun	41
Gordon, Harold W.	52
Gordy, Tracy R.	17
Gorelick, David	45
Grady-Weliky, Tana A.	11, 28
Granacher, Robert P.	4
Grant, Jon E.	48
Grant, Steven	11
Gray, Sheila Hafter	53
Greco, Nicholas, IV	32
Green, Alan I.	18, 58
Green, Stephen	32
Greenberg, Benjamin D.	37
Greene, James A.	55
Greenfield, Shelly F.	13
Greenwald, Phyllis	5
Gregory, Robert J.	59
Gregory, Simon	39
Grewal, Arvinder K.	5
Greydanus, Donald	7
Groen, Wouter	36
Grossberg, George T.	1, 3, 4
Guarino, Kathleen	40
Gunderson, John G.	3, 21, 22, 26, 33, 38, 60
Gupta, Nitin	16, 32, 44, 55
Gutheil, Thomas G.	3, 38
Guyann, Robert	42

H

Hales, Deborah	3, 17, 41
Hales, Robert E.	18
Hall, Ryan	32
Haller, Ellen	53
Halmi, Katherine A.	12, 37, 43
Hameed, Noumana	54
Hammer, Paul	42
Hammerness, Paul	6
Han, Jaesu	1
Harding, Kelli	13
Harlow, Michael	49
Harris, Treniece Lewis	11
Harrow, Martin	15
Hartmann, Lawrence	22
Harvey, Philip	4
Harvey, Steven	11
Hasan, Nidal N. H.	32
Hasin, Deborah S.	50
Hatti, Shivkumar	2, 10
Hauser, Peter	17
Healy, David T.	59
Henderson, David C.	49
Hendren, Robert L.	1
Hendriksen, Mariëlle	5
Hepburn, Brian Matthew	55
Herbert, Sarah E.	11
Hercher, Laura	27
Herie, Marilyn	33
Herman, Barry K.	2, 3, 10
Hermann, Richard	5
Herrman, Helen E.	37
Hersh, Richard G.	16
Heru, Alison M.	57
Hickson, Gerald	1
Hien, Denise	38
Higgins, Brian D.	16
Hill, Darryl	50
Hilty, Donald	11, 13, 43
Hines, Kevin	43
Hines, Patrick	43
Hinterhuber, Hartman	57
Hippman, Catriona	27
Hira-Brar, Shabneet	42
Hirshkowitz, Max	29
Hoffman, Perry D.	16, 60
Hoffman, Sarah	50
Hoge, Charles	16
Hoge, Steven K.	27, 32
Hoglund, Per	57
Hollander, Eric	48
Hollon, Steven	37
Holmes, Ken	47
Holsch, Cyril	43
Hommer, Rebecca E.	56
Hoop, Jinger G.	60
Hopkinson, Marta	10
Horgan, Constance M.	33
Horowitz, Mardi J.	53, 57

PRESENTER INDEX

Houston, Michael	11
Hsiung, Robert C.	1
Hudson, James I.	22
Huebner, Robert	54
Huffine, Charles W.	52
Huguelet, Philippe	15
Hung, Erick	41
Huremovic, Damir	41
Hurley, Robin A.	18
Hurwitz, Thomas D.	29
Husain, Arshad	10
Husain, Mustafa	51
Hussain, Mustafa	1
Hutsebaut, Joost	14

I

Ibe, Aloysius	31
Iftekhar, Ruksana	54
Ignacio, Luis Faustino	50
Ilorente, Maria	27
Indest, David	17
Irigoyen, Fructuoso	45
Irwin, Michael R.	52
Isaacs, Julian	43
Ishak, Waguih	15
Ivanov, Iliyan	7

J

Jabbarpour, Yad M.	49, 57
Janicak, Philip G.	29
Janofsky, Jeffrey	27, 32
Javed, Afzal	49
Jayaram, Geetha	34, 43, 49
Jenkins, Rachel	37
Jensen, Peter	56
Jeste, Dilip	14, 17
Jibson, Michael D.	48
Jimerson, David C.	12
Joffe, Carole E.	34, 35
Johnson, Bankole A.	8, 36
Johnson, Bradley R.	3
Johnson, Jeffrey	50
Joiner, Lasa	16
Jorgenson, Linda M.	5, 11

K

Kahan, Kara	4
Kalali, Amir	4
Kane, John	6
Kang, Shimi	33
Kaplan, Gabriel	7
Kaplan, Sandra J.	59
Kaplan, Stuart	32
Karlawish, Jason	53
Kaskutas, Lee Ann	13

Katz, Craig I.	3
Katz-Bearnot, Sherry P.	47
Katzelnick, David	26
Katzman, Martin	29, 43
Kay, Jerald	10
Kaye, Walter H.	37
Kazim, Batool	41
Keitner, Gabor I.	57
Kellner, Charles	26, 40, 51
Kemp, David	24
Kendler, Kenneth	9
Kennedy, Robert S.	7
Kent, Laura K.	58
Kernberg, Otto F.	4
Kertzner, Robert M.	12
Ketter, Terence	18
Khan, Sarah	28
Khoury, Kenneth A.	59
Kim, Borah	32
Kim, Eugene	47
Kingdon, David	4, 16
Kirsch, Andrew	56
Kleber, Herbert D.	18, 49
Kleber, Mark	18
Klein, Carolina	28
Klin, Ami	36
Knight, Sara J.	51
Kocsis, James	44
Kohn, Robert	44
Koike, Alan	1
Koivukangas, Jenni	31
Koob, George F.	22
Kool, Simone	5, 58
Koopman, Cheryl	55
Koponen, Hannu	45
Kosten, Thomas R.	38
Koyanagi, Chad	11
Kraemer, Helena	53
Krakovski, Menahem	45
Kramer, Milton	15, 45, 53, 56
Kranzler, Henry R.	36
Krishnan, Ranga	45
Kronenberg, Anne	22
Krueger, Robert	18, 50
Krystal, Andrew	26, 40
Kua, Ee-Heok Ehk	37
Kudler, Harold	47
Kung, Simon	59
Kuo, Felicia Y.	41
Kuo, Irving	27
Kupfer, David	13
Kuzenko, Nina	45

L

LaBoy, Felicity L.	16
Laje, Gonzalo	21
Lamb, William K.	57
Landau, Judith	57
Lane, Richard	11

PRESENTER INDEX

Lansky, Melvin	9	Maki, Pirjo H.	44
Larson, Justine	20	Malaspina, Dolores	41
Lazarus, Arthur	3	Malison, Robert T.	52
Leamon, Martin	1	Malmquist, Carl P.	11, 27
Lebowitz, Barry D.	8	Malphurs, Julie E.	28
Lee, Allison	32	Manber, Rachel	40
Lee, Elliott	29	Mangurian, Christina V.	41, 50
Lee, Eugene	56	Manring, John	3, 46
Leigh, Hoyle	31, 56	Mao, Alice	4
Lerman, Caryn	60	Marazziti, Donatella	31
Leucht, Stefan	6	Marchionni, Christine	33
Leuchter, Andrew F.	21	Marder, Stephen R.	29
Levander, Eric	25	Markov, Dimitri D.	10, 33
Levav, Itzhak	44	Markowitz, John C.	1, 25
Levenson, Hanna	25	Marks, Glenn	43
Levenson, James L.	25	Marks, Saul I.	21
Levin, Edmund C.	38	Marks, Tracey I.	7
Levin, Frances R.	19, 49	Martens, Elizabeth	37
Levine, Stephen B.	3	Martinez, Humberto L.	55
Levounis, Petros	27, 45	Martin-Katzman, Roy D.	28
Levy, Matthew	56	Marzani-Nissen, Gabrielle	21
Levy, Norman B.	35	Mason, Barbara J.	36
Lewis, Jerry L.	40	Massie, Mary Jane	33
Lewis, Stephen	15	Matenik, Jeffery	34
Lewis-Fernandez, Roberto	55	Mathalon, Daniel	13
Lewy, Alfred J.	5	Matharu, Yogi	17
Liberman, Robert P.	22, 51	Matorin, Anu A.	41
Licino, Julio	9, 34, 45	Matthews, Annette	30
Lieberman, Alicia	28	May, Alison	31, 41
Lim, Russell F.	8	May, Catherine	32
Lin, Chieh-Hsin	55	McCabe, Sean	11
Linden, Michael	19	McCann, Una D.	52
Lipsitt, Don	56	McCarron, Robert	1, 43
Liptzin, Benjamin	42	McCarthy, Malia	1
Lisanby, Sarah H.	26	McClung, Colleen A.	52
Litten, Raye Z.	58	McCormick, Laurie	40
Liu, Shirley	10	McCrary, Barbara	29
Livesley, John	51, 58	McDonald, Scott	11
Llocra, Pierre Michel	22	McDonald, William M.	18, 26
Lo, Ted	40	McFarland, Bentson	45
Loo, Colleen K.	51	McFarr, Lynn	25
Lopez-Ibor, Juan J.	20	McGee, Michael D.	2
Lowenkopf, Eugene L.	54	McGlashan, Thomas H.	60
Loza, Nasser N.	36	McHugh, Paul R.	12, 26
Lu, Francis G.	8, 28	McIntyre, John	26
Luby, Joan	53	McIntyre, Kathryn	42
Luce, John	53	McKay, James R.	27
Lukas, Scott E.	52	McLean, Alexandra	22
Luo, John	7	McLean, Andrew J.	52
Luskin, Shari	5	McNicholas, Laura F.	18, 40
Lynch, Katherine	15	McVoy, Molly K.	10, 36
Lynch, Minda R.	60	Mee-Lee, David	33
Lynch, Wendy J.	35	Mehl-Madrona, Lewis	43
M			
Madaan, Vishal	28, 31	Mehta, Shivani	54
Maercker, Andreas	19	Melonas, Jacqueline M.	2, 10
Mago, Rajinish	15	Menezes, Paulo	37
Maj, Mario	20	Menvielle, Edgardo J.	11, 50
		Merikangas, Jame R.	48
		Messing, Robert O.	22
		Metzner, Richard	44
		Meyer, Eve	47

PRESENTER INDEX

Meyerson, David	44
Micevski, Aleksandar	56
Michaels, Laura	16
Michaels, M.	51
Michaels, Robert	26
Miettunen, Jouko	15
Mikalac, Cecilia M.	12, 25
Miller, Leonard	43
Miller, Lisa S.	43
Milrod, Barbara	3
Minoletti, Alberto	35
Minschew, Nancy	12
Minter, Shannon P.	20
Mintz, David L.	28, 47
Miotto, Karen	33
Mischoulon, David	49
Mishra, Asha S.	8, 46
Mitchell, James E.	12, 37
Mohamed, Zahurin	15
Mohandessi, Soroush	49
Mojtabai, Ramin	41
Molofsky, Anna	14
Moncrieff, Joanna	59
Montenegro, Roger	54
Mora, Marie Elena Medina	36
Morciglio, April	46
Morey, Leslie C.	60
Moriarty, Zach	33
Mrazek, David A.	8, 42, 60
Mucic, Davor	55
Munoz, Rodrigo A.	10, 51, 59
Munyandamutsa, Naasson M. N.	57
Musaleck, Michael	43
Musher, Jeremy	17
Muskin, Philip R.	13, 47
Mustafa, Husain	26
Myers, Michael F.	5, 7, 28, 30, 34, 35, 42, 46, 56
Myers, Wade	32
Myrick, Hugh	18

N

Nace, David	2, 17
Nadelson, Carol	22
Nader, Michael A.	36
Nahas, Ziad H.	1
Najavits, Lisa M.	38, 48
Nand, Surinder Sucha	8, 28, 46
Napoli, Joseph C.	10, 25
Narasimhan, Meera	21
Nardi, Antonio	32
Narrow, William E.	18, 20
Nash, Sara S.	58
Nasky, Kevin	44
Nau, Melissa	31, 41, 54, 56
Nelson, Charles	11
Nemat, Ali	17
Nemeroff, Charles B.	18, 60
Neufeld, Ronald	1

Newcorn, Jeffrey H.	7
Newmark, Thomas S.	10, 21
Newport, D. Jeffrey	18
Ng, Anthony T.	39
Nielssen, Olav	14
Nolen, Willem W. A.	37
Nooteboom, Annemieke	5
Norko, Michael	46
Northcott, Colleen	53
Notman, Malkah T.	11, 27
Nunes, Edward V.	49
Nyhus, Nadine J.	50

O

Obatusin, Tayo	45
O'Brien, Charles	19
O'Brien, Moira P.	11
Ochs, Len	43
Oele, Bastiaan	46
Ogundipe, Kehinde A.	27
Okasha, Ahmed	20
Okin, Robert L.	23
Okpaku, Samuel O.	47, 48
Oldham, John M.	33, 42, 53
O'Leary, Paul J.	16
Oleshansky, Marvin	26
Oms, Juan	46
Onate, John C.	43
Ong, Jason	40
Ongur, Dost	28
Ornish, Dean	54, 55
Osinski, Alphonse	42
Oslin, David	27, 42
Osofsky, Howard J.	28
Osofsky, Joy	28
Ostacher, Michael	5
Ostermeyer, Britta	32

P

Palmer, Christina	27
Pandya, Anand	3, 13, 43
Papakostas, George	6, 7
Parikh, Rajesh M.	48, 49
Paris, Joel	60
Parish, Brooke	32
Parks, Joseph J.	39
Parnham, George	27
Parry, Peter I.	38
Patel, Vikram	34
Patkar, Ashwin A.	15
Pato, Michele T.	8, 25, 43, 56
Payne, James O.	60
Peay, Holly L.	27
Pecora, Peter,	59
Peele, Roger	38, 51
Peeters, Frenk	15
Perlis, Roy	6, 7

PRESENTER INDEX

Perry, Christopher	53
Peselow, Eric D.	42
Pessar, Linda F.	20
Peteet, John R.	50
Petrakis, Ismene L.	48
Pettinati, Helen M.	58
Pflanz, Steven E.	33
Phillips, James	19, 59
Pi, Edmond Hsin-Tung	29
Pilon, Dave	43
Pilotte, Nancy S.	36
Pini, Stefano	32
Plakun, Eric M.	28, 41, 54, 56
Pleak, Richard R.	11
Pollack, David	16
Pontius, Edward	53
Ponton, Lynn	56
Pope, Kayla	10
Postlethwaite, Alejandra	31
Potash, James	8
Potenza, Marc N.	35, 48
Potkin, Steven	4
Powsner, Seth	56
Prabhakar, Deepak	45
Preda, Adrian	4
Preven, David	32
Price, Marilyn	5, 28
Primm, Annelle	16
Prince, Jefferson B.	4, 7, 49
Prudic, Joan	51
Puchalski, Christina	2
Pumariega, Andres J.	2, 55

Q

Qian, Yifang	56
Quadrio, Carolyn	53
Quanbeck, Cameron	1

R

Rabow, Michael W.	51
Rachal, Funmilayo	3
Radke, Alan Q.	39
Ragins, Mark	43, 51
Ramani, Meena	54
Ramchandani, Vijay A.	22
Ramirez, Luis F.	7, 17
Randall, Carrie L.	58
Ranz, Jules	56
Rao, Nyapati R.	3, 10, 13–14, 41
Rapaport, Mark	17
Raphael, Beverley	18
Rasic, Daniel	32
Rathod, Shanaya	16
Rathore, Varinder	27
Ratliff, Brenda M.	54
Ravindranath, Divy	41
Raynor, Jeffrey D.	21

Reardon, Claudia L.	10, 41
Recupero, Patricia R.	32, 42
Redden, Maurice	4
Regier, Darrel A.	13, 18
Rego, Mark D.	19
Reich, James H.	58
Reid, Michele	8
Reid, William	3
Reifler, Burton V.	32
Reliford, Aaron	41
Resnick, Phillip J.	3, 7, 17, 25
Reus, Victor	42
Reyes, Raymond	42
Riba, Michelle B.	33, 41, 54, 56
Richards, Lawrence K.	38, 46
Richeimer, Steven	17
Richman, Jennifer	11
Rifai, Muhamad Aly	17
Rigaud, Marie-Claude	13, 28, 45
Ritchie, Elspeth C.	27, 32, 42, 48
Roberts, Laura	19
Robinowitz, Carolyn B.	10, 47, 54, 60
Robinson, David	17
Robinson, Gail E.	5, 19, 20, 35, 41, 50, 59
Robinson, Robert G.	18
Rodriguez-Suarez, Mercedes	53
Roessel, Mary H.	41
Roman, Brenda J. B.	21
Romanoski, Alan	12
Rondon, Marta B.	22
Rone, Lisa A.	57
Rose, Diana	35
Rosenberg, Stanley D.	19
Rosenburg, Zack	28
Rosenquist, Peter	40
Rosenstock, Jason B.	21
Roskes, Erik	27
Ross, Stephen	33
Roth, Thomas	15
Rothschild, Anthony J.	2, 40
Ruano, Gualberto	59
Rubik, Beverly	43
Ruiz, Pedro	6, 10, 41, 43
Russakoff, L. Mark	2, 55
Rutter, Joni L.	60
Ryan, Deirdre	5
Ryan, Elizabeth	35
Rychik, Abe M.	54

S

Saavedra, Javier, E.	22
Sabshin, Melvin	22
Sachs, Gary	5
Sadre-Chirazi-Stark, Michael F.	50
Saeed, Sy	2
Sahler, Olle Jane	41
Sajatovic, Martha	24
Saks, Elyn	14
Salloum, Ihsan M.	58

PRESENTER INDEX

Samenow, Charles	1	Sitzer, Lauren	10
Sampson, Shirlene M.	51	Sivrioglu, Yusuf	3
Sanders, Kathy M.	28	Sizoo, Bram B.	36
Santiago, Patcho	10	Skodol, Andrew E.	33, 50, 60
Sareen, Jitender	15	Slattery, Marcia J.	41
Sartorius, Norman	13, 20, 34	Small, Gary	4
Sass, Henning	5,6	Smith, David E.	47
Sattar, Syed	45	Smith, Eric	45
Sawa, Akira	34	Soloff, Paul H.	33, 59
Saxena, Shekhar	34	Sonawalla, Shamsah B.	49
Saxon, Andrew J.	40, 48	Song, Suzan	41
Schäfer, Ingo	38	Sorel, Eliot	27
Schatzberg, Alan F.	18, 23, 51	Soygur, Haldun	44
Schiffer, Randolph	12	Spack, Norman	21
Schmidt, Chester W.	17	Speller, Heather	56
Schnaas, Francisco	54	Spencer, C. Edgar	54
Schneidman, Barbara	42	Sperber, Jacob	3, 10, 42
Schoener, Gary	5, 53	Spinelli, Margaret	27, 50
Schooler, Nina	55, 56	Spitz, Deborah	9, 43
Schroeder, Steve	54	Srabstein, Jorge	41
Schubmehl, James Q.	12	Srinivasan, Shilpa	21
Schummer, Gary	43	Srinivasaraghavan, Jagannathan	29
Schwartz, Harold I.	42	Srivastava, Shefali	53, 56
Scimeca, Michael M.	16	St. Pierre, Jeanne M.	51
Scott, Charles	1, 49	Stabinsky, Susan	15, 55
Scott, Marcia	28	Stahle, Galen W.	19
Scully, James, Jr.	13	Stanley, Barbara H.	37, 59
Sen, Srijan	8, 13, 43	Starcevic, Vladan	55
Seritan, Andrea	1, 55	Steele, Annie	32
Servis, Mark	1	Steinglass, Peter	25
Sevilla, Brett	27	Stevens, Michael	31
Sexson, Sandra B.	41, 48	Stewart, Caroline	59
Shafestein, Steven	18	Stewart, Donna E.	22, 45
Shanfield, Stephen	31	Stigler, Kimberly A.	4
Shapiro, Edward	28, 54	Stolar, Andrea	28
Shapiro, Edward Robert	56	Stone, Michael	47
Shapiro, Peter A.	25	Stone, Walter N.	40
Sharfstein, Steven S.	42, 57	Stotland, Eve	56
Shaw, Kailie	42	Stotland, Nada L.	19, 22, 23, 35, 41
Shea, Shawn C.	29	Stotland, Naomi	56
Shea, Tracie	60	Strain, Eric	40
Shear, Katherine	19	Strain, James J.	19, 35
Shen, Hong	41	Strauss, David H.	53
Shihabuddin, Lina	53	Streltzer, Jon	56
Shim, Jewel	41	Stroeh, Oliver	53, 56
Shinfuku, Naotaka	50	Sudak, Donna M.	1, 54
Shrivastava, Amresh K. A.	11, 32, 36	Sukumaran, Anand	28
Shuckit, Marc	30	Sullivan, Maria	49
Shuman, Daniel	34	Sullivan, Pamela	26
Shumay, Dianne M.	51	Summers, Richard F.	48
Siever, Larry J.	22, 33, 37, 58	Suo, Shannon	55
Silberman, Edward	8, 32	Susman, Virginia L.	45
Silberschatz, George	57	Sutcliffe, James,	4
Silk, Kenneth R.	13, 26, 38, 43, 60	Sutton, Loree	42
Silver, Jonathan	18	Swartz, Holly A.	2
Simmer, Ed	42	Swartz, Marvin S.	46, 49
Simmons, Chantelle	53	Swift, Robert M.	10
Simon, Robert I.	34	Swiggart, William H.	1
Simon, Witold	15	Szarek, Bonnie	31
Sinclair, Beryl D.	16	Szigethy, Eva	28, 41
Singh, Vivek	15		

PRESENTER INDEX

T

Taintor, Zebulon	49, 50, 53
Talbott, John A.	22, 49
Tandon, Rajiv	29
Temporini, Humberto D.	1, 49
Terhakopian, Artin	10
Terilli, Dale	16
Terr, Lenore C.	23
Thase, Michael E.	4, 57
Tiainen, Anne	15
Tiamson-Kassab, Maria	29
Tillman, Jane	54
Tong, Lowell	41
Toomey, Jennifer	33
Torres, Michael A.	50
Townsend, Mark	29
Tracy, Martin G.	10, 42
Triesman, Glenn	12, 26
Trivedi, Madhukar H.	6, 7, 21, 26
Trzepacz, Paula	18
Tschan, Werner	20
Tsuang, John W.	33
Tsuang, Ming T.	20
Tuerk, Catherine L.	50
Turkington, Douglas	4, 16
Turner, Erick H.	37
Tyrer, Peter	58
Tyrka, Audrey	24
Tzuang, Dan	10

U

Un, Hyong	33
Unutzer, Jurgen	21
Unwalla, Khushro	27, 29
Ursano, Amy M.	51
Ursano, Robert	10, 42, 47

V

Vaburosa, Livia	43
Vaillant, George	60
Van, Henricus	5
Van Dahlen Romberg, Barbara	47
Van der Gaag, Rutger J.	36
Van Horn, Patricia J.	59
Van Nieuwenhuizen, Adrienne	31
Van Wijngaarden-Cremers, Patricia J.	36
Vanderpool, Donna	2, 42
Varghese, Mathew	23, 43-44
Varma, Sudepta S. V.	46
Varma, Vijoy	16
Vaswani, Merrra	15, 31, 45, 55
Vaswani, Sanjay	44
Vejjola, Juha M.	44
Vela, Ricardo M.	5
Verghese, Abraham	23
VerHalen, Nisha	32

Vermani, Monica	29, 43
Vianin, Pascal	22
Vickar, Garry	53
Victor, Lisa	17
Viguera, Adele	24, 50
Vincent, Kathy	46
Viron, Mark	32
Viswanathan, Ramaswany	29
Vogel-Scibilia, Suzanne E.	42
Volberding, Paul	21
Volkow, Nora D.	11

W

Wagner, Eric F.	20
Walker, Sandra	27
Warshaw, Carole E.	59
Webb, Roger	45
Weerasekera, Priyanthy	3, 46
Weiner, Elyse D.	42
Weiner, Richard	26
Weinstock, Robert	32
Weisler, Richard	15
Weisner, Constance	33
Weisser, Lydia	55
Weissman, Sidney	32
Weker, Jonathan I.	19
Welch, Kristen U.	57
Westgate, Harland	10
Wetherington, Cora Lee	35
White, Leigh Anne	10
White, Stephen G.	20
White-Labora, Deborah	46
Whyte, Doug	11
Wilens, Timothy	6, 11
Willenbring, Mark	33, 54
Williams, Eric	53
Wills, Marketa	28
Windle, Michael	20
Winick, Bruce J.	38, 46
Winters, Kelley	20
Wise, Michael Jan	28
Wise, Robert	49
Witte, Janet	39
Wolf, Robert	52
Wood, William C.	28, 53, 56
Woolley, Stephen	31
Worley, Jena	11
Wright, Jesse H.	1, 4, 25, 54
Wulsin, Lawson	60
Wynn, Gary H.	12, 27

X

Xiang, Yingqiang	56
Xie, Yuhuan	1
Xiong, Glen L.	1, 43

PRESENTER INDEX

Y

Yaffe, Kristine	13
Yager, Joel	12, 19
Yalom, Irvin D.	40
Yaswani, Sanjay	31
Yellowlees, Peter	11
Yeoman, Alfred	22
Yen, Jennifer	41
Yen, Shirley	58
Yeomans, Frank E.	4, 38
Yeung, Albert	49
Yohanan, Monique	13, 25
Yonkers, Kimberly	18
Yoo, Tai P.	11
Youn, John Q.	41
Young, Jeffrey E.	38
Young, Tina	17
Yudofsky, Stuart C.	18, 26, 60

Z

Zabletny, Raymond	42
Zainal, Nor	31
Zajacka, John	23
Zanarini, Mary C.	22, 58
Zangen, Abraham	37
Zaretsky, Ari	40
Zatzick, Douglas F.	48
Zeller, Scott L.	39
Zhu, Ziqing	56
Ziegler, Penelope	7
Zubieta, Jon-Kar	37
Zucker, Robert A.	20
Zurowski, Mateusz	33
Zweben, Allen	10

American Psychiatric Association




162ND ANNUAL MEETING

San Francisco

**SHAPING OUR FUTURE:
SCIENCE AND SERVICE**

MAY 16-21, 2009



**NEW RESEARCH
PROGRAM**



American Psychiatric Association

1000 Wilson Boulevard
Suite 1825
Arlington, VA 22209-3901
Telephone: 703.907.7808
Fax: 703.907.1090
E-mail: apa@psych.org

162nd Annual Meeting
San Francisco, CA
May 16-21, 2009

May 16, 2009

President

Nada L. Stotland, M.D., M.P.H.

Scientific Program Committee 2007-2008

Joseph Cheong, M.D.
Chairperson

Donald M. Hilty, M.D.
Vice-Chairperson

Members

Renato D. Alarcón, M.D.
Iqbal Ahmed, M.D.
Catherine C. Crone, M.D.
Edward F. Foulks, M.D., Ph.D.
Robert W. Guynn, M.D.
Geetha Jayaram, M.D.
Maria I. Lapid, M.D.
Julio Licinio, M.D.
Annette Matthews, M.D.
Anu Matorin, M.D.
Michael F. Myers, M.D.
Surinder S. Nand, M.D.
Michele T. Pato, M.D.
Edmond Hsin T. Pi, M.D.
Kenneth R. Silk, M.D.
Deborah Spitz, M.D.

Consultants

Amin N. Azzam, M.D.
David Baron, D.O., M.S.Ed.
Robert J. Boland, M.D.
John Luo, M.D.
Donna M. Mancuso, M.D.
Tracey Marks, M.D.
Arnaldo Moreno, M.D.
Anand Pandya, M.D.
Joyce Spurgeon, M.D.
Linda L.M. Worley, M.D.

Dear Fellow APA Attendees:

On behalf of the members and staff of the Scientific Program Committee, I would like to welcome you to the 2009 New Research Program. This year's program reflects the importance of basic and clinical neuroscience, as well as contributions from social sciences and other disciplines to psychiatry now and in the future.

The sessions are organized by topic and have been expanded to accommodate a myriad of excellent submissions. The events of this part of the Scientific Program will be held at the Moscone Convention Center in San Francisco, CA (Hall D, Exhibit Level).

The program begins Monday, May 18th, with the New Research Poster Sessions at 9:00 a.m. and 12:30 p.m., Tuesday, May 19th, at 12 noon – 2 p.m., Wednesday, May 20th, at 12 noon – 2 p.m., and 3:00 p.m. – 5:00 p.m.

The Young Investigator Posters will be held Monday, 3:00 p.m.-5:00 p.m., and Tuesday, 3:00 p.m.-5:00 p.m. These sessions feature the top graded submissions and highlight some of the most exciting new research conceived and developed by young investigators, covering a broad range of topics with fresh perspectives and cogent results.

The more than 700 presentations (including nearly 200 Young Investigator Posters) are a diverse and, we believe, representative sampling of that which is new and significant in psychiatric research. We hope that you will find them both, informative and provocative.

Sincerely,

Renato D. Alarcón, MD, MPH.
Chairperson, New Research Subcommittee of the
Scientific Program Committee

DISCLOSURE INDEX

Addiction Psychiatry ... NR2-001 to NR2-009, NR5-001 to NR5-005, NR5-007 to NR5-009
AIDS and HIV-Related Disorders ... NR2-010, NR5-010
Alcohol and Drug-Related Disorders ... NR2-011 to NR2-018, NR5-011 to NR5-014
Anxiety Disorders ... NR3-001 to NR3-008, NR4-001 to N4-022
Attention Spectrum Disorders ... NR2-019 to NR2-054, NR5-015 to NR5-020
Behavior and Cognitive Therapies ... NR6-001, NR6-002
Biological Psychiatry and Neuroscience ... NR3-009 to NR3-012, NR7-001 to NR7-019
Brain Imaging ... NR3-013 to NR3-016, NR7-020 to NR7-028
Child & Adolescent ... NR2-055 to NR2-074, NR3-054, NR5-021 to NR5-030, NR5-032 to NR5-037, NR5-039
Cognitive Disorders ... NR2-075 to NR2-084
Combined Pharmacotherapy & Psychotherapy ... NR3-017, NR6-003
Creativity and the Arts ... NR7-029, NR7-030
Cross-Cultural and Minority Issues ... NR2-085 to NR2-088, NR5-040 to NR5-045, NR6-025
Diagnostic Issues ... NR1-062, NR3-018, NR3-019, NR7-031
Dissociative Disorders ... NR3-020, NR7-032
Eating Disorders ... NR2-089 to NR2-092, NR5-046 to NR5-050
Epidemiology ... NR3-021 to NR3-028, NR3-077, NR6-083, NR7-033 to NR7-038
Forensic Psychiatry ... NR5-051 to NR5-053, NR6-004 to NR6-007
Gender Issues ... NR5-054
Genetics ... NR3-029 to NR3-037, NR3-039, NR3-078, NR7-039 to NR7-054
Geriatric Psychiatry ... NR2-093 to NR2-103, NR5-055 to NR5-060
Group Therapy ... NR6-008
Health Services Research ... NR5-061 to NR5-068, NR7-055 to NR7-062
Historical Questions ... NR7-063
Information Technology, Internet, Virtual Reality ... NR5-069, NR5-113, NR7-064
Lesbian/Gay/Bisexual/Transgender Issues ... NR2-104
Managed Care and Health Care Funding ... NR5-070, NR7-065
Mood Disorders ... NR3-040 to NR3-063, NR4-023 to NR4-119
Neuropsychiatry ... NR3-064 to NR3-067, NR7-066 to NR071
Other Somatic Therapies ... NR5-071, NR5-072, NR6-009 to NR6-011
Pain Management ... NR5-073, NR6-012 to NR6-017
Personality Disorders ... NR3-068, NR7-072 to NR7-075
Political Questions ... NR7-076
Psychiatric Administration and Services ... NR6-018 to NR6-021
Psychiatric Education ... NR5-074 to NR5-077, NR7-011, NR7-077, NR7-078
Psychiatric Rehabilitation ... NR6-023, NR6-024, NR6-026
Psychopharmacology ... NR3-069 to NR084, NR4-115, NR5-078, NR6-022, NR6-027 to NR6-074
Psychosomatic Medicine ... NR5-079 to NR5-086, NR6-075 to NR6-079
Religion, Spirituality and Psychiatry ... NR5-087, NR5-088
Research Issues ... NR7-080 to NR7-084
Resident & Medical Student Concerns ... NR5089, NR5-090
Schizophrenia & Psychotic Disorders ... NR1-001 to NR1-099, NR3-038, NR3-085 to NR3-098, NR5-006, NR5-031
Sexual & Gender Identity Disorders ... NR2-105, NR2-106
Sleep Disorders ... NR3-099 to NR3-108, NR7-085 to NR7-105
Social and Community Psychiatry ... NR5-091, NR5-092, NR5-111, NR6-080 to NR6-086
Somatoform Disorders ... NR3-109, NR3-110, NR6-087, NR6-088
Stigma/Advocacy ... NR5-093 to NR5-096
Stress ... NR3-111 to NR3-114, NR4-120, NR4-121
Suicide ... NR2-107 to NR2-119, NR5-097 to NR5-101, NR7-106
Telepsychiatry ... NR6-089, NR6-090
Treatment Techniques and Outcome Studies ... NR5-038, NR5-102, NR6-091 to NR6-100
Violence, Trauma and Victimization ... NR2-120 to NR2-125, NR5-103 to NR5-112
Women's Health Issues ... NR2-126 to NR2-131, NR5-114

DISCLOSURE INDEX

AMERICAN PSYCHIATRIC ASSOCIATION CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliation with commercial organization(s) that may have a direct or indirect interest in the subject matter of the scientific program. A “financial interest” may include, but is not limited to: being an employee, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An “affiliation” may include holding a position on an advisory committee, speakers bureau or some other role or benefit to a supporting organization.

In compliance with the ACCME’s Standards for Commercial Support, the APA has a management of conflict (MCI) process for all CME activities. This process ensures that all potential conflicts of interest are identified, managed and resolved prior to the educational activity. The prospective audience must be informed of the presenter’s affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The presenters on the following pages have indicated that either they or an immediate family member have a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s), and the company name is listed.

The second group of presenters has indicated neither they nor an immediate family member has any significant relationship to disclose.

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Able, Stephen L. Alain, Katic	Shire Pharm. Dev.	Eli Lilly	Shire Pharm. Dev., Novartis, Wyeth-Ayerst Labs., Takeda Abbott, Pfizer, Sepracor, Cyberonics, Abbott Labs., Merck, Johnson & Johnson PRD, Somerset	Shire Pharm. Dev., Novartis		
Amatniek, Joan		Ortho-McNeil Janssen Scientific Affairs Eli Lilly			Johnson & Johnson PRD	
Anthony, Lawson Antonucci, Donna	Shire Pharm. Dev.	Lundbeck		Shire Pharm. Dev.		
Areberg, Johan Artigas, Francesc	Lundbeck					Boehringer Ingelheim, Lundbeck, GSK, Lilly Research Labs. (lecturer)
Ascher-Svanum, Haya Awaad, Rania		Eli Lilly	NIMH			
Baird-Bellaire, Susan Baker, Ross A		Wyeth-Ayerst BMS Eli Lilly				
Barraco, Alessandra Becker, Philip M			Boehringer Ingelheim, Cephalon, GSK, Sanofi, Xenoport	GSK, Boehringer Ingelheim		
Berwaerts, Joris		Johnson & Johnson PRD				
Birgit, Amann	Shire, McNeil, Eli Lilly, Forest Labs., Sepracor, GSK		Shire Pharm. Dev.	Shire, McNeil, Novartis, Eli Lilly, Forest Labs., Noven, BMS, UCB Pharma, Celltech, GSK, Sanofi, Aventis, Wyeth-Ayerst, Pfizer, Janssen		
Boess, Frank Bolge, Susan C	Ortho-McNeil Janssen Scientific Affairs	Eli Lilly				
Bollu, Vamsi Bramson, Candace Brunner, Elizabeth Bullen, William Calabrese, Joseph R		Pfizer Pfizer Eli Lilly Pfizer			Pfizer	
Camacho, Alvaro Canafax, Daniel M	GSK, Janssen, Johnson & Johnson PRD, Solvay, Wyeth-Ayerst, Abbott Labs., AZ, BMS, Forest Labs., Organon, Ortho McNeil, Supernus		Cephalon, AZ, NARSAD, Stanley Medical Research Institute, Abbott Labs., GSK, Janssen, Eli Lilly, NIMH, NARSAD	Janssen, Pfizer		Xenoport

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Canuso, Carla		Ortho-McNeil Janssen Scientific Affairs BMS			Johnson & Johnson PRD	
Carlson, Berit X Carothers, Jennifer		Ortho-McNeil Janssen Scientific Affairs			Johnson & Johnson PRD	
Carpenter, Linda L	Neuronetics Inc., Medtronics, Novartis, Wyeth-Ayerst, BMS, Abbott Labs., Pfizer, Cyberonics, Sepracor		NIMH, Cyberonics, Pfizer, Sepracor, UCB Pharma, NARSAD	Pfizer, Wyeth-Ayerst, Cyberonics, AZ		Neuronetics (travel support, 2007)
Chen, Ying-Sheue Choy, Ernest	Eli Lilly, Allergan, Jazz, Pfizer		Janssen	Janssen, Otsuka Pfizer, Eli Lilly		
Cognata-Smith, Christina Cohen, Lisa J Connor, Daniel F		BMS	BMS Shire Pharm. Dev.	Shire Pharm. Dev., Abbott Labs. Wyeth-Ayerst	NIMH	
Cook, Ian A			Aspect Medical Systems, Cyberonics, Eli Lilly, NIH, Novartis, Sepracor			
Corey-Lisle, Patricia Correll, Christoph U	AZ, BMS, Eli Lilly, Otsuka, Pfizer, Supermus, Vanda BMS	BMS	BMS	AZ, BMS, Janssen, Otsuka, Pfizer		
D'Mello, Dale Darwish, Mona De Dios, Consuelo	BMS	Cephalon	AZ	Pfizer AZ, Eli Lilly, Boehringer Ingelheim		
deGreef, Rik Demitrack, Mark Detke, Holland C Dodson, William W	Novartis, Shire Pharm. Dev., Shire	Schering Neuronetics Inc. Eli Lilly			Eli Lilly, Wyeth-Ayerst	
Dogterom, Peter Dunayevich, Eduardo Durell, Todd M Durkin, Michael		Schering Orexigen Eli Lilly Ortho-McNeil Janssen Scientific Affairs				
Ellenbogen, Aaron L Ermer, James Faridi, Kia	Jazz, Xenoport	Shire Pharm. Dev.	Pfizer	GSK, Teva		

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Findling, Robert L	Abbott Labs., AZ, Cypress Bioscience, Forest Labs., GSK, Johnson & Johnson PRD, Lilly Research Labs., Novartis, Organon, Otsuka, Pfizer, BMS, Sanofi-Synthelabo, Sepracor, Shire Pharm. Dev., Solvay, Wyeth-Ayerst Research, Supernus Johnson & Johnson PRD		Abbott Labs., AZ, Forest Labs., Johnson & Johnson PRD, Eli Lilly, Otsuka, Pfizer, GSK, Wyeth-Ayerst Research, Novartis, BMS, Solvay, Shire Pharm. Dev.	Johnson & Johnson PRD, Shire Pharm. Dev.		
Fleischhacker, Wolfgang	Research, Supernus Johnson & Johnson PRD					Johnson & Johnson PRD (divisory board) NULL
Frasch, Karel J	Shire Pharm. Dev.					
Frazier, Thomas			Pfizer, GSK			Eli Lilly, Pfizer, GSK, Otsuka (speaking fees)
Furukawa, Toshiaki A						
Galan, Jaime		AZ	AZ, NARSAD			
Gao, Keming			Janssen-Cilag			
Gattaz, Wagner	Janssen-Cilag		Eli Lilly, Janssen-Cilag	Eli Lilly, Janssen-Cilag		
Gau, Susan Shur-Fen						
Gendreau, R Michael		Cypress Bioscience				
Ginsberg, Lawrence D	AZ, BMS, Cephalon, Forest Labs., GSK, Abbott Labs., Eli Lilly, McNeil, Novartis, Ortho McNeil, Pfizer, Sanofi Aventis, Sepracor, Shire Pharm. Dev., Takeda, UCB Pharma, Wyeth-Ayerst, Janssen, Cyberonics		Wyeth-Ayerst Labs., Abbott Labs., Alkermes, AZ, BMS, Cephalon, Forest Labs., GSK, McNeil, Janssen, Neurocrine Biosciences, Novartis, Organon, Ortho McNeil, Otsuka, Pfizer, Sanofi Aventis, Sepracor, Shire Pharm. Dev., Takeda, UCB Pharma, Eli Lilly	AZ, BMS, Cephalon, Cyberonics, Eli Lilly, McNeil, Novartis, Organon, Pam Lab, Pfizer, Sanofi Aventis, Sepracor, Shire Pharm. Dev., Takeda, UCB Pharma, Wyeth-Ayerst Labs., Alkermes, Forest Labs., GSK, Janssen, Jazz		
Gitlin, Michael			Pharma, Eli Lilly	Lilly Research Labs., BMS, Takeda, Pfizer, AZ Cephalon, GSK, Forest Labs., Lilly Research Labs., Shire Pharm. Dev., McNeil, Wyeth-Ayerst Labs., Novartis		
Goodman, David W	Eli Lilly, Shire Pharm. Dev., McNeil, Forest Labs.		Forest Labs., Shire Pharm. Dev., McNeil, Cephalon			Eli Lilly, Forest Labs., Shire Pharm. Dev., McNeil, Wyeth-Ayerst Labs. (honoraria)
Gopal, Sri		Johnson & Johnson PRD			Johnson & Johnson PRD	
Grinspan, Augusto		Ortho-McNeil Janssen Scientific Affairs			Johnson & Johnson PRD	

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Grossberg, George	Novartis, Forest Labs., Pfizer, Medtronics	Wyeth-Ayerst Research				
Guico-Pabia, Christine				AZ		
Gupta, Nitin		Eli Lilly	AZ	Eli Lilly		Pfizer (travel reimbursement for presentations)
Hardy, Thomas A	Daimippon Summitomo, Wyeth-Ayerst Labs., Eli Lilly, Johnson & Johnson PRD					
Harvey, Philip D						
Haskins, J Thomas		Ortho-McNeil Janssen Scientific Affairs				
Hirshkowitz, Max	Sanofi-Synthelabo		Vanda, Merck, Cephalon, Sanofi Aventis, Sepracor, Takeda Abbott., Organon USA	Sanofi Aventis, Takeda, Cephalon		
Hoffmann, Vicki P		Eli Lilly				
Hollander, Eric	Trasept Pharm					
Hong, Liu-Seifert		Eli Lilly				
Huh, John			Novartis			
Huiskorte, Ellen		Schering				
Iosifescu, Dan V						
Jochelson, Philip		Somaxon	Aspect Medical Systems, Forest Labs., Janssen	Eli Lilly, Forest Labs., Pfizer		
Johnson, Kaja			AZ			
Kahn, Rene S			Janssen-Cilag, Sanofi Aventis, BMS, Eli Lilly, Pfizer, Roche Biosciences, AZ			
Kamen, Lisa		BMS				
Kane, Cecelia		Wyeth-Ayerst				
Kasckow, John W	Forest Labs., Eli Lilly, Janssen Research Foundation, Pfizer, BMS		AZ, BMS, Forest Labs.	BMS, Eli Lilly		
Kelly, Megan M			NIMH			
Kemp, David E			GSK			BMS Educational grant, Abbott Labs. Educational grant
Kern Sliwa, Jennifer		Ortho-McNeil Janssen Scientific Affairs			Ortho-McNeil Janssen Scientific Affairs	
Knesevich, Mary Ann			Johnson & Johnson PRD, AZ, Cephalon, Janssen, Pfizer, Merck, Forest Research Inst., Acadia, Novartis, Organon, Roche			Forest Research Inst., Janssen, Merck, Roche Labs. (advisory boards)
Kollack-Walker, Sara		Eli Lilly				

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Kosik-Gonzalez, Colette		Ortho-McNeil Janssen Scientific Affairs			Johnson & Johnson PRD	
Krystal, Andrew	Arena, AZ, BMS, Eli Lilly, GSK, Jazz, Johnson & Johnson PRD, King, Novartis, Organon, Roche		Sanofi Aventis, Cephalon, GSK, Merck, Neurocrine, Pfizer, Sepracor, Somaxon, Takeda, Neurocrine			
Kryzhanovskaya, Ludmila Lam, Raymond W	Takeda Abbott	Eli Lilly	Advanced Neuromodulation Systems, BrainCells, Litebook Co., Lundbeck Somaxon, Neurocrine	AZ Canada, Biovail Labs., Eli Lilly Canada, Janssen Canada, Lundbeck, Servier		
Lankford, Alan			Biosciences, Pfizer, Takeda	Janssen Cilag, Pfizer		
Lee, Joseph WY	Pfizer, Janssen Cilag	Eli Lilly	Janssen Cilag			
Liu, Xianchen		AZ				
Locklear, Julie		Pfizer			Pfizer	
Lockwood, Peter						
Loebel, Anthony	Pfizer, Memory Pharmaceuticals					
Louza, Mário	Janssen-Cilag		Janssen-Cilag			
Macfadden, Wayne		Ortho-McNeil Janssen Scientific Affairs			Johnson & Johnson PRD	
Malone, Donald A			Medtronic			
Mancini, Catherine			AZ Canada, Cephalon, GSK Canada, Eli Lilly Canada, Janssen-Ortho, NIH, Novartis, Pfizer, Sanofi Aventis, Servier Canada, Wyeth-Ayerst Canada	BMS, Eli Lilly Biovail Labs., GSK Canada		
Manos, Michael J	Shire Pharm. Dev., Eli Lilly, McNeil Consumer Healthcare		Eli Lilly, McNeil Consumer Healthcare, Shire Pharm. Dev.	Shire Pharm. Dev.		
Martin, Michael		BMS				
Masand, Prakash	Forest Labs., GSK, Janssen, Jazz, Pfizer, BMS, Cephalon, Eli Lilly, Organon, Wyeth- Ayerst		AZ, GSK, BMS, Cephalon, Eli Lilly, Forest Labs., Ortho McNeil, Janssen, Wyeth- Ayerst	AZ, BMS, Eli Lilly, Forest Labs., GSK, Janssen, Pfizer, Wyeth- Ayerst		
Matthews, John D			AZ, Pfizer, Eli Lilly, Abbott Labs., Aspect Medical Systems, Cyberonics	AZ, Pfizer, Wyeth- Ayerst, BMS, Janssen		
Mattos, Paulo			Janssen-Cilag		Janssen-Cilag, Novartis (advisory boards)	

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
McBurnett, Keith	Eli Lilly, Shire Pharm. Dev.		Alza Corp., Johnson & Johnson PRD, Eli Lilly, Shire Pharm. Dev.	McNeil Consumer Healthcare		
McDonnell, David P		Eli Lilly				
McIntyre, Roger	AZ, Eli Lilly, Janssen-Ortho, Schering Corp., Wyeth-Ayerst, Lundbeck, GSK, Oryx, Biovail Labs., Pfizer, Prestwick Pharm., Shire		Wyeth-Ayerst, GSK, Servier, AZ			
Milev, Roumen V				AZ Canada, Eli Lilly Canada, Pfizer Canada Pam Lab		
Mischoulon, David	BMS, Pam Lab	BMS				
Moghadam, Reza						
Morrato, Elaine H			Proctor & Gamble, NIH, Pfizer			
Musngung, Jeff		Wyeth-Ayerst Research				
Narasimhan, Meera	BMS		AZ, BMS, Janssen, Forest Labs, NIMH, NARSAD, Janssen, BMS, Wyeth-Ayerst, Pfizer	Janssen, AZ, Eli Lilly		Organon, Dainippon Sumitomo (data safety monitoring committees)
Newcomer, John W	Vanda, Lundbeck, Otsuka, AZ, BMS, GSK, Janssen, Pfizer, Organon, Solvay, Wyeth-Ayerst		Takeda, BMS	Wyeth-Ayerst		
Norris, Edward R R		Eli Lilly				
Nyhuis, Allen W				GSK, Sepracor, Forest Labs.		
Oepen, Godehard					Novartis	
Olin, Jason T						
Owens, Judith	Takeda, Shire, Boehringer Ingelheim, Eli Lilly	Novartis	Shire Pharm. Dev., Boehringer Ingelheim, Eli Lilly	Johnson & Johnson PRD, Eli Lilly		
Pandina, Gahan		Johnson & Johnson PRD				
Pangallo, Beth A		Eli Lilly				
Panish, Jessica M		Ortho-McNeil Janssen Scientific Affairs			Johnson & Johnson PRD	
Papakostas, George I	GSK, Pfizer, Wyeth-Ayerst, BMS, Eli Lilly, Jazz, Pam Lab, Shire		Pfizer, BMS, NIMH, Pam Lab	BMS, Pfizer		Lundbeck Honorarium
Papadopoulos, Elizabeth		Pfizer				
Park, Lawrence T			Janssen, Abbott Labs., Pfizer, Cyberonics, Aspect Medical Systems, Medtronic	Eli Lilly		
Parkar, Ashwin A			Pfizer, BMS, GSK, Forest Labs., Titan, Organon, Merck, Cephalon	Cephalon, BMS, Pfizer, Reckitt Benckiser		

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Peuskens, Joseph	AZ, BMS, Eli Lilly, Lundbeck, Janssen Cilag, Sanofi Aventis		AZ, BMS, Eli Lilly, Janssen-Cilag, Sanofi Aventis, Pfizer, Lundbeck	Sanofi Aventis, Lundbeck, Pfizer, AZ, BMS, Eli Lilly, Janssen		AZ, BMS, Sanofi Aventis, Eli Lilly, Janssen, Lundbeck, Pfizer (honoraria)
Phillips, Katharine A			Forest Labs., AFSP, NIMH, UCB Pharma			Merck (writing honorarium), Guilford Publications (potential royalties)
Pikalov, Andrei		Otsuka				
Potkin, Steven G	Arena, Acadia, AZ, BMS, Janssen, Novartis, Organon, Otsuka, Pfizer, Roche Labs.		Sanofi-Synthelabo, Solvay, Allergan, AZ, BMS, Lilly Research Labs., Forest Labs., Janssen, Mitsubishi Pharma Corp., Novartis, Ono, Organon, Otsuka, Pfizer	AZ, Pfizer, BMS, Novartis		
Pratts, Michael				Eli Lilly		
Quiroz, Jorge A		Johnson & Johnson PRD				
Rathod, Shanaya				AZ		
Raun, Melmed D	Lilly Research Labs., Shire Pharm. Dev., Cephalon		Lilly Research Labs., Shire Pharm. Dev., Cephalon, BMS	Lilly Research Labs., McNeil, Novartis, Shire Pharm. Dev., UCB Pharma, Cephalon		
Reed, Michael L	GSK, Merz, Ortho McNeil, Ortho-McNeil Janssen Scientific Affairs, AZ					
Reimherr, Frederick W	Johnson & Johnson PRD, Shire Pharm. Dev., Eli Lilly, Novartis, Roche Labs.		Eli Lilly, Johnson & Johnson PRD, Shire Pharm. Dev., Eli Lilly, GSK			
Renshaw, Perry F				BMS		
Rittmannsberger, Hans	Eli Lilly, Janssen Cilag, AZ					
Robb, Adelaide S	Otsuka, Eli Lilly, Lundbeck, BMS, Forest Labs.		BMS, Forest Labs., Johnson & Johnson PRD, Otsuka, Pfizer, GSK, Supernus, Sepracor	McNeil, Abbott Labs., BMS, Eli Lilly		
Rodriguez, Stephen		Ortho-McNeil Janssen Scientific Affairs, Somaxon			Johnson & Johnson PRD	
Rogowski, Roberta						
Rosenberg, Russell			Arena, Pfizer, Takeda, Organon USA, Cephalon, Vanda			

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Roth, Thomas	Abbott Labs., AZ, Cephalon, Cypress Bioscience, Elan, Eli Lilly, Purdue Pharma, Roche Labs., Sanofi, Schering Corp., BMS, Sepracor, Servier, Shire, Somaxon, Takeda Abbott, Wyeth-Ayerst Labs., Xenoport, Acadia, Alza Corp., Ancile, Alkermes, Aventis, Eli Lilly, Cephalon, Novartis, Shire Pharm. Dev.		Aventis, Cephalon, GSK, Neurocrine, Pfizer, Sanofi, Sepracor, Somaxon, Takeda Abbott, Wyeth-Ayerst Labs., Xenoport	Cephalon, Sanofi, Takeda Abbott		
Rubin, Richard L	Aventis, Eli Lilly, Cephalon, Novartis, Shire Pharm. Dev.		Cephalon, Abbott Labs., Eli Lilly, Shire Pharm. Dev.	Eli Lilly, Novartis, Shire		
Sachs, Gabriele				AZ, BMS, Eli Lilly, Janssen Cilag, Novartis, Pfizer		
Sadowsky, Carl H	Novartis					Pfizer, Merck, Elan, Medivation, Wyeth-Ayerst Labs., Novartis (clinical trial support)
Sajatovic, Martha	GSK, AZ		GSK, AZ, NIMH Pfizer	AZ		
Samochowicz, Jerzy						
Sasane, Rahul		Shire Pharm. Dev.				
Schaffer, Ayal	AZ Canada, Pfizer Canada, BMS, Eli Lilly Canada		Servier Canada, BrainCells	AZ Canada, Eli Lilly Canada		
Schulz, S Charles	AZ, Eli Lilly, Vanda		Abbott Labs., Eli Lilly, AZ	AZ, BMS, Eli Lilly		
Shahid, Mohammed		Schering				
Shrivastava, Amresh K A			Janssen Cilag, Roche Labs.	AZ Canada, AZ, Eli Lilly, Janssen Cilag, Janssen Canada, Roche Labs.		
Sikirica, Mirko		Ortho-McNeil Janssen Scientific Affairs				
Singh, Mala			Janssen Cilag			
Spaeth, Michael	Allergan, Eli Lilly, Pfizer					
Starr, H Lynn		Ortho-McNeil Janssen Scientific Affairs, Eli Lilly				
Stauffer, Virginia						
Stewart, Michelle		Pfizer				
Stocks, Thomas		Pfizer			Pfizer	

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Strand, Vibeke	Forest Labs., Pfizer, Jazz, Cypress Bioscience, Allergan, Wyeth-Ayerst					
Strejilevich, Sergio A	Janssen, Eli Lilly			AZ, GSK		
Stroup, Thomas S	McNeil, Shire		Abbott Labs., Takeda, Pfizer, Alza/McNeil, Organon, Merck, Eli Lilly	Novartis, Shire, McNeil		Shire Pharm. Dev. (educational grant), Janssen-Ortho (speaker)
Surman, Craig B						
Svedäter, Henrik		AZ				
Szamosi, Johan		AZ				
Tobias, Kathy		Pfizer			Pfizer	
Tourian, Karen		Wyeth-Ayerst				
Turgay, Atilla	Shire Pharm. Dev., Eli Lilly, Purdue Pharma, Lundbeck, Sanofi Aventis, Celtech, Janssen-Ortho, AZ	Research	Celtech, Shire Pharm. Dev., Eli Lilly, Purdue Pharma, Janssen-Ortho, AZ, Lundbeck, Sanofi Aventis			Shire Pharm. Dev., Eli Lilly, Purdue Pharma, Janssen-Ortho, AZ, Lundbeck, Sanofi Aventis, Celtech (honoraria)
Turner, Norris		Ortho-McNeil			Johnson & Johnson PRD	
Van Ameringen, Michael	Janssen Scientific Affairs					
	Lundbeck Canada, Biovail Labs., Cephalon, Janssen Canada, Novartis, Servier Canada, Wyeth-Ayerst Canada, GSK Canada, Pfizer, Shire Pharm. Dev.		AZ Canada, NIMH, GSK Canada, Eli Lilly, Pfizer Canada, Janssen Canada, Sanofi, Wyeth-Ayerst Canada, Servier Canada, Novartis	Biovail Labs., GSK Canada, Janssen Canada, Pfizer, Wyeth-Ayerst Canada		
Ventura, Daniel		Forest Research Inst.				
Vieta, Eduard	Lundbeck, UCB Pharma, AZ, BMS, Eli Lilly, GSK, Janssen Cilag, Merck Sharp & Dohme, Organon, Novartis, Otsuka, Pfizer, Servier		AZ, Eli Lilly, GSK, Janssen Cilag, Merck Sharp & Dohme, Novartis, Organon, Otsuka, Pfizer, Servier	AZ, BMS, Eli Lilly, Janssen, Novartis		
Wang-Weigand, Sherry	Pfizer, Sanofi, Servier	Takeda				

DISCLOSURE INDEX OF COMPANIES

Name	Consultant	Full-Time Employee	Grant/Research Support	Speaker's Bureau	Stock/Other Financial Options	Other Financial Interest (specify)
Weisler, Richard			Support NIMH, Abbott Labs., BMS, AZ, Biovail Labs., BMS, Cephalon, Corcept Therapeutics, Eisai, Eli Lilly, Forest Labs., GSK, Janssen, Johnson & Johnson PRD, Lundbeck, McNeil, Merck, Novartis, Organon, Pfizer, Sanofi, Schwabe, Shire Pharm. Dev., Solvay, Synaptic, TAP, UCB Pharma, Vela, Wyeth-Ayerst AZ, BMS, Eli Lilly, Forest Labs., Janssen, Pfizer, Wyeth-Ayerst		BMS, Merck, Pfizer	
West, Joyce C			Wyeth-Ayerst AZ, BMS, Eli Lilly, Forest Labs., Janssen, Pfizer, Wyeth-Ayerst			
Whitehead, Richard E						
Wigal, Sharon	McNeil Consumer Healthcare, Abbott Labs., NIMH, Shire	Otsuka	Shire, NIMH, Eli Lilly, McNeil, Novartis	Shire, McNeil Consumer Healthcare		McNeil Consumer Healthcare, Abbott Labs., NIMH, Shire (advisory board)
Wilens, Timothy E	Shire, Abbott Labs., Ortho McNeil, Eli Lilly, Merck, NIDA, Novartis		Abbott Labs., Merck, Ortho McNeil, Eli Lilly, NIDA, Shire	Eli Lilly, Ortho McNeil, Novartis, Shire		
Young, Joel	Novartis Eli Lilly, Shire Pharm. Dev.		Shire Pharm. Dev., Eli Lilly, Novartis	AZ, BMS, Novartis, Sanofi Aventis, Wyeth-Ayerst Labs., Eli Lilly, McNeil, GSK, Sepracor, Shire AZ Canada		
Young, Allan H			AZ Canada			
Zee, Phyllis	Takeda		Takeda, GSK	Takeda, Sanofi Aventis		
Zhao, Fangyi		Eli Lilly				
Zhong, Huaiting		Lundbeck				
Zimmerman, Mark						
Zohar, Joseph	Servier, Pfizer, Solvay		Lundbeck, Pfizer	GSK, Wyeth-Ayerst Lundbeck, GSK, Jazz		

DISCLOSURE INDEX

PRESENTERS WITH NOTHING TO DISCLOSE

Abbas, Muhammad A
Abdallah, Chadi
Abdel Meguid, Marwa
Abdel Razek, Ghada
Abd-Elseyed, Alaa
Abreu, Lena Lna
Abubakar, Tunku-
A.R. Ben
Ahn, Joon-Ho
Albright, Mitzi M
Almeida, Karla
Alonso, Pino
Alphs, Larry D.
Alzahrani, Mohamed
Amir, Asad
Ando, Shuntaro S.A
Andreica, Bianca
Apfel, Brigitte
Areberg, Johan
Arrojo-Romero,
Manuel
Asaad, Tarek
Aslam, Sunny P
Aslam, Mahboob A
Athappilly, Geena K
Avasthi, Ajit
Babiss, Lindsay A.
Bahk, Won-Myong
Balzan, Ryan
Baptista, Trino J
Barker, Sandra B
Barnea-Goraly,
Naama
Barros-Bermudez,
Jaider JA
Battula, Smitha
Bauer, Michael
Bauza, Patricia C
Båve, Ullvi
Bell, Stacy
Benitez Alonso,
Maria
Benton, Tami
Berberian, Arthur
Bhatia, Ajay
Bhupendra, Gupta
Bob, Petr
Bobes, Julio J
Bollegala, Dimitri
Bo-Ra, Kim
Bosch, Rosa
Bossu, Paola
Bousquet, Benjamin
B B
Boyarsky, Gregory
Brent, Elizabeth L
Bui, Eric E
Cabassa, Johanna A
Caldwell, Laura
Calico, Nivea B
Calò, Salvatore
Campo-Arias,
Adalberto
Cardoner, Narcís
Carta, Mauro
Giovanni
Casamassima,
Francesco
Castillo, Enrico
Castro-Loli, Piero
I
Catalán, Rosa
Cernovsky, Zack Z
Cervenka, Simon
Chang, Hui Hua
Chang, Hyoungyoon
Chang, Sung Man
Charnsil, Chawanun
Chee, Christopher B
Chee, Ik-Seung
Ischee
Cheema, Faiz A
Chen, Wei Tzeng
Chen, Po See
Chen, Laura P
Cheng, Chih-Tao
Cheon, Jin Sook
Chien, Yi-Ling
Chiu, Simon
Cho, Chul-Hyun
Choi, Soo-Hee
Choi, Jeewook
Choi, Hong-Min C
Chopra, Amit
Chou, Frank Huang-
Chih
Choua, Raquel
Chow, Kavin
Christensen, Laura
L
Chu, Kim
Chung, Jaewon
Chung, Sang-Keun
Chung, Moon Yong
Church, Heather A
Clifford, Lucinda J
Colin, Stephanie
Cordero, Amelia
Cortes, Edmi Y
Cowperthwait,
Colleen M
Cox, Daniel J
Crail M, Daniel
Crocq, Marc-Antoine
Cummings, Elizabeth
D.Hwan, Cho
Dahl, Jacqueline T
Damsa, Cristian
Dang, Kien T
De Frutos Guijarro,
Juan Jose
De Oliveira,
Irismar Reis IR
Delgado, Ofelia
Delle Chiaie,
Roberto
Dell'osso, Bernardo
Dervic, Kanita
Diamond, Laura
Diller, Kathleen C
Donnelly, Vidis
Duisin, Dragana R
Durrence, H. Heith
Duval, Fabrice
Ekman, Agneta
Ellenwood, Amanda
Elsayed, Yasser A
Enoch, Mary-Anne
Epstein-Lubow, Gary
Erim, Rahsan
Eun-Jung, Jung
Fagbami, Olusola
Fernandez Biesa,
Silvia
Fernandez Garcia-
Andrade, Rafael
Fernandez-Miranda,
Juan J
Flynn, Grainne
Fox, Serena J
Frasch, Karel J
Frydecka, Dorota
Gagnon, Pierre R
Galletly, Cherrie A
Garcia Rosales,
Alejandra
Garcia-López,
Aurelio
Garcia-Portilla,
Maria P
Garcia-Sosa,
Icelini
Gaspar, Enrique
Geraci, Marilla B
Gerlach, Lauren B
Giacobbe, Peter
Giblin, John M
Giltay, Erik
Gines, Jose
Glatt, Stephen J
Goikolea, Jose M
Goldbloom, David L
Goldstein, Benjamin
I
Gonenli, Sinem
Gonzalez, Felix
Gonzalez, Alfonso V

DISCLOSURE INDEX

González Diaz,
Jairo
Goswami, Utpal
Goveas, Joseph S
Grabylnikov,
Stanislav Sg
Graell Berna,
Montserrat
Granados, Armida
Grant, Jon E
Greene, Melissa L
Greenhagen, Jason K
Grieger, Thomas A
Grover, Sandeep
Guillaume,
Sebastien
Gupta, Aarti A-G
Gupta, Bhanu
Ha, Rayeon
Hader, Astrid
Haeri, Sophia H
Haghour, Marina
Hammond,
Christopher J
Harnic, Désirée
Helldin, Lars
Heller, Randi E
Hendriks, Margaret
H
Hensel, Jennifer M
Herazo, Edwin
Ho, Hon
Hojo, Aya
Hopyan, Talar
Horigian, Viviana E
Hraniotis, Nicole
Huang, Huichun
Huang, Shang-Chien
Huber, Samuel J
Hung, Erick
Hwang, Jaerin
Hyun-Jin, Kim
Ibrahim, Fayaz A
Ilankovic, Lana
Marija
Inczedy-Farkas,
Gabriella
Iragorri, Angela
Jagdeo, Amit
Jahng, Eun Jin EJJ
Jalees, Shah
Janish, Christopher
D
Jeon, Hong Jun
Jeon, Hong Jin
Jeong, Jong-Hyun
Jeong, Bumseok
Jin Ok, Song
Johnsen, Erik
Jon, Duk-In
Joshi, Ashish V
Joy, Javed A
Ju, Gawon
Jun, Tae-Youn
Jun Won, Hwang
Jung, Sung Won
Jung Suk, Lee
Jung-Ah, Min Mja
Jurjanz, Luisa
Kang, Il
Kang, Jee In
Kansky, Christine I
Kapetanovic, Suad
Karamustafalioglu,
Nesrin
Karippt, Anoop
Karslioglu, Ersin
Hatice
Katz, Curren E.
Kaunismaki, Yvette
Kim, Seong Hwan
Kim, Seung-Jun
Kim, Seog Ju
Kim, Jeong-Lan
Kim, Woojae
Kim, Min-Ji
Kim, Chi-Won
Kim, Younghee
Kim, Deborah R
Kim, Won
Kim, Jung Jin
Kim, Sehee Ksh
Kim, Shin Gyeom
Kim, Chan-Hyung
Kim, Namkwon
Kim, Sung-Gon
Kim, Jin-Sung
Kim, Chul Eung
Kim, Sung-Wan
Kim, Kyung Ran
Kim, Won-Hyoung
Kito, Shinsuke
Koeber, Ralf
Koehler, Stephan
Koo, Bon-Hoon
Köstlbacher, Anton
Koszycki, Diana
Kounou, Kossi K
Kravos, Matej
Kuan-Pin, Su
Kulhara, Parmanand
Kung, Simon
Kwon, Youngdo
Lan, Tsuo-Hung
Lapidus, Manana
Lazignac, Coralie
Lee, Hwang Bin
Lee, Byungook
Lee, Sang-Yeol
Lee, Min-Soo
Lee, Hoseon
Lee, Se Joung
Lee, Antoinette M
Lee, Seyeon
Lee, Sojin
Lee, Youngmin Lym
Lee, Kyu Young
Lee, Youngjoon
Lee, Jung Sik
Lee, Jun-Yeob
Lee, Byung Dae
Lee, Hae Woo
Lee, Jae-Jin
Lee, Sheng-Yu
Lee, Hamin
Lee, Allison M.R.
Lee, Yujin
Lekwauwa, Ruby E
Leutwyler, Heather
Lewy, Colleen S
Lhommée, Eugénie
Lim, Myung Ho
Lima, Lucimey L
Lin, Shih-Ku
Link, Patrick
Liu, I-Chao
Ljubicic, Rudolf
Lopez, David
Lopez-Carmargo,
Maria
Teresa
Lopez-Castroman,
Jorge
López-Moríñigo,
Javier D
Lothringer,
Lorraine
Lu, Dunyue
Luthringer, Remi
Maclean, Joanna
Mahendran, Rathi
Malcolm, Lader
Maldari, Liza A.
Mane, Anna
Manevitz, Alan Z.
Mangurian,
Christina V
Mannelli, Paolo
Marengo, Eliana
Marsh, Wendy
Martinez, Karen G
Martinez, Susana
Maruyama, Nancy C
Mata, Salvador M
Mateen, Farrah J
Mauro, Mauri
Mayanil, Tushita
Mayerhoff, David I
Mazza, Marianna
McCormick, Laurie M
McGovern, Damian M
Meffert, Susan M
Mehdi, Asad Am

DISCLOSURE INDEX

Mellk, Harlan M
Merideth, Charles
Merkel, Richard L
Meyer, Shirin
Micallef-Roll,
Joelle
Miceli, Jeffrey
Milev, Roumen V
Miller, Nick
Miller, Brian J
Min, Hye Ji
Min-Sup, Shin
Misdrahi, David
Moamai, Javad
Mohamed, Omar
Monleon, Andres
Montes, José Manuel
Jm
Mozos-Ansorena,
Alfonso
Mullins, Diane
Muñoz San José,
Ainoa
Nascimento, Antonio
Naughton, Leena
Nesci, Cristina
Ng, Bernardo
Nguyen, Tuan-Anh
Ni, Hsing-Chang
Nicol, Ginger E
Noorani, Gulam A
Nunes, Luciana L
O Connor, Karen
Ochoa, Rosalba
Odlaug, Brian L
Oh, Inkyung
Olsson, Eric
Omer, Aydemir
O'neil, Oreisa
Oravec, Geoffrey J
Özyildirim, Ilker
Pae, Chi-Un
Pallanti, Stefano
Park, Sae-Han
Park, Min-Cheol
Partti, Krista
Passov, Victoria
Patel, Kajal R
Patil, Uday
Pergolizzi,
Fabianna R
Perlick, Deborah A
Pham-Scottez,
Alexandra
Polosan, Mircea
Portillo, Guillermo
Pozzoli, Sara
Prado, Eduardo
Preen, Ellen C
Pujara, Akshat C
Pulas, Troy
Quelhas, Rosa
Raboch, Jiri
Raja, Shubha
Ramirez Moya,
Lorerky M
Ramirez-Cardenas,
Angelica
Ramos-Quiroga, J.
Antoni
Rangel-Martinez-
Villalba,
Andres M
Rapin, Lucile
Reich, D. Bradford
Reierson, Gillian
Renshaw, Perry F
Resler, Gustavo D
Richmond, Darren
Riolo, Stephanie A
Roca, Miquel
Rodgers, Rachel F
Rodrigues, Tiago
Rodriguez, Lissette
Rodriguez Vega,
Beatriz
Roh, Daeyoung
Rojo, Agueda A
Roman Mazuecos, Eva
Romanowicz,
Magdalena
Römer, Benedikt
Rosenberg, Ilyse
Roy, Mandy
Rueda-Jaimes,
German E
Rutherford, Cynthia
A
Ryan, Christine E
Saad, Ana C
Saatcioglu, Omer
Safadi, Ziad
Saiz-Ruiz, Jerónimo
J
Salman, Anoosh
Samalin, Ludovic
Samardzic, Radomir
San, Luis
Sang-Bin, Baek
Santamarina, Susana
Sasane, Rahul
Sauer, Tizbé
Schmidt, Karmen
Schwarz, Eitan D
Seo, Young Hee
Seungyoun, Lee
Shafiroff,
Jacqueline
Shamal, Amin
Shanahan, Brian R
Shi Hyun, Kang
Shim, Se-Hoon
Shin, Yunmi
Shin, Woo-Yong
Shin, Eunyoung
Shiner, Brian
Shinozaki, Gen
Si, Tianmei
Sidhu, Kanwar Ajit
S
Sidor, Michelle M
Siefert, Caleb J
Smith, Erica D
Sodhi, Dimple
Sohn, Bokyoung
Soo-Churl, Cho
Sotelo, Gabriel
Speller, Heather K
Spiric, Zeljko
Srivastava, Shefali
Stange, Jonathan P
Steele, Annie K
Stein, Dan J
Stone, Karina
Streeter, Chris C
Strydom, Andre A
Susta, Marek
Swartz, Conrad M
Taha, Ghada R
Tajes-Alonso, Maria
Tajima Pozo,
Kazuhiro
Tanev, Kaloyan S
Theeman, Meredith L
Thode, Kirstin I
Tompkins, David A
Tomruk, Nesrin
Tosun, Taner
Tourian, Leon
Townsend, Jennifer
D
Trancoso, Mirna
Trivedi, Jitendra
Turner, Adrienne E
Tyler, Kelly
Unger, Theresa
Van Den Bossche,
Maarten J
Van Noorden,
Martijn S
Vanderkruik, Rachel
Vemuri, Mytilee
Vevera, Jan
Vicente, Benjamin
Vigod, Simone N
Villegas, Lina
Von Der Goltz,
Christoph
Wang, Sheng-Chang
Warnell, Ronald L
Warren, Susan L



Monday, May 18, 2009

9:00 a.m. - 10:30 a.m.

Hall D, Exhibit Level,
Moscone Convention Center

**New Research Poster Session 1:
*Schizophrenia & Other Psychotic Disorders***

NR1-001

SUBJECTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AND HEPATIC ILLNESS: BASELINE CHARACTERISTICS FROM A TRIAL OF PALIPERIDONE ER

Joan Amatniek M.D., Carla M. Canuso, M.D., Stephen Rodriguez, M.S., Lian Mao, Ph.D., Eriene A. Youssef, Pharm.D., David C. Henderson, M.D.

NR1-002

PATIENT-REPORTED PREVALENCE, SEVERITY, & BOTHERSOMENESS OF MEDICATION-EMERGENT ADVERSE EVENTS AMONG INPATIENTS TREATED FOR SCHIZOPHRENIA

Lawson Anthony M.A., Anthony H. Lawson, M.A., Xianchen Liu M.D., Haya Ascher-Svanum, Ph.D., Michael D. Stensland Ph.D., Virginia Stauffer Pharm.D., Robert R. Conley M.D.

NR1-003

METABOLIC SYNDROME AND GLUCOSA DISTURBANCES IN A SPANISH SAMPLE OF ELDERLY CHRONIC SCHIZOPHRENIC INPATIENTS

Manuel Arrojo-Romero, Ramón Ramos-Ríos, M.D., Eduardo Paz-Silva, M.D., Fernando Carballal-Calvo, M.D., Alicia Crespí-Armenteros, M.D., Ramón Fernández-Pérez, M.D., José Luis Bouzón-Barreiro, M.D., Jorge Seoane-Prado, M.D., Rosario Codesido-Barcala, M.D., Javier D. López-Morriño, Ignacio Tortajada-Bonaset, M.D.

NR1-004

ORAL SUPPLEMENTATION AND CONCOMITANT MEDICATION IN THE TREATMENT OF SCHIZOPHRENIA WITH LONG-ACTING ATYPICAL ANTIPSYCHOTICS

Haya Ascher-Svanum Ph.D., Xiaomei Peng, M.D., M.S., Elena Perrin, M.D., William Montgomery, B.Pharm., Douglas E. Faries, Ph.D., Nadia Jemiai, M.S., Anthony H. Lawson, M.S., Michael Witte, Ph.D., Diego Novick, M.D., Nadia Jemiai, M.S.

NR1-005

COST-EFFECTIVENESS OF OLANZAPINE LONG-ACTING INJECTION IN THE TREATMENT OF NON ADHERENT PATIENTS WITH SCHIZOPHRENIA IN THE UNITED STATES

Haya Ascher-Svanum Ph.D., Nicholas M. Furiak, M.S., Robert W. Klein, M.S., William Montgomery, B.Pharm., Lee J. Smolen, B.S., Anthony H. Lawson, M.S., Robert R. Conley, M.D.

NR1-006

RECURRENCE PATTERN OF THE PATIENTS WHO HAD BEEN DIAGNOSED WITH BRIEF PSYCHOTIC DISORDER: 2 YEARS OF FOLLOW UP BY RETROSPECTIVE CHART REVIEW

Won-Myong Bahk M.D., Won-Myong Bahk, M.D., Young-Eun Jung, M.D., Ho-Jun Seo, M.D., Tae-Youn Jun, M.D.1, Jeong-Ho Chae M.D.

NR1-007

EFFECT OF ARIPIPIRAZOLE VS. HALOPERIDOL IN PANSS PROSOCIAL ITEMS IN EARLY EPISODE PATIENTS WITH SCHIZOPHRENIA

Ross Baker Ph.D., John P Docherty, M.D., Edward Kim, M.D., M.B.A., Andrei Pikalov, M.D., Ph.D., James Eudicone, M.S., Suja Mathew, B.S., Raymond Mankoski, M.D., Ph.D., Robert D McQuade, Ph.D., Ronald N Marcus, M.D.

NR1-008

CARDIOVASCULAR AND RESPIRATORY COMORBIDITIES IN PATIENTS WITH BIPOLAR DISORDER: A SYSTEMATIC REVIEW

Julio Bobes M.D., José M. Montes, M.D., José Mostaza, M.D., Fernando Rico-Villademoros, M.D., Eduard Vieta, M.D., Jerónimo Saiz-Ruiz, M.D., on behalf of the Spanish Consensus Group of Experts on Physical Health in Patients with Bipolar Disorders.

NR1-009

FACTORS ASSOCIATED WITH METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA - RESULTS FROM A GERMAN OBSERVATIONAL STUDY

Frank Boess, Anette Minaryk, M.S., Catherine Beal, M.S., Hans-Peter Hundemer, M.D., Thomas Forst, M.D., Daniel Kopf, M.D.

NR1-010

TREATMENT PATTERNS AMONG A NATIONWIDE COMMUNITY SAMPLE OF PEOPLE WITH SCHIZOPHRENIA USING ATYPICAL ANTIPSYCHOTICS

Susan Bolge Ph.D., Jessica Panish, M.H.S., Riad Dirani, Ph.D., Debbie Kenworthy, Deborah Freedman, M.B.A.

NR1-011

POST-INJECTION DELIRIUM/SEDATION SYNDROME OBSERVED WITH OLANZAPINE LONG-ACTING INJECTION

Elizabeth Brunner M.D., David P. McDonnell, M.B.B.Ch., M.R.C.Psych., Sebastian Sorsaburu, M.D., Holland C. Detke, Ph.D., Scott W. Andersen, M.S., Richard F. Bergstrom, Ph.D., Malcolm Mitchell, M.B.B.S., M.F.P.M., Kristen Ogle, Ph.D., Angela Gulliver, Pharm.D., Susan B. Watson, Ph.D., Sara A. Corya, M.D.

NR1-012

RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF FLEXIBLE-DOSE PALIPERIDONE ER IN THE TREATMENT OF PATIENTS WITH SCHIZOAFFECTIVE DISORDER

Carla Canuso M.D., Nina Schooler, Ph.D., Colette Kosik-Gonzalez, M.A., Jennifer Carothers, M.B.A., Sc.D., Ibrahim Turkoz, M.S., Jean-Pierre Lindenmayer, M.D.

NR1-013

RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF TWO DOSE RANGES OF PALIPERIDONE ER IN THE TREATMENT OF SUBJECTS WITH SCHIZOAFFECTIVE DISORDER

Jennifer Carothers, Carla M. Canuso, M.D., Nina Schooler, Ph.D., Jean-Pierre Lindenmayer, M.D., Colette Kosik-Gonzalez, M.A., Ibrahim Turkoz, M.S.

NR1-014

ANALYSIS OF NINE ARIPIPIRAZOLE TRIALS TO EVALUATE STRATEGIES FOR SWITCHING PATIENTS WITH SCHIZOPHRENIA TO ARIPIPIRAZOLE

Christina Cognata-Smith Pharm.D., Ross A Baker, Ph.D., M.B.A., Andrei Pikalov, M.D., Ph.D., Suja Mathew, B.S., Stephen Kaplita, M.S., William H Carson, M.D. Randall Owen, M.D.



NR1-015

TREATMENT EFFECTIVENESS IN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDERS: PRELIMINARY VALIDATION OF THE PATIENT ASSESSMENT QUESTIONNAIRE (PAQ)

Lisa Cohen Ph.D., Ramin Mojtabai, M.D., Ph.D., Edward Ip, Ph.D., Patricia Corey-Lisle, Ph.D., , Sophia Haeri, B.A., Sally Shumaker, Ph.D.

NR1-016

EARLY RESPONSE PREDICTS FUTURE TREATMENT SUCCESS DURING ARIPIPRAZOLE TREATMENT OF ADOLESCENTS WITH SCHIZOPHRENIA

Christoph Correll M.D., Robert D. McQuade, PhD, William H. Carson, MD, Margaretta Nyilas, MD, Robert A. Forbes, PhD, Taro Iwamoto, PhD, Ray Mankoski, MD, PhD, Suja J. Mathew, Andrei Pikalov, MD, PhD

NR1-017

CLINICAL AND FUNCTIONAL OUTCOMES IN SCHIZOPHRENIA AFTER INITIATION OF RISPERIDONE LONG-ACTING THERAPY: RESULTS FROM US, SPAIN, AUSTRALIA AND BELGIUM

Concetta Crivera Pharm.D., Concetta Crivera, Pharm.D., M.P.H., Chris M. Kozma, Ph.D., An Jacobs, Riad G. Dirani, Ph.D., Kasem S. Akhras, Pharm.D., Lian Mao, Ph.D., Wayne Macfadden, M.D. Stephen C. Rodriguez, M.S.,

NR1-018

INITIATION OF RISPERIDONE LONG-ACTING THERAPY IN PATIENTS WITH SCHIZOPHRENIA IN THE VA: EFFECTS OF COMORBID CONDITIONS ON HEALTH CARE UTILIZATION

Concetta Crivera Pharm.D., Xinhua S. Ren, Ph.D., Lewis E. Kazis, Sc.D. Mirko Sikirica, Pharm.D., Wayne Macfadden, M.D., Riad Dirani, Ph.D., Shirley Qian, M.S.

NR1-019

EFFECT OF NICOTINE REPLACEMENT ON AGITATION AND AGGRESSION IN SMOKERS WITH SCHIZOPHRENIA: A DOUBLE BLIND, RANDOMIZED PLACEBO CONTROLLED PILOT STUDY

Cristian Damsa M.D., Coralie Lazignac, M.D., Eric Adam, MSc., Salvatore Virgillito MSc., Michael H. Allen, M. D.

NR1-020

DOSE SELECTION OF ASENAPINE: APPLICATION OF MATHEMATICAL MODELS BASED ON D2 RECEPTOR OCCUPANCY

Rik DeGreef, Alan Maloney, Per Olsson-Gisleskog, Klaas Prins, Joep Schoemaker, John Panagides

NR1-021

VALIDATION OF A LONG-TERM SURVEILLANCE TOOL FOR USE BY PSYCHIATRIC NURSES EVALUATING PATIENTS SUFFERING FROM A PSYCHOSIS, PARTICULARLY SCHIZOPHRENIA

Antonio Delgado, Yves Lecrubier

NR1-022

IMPAIRMENT IN VERBAL FLUENCY IN SCHIZOPHRENIA: A PREFRONTAL DEFICIT?

Ofelia Delgado Ph.D., Antonieta Nieto, Ph.D., Dr. José Barroso, Ph.D., Daniel Ferreira, Ph.D., Josefa Ramos, Ph.D., Mercedes de la Varga, M.D., Fernández, Silvia, M.D.

NR1-023

COMPARISON OF OLANZAPINE LONG-ACTING INJECTION SWITCHING METHODS: AN 8-MONTH ANALYSIS OF PATIENTS WITH

SCHIZOPHRENIA AT RISK OF RELAPSE

Holland Detke Ph.D., Fangyi Zhao, Ph.D., Scott W. Andersen, M.S., Susan B. Watson, Ph.D., David P. McDonnell, M.B., M.R.C.Psych.

NR1-024

ASENAPINE PHARMACOKINETICS: INFLUENCE OF CYTOCHROME P450 MODULATORS AND UDP-GLUCURONYLTRANSFERASE INHIBITION

Peter Dogterom, Ellen Hulskotte, Mireille Gerrits, Cees Timmer, Ad Sitsen, Rik de Greef, Edwin Spaans, Pierre Peeters

NR1-025

IMPACT OF MARIJUANA USE ON SYMPTOM SEVERITY AND OUTCOME IN FIRST EPISODE PSYCHOSIS

Kia Faridi M.D., Ashok K. Malla, M.B.B.S., FRCPC(C)

NR1-026

THE COMPARATIVE EFFICACY OF ILOPERIDONE AND HALOPERIDOL ACROSS FOUR SHORT-TERM CONTROLLED TRIALS

John Feeney M.D., Curt Wolfgang, Ph.D., Mihael Polymeropoulos, M.D., Paolo Baroldi, M.D., Ph.D., Jennifer Hamilton, M.S.

NR1-027

OPTIMIZATION OF DOSING STRATEGY FOR PALIPERIDONE PALMITATE IN SCHIZOPHRENIA: RESULTS OF DOUBLE-BLIND STUDIES AND POPULATION PHARMACOKINETIC SIMULATIONS

W. Wolfgang Fleischhacker M.D., Srihari Gopal, M.D., M.H.S., Mahesh N. Samtani, Ph.D., Jorge A. Quiroz, M.D., Gahan Pandina, Ph.D., An Vermeulen, Ph.D., Virginie Herben, Ph.D., Pilar Lim, Ph.D., Cristiana Gassmann-Mayer, Ph.D., Vivek Kusumakar, M.D., Joseph Palumbo, M.D.

NR1-028

THOUGHT DISORDER – A NEW PERSPECTIVE

Cherrie Galletly Ph.D., Jonathan Crichton, Ph.D.

NR1-029

CONVICTION AND DOUBT IN DELUSIONS

Icelini Garcia-Sosa M.D., Michael Garrett, M.D.

NR1-030

SWITCHING FROM RISPERIDONE TO PALIPERIDONE ER IN STABLE BUT SYMPTOMATIC OUTPATIENTS WITH SCHIZOPHRENIA – INTERIM ANALYSIS

Wagner Gattaz M.D., Marcio Versiani, Ph.D., Rodrigo A. Bressan, Ph.D., Sandra Ruschel, Ph.D., Mário Louzã, Ph.D., Elaine Henna, M.D., Acioly L. T. Lacerda, Ph.D., Fábio Rocha, Ph.D., Hélio Elkis, Ph.D., Irismar R. Oliveira, Ph.D., Ernindo Sacomani, Ph.D., André Brasil, Ph.D., Hamilton M. Grabowski, Ph.D., João A. Campos, M.D., João Quevedo, Ph.D., José C.B. Appolinário, Ph.D.

NR1-031

LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF PALIPERIDONE PALMITATE IN PATIENTS WITH SCHIZOPHRENIA

Sri Gopal M.D., Ujjwala Vijapurkar, Ph.D., Pilar Lim, Ph.D., Margarita Morozova, M.D., Ph.D., Mariëlle Eerdeken, M.D., M.B.A.

NR1-032

MEDICATION SATISFACTION IN SUBJECTS WITH SCHIZOPHRENIA TREATED WITH PALIPERIDONE ER AFTER SUBOPTIMAL RESPONSE TO ORAL RISPERIDONE

Augusto Grinspan M.D., Carla M. Canuso, M.D., Ursula Merriman, B.S., C.V. Damaraju, Ph.D., Larry Alphs, M.D., Ph.D., Amir Kalali, M.D.



NR1-033

EFFICACY OF ILOPERIDONE IS COMPARABLE TO RISPERIDONE IN A META-ANALYSIS OF A PLACEBO- AND RISPERIDONE-CONTROLLED CLINICAL TRIAL FOR SCHIZOPHRENIA

Jennifer Hamilton M.S., Mihael Polymeropoulos, MD, John Feeney, MD, Paolo Baroldi, MD, PhD and Curt Wolfgang, PhD

NR1-034

INSULIN SENSITIVITY IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER TREATED WITH OLANZAPINE OR RISPERIDONE

Thomas Hardy M.D., Robert R. Henry, M.D., Tammy D. Forrester, M.S., Ludmila A. Kryzhanovskaya, M.D., Ph.D., Susan B. Watson, Ph.D., David M. Marks, M.D., Sunder Mudaliar, M.D.

NR1-035

A DOUBLE-BLIND COMPARISON OF LURASIDON AND ZIPRASIDONE ON COGNITIVE FUNCTION IN OUTPATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER

Philip D. Harvey Ph.D., Masaaki Ogasa, MD, Josephine Cucchiari, Ph.D., Antony Loebel, MD, Richard SE Keefe, PhD

NR1-036

MAINTENANCE DOSING OF ONCE-MONTHLY (4-WEEKLY) PALIPERIDONE PALMITATE IN SCHIZOPHRENIA: PHARMACOKINETIC RATIONALE BASED ON POPULATION BASED SIMULATIONS

J. Thomas Haskins Ph.D., Mahesh N. Samtani, Ph.D., Larry Alphas, M.D., Jennifer Kern Sliwa, PharmD., B.C.P.P., Kim Stuyckens, M.Sc., Virginie Herben, Ph.D., An Vermeulen, Ph.D.

NR1-037

INCREASE OF SYMPTOM REMISSION IN PSYCHOSIS – INTEGRATING SCIENCE AND SERVICE IN THE SWEDISH CLIPS STUDY

Lars Helldin, Fredrik Hjärthag, M.Sc., Ulla Karilampi, M.Sc., Anna-Karin Olsson, M.Sc., Torsten Norlander, Ph.D.

NR1-038

ALGORITHMS INCLUDING AMANTADINE, METFORMIN AND ZONISAMIDE FOR MITIGATION OF WEIGHT GAIN DURING OLANZAPINE TREATMENT IN OUTPATIENTS WITH SCHIZOPHRENIA

Vicki Hoffmann Pharm.D., Michael Case, MS, Jennie Jacobson, PhD

NR1-039

REASONS FOR ADHERENCE TO ANTIPSYCHOTIC TREATMENT: THE PATIENT'S PERSPECTIVE

Liu-Seifert Hong Ph.D., Olawale O. Osuntokun, M.D., Jenna L. Godfrey, M.S., Peter D. Feldman, Ph.D.

NR1-040

EFFECTS OF WATER INTAKE AND SMOKING ON THE ABSORPTION OF SUBLINGUALLY ADMINISTERED ASENAPINE

Ellen Hulskotte, Edwin Spaans, Cees Timmer, Andreas Schrödter, Christel Machiels, Peter Schnabel, Michiel Van Den Heuvel, Rik De Greef, Pierre Peeters

NR1-041

ATTENTIONAL MODULATION OF EXTERNAL SPEECH ATTRIBUTION IN PATIENTS WITH PARANOID SCHIZOPHRENIA

Lana Marija Ilankovic M.S.C., Rolf Engel, Prof., Joseph Kambeitz, Hans-Juergen Moeller, Prof., Kristina Hennig-Fast, Prof.

NR1-042

DIFFERENTIAL BRAIN VOLUME CORRELATES OF TRAIT ANHEDONIA IN SCHIZOPHRENIA: A VOXEL-BASED MORPHOMETRIC STUDY

Lee Jung Suk, Jung Suk Lee, M.D., Ji Won Chun, M.A., Jeong-Ho Seok, M.D., Ph.D., Hae-Jeong Park, Ph.D., Jae-Jin Kim, M.D., Ph.D

NR1-043

EUFEEST: THE EFFECTS OF FIRST AND SECOND GENERATION ANTIPSYCHOTICS ON METABOLIC AND CARDIOVASCULAR RISK FACTORS

Rene Kahn M.D., Wolfgang Fleischhacker, M.D., Onur Karayal, MD., Cynthia Siu, Ph.D., Elizabeth Pappadopulos, Ph.D., EUFEEST Study Group

NR1-044

ZIPRASIDONE WITH ADJUNCTIVE MOOD STABILIZER IN MAINTENANCE TREATMENT OF BIPOLAR DISORDER: METABOLIC AND WEIGHT EFFECT PROFILES

Onur Karayal M.D., Kathleen S. Ice, Ph.D., Elizabeth Pappadopulos, Ph.D. Cynthia Siu, Ph.D.

NR1-045

SCHIZOTAXIA AS A SYNDROME

Ersin Hatice Karslioglu M.D., Nevzat Yuksel, M.D., Belma Bekci, Ph.D., Sirel Karakas, Ph.D.

NR1-046

INITIATION DOSING OF DELTOID INTRAMUSCULAR PALIPERIDONE PALMITATE IN SCHIZOPHRENIA: PHARMACOKINETIC RATIONALE BASED ON MODELING AND SIMULATION

Jennifer Kern Sliwa Pharm.D., Mahesh N. Samtani, Ph.D., J. Thomas Haskins, Ph.D., Larry Alphas, M.D., Kim Stuyckens, M.Sc., Virginie Herben, Ph.D., An Vermeulen, Ph.D.

NR1-047

COMPARISON OF SWITCHING STRATEGIES TO ARIPIPRAZOLE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA

Chul Eung Kim M.D., Tae Yeon Suh M.D., Min Hee Kang M.D., Jung Seop Lee M.D., Jae Nam Bae, M.D.

NR1-048

SWITCHING FROM ATYPICAL ANTIPSYCHOTICS TO ARIPIPRAZOLE IMPROVES COGNITIVE FUNCTION, ATTITUDE TOWARD MEDICATION, AND METABOLIC ABNORMALITIES

Sung-Wan Kim M.D., Sung-Wan Kim, M.D., Il-Seon Shin, M.D., Jae-Min Kim, M.D., Jeong-Hoon Lee, M.D., Yo-Han Lee, M.D., Su-Jin Yang, M.D., Kyung-Yeol Bae, M.D., Seon-Young Kim, M.D., Jin-Sang Yoon, M.D.

NR1-049

THE EFFICACY AND TOLERABILITY OF CARIPRAZINE IN ACUTE MANIA ASSOCIATED WITH BIPOLAR DISORDER: A PHASE II TRIAL

Mary Ann Knesevich M.D., Kelly Papadakis, MD; Anjana Bose, PhD; Qing Wang, PhD; Andrew Korotzer, PhD; Istvan Laszlovszky, PharmD

NR1-050

EARLY RESPONSE TO ANTIPSYCHOTIC DRUG THERAPY AS A PREDICTOR OF SUBSEQUENT RESPONSE IN THE TREATMENT OF PATIENTS WITH FIRST EPISODE PSYCHOSIS

Sara Kollack-Walker Ph.D., Virginia Stauffer, PharmD, Michael Case, MS, Robert Conley, MD, Haya Ascher-Svanum, PhD, Bruce J Kinon, MD



NR1-051

A CLINICAL RESEARCH PROGRAM FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER

Colette Kosik-Gonzalez, Carla M. Canuso, M.D., Nina Schooler, Ph.D., Jennifer Carothers, M.B.A., Sc.D., Amir Kalali, M.D., Jean-Pierre Lindenmayer, M.D., Ibrahim Turkoz, M.S.

NR1-052

A LONGITUDINAL ANALYSIS OF CHANGES IN TOTAL CHOLESTEROL AND FASTING GLUCOSE IN ADULTS TREATED WITH OLANZAPINE

Ludmila Kryzhanovskaya M.D., Brian Millen, PhD; Nayan Acharya, MD Olawale Osuntokun, MD; Carol Robertson-Plouch, DVM; Janice Carlson, PhD

NR1-053

THE IMPACT OF SYMPTOMATOLOGY ON RESPONSE TO A HEALTH PROMOTING INTERVENTION AMONG OLDER ADULTS WITH SCHIZOPHRENIA

Heather Leutwyler, Heather Leutwyler, MSN, FNP, CNS, Margaret Wallhagen, PhD, GNP-BC, Christine McKibbin, PhD

NR1-054

LURASIDONE FOR SCHIZOPHRENIA: SYMPTOMATIC REMISSION DURING SHORT-TERM TREATMENT

Anthony Loebel Ph.D., Josephine Cucchiaro, Ph.D., Masaaki Ogasa, M.S., Robert Silva, Ph.D., Cynthia Siu, Ph.D.

NR1-055

BEYOND THE METABOLIC SYNDROME: CHRONIC MEDICAL COMORBIDITY IN INSTITUCIONALIZED SCHIZOPHRENIC PATIENTS

Javier López-Morínigo, Fernando Carballal-Calvo, M.D., Manuel Arrojo-Romero, M.D., Eduardo Paz-Silva, M.D., Ramón Ramos-Ríos, M.D., Rosario Codesido-Barcala, M.D., Alicia Crespi-Armenteros, M.D., Ramón Fernández-Pérez, M.D., José Luís Bouzón-Barreiro, M.D., Jorge Seoane-Prado, M.D., Ignacio Tortajada-Bonaselt, M.D.

NR1-056

AN OPEN LABEL STUDY OF SWITCHING FROM ORAL ANTIPSYCHOTICS TO RISPERIDONE LONG ACTING IN SCHIZOPHRENIC SUBJECTS WITH NON-ADHERENCE TO THE TREATMENT

Mário Louzã M.D., Hélio Elkis, Ph.D., Sandra I. Ruschel, Ph.D., Eduarodo P. Sena, Ph.D., Rodrigo Bressan, Ph.D., Paulo B. Abreu, Ph.D., Hamilton Grabowski, Ph.D., José C.B. Appolinário, Ph.D.

NR1-057

LONG-ACTING RISPERIDONE ADJUNCTIVE TO STANDARD CARE IN PATIENTS WITH BIPOLAR DISORDER WHO ARE EXPERIENCING MOOD SYMPTOMS

Wayne Macfadden M.D., Caleb M. Adler, M.D., Ibrahim Turkoz, M.S., Norris Turner, Pharm.D., Ph.D., J. Thomas Haskins, Ph.D., Larry Alphs, M.D., Ph.D.

NR1-058

EFFECT OF POLYMORPHISMS IN THE DOPAMINE RECEPTOR 2 GENE ON ILOPERIDONE EFFICACY FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA

Kendra Mack M.S., Louis Licamele, M.S., Andrew Thompson B.S., Christian Lavedan Ph.D., Simona Volpi, Ph.D.

NR1-059

PREDICTORS OF REMISSION IN SCHIZOPHRENIA

Prakash Masand M.D., Cedric O’Gorman, M.D., Francine Mandel, Ph.D.

NR1-060

LONG-TERM OPEN-LABEL SAFETY OF OLANZAPINE LONG-ACTING INJECTION: A 190-WEEK INTERIM RESULTS

David McDonnell M.B., Scott W. Andersen, M.S., Holland C. Detke, Ph.D., Fangyi Zhao, Ph.D., Susan B. Watson, Ph.D.

NR1-061

THE RELATIONSHIPS BETWEEN SYMPTOMS OF SCHIZOPHRENIA AND THE COGNITIVE DOMAINS OF MATRICS COGNITIVE BATTERY

Shin Min-Sup Ph.D., Choong-Wan, Woo, M.A.

NR1-062

DIAGNOSTIC VALIDITY OF MMPI-2 FOR PATIENTS WITH SCHIZOPHRENIA AND DEPRESSIVE DISORDER

Shin Min-Sup Ph.D., Soon-Ho Seol, M.A.

NR1-063

EVALUATION OF TREATMENT ADHERENCE AND THERAPEUTIC ALLIANCE IN PSYCHOTIC PATIENTS IN TRANSITION FROM ORAL TO LONG ACTING INJECTABLE RISPERIDONE

David Misdrahi, Antonio Delgado, Denis Comet, Jean-François Chiariny

NR1-064

PERSONALITY DISORDER IN FIRST ADMITTED SCHIZOPHRENIC PATIENTS: PREVALENCE AND DIAGNOSTIC STABILITY

Javad Moamai M.D., Jacques Seguin, MD, FRCPC.

NR1-065

EVALUATION OF COGNITIVE FUNCTION IN PATIENTS SWITCHED FROM RISPERIDONE TO ARIPIPIRAZOLE USING DIFFERENT TITRATION STRATEGIES: AN OPEN-LABEL STUDY

Reza Moghadam Pharm.D., Jean-Pierre Kahn, M.D., Ph.D.; Anne Dillenschneider, M.D., Sieglinde Modell, M.D.; Jurgen Lissens, M.Sc. Christian Werner, M.D.; Wendy Kerselaers, M.S.; Raymond Sanchez, M.D. Jean-Yves Loze, M.D.; Robert D. McQuade, Ph.D.; Vincent Rykmans, M.D. William H. Carson, M.D.

NR1-066

FEASIBILITY AND ACCEPTABILITY OF AN AUDIO COMPUTER-ASSISTED SELF-INTERVIEW INSTRUMENT (ACASI) TO ASSESS SYMPTOMS AND SIDE-EFFECTS IN OUTPATIENTS

Ramin Mojtabai M.D., Sophia Haeri, BA; Eda Inan, BA; Jamie Johnson, BA.; Lisa Cohen, PhD; Igor Galynker, PhD, MD; Patricia K. Corey-Lisle, PhD

NR1-067

NEUROLOGICAL COMORBIDITIES IN PATIENTS WITH BIPOLAR DISORDER: A SYSTEMATIC REVIEW

José Manuel Montes M.D., Jerónimo Saiz-Ruiz, M.D., Julio Bobes, M.D., José Mostaza, M.D., Eduard Vieta, M.D., Fernando Rico-Villademoros, M.D., Spanish Consensus Group.

NR1-068

REMISSION IN SCHIZOPHRENIA – COURSE AND CORRELATES

Leena Naughton M.D., Olivia Gibbons MD, Aideen Lynch MSc, Paul O’Connell MD, Harry G Kennedy MD.

NR1-069

CHANGES IN ADIPOSITY, INSULIN SENSITIVITY AND LIPID METABOLISM DURING RANDOMIZED ANTIPSYCHOTIC TREATMENT IN SCHIZOPHRENIA



John W. Newcomer M.D., John W. Newcomer, M.D.; Dan W. Haupt, M.D.;
Peter A. Fahnstock, M.D.; Karen S. Flavin, R.N., C.C.R.C.;
Ginger E. Nicol, M.D.; Julia A. Schweiger, C.C.R.C.;
Elizabeth T. Westerhaus, M.A.; Angela M. Stevens, B.S.;
Michael D. Yingling, B.S.

NR1-070
**STRATEGIES FOR THE MANAGEMENT OF
ANTIPSYCHOTIC-INDUCED SEXUAL DYSFUNCTION**
Luciana Nunes M.D., Márcio Gerhardt Soeiro de Souza, M.D.,
Luiz Henrique Junqueira Dieckmann, M.D., Fernando Sargo Lacaz, M.D.,
Mariane Nunes, M.D., Sandra Nunes, Ph.D., Rodrigo Bressan, Ph.D.,
Jair de Jesus Mari, Ph.D.

NR1-071
**REASONS FOR DISCONTINUATION AND
CONTINUATION OF ANTIPSYCHOTIC THERAPY FROM
PATIENT AND CLINICIAN PERSPECTIVES**
Allen Nyhuis M.S., Haya Ascher-Svanum, Ph.D.,
Virginia L. Stauffer, Pharm.D., Bruce J. Kinon, M.D.,
Douglas E. Faries, Ph.D., Glenn A. Phillips, Ph.D., Diana O. Perkins, M.D.

NR1-072
**PREDICTIVE POWER OF EARLY IMPROVEMENT WITH
ATYPICAL ANTIPSYCHOTICS FOR LATER TREATMENT
RESPONSE IN PATIENTS WITH SCHIZOPHRENIA**
Cedric O'Gorman M.D., John Kane, M.D., Shitij Kapur, M.D., Ph.D.,
Sheela Kolluri, Ph.D., Elizabeth Pappadopulos, Ph.D.

NR1-073
**A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED, DOSE-RESPONSE EFFICACY/SAFETY
STUDY OF PALIPERIDONE PALMITATE IN ADULTS
WITH SCHIZOPHRENIA**
Gahan Pandina Ph.D., Jean-Pierre Lindenmayer, M.D., Julia Lull, M.A.,
Pilar Lim, Ph.D., Cristiana Gassmann-Mayer, Ph.D., Srihari Gopal, M.D.,
M.H.S., Eric Yuen, M.D., Joseph Palumbo, M.D.

NR1-074
**PSYCHIATRIC-RELATED UTILIZATION AND COSTS
ASSOCIATED WITH PALIPERIDONE ER COMPARED
WITH OTHER ATYPICAL ANTIPSYCHOTICS IN A
COMMERCIAL HEALTH PLAN**
Jessica Panish, Riad Dirani, Ph.D., Rachel Halpern, Ph.D., Feng Cao, Ph.D.

NR1-075
**SUICIDE PREDICTORS IN A LARGE SIMPLE TRIAL OF
PATIENTS WITH SCHIZOPHRENIA**
Elizabeth Pappadopulos Ph.D., Wolfgang Fleischhacker, M.D.,
John Kane, M.D., Sybil Eng, Ph.D., Jamie Geier, Ph.D.,
Charlotte Kremer, M.D., Yikang Xu, Ph.D.

NR1-076
**LONG TERM MAINTENANCE OF WEIGHT LOSS IN
PATIENTS WITH SERIOUS MENTAL ILLNESS (SMI)
THROUGH A BEHAVIOURAL PROGRAMME IN U.K.
RESULTS AT 8 YEARS**
John Pendlebury, Holt R, Wildgust H, Bushe CJ

NR1-077
**EVALUATION OF THE EFFECTIVENESS, THE EFFECT
ON COGNITIVE FUNCTIONING AND WEIGHT CHANGE
IN SCHIZOPHRENIA: AN OPEN-LABEL STUDY
(CN138-166)**
Joseph Peuskens M.D., Joseph Peuskens, M.D., Ph.D.,
Eric Constant, M.D., Ph.D., Chris Bervoets, M.D., André De Nayer, M.D.,
Haitam Mourad, M.D., Bart Roussard, M.D., Stefaan Geerts, M.D.,
Wendy Kerselaers, M.S., Annick de Patoul, M.D., William H Carson, M.D.,
Robert D. McQuade, Ph.D., Véronique Halkin, M.D., M.P.H, M.P.A

NR1-078
**COLLECTING TRACES OF ACTIVITY IN OROFACIAL
MUSCLES DURING AUDITORY VERBAL
HALLUCINATIONS IN SCHIZOPHRENIC PATIENTS**
Lucile Rapin, Polosan M., M.D., Dohen M., Ph.D., Bougerol T., M.D.,
Ph.D., Loevenbruck H., Ph. D.

NR1-079
**SOMNOLENCE AND SEDATION IN ADOLESCENT
PATIENTS WITH SCHIZOPHRENIA TREATED WITH
ARIPIPRAZOLE IN AN ACUTE STUDY WITH LONG
TERM FOLLOW-UP**
Adelaide Robb M.D., Robert D. McQuade, PhD, William H. Carson, MD,
Margaretta Nyilas, MD, Robert A. Forbes, PhD, Taro Iwamoto, PhD,
Ray Mankoski, MD, PhD, Suja J. Mathew, Andrei Pikalov, MD, PhD

NR1-080
**SCHIZOPHRENIA COLLABORATIVE RESOURCE
(SCORE) TOOL: TRACKING PATIENT PROGRESS**
Stephen Rodriguez M.S., Cynthia Bossie, Ph.D., Wayne Macfadden, M.D.,
J. Thomas Haskins, Ph.D., John Docherty, M.D.

NR1-081
**ANTIDEPRESSANT EFFECT OF ANTIPSYCHOTICS IN
SCHIZOPHRENIA: COMPARISON OF TYPICAL AND
ATYPICAL ANTIPSYCHOTIC DRUGS**
Antonio Sa M.D., Antonio R Sa, M.D., M.Sc., Belquiz Avrachim, M.D., Ph.D.,
Helio Elkis, M.D., Ph.D.

NR1-082
**THE EFFECT OF ARIPIPRAZOLE ON AUDITORY
EVENT-RELATED POTENTIAL IN SCHIZOPHRENIA**
Gabriele Sachs M.D., Oliver Pintsov, M.D., Peter Anderer, Ph.D., Doz.,
Gerda Saletu-Zyhlarz, M.D., Prof., Bernd Saletu, M.D., Prof.

NR1-083
**SELECTIVE ATTENTION AND SELECTION FOR ACTION
AMONG CHRONIC SCHIZOPHRENIA PATIENTS**
Ziad Safadi Ph.D., Avishai Henik Ph.D., William B. Lawson, Ph.D., M.D.,
Ora Kofman, Ph.D., Limor Lichtenstein-Vidne, M.A., Maria Hipolito, M.D.

NR1-084
**MORTALITY IN PATIENTS WITH BIPOLAR DISORDER:
A SYSTEMATIC REVIEW**
Jerónimo Saiz-Ruiz M.D., Fernando Rico-Villademoros, M.D.,
José M. Montes, M.D., José Mostaza, M.D., Julio Bobes, M.D.,
Eduard Vieta, M.D.

NR1-085
**PROFILES AND THERAPEUTIC STRATEGIES OF
ANTIPSYCHOTIC TREATMENT NON-ADHERENCE IN
PATIENTS WITH SCHIZOPHRENIA**
Luis San M.D., Luis San, M.D., Ph.D., Antonio Ciudad, M.D., Ph.D.,
Miguel Bernardo, M.D., Ph.D., José M. Olivares, M.D., Ph.D.,
Pepa Polavieja, D.Stat., Belen Yrretagoyena, Ph.D.,
Inmaculada Gilaberte, Ph.D.

NR1-086
**TRANSLATIONAL MODELING OF THE ASENAPINE
PLASMA CONCENTRATION-DOPAMINE D2
RECEPTOR OCCUPANCY RELATIONSHIP IN RATS AND
HUMANS**
Mohammed Shahid, Brian Henry, Marita Prohn, Rik de Greef

NR1-087
**BASELINE SERUM PROLACTIN IN DRUG NAIVE FIRST
EPISODE SCHIZOPHRENIA PREDICTS A POSITIVE
CLINICAL & SOCIAL OUTCOME AT FIVE YEARS POST
DISCHARGE FOLLOW**



Amresh K. Shrivastava M.D., Manoj Tamhane, M.D.,
Meghana Thakar, M.A., Yves Bureau, Ph.D., Nilesh Shah, M.D.

NR1-088

PREVALENCE OF LIVER DISEASE IN VETERANS WITH BIPOLAR DISORDER OR SCHIZOPHRENIA

Mirko Sikirica Pharm.D., Bret E. Fuller, Ph.D., Veronica Rodriguez, Ph.D.,
Alex Linke, B.S., Mirko V.Sikirica, Pharm.D., Riad Dirani, Ph.D.,
Peter Hauser, M.D.

NR1-089

EFFECT OF RISPERIDONE LONG-ACTING INJECTION ON HOSPITALISATION IN SCHIZOPHRENIA PATIENTS: A MIRROR IMAGE ANALYSIS

Mala Singh, M.D.

NR1-090

SWITCHING ANTIPSYCHOTIC DRUGS ENHANCES IMPROVEMENT IN PATIENTS WHO SHOW LACK OF AN EARLY RESPONSE TO THEIR INITIAL ANTIPSYCHOTIC THERAPY

Virginia Stauffer Pharm.D., Lei Chen, MD, Haya Ascher-Svanum, PhD,
Sara Kollack-Walker, PhD, Wei Zhou, MS, Shitij Kapur, MD,
John Kane, MD, Bruce J Kinon, MD

NR1-091

DISSOCIATIVE SYMPTOMS AND INTERREGIONAL EEG CROSS-CORRELATIONS IN PARANOID SCHIZOPHRENIA

Marek Susta Ph.D., Petr Bob, Ph.D.

NR1-092

SELECTIVE ESTROGEN RECEPTOR MODULATORS SHARE THE ANTIPSYCHOTIC GENE EXPRESSION PROFILE, SUGGESTING THEIR POTENTIAL IN THE TREATMENT OF SCHIZOPHRENIA

Andrew Thompson B.S., Louis Licamele, M.S., Simona Volpi, Ph.D.,
Shruti N. Mitkus, Ph.D., Kendra Mack, M.S.,
Mihael H. Polymeropoulos, M.D., Christian Lavedan, Ph.D.

NR1-093

FACTORS ASSOCIATED WITH WEIGHT GAIN DURING OLANZAPINE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER: RESULTS FROM A PROSPECTIVE, SIX-MONTHS

Tamas Treuer M.D., Vicki Poole-Hoffmann, Pharm.D., Susanna Holt, Ph.D.,
Antony Kuang-Peng Chen, M.D., Victoria Irimia, M.D., Ph.D.,
Magdalena Ocampo, M.D., Gang Wang, M.D., Pritibha Singh, M.Sc.

NR1-094

RISK OF CANCER AND HIV INFECTION IN PATIENTS WITH BIPOLAR DISORDER: A SYSTEMATIC REVIEW

Eduard Vieta M.D., Julio Bobes, M.D., Fernando Rico-Villademoros, M.D.,
José Mostaza, M.D., José Manuel Montes, M.D., Jerónimo Saiz-Ruiz, M.D.

NR1-095

EFFECT OF 6 GENETIC MAKERS ASSOCIATED WITH ILOPERIDONE EFFICACY ON LONG TERM CLINICAL OUTCOME OF PATIENTS WHO SWITCH TO LOPERIDONE

Simona Volpi Ph.D., Christian Lavedan, Ph.D.

NR1-096

ACTIGRAPHICALLY ASSESSED ACTIVITY AND REST IN SCHIZOPHRENIC PATIENTS TREATED WITH OLANZAPINE

Adam Wichniak M.D., Aleksandra Wierzbicka, M.D.,
Elzbieta Waliniowska, M.S., Iwona Musinska, M.S.,

Krystyna Czasak, Eugenia Szatkowska, Wojciech Jernajczyk, M.D., Ph.D.,
Marek Jarema M.D., Ph.D.

NR1-097

PHARMACOKINETIC-PHARMACODYNAMIC MODELING INDICATES HALOPERIDONE DOSES ABOVE 12 MG/D REACH A THERAPEUTIC PLATEAU IN PATIENTS WITH SCHIZOPHRENIA

Curt Wolfgang Ph.D., Mihael Polymeropoulos, MD, Paolo Baroldi, PhD

NR1-098

RELATIONSHIP OF CHANGE IN WHOLE-BODY ADIPOSITY TO PSYCHIATRIC SYMPTOM CHANGE DURING RANDOMIZED ANTIPSYCHOTIC TREATMENT IN SCHIZOPHRENIA

Michael Yingling, Michael D. Yingling, BS; Peter A. Fahnstock, MD;
Dan W. Haupt, MD; Ginger E. Nicol, MD; Karen S. Flavin, RN, CCRC;
Julia A. Schweiger, CCRC; Elizabeth T. Westerhaus, MA;
Angela M. Stevens, BS; John W. Newcomer, MD

NR1-099

ACUTE EFFICACY OF OLANZAPINE LONG-ACTING INJECTION, ORAL OLANZAPINE, AND HALOPERIDOL IN PATIENTS WITH SCHIZOPHRENIA: A CROSS-STUDY COMPARISON

Fangyi Zhao Ph.D., Holland C. Detke, Ph.D., Janice Carlson, Ph.D.,
David McDonnell, M.D., M.R.C.Psych.



Monday, May 18, 2009

**12:30 p.m. - 2:00 p.m.
Hall D, Exhibit Level,
Moscone Convention Center**

**New Research Poster Session 2:
Patient Populations & Nonpsychotic
Disorders**

NR2-001

**RELATIONSHIPS OF BODY COMPOSITION DATA TO
CONCURRENT DRUG ABUSE IN A METHADONE CLINIC**
*Zack Cernovsky Ph.D., Gamal E. Sadek, M.D., Simon Chiu, M.D., Ph.D.,
Heba Youssef, M.D*

NR2-002

**CONCURRENT DRUG ABUSE IN A METHADONE
CLINIC: ITS RELATIONSHIP TO PAST CRIMINAL
HISTORY**
*Zack Cernovsky Ph.D., Heba Youssef, M.D., Gamal E. Sadek, M.D.,
Simon Chiu, M.D., Ph.D.*

NR2-003

**ADDICTION TREATMENT OUTCOMES FOR A
COHORT OF AFRICAN-AMERICAN PHARMACISTS
WITH DIAGNOSES OF SUBSTANCE ABUSE OR
DEPENDENCE: IS THERE AN INEQUALITY?**
*Christopher Hammond B.A., Noni A Graham, M.P.H., R Pomm, M.D.,
Mark S Gold, M.D.*

NR2-004

**HOSTILITY AND IMPULSIVITY OF NICOTINE
DEPENDENCE**
*Jaerin Hwang, Sungho Min, M.D., Department of Psychiatry,
Wonju College of Medicine, Yonsei University, Korea*

NR2-005

**DRINKING PATTERNS, TEMPERAMENT AND
CHARACTER OF FEMALE INPATIENTS WITH
ALCOHOL DEPENDENCE**
Jung Sik Lee M.D., Soon Woo Chang, M.D., Sang Baek Lee, M.D.

NR2-006

**COUNSELOR CHARACTERISTICS PREDICT
SUBSTANCE ABUSE TREATMENT
RECOMMENDATIONS**
*Colleen Lewy Ph.D., Holly E. Fussell, Ph.D., Celina Oliver, M.S.,
Bentson McFarland, M.D., Ph.D.*

NR2-007

**CANNABIS USE FOLLOWING LOW DOSE
NALTREXONE ADDITION IN OPIOID DETOXIFICATION**
*Paolo Mannelli, Paolo Mannelli MD, Kathi Peindl PhD, Li-Tzy Wu Sc.D.,
Ashwin A Patkar, MD*

NR2-008

POKER AND PSYCHOSTIMULANTS: A CASE STUDY
Troy Pulas M.D., Dwight Zach Smith, M.D., John Renner, M.D.

NR2-009

**THE MEDICATION USE FOR NICOTINE DEPENDENCE
AT A PUBLIC TREATMENT PROGRAM IN RIO DE
JANEIRO, BRAZIL**

*Ana Saad M.D., Jorge Antonio Jaber Filho, MD, MBA;
Ana Cristina Sáad, MD, PhD; Eduardo Hoffmann, Psy. D;
Angela Hoffmann, Psy. D; Antonio Tomé, therapist*

NR2-010

**RELATIONSHIPS BETWEEN USE OF ANTIPSYCHOTICS
AND CHANGES IN PHYSICAL GROWTH IN CHILDREN
AND ADOLESCENTS WITH HIV**
*Suad Kapetanovic M.D., Lisa Aaron, B.S., Patricia A. Sirois, Ph.D., Grace
Montepiedra, Ph.D., Paige L. Williams, Ph.D., Deborah A. Pearson, Ph.D.,
Kathleen Malee, Ph.D., Patricia A. Garvie, Ph.D., Betsy L. Kammerer,
Ph.D., Sharon L. Nichols, Ph.D., Molly L. Nozyce, Ph.D., Mark Mintz,
M.D., James M. Oleske, M.D., and the IMPAACT/PACTG 219C Team*

NR2-011

**AMPHETAMINE RELATED SYMPTOMS: DESCRIPTIVE
ANALYSIS AND REASONING**
*Ghada Abdel Razek M.D., Y. Abdel Razek, M.D., G. Refaat, M.D.,
Mahmoud Rashad, PhD., Mohamed Al-Zahrany ,PhD.,
Abdalla Al-Johi, PhD.*

NR2-012

**THE IMPACTS OF SUBSTANCE ABUSE & DEPENDENCE
ON NEUROPSYCHOLOGICAL FUNCTIONS IN A
SAMPLE OF PATIENTS FROM SAUDI ARABIA**
Mohamed Alzahrani, Ph.D., Yasser A. Elsayed

NR2-013

**ALCOHOL PROBLEM USE IN MALE POPULATION IN
COLOMBIA: ASSOCIATION WITH CIGARETTE
SMOKING**
*Jaider Barros-Bermudez M.D., German E. Rueda-Jaimes, MD,
Luis A. Diaz-Martinez, MD, MSC, Edwin Herazo, MD, MSc,
Adalberto Campo-Arias, M.D*

NR2-014

DUAL DIAGNOSIS IN PSYCHIATRIC IN PATIENTS
*Jose Gines, David Corcoles M. D., Jose M Arcega M. D.,
Angeles Malagon M.D., Carles Garcia-Ribera M. D., Anna Merino M. D.,
Antoni Bulbena Ph.D. M. D.*

NR2-015

**STUDY OF FACTORS THAT INFLUENCE DRINKING
BEHAVIOR AMONG KOREAN PREGNANT WOMEN**
*Sung-Gon Kim M.D., Ji-Hoon Kim, M.D., Sang-Shin Lee, M.D.,
Soo-Mi Shin, M.D., Byung-Dae Lee, M.D., Woo-Young Jung, M.D.,
Ji-Hye Park, M.D.*

NR2-016

**TRACTOGRAPHY BASED SEGMENTATION OF THE
CORPUS CALLOSUM IN ALCOHOL DEPENDENCE**
I-Chao Liu M.D., Chen-huan Chiu, M.D, Ph.D., Issac WY Tseng, M.D., Ph.D

NR2-017

**DOES ANY METHOD OF DEFINING FAMILIAL
ALCOHOLISM PREDICT REMISSION FROM AN AUD
FORTY YEARS LATER?**
*Shubha Raja M.D., Elizabeth C. Penick, Ph.D., Bjorn Ebdrup, M.D.,
Joachim Knop, M.D., Elizabeth J. Nickel, M.A., Per Jensen, M.D.,
William F. Gabrielli, M.D., Ph.D., Ann M. Manzardo, Ph.D.,
Sreelatha S. Spieker, M.D.*

NR2-018

**DISRUPTING RECONSOLIDATION OF ALCOHOL-
RELATED MEMORIES REDUCES CUE-INDUCED
ALCOHOL-SEEKING BEHAVIOR IN RATS**
*Christoph Von Der Goltz M.D., Valentina Vengeliene, Ph.D.,
Falk Kiefer, M.D., Rainer Spanagel, Ph.D.*



NR2-019

IMPROVEMENT IN EMOTIONAL EXPRESSION IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER TREATED WITH 20 TO 70 MG/DAY LISDEXAMFETAMINE DIMESYLATE

Katic Alain M.D., Lawrence D. Ginsberg, M.D., Rakesh Jain, M.D., Cynthia Richards, M.D., Ben Adeyi, M.S., Tom Babcock, D.O., Bryan Dirks, M.D., Brian Scheckner, Pharm.D., Robert L. Findling, M.D.

NR2-020

PATIENT EXPERIENCE AND SATISFACTION WITH LISDEXAMFETAMINE DIMESYLATE IN ADULTS WITH ADHD

Donna Antonucci M.D., Donna Kerney, Ph.D., Frank A. Lopez, M.D., Michael Manos, Ph.D.

NR2-021

LONG-TERM EFFICACY AND SAFETY OF OROS® MPH IN AFRICAN AMERICAN ADULTS WITH ADHD

Robert Armstrong M.D., H. Lynn Starr, M.D., C.V. Damaraju, Ph.D., Diane M. Hasner

NR2-022

VIDEO GAMES: A NOVEL METHOD TO IMPROVE ATTENTION IN CHILDREN WITH ADHD

Gupta Bhupendra M.D., Jay Flynn, B.S.; Akash Gupta

NR2-023

METHYLPHENIDATE TRANSDERMAL SYSTEM USE AND QUALITY OF LIFE IN ADOLESCENTS WITH ADHD

Amann Birgit M.D., Robert Findling, M.D., Richard Civil, M.D., Manisha Madhoo, M.D.

NR2-024

SOCIOLINGUISTIC ANALYSIS OF DIALOGUE BETWEEN PSYCHIATRISTS AND ADULTS WITH DEPRESSION AND POSSIBLE COMORBID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

William Dodson M.D., Robert L. Findling, MD; Corey Eagan; Meaghan Onofrey, MS

NR2-025

BASELINE CHARACTERISTICS AND ATOMOXETINE TREATMENT EFFICACY IN ADULTS WITH ADHD AND ADULTS WITH ADHD AND COMORBID SOCIAL ANXIETY DISORDER

Todd Durell M.D., Lenard Adler, M.D., Richard Rubin, M.D., Meihua Qiao, Ph.D., Bethany Boardman, Ph.D.

NR2-026

SELF-REPORTED COMORBID PSYCHIATRIC CONDITIONS AMONG ADULTS AT RISK FOR ADHD

Michael Durkin M.S.C., Robert Armstrong, M.D., Lynn Starr, M.D., Michael L. Reed, Ph.D.

NR2-027

PHARMACOKINETICS OF INTRANASAL VERSUS ORAL ADMINISTRATION OF LISDEXAMFETAMINE DIMESYLATE IN HEALTHY ADULTS

James Ermer, Kerry Dennis, B.Sc; Mary Haffey, R.Ph; Walter J. Doll, Ph.D.; Erik P. Sandefer, Ph.D; Mary Buckwalter, M.S.; Richard C. Page, Ph.D.; Brian Diehl, B.S.; Patrick Martin, M.D.

NR2-028

EFFICACY AND SAFETY OF THE METHYLPHENIDATE TRANSDERMAL SYSTEM IN ADOLESCENTS WITH ADHD

Robert Findling M.D., Richard Civil M.D., Manisha Madhoo M.D.

NR2-029

DURATION OF EFFECTS OF LISDEXAMFETAMINE DIMESYLATE ON BEHAVIOR OF CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN NATURALISTIC SETTINGS

Thomas Frazier, Donald A. Caserta, M.A., M.S.S.A., L.I.S.W., Michael J. Manos, Ph.D.

NR2-030

EFFICACY OF ONCE-DAILY ATOMOXETINE ON NON-VERBAL EXECUTIVE FUNCTION IN TAIWANESE CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

Susan Shur-Fen Gau M.D., Chi-Yung Shang, MD

NR2-031

PREDICTION OF INATTENTION SYMPTOMS ON VERBAL AND SPATIAL WORKING MEMORY AT CHILDHOOD AND ADOLESCENCE

Susan Shur-Fen Gau M.D.

NR2-032

EFFECT OF LISDEXAMFETAMINE DIMESYLATE ON SLEEP IN CHILDREN AGED 6-12 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

John Giblin M.D., John Giblin, M.D., Allison Hudson, Aaron Strobel, Jesse Byrd

NR2-033

PARENTAL EVALUATION OF LISDEXAMFETAMINE DIMESYLATE IN THE TREATMENT OF CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

Lawrence Ginsberg M.D., Valerie Arnold, M.D., Joe Gao, Ph.D., Cynthia Richards, M.D., Robert Findling, M.D.

NR2-034

COMPARING THE EFFICACY OF MEDICATIONS FOR ADULT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER USING META-ANALYSIS OF EFFECT SIZES

Stephen Glatt Ph.D., Stephen V. Faraone, Ph.D.

NR2-035

LINKING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER RATINGS AND CLINICAL GLOBAL IMPRESSIONS SCORES IN STUDIES OF LISDEXAMFETAMINE DIMESYLATE IN ADHD

David Goodman M.D., Richard Weisler, M.D., Lenard A. Adler, M.D., Stephen V. Faraone, Ph.D., Bryan Dirks, M.D., Mohamed Hamdani, M.S.

NR2-036

ASSESSMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) DOCUMENTATION FROM CANDIDATES REQUESTING AMERICANS WITH DISABILITIES ACT (ADA) ACCOMMODA

Javed Joy M.D., Rose J. Julius DO MPH, Rashida Akter MD, David A. Baron, DO

NR2-037

EFFECTS OF EXTENDED RELEASE METHYLPHENIDATE ON THE FREQUENCY OF CYTOGENETIC ABNORMALITIES IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY

Vinod Kumar M.D., James D. Tucker, Ph.D., Yinong Zhou, M.D., Rafael Muniz, M.D.



NR2-038

CHANGES IN EMOTIONAL EXPRESSION RELATED TO MEDICATION USED TO TREAT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

Michael Manos Ph.D., Matthew Brams, M.D., Ann Childress, M.D., Robert L. Findling, M.D., Frank A. López, M.D., Peter S. Jensen, M.D.

NR2-039

METHYLPHENIDATE TRANSDERMAL SYSTEM IN THE TREATMENT OF ADULTS WITH ADHD: A PRELIMINARY REPORT

Barrie Marchant M.S., Frederick W. Reimherr M.D., Corinne Halls M.S., Erika D. Williams, M.S.W., Robert E. Strong D.O., John L. Olsen M.D., Doug C. Christopherson B.S., Reid Robison M.D.

NR2-040

EVALUATION OF THE QUALITY OF LIFE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER TREATED WITH OROS METHYLPHENIDATE – THE CONQOL STUDY

Paulo Mattos M.D., Daniel Segenreich, M.D., Gabriela Macedo Dias, M.D., Bruno Nazar, M.D., Eloisa Saboya, Psy.

NR2-041

INTERNAL CONSISTENCY AND VALIDITY OF THE ADHD RATING SCALE IV FOR ADULTS

Keith McBurnett Ph.D., Stephen V. Faraone, Ph.D., Lenard A. Adler, M.D., Thomas J. Spencer, M.D., Scott Kollins, Ph.D., Richard Weisler, M.D., David Goodman, M.D., Stephen Glatt, Ph.D., Joseph Biederman, M.D.

NR2-042

INCIDENCE OF VEHICULAR COLLISIONS AND CITATIONS AMONG DRIVERS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD): A GROWING PROBLEM

Richard Merkel M.D., Margaret T. Davis, B.A., Brian S. Cox, B.S., Melissa Moore, M.D., Roger C. Burket, M.D., Daniel J. Cox, Ph.D.

NR2-043

METHYLPHENIDATE TRANSDERMAL SYSTEM USE AND SLEEP QUALITY IN ADOLESCENTS WITH ADHD

Judith Owens M.D., Robert Findling, M.D., Richard Civil, M.D., Manisha Madhoo, M.D.

NR2-044

EFFICACY AND SAFETY OF THE METHYLPHENIDATE TRANSDERMAL SYSTEM IN ADOLESCENTS WITH ADHD AS EVALUATED BY CLINICIANS AND PARENTS/LEGAL GUARDIANS

Melmed Raun M.D., Robert Findling, M.D., Richard Civil, M.D., Manisha Madhoo, M.D.

NR2-045

SELF-REPORTED SYMPTOM-BASED PREVALENCE OF ADHD IN THE US COMPARED WITH RATES OF PREVIOUS DIAGNOSIS

Michael Reed Ph.D., Mike Durkin, Ph.D., Robert Armstrong, M.D., Lynn Starr, M.D.

NR2-046

METHYLPHENIDATE TRANSDERMAL SYSTEM IN THE TREATMENT OF ADULTS WITH ADHD: A PRELIMINARY REPORT

Frederick Reimherr M.D., Barrie K. Marchant M.S., Corinne Halls M.S., Erika D. Williams, M.S.W., Robert E. Strong D.O., John L. Olsen M.D., Doug C. Christopherson B.S., Reid Robison M.D.

NR2-047

ADHD TREATMENT RESPONSE MEASUREMENT WITH THE ADULT SELF REPORT SCALE

Richard Rubin M.D.

NR2-048

EFFICACY AND SAFETY OF OROS® MPH IN ADULTS WITH PREVIOUSLY UNDIAGNOSED ADHD

H. Lynn Starr M.D., C.V. Damaraju, Ph.D., Diane M. Hasner, Robert B. Armstrong, M.D.

NR2-049

HOW REPRESENTATIVE ARE PARTICIPANTS IN A CLINICAL TRIAL FOR ADHD? COMPARISON WITH ADULTS FROM A LARGE OBSERVATIONAL STUDY

Craig Surman M.D., Michael C. Monuteaux, Sc.D., Carter R. Petty, M.S., Stephen V. Faraone, Ph.D., Thomas J. Spencer, M.D., Nicole F. Chu, B.A., Joseph Biederman, M.D.

NR2-050

INFERIOR FRONTAL CORTEX (IFC) DYSFUNCTION DURING AN INHIBITION TASK IN ADULT ADHD COMPARED WITH CONTROL SUBJECTS USING FMRI

Jennifer Townsend B.A., Lara Foland-Ross, B.A., James McGough, M.D., Jeff Fischer, B.A., Susan Y. Bookheimer, Ph.D., Lori L. Altshuler, M.D.

NR2-051

IMPROVEMENT IN EXECUTIVE FUNCTION IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER TREATED WITH 20 TO 70 MG/DAY LISDEXAMFETAMINE DIMESYLATE

Atilla Turgay M.D., Lawrence Ginsberg, M.D., Rakesh Jain, M.D., Joseph Gao, Ph.D., Cynthia Richards, M.D., Robert L. Findling, M.D.

NR2-052

SUSTAINED EFFICACY OF LISDEXAMFETAMINE DIMESYLATE OVER 13 HOURS AS ASSESSED BY EFFECT SIZE IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

Sharon Wigal Ph.D., Scott Kollins, Ph.D., Ann Childress, M.D., Ben Adeyi, M.S., Liza Squires, M.D.

NR2-053

BEFORE SCHOOL ADHD SYMPTOMS AND FUNCTIONING IN YOUTH TREATED WITH THE METHYLPHENIDATE TRANSDERMAL PATCH (MTS)

Timothy Wilens M.D., Paul Hammerness, M.D., Linsey Utzinger, B.A., Anne Georgiopoulos, M.D., Robert Doyle, M.D., Kerry Brodzia, B.A., MaryKate Martelon, M.P.H., Joseph Biederman, M.D.

NR2-054

RESPONSE AND SYMPTOMATIC REMISSION IN A LONG-TERM TRIAL OF LISDEXAMFETAMINE DIMESYLATE IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

Joel Young M.D., Greg Mattingly, M.D., Richard Weisler, M.D., Liza Squires, M.D., Ben Adeyi, M.S., Bryan Dirks, M.D., Thomas Babcock, D.O., Brian Scheckner, Pharm.D.

NR2-055

SELF IMAGE PERCEPTION OF 171 CHILDREN AND ADOLESCENTS WITH CLEFT LIP AND PALATE FROM 23 DIFFERENT COUNTRIES

Alaa Abd-Elseyed, Morgan Livingstone CCLS

NR2-056

ASSOCIATION OF PANDAS(PEDIATRIC AUTOIMMUNE NEURODEVELOPMENTAL DISORDER ASSOCIATED



WITH STREPTOCOCCAL INFECTION) WITH PERVASIVE DEVELOPMENTAL DISORDER

Asad Amir M.D., Imran Anjum MD, Valerie D'Aurora BS, Bliss Chalemian MD, Javed Iqbal MD

NR2-057

ATOMOXETINE FOR HYPERACTIVITY IN CHILDREN WITH SEVERE AUTISTIC DISORDERS: AN OPEN-LABEL STUDY

Chawanun Charnsil M.D.

NR2-058

OPTIMAL RESPONSE TO OROS MPH AMONG CHILDREN AND ADOLESCENTS WITH ADHD: THE ANALYSIS OF DEMOGRAPHIC & CLINICAL CHARACTERISTICS

Ying-Sheue Chen M.D., Chou Wen-Jin, M.D., Chen Shin-Jaw, M.D., Chang Hsueh-Lin, M.D., Lin Chih-Chien, M.D., Yeh Chin-Bin, M.D.

NR2-059

DIFFUSION TENSOR IMAGING ABNORMALITIES IN KOREAN ATTENTION DEFICIT/HYPERACTIVITY DISORDER BOYS

Jeewook Choi M.D., Bumseok Jeong, M.D., Ph.D., Seyeon Lee, M.D., Jiyoung Ahn, M.D., Ph.D., Younghee Seo, M.D.

NR2-060

EFFECTS OF GUANFACINE EXTENDED RELEASE ON SECONDARY MEASURES IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER AND OPPOSITIONAL SYMPTOMS

Daniel Connor M.D., Thomas Spencer, M.D., Christopher Kratochvil, M.D., Frank A. López, M.D., Andrew Lyne, M.Sc., C.Stat., Gerald Tremblay, M.D.

NR2-061

EFFECT OF ARIPIRAZOLE ON QUALITY OF LIFE AND CAREGIVER STRAIN IN THE TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

Patricia Corey-Lisle Ph.D., George Manos, Ph.D., William H Carson, M.D., Robert D McQuade, Ph.D., Andrei Pikalov, M.D., Ph.D., Suja Mathew, B.S., Diane K Ammerman, Pharm.D., Michael Nashat, Pharm.D., Ben Handen, Ph.D., Ronald N Marcus, M.D., Randall Owen, M.D.

NR2-062

TEMPORAL RELATIONSHIP BETWEEN CANNABIS USE AND DEPRESSION AMONG ADOLESCENTS IN THE UNITED STATES

Hon Ho M.D., Hon Ho, M.D., M.P.H., Christian Hopfer, M.D., John K. Hewitt, Ph.D., Brett C. Haberstick, Ph.D., Jeffrey Lessem, Ph.D.

NR2-063

SAFETY AND TOLERABILITY OF ARIPIRAZOLE IN THE TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER (CN138-178 / CN138-179)

Lisa Kamen M.H.A., Randell Owen, M.D., Jully Kim, Pharm.D., George Manos, Ph.D., William H Carson, M.D., Robert D McQuade, Ph.D., Taro Iwamoto, Ph.D., Raymond Mankoski, M.D., Ph.D., Ronald N Marcus, M.D.

NR2-064

EXPOSE TO CHRONIC AIRCRAFT NOISE AND EMOTION, BEHAVIOR CHARACTERISTICS IN KOREAN CHILDREN

Myung Ho Lim M.D., Ki Chung Paik, M.D., Young June Jeon, M.D.,

Won Seok Lim, M.D., Kyung Kyu Lee, M.D., Seok Bum Lee, M.D., Hyun Woo Kim, M.D., Myung Ho Lim, M.D.

NR2-065

PREDICTORS OF IMPROVEMENT IN FUNCTIONAL DISABILITY FROM ADMISSION TO 120 DAYS POST DISCHARGE IN ADOLESCENT PSYCHIATRIC INPATIENTS

Liza A. Maldari Ph.D., David L. Pogge, Philip D. Harvey

NR2-066

COMPARATIVE SEVERITY & OUTCOME OF ADHD IN A PSYCHIATRIC PRIVATE PRACTICE: HIGH-RISK/ LOW-INCOME VS MIDDLE-CLASS YOUTH

Godehard Oepen M.D., Joseph Llinas, M.D., Edward J. Federman, Ph.D., Richard N. Akins, M.D., M.B.A.

NR2-067

SUICIDALITY AND DELIBERATE SELF-HARM IN ADOLESCENT BORDERLINE PERSONALITY DISORDER

Uday Patil M.A., Marianne Goodman, M.D., Joseph Triebwasser, M.D., Elizabeth Diamond, M.A., Larry Siever, M.D.

NR2-068

SCREENING AND BRIEF INTERVENTION FOR UNDERAGE DRINKING IN UNDERSERVED POPULATIONS

Ashwin A. Patkar M.D., Ashwin A. Patkar, M.D., Alex Kemper, M.D., Rowena Dolor, M.D., John Anderson, M.D., Jayaselvi Thanaseelan, M.D., Lillian Robinson, Ph.D., Robert Hubbard, Ph.D., Kathleen S. Peindl, Ph.D.

NR2-069

EFFECTS OF ARIPIRAZOLE ON METABOLIC MEASURES IN PEDIATRIC AND ADOLESCENT PATIENTS: A POOLED ANALYSIS OF PLACEBO-CONTROLLED TRIALS

Andrei Pikalov M.D., John W Newcomer, M.D., Ross A Baker, Ph.D., M.B.A.; Stephen Kaplita, M.S.; Jian Han, Ph.D.; Suja Mathew, B.S.; Raymond Mankoski, M.D., Ph.D.; William H Carson, M.D.; Randall Owen, M.D. R Andrew Forbes, Ph.D.; Margaretta Nyilas, M.D.; Taro Iwamoto, Ph.D.; Randall Owen, M.D.

NR2-070

A CASE-CONTROL ASSOCIATION STUDY OF 5-HYDROXYTRYPTAMINE 1A RECEPTOR GENE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN A KOREAN SAMPLE

Se-hoon Shim M.D., Se-Hoon Shim, M.D, Ph.D., Hyun-Woong Ahn, M.D., Young Hwangbo, M.D, Ph.D., Young -Joon Kwon, M.D, Ph.D., Hee-Yeon Jeong, M.D, Ph.D., Bun-Hee Lee, M.D, Ph.D., Yong-Ku Kim, M.D, Ph.D.

NR2-071

CO-EXPOSURE TO ENVIRONMENTAL LEAD AND MANGANESE AFFECTS THE INTELLIGENCE OF SCHOOL-AGED CHILDREN

Cho Soo-Churl M.D., Yeni Kim, M.D., Ph.D., Boong-Nyun Kim, M.D., Ph.D., Yun-Chul Hong, M.D., Ph.D., Min-Sup Shin, Ph.D., Hee-Jeong Yoo, M.D., Ph.D., Jae-Won Kim, M.D., Ph.D., Soo-Young Bhang, M.D.

NR2-072

PREDICTORS OF RESPONSE AND REMISSION IN PEDIATRIC PATIENTS WITH BIPOLAR DISORDER TREATED WITH ZIPRASIDONE

Michelle Stewart Ph.D., Christoph U. Correll, M.D., Elizabeth Pappadopulos, Ph.D., Francine Mandel, Ph.D.



NR2-073

CDRS-R SUBSCALE ANALYSIS IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF ESCITALOPRAM IN DEPRESSED ADOLESCENTS

Daniel Ventura Ph.D., Adelaide Robb, M.D., Anjana Bose, Ph.D., Andrew Korotzer, Ph.D., Stavros Tourkoudimitris, Ph.D.

NR2-074

PATIENT ASSESSED QUALITY OF LIFE VS. CLINICIAN ASSESSMENT IN A TRIAL OF ARIPIPRAZOLE IN PEDIATRIC PATIENTS WITH BIPOLAR DISORDER

Richard Whitehead B.S., Chien-Feng Chen, Ph.D.; Edward Kim, M.D., M.B.A.; William H. Carson, M.D.; Taro Iwamoto, Ph.D.; Suja Mathew, B.S.; Andrei Pikalov, M.D., Ph.D.

NR2-075

THE PRO-INFLAMMATORY CYTOKINE INTERLEUKIN-18 AND ITS RELATED MOLECULES ARE IMPLICATED IN COGNITIVE DECLINE OF ALZHEIMER'S DISEASE PATIENTS

Paola Bossu Ph.D., Antonio Ciaramella, Ph.D., Diego Vanni, M.S., Francesca Salani, M.S., Carlo Caltagirone, M.D., Gianfranco Spalletta M.D., Ph.D. and Giuseppe Scapigliati Ph.D.

NR2-076

PLANNING IN DEPRESSION AND ANXIETY: THE IMPORTANCE OF USING DIFFERENT INDICATORS FOR FEATURING ITS IMPAIRMENT

Silvia Fernandez Biesa M.D., Antonieta Nieto, Ph.D., Jose Barroso, Ph.D., Ivan Galtier, Ph.D., Belen Curbelo, M.D.

NR2-077

DELIRIUM AND PSYCHO-ACTIVE MEDICATIONS IN TERMINAL CANCER

Pierre Gagnon M.D., Pierre Gagnon, MD, Pierre Allard, MD, PhD, Bruno Gagnon, MD, PhD, Chantale Mérette, PhD, François Tardif, MSc, Claudia Émond, MSc, Valérie Jomphe, MSc.

NR2-078

EXTENDED-RELEASE MEMANTINE (28 MG, ONCE DAILY) IMPROVES ATTENTION AND VERBAL FLUENCY IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE

Stephen Graham Ph.D., George T. Grossberg, M.D., Facundo Manes, M.D., Ricardo Allegri, M.D., Ph.D., Luis Miguel Gutierrez Robledo, M.D., Ph.D., Sergio Gloger, M.D., Lei Xie, Ph.D., Xinwei Daniel Jia, Ph.D., Michael Tocco, Ph.D., James L. Perhach, Ph.D.

NR2-079

EXTENDED-RELEASE MEMANTINE (28 MG, ONCE DAILY) IMPROVES BEHAVIOR IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE

George Grossberg M.D., Facundo Manes, M.D., Ricardo Allegri, M.D., Ph.D., Luis Miguel Gutierrez Robledo, M.D., Ph.D., Sergio Gloger, M.D., Lei Xie, Ph.D., Xinwei Daniel Jia, Ph.D., James L. Perhach, Ph.D., Stephen M. Graham, Ph.D.

NR2-080

MEMANTINE TREATMENT IN PATIENTS WITH ALZHEIMER'S DISEASE: BRAIN IMAGING AND NEUROPSYCHOLOGICAL RESULTS OF AN OPEN-LABEL, MULTI-CENTER TRIAL

Robert Hofbauer Ph.D., Mike Weiner, M.D. Carl Sadowsky, M.D. Judith Saxton, Ph.D. Robert K. Hofbauer, Ph.D. Stephen M. Graham, Ph.D. Sung Yun Yu, Ph.D. Hai-An Hsu, Ph.D. James L. Perhach, Ph.D.

NR2-081

POST-STROKE DEMENTIA: COGNITIVE FUNCTION EVALUATION WITHIN THE FIRST SIX MONTHS AFTER A STROKE

Angela Iragorri M.D., Olga L. Pedraza M.D, Msc, Pablo Reyes, Sandra Plata, Laura Castiblanco M.D, Fabián Gil, Diana Torres M.D, Erick Sánchez M.D, Luis Morillo M.D.

NR2-082

MEMORY DYSFUNCTIONS OF THE MILD AND MODERATE TBI WITH FRONTAL LOBE INJURY

Jin-Sung Kim M.D., Bon-Hoon Koo, MD., Min-Ji Kim, MD., Kwang-Hun Lee, MD., Young-Hoon Han MD., Hye-Jeong Hong, MA.

NR2-083

SKIN TOLERABILITY OF RIVASTIGMINE TRANSDERMAL PATCH: LARGE PLACEBO-CONTROLLED MULTICENTER TRIAL IN MILD TO MODERATE ALZHEIMER'S DISEASE

Martin Farlow, Jeffrey Cummings, Jason Olin

NR2-084

A 24-WEEK PLACEBO-CONTROLLED TRIAL OF RIVASTIGMINE CAPSULE IN PATIENTS WITH PARKINSON'S DISEASE DEMENTIA: ANALYSES OF NEUROPSYCHIATRIC INVENTORY ITEMS

James E. Galvin, James B. Leverenz, Daniel Weintraub, Jason Olin

NR2-085

UNDERREPRESENTATION OF ELDERLY MINORITY IN ANTIDEPRESSANT TRIALS

Geena Athappilly M.D., Maria German, M.D., Moises Martinez, M.D., Shunda McGahee, M.D., Maria Llorente, M.D.

NR2-086

EFFECT OF ETHNICITY ON PSYCHIATRIC DIAGNOSIS IN A GROUP OF FOREIGNERS PRESENTED TO MENTAL HEALTH SERVICES IN SAUDI ARABIA

Ghada Taha, Farouk Lotaief, M.D., Ghada Abdel Razek, M.D., Yasser Abdel Razek M.D., Khaled Abdel Azim, M.D.

NR2-087

THE EFFECT OF TYPE-D PERSONALITY AND A PARTNER ON EMOTIONAL DISTRESS

Ko Young-Hoon M.D., Moon-Soo Lee, M.D., Ph.D., Hong Euy Lim, M.D., Ph.D., Young-Min Park, M.D., Ph.D., Sook-Haeng Joe, M.D., Ph.D., Chang-Su Han, M.D., Ph.D., Rhee-Hun Kang, M.D., Ph.D.

NR2-088

CULTURAL IDENTITY, QUALITY OF LIFE, AND METALHEALTH IN FIRST-GENERATION IMMIGRANTS

Maria Zapata-Vega M.D., Maria A. Ruiperez, Ph.D., Juan E. Mezzich, M.D., Ph.D.

NR2-089

BODY APPEARANCE, WEIGHT PREOCCUPATIONS, AND EATING HABITS-GENDER DIFFERENCES IN MEDICAL STUDENTS- A STUDY IN MUMBAI, INDIA

Tushita Mayanil M.D., Neena Sawant, M.D., Shubhangi Parkar, M.D., Ph.D., Biswarup Ghosh, M.D.

NR2-090

DROP-OUT FROM IN-PATIENT TREATMENT FOR EATING DISORDER : THE ROLE OF PERSONALITY FACTORS



Alexandra Pham-Scottet, M.D., Ludovic Gicquel, MD.,
Roland Dardennes, PhD., Frederic Rouillon, PhD.

NR2-091

**DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF
QUETIAPINE FOR ANOREXIA NERVOSA:
PRELIMINARY REPORT**

Pauline Powers M.D., Megan Klabunde, M.A., Mary Ellen Trunko, M.D.,
Patti Lowery, Vikas Duvvuri, M.D., Ph.D., Walter Kaye, M.D.

NR2-092

**IMPULSIVITY, BUT NOT SENSATION-SEEKING, AS
A CHARACTERISTIC TRAIT IN BULIMIC SPANISH
WOMEN**

María Tajés-Alonso, María J. Gastañaduy-Tilve, M.D.,
Ramón Ramos-Ríos, M.D., Pablo Martínez-Gómez, M.D.,
Isabel González-Lado, M.D., Silvia Martínez-Formoso, M.D.,
Manuel Arrojo-Romero, M.D.

NR2-093

**THE EFFECT OF MEMANTINE ON SERUM TOTAL
ANTIOXIDANT CAPACITY IN ALZHEIMER'S
DEMENTIA**

Jin Sook Cheon M.D., Byoung Hoon Oh, M.D., Ph.D.

NR2-094

**OVEREXPRESSION OF CELL CYCLE PROTEINS OF
PERIPHERAL LYMPHOCYTES IN PATIENTS WITH AL-
ZHEIMER'S DISEASE**

Jaewon Chung M.D., Hyeran Kim, M.D., Ph.D., Young-Ah Kwon, M.S.,
Inn Sook Ahn, M.A., Seonwoo Kim, Ph.D., Sangmee Ahn Jo, Ph.D.,
Doh Kwan Kim, M.D., Ph.D.

NR2-095

**FAMILY CAREGIVERS OF HOSPITALIZED PATIENTS
WITH DEMENTIA REPORT GREATER DEPRESSIVE
SYMPTOMS THAN CAREGIVERS OF OUTPATIENTS
WITH DEMENTIA**

Gary Epstein-Lubow M.D., Mathew Hinckley, B.A., Ellen Darling, B.A.,
Ivan W. Miller, Ph.D.

NR2-096

**AGE-RELATED CHANGES IN THE VISUAL PROCESSING
OF FACES: POTENTIAL SUPPORTIVE INTERVENTIONS
FOR PERSONS WITH DEMENTIA**

Jason Greenhagen B.S., Ann D. Gathers, Ph.D.

NR2-097

**SUCCESSFUL AGING IN OLDER ADULTS WITH
SCHIZOPHRENIA: PREVALENCE AND ASSOCIATED
FACTORS**

Fayaz Ibrahim M.D., Carl I. Cohen, M.D., Paul M. Ramirez, Ph.D.

NR2-098

**OVERGENERALITY OF AUTOBIOGRAPHICAL
MEMORY IN PATIENTS WITH EARLY ALZHEIMER'S
DISEASE**

Luisa Jurjanz, Markus Donix, M.D., Christina Brons, M.D.,
Katrin Poettrich, Ph.D., Peter Winiecki, Ph.D., Vjera A. Holthoff, M.D.

NR2-099

**EFFECTS OF APOLIPOPROTEIN E GENOTYPE ON
MORTALITY IN PATIENTS WITH ALZHEIMER'S
DISEASE**

Shin Gyeom Kim M.D., Han Yong Jung, MD, PhD, So Young Lee, MD,
PhD, Eun Young Shin, MD, Yu Jin Lee, MD, Joon Ho Park, PhD,
Yeon Jung Lee, MD, Sung Il Woo, MD, PhD

NR2-100

**THE RIVASTIGMINE TRANSDERMAL PATCH
COMPARED WITH THE RIVASTIGMINE CAPSULE IN
PATIENTS SWITCHED FROM DONEPEZIL: SAFETY
DATA FROM THREE CLINICAL TRIALS**

Jason Olin Ph.D., Carl H. Sadowsky, M.D., Xiangyi Meng, Ph.D.

NR2-101

**A CROSS-SECTIONAL COMPARISON OF THE CLINICAL
FEATURES OF ADULT VERSUS GERIATRIC BIPOLAR
PATIENTS IN AN URBAN OUTPATIENT SETTING**

Ilyse Rosenberg D.O., James Prosser, M.D., Khayti Shah, M.D.,
Igor Galynker, M.D., Melinda Lantz, M.D.

NR2-102

**SWITCHING FROM DONEPEZIL TO RIVASTIGMINE
TRANSDERMAL PATCH: CLINICAL OUTCOMES AND
PREFERENCE OVER 25 WEEKS IN PATIENTS WITH
ALZHEIMER'S DISEASE**

Carl Sadowsky M.D., Alan Dengiz, M.D., Xiangyi Meng, Ph.D.,
Jason T. Olin, Ph.D.

NR2-103

**INTERACTIVE WEB-BASED NETWORKING TOOL FOR
LINKING SERVICES AND INTERVENTIONS RESEARCH
TRAINING AND EDUCATION PROGRAMS**

Brian Shanahan, Stephen J. Bartels, M.D., M.S.,
Martha L. Bruce, M.D., M.P.H., Jürgen Unützer, M.D., M.P.H.,
Yvette Sheline, M.D., Jo Anne Sirey, Ph.D., Gwenn Smith, Ph.D.,
Jeffrey Lyness, M.D., Patricia Arean, Ph.D., Yeates Conwell, M.D.,
Benjamin Druss, M.D., M.P.H., Paul Duberstein, Ph.D.,
Joseph Gallo, M.D., M.P.H., Anand Kumar, M.D., Benoit Mulsant, M.D.,
Bruce Pollock, M.D., Ph.D., David Steffens, M.D., M.H.S.

NR2-104

**PERSONALITY DISORDERS AND GENDER IDENTITY
TRANSSEXUALS VS. HETEROSEXUALS**

Dragana Duisin M.D., Gordana Nikolic-Balkoski, MD, Ph.D.

NR2-105

**MARITAL AND SEXUAL SATISFACTION AMONG
PARTNERS OF MEN WITH AND WITHOUT SEXUAL
DYSFUNCTION**

Ajit Avasthi M.D., Rajinder Kaur, M.A.; Sandeep Grover, M.D.;
Om Prakash, M.D.; Parmanand Kulhara, M.D., FRCPSych.

NR2-106

**HOW DO PEDOPHILES COMPARE WITH OPIATE
ADDICTS AND HEALTHY CONTROLS ON MEASURES
OF NEUROCOGNITIVE FUNCTIONING?**

Cristina Nesci B.A., Curren Katz, MA, Matthew Steinfeld, MA,
Igor I. Galynker, MD, Lisa J. Cohen, PhD

NR2-107

**SUICIDAL RISK IN MOOD DISORDERS:
RELATIONSHIP WITH CLONINGER'S TEMPERAMENT
AND CHARACTER**

Marwa Abdel Meguid M.D., Moustafa Kamel, M.D.,
Abdel Naser Omar, M.D., Yasser Abdel Razek, M.D.

2009 Annual Meeting • New Research



NR2-108

DIFFERENCES IN SUICIDAL INTENTION, DEPRESSION, AND DISSOCIATION AMONG SELF-POISONING PATIENTS WITH MOOD DISORDER AND THOSE WITH PERSONALITY DISORDER

Shuntaro Ando M.D., Toshihiko M. M.D., Ph.D., Rie O, M.D., Aya H, M.D., Daisuke, Y, M.D., Hotsumi K, M.D., Takao N, M.D.

NR2-109

THE DEVELOPMENT OF A STRUCTURED INTERVIEW USING THE SUICIDE RISK ASSESSMENT AND MANAGEMENT MANUAL (S-RAMM) AND AN ASSESSMENT OF INTERRATER RELIABILITY

Elizabeth Cummings, M.D., Emma Unoh M.D., Ijaz Atif M.D., Alexia Papaconstantinou M.D., Harry Kennedy M.D., Helen O'Neill M.D.

NR2-110

RELIGIOUS AFFILIATION AND SUICIDAL BEHAVIOR IN PATIENTS WITH BIPOLAR DISORDER

Kanita Dervic M.D., Juan J. Carballo, M.D., Enrique Baca-Garcia, M.D., Hanga Galfalvy, Ph.D., Ossama T. Osman, M.D., Maria A. Oquendo, M.D.

NR2-111

RISK FACTORS FOR LOW PLAN/IMPULSIVE SUICIDE ATTEMPTS (LPI-SA)

Serena Fox M.D., Anita Jothy, MD, Mudassar Tariq, MD, Muhammad Majeed, MD, Igor Galynker, MD, PhD

NR2-112

CORRELATION BETWEEN GROSS DOMESTIC PRODUCT AND SUICIDE RATES IN COLOMBIA

Edwin Herazo M.D., Andrea Carolina Acevedo, Econ, Adalberto Campo-Arias, MD

NR2-113

CASE-CONTROL STUDY OF THE RELATIONSHIP OF DEPRESSIVE SYMPTOMS TO SUICIDE IN A COMMUNITY-BASED SAMPLE OF INDIVIDUALS WITH SCHIZOPHRENIA IN CHINA

John Kasckow M.D., John Kasckow, MD, PhD, Nancy Liu M.S., Gretchen L. Haas, PhD, Michael R Phillips, MD, MPH

NR2-114

HOW PEOPLE COPE BY ATTEMPTING SUICIDE

Yvette Kaunismaki M.D., Marta Elliott, PhD, Barbara Kohlenberg, PhD, Morgan Green, MA, Barbara Larsen, MA

NR2-115

PREDICTIVE VALIDITY OF THE SUICIDE BEHAVIOR QUESTIONNAIRE-REVISED IN COLOMBIAN PSYCHIATRY PATIENTS WITH SUICIDE RISK

Andres Rangel-Martinez-Villalba M.D., Paul Anthony Camacho Lopez, M.D., M.Sc. German Eduardo Rueda-Jaimes, M.D.,

NR2-116

LIFETIME HISTORY OF SUICIDE ATTEMPTS IS ASSOCIATED WITH POORER SOCIAL SKILLS IN PATIENTS WITH BIPOLAR PATIENTS TYPE I

Cristiana Rocca Ph.D., Cristiana Castanho de Almeida Rocca, Lena Nabuco de Abreu, Luciana Gerchmann, Beny Lafer

NR2-117

EFFECTIVENESS OF A PRACTICE GUIDELINE FOR AMBULATORY TREATMENT OF COLOMBIAN PATIENTS WITH SUICIDE RISK

German Rueda-Jaimes M.D., Andres Mauricio Rangel-Martinez-Villalba, MD., Paul Anthony Camacho, MSc, MD., Maria Teresa Lopez-Camargo, MD.

NR2-118

EXTENDED RELEASE QUETIAPINE FUMARATE (QUETIAPINE XR) IN MAJOR DEPRESSIVE DISORDER (MDD): SUICIDALITY DATA FROM ACUTE AND MAINTENANCE STUDIES

Richard Weisler M.D., Hans Eriksson, M.D., Ph.D., M.B.A., Willie Earley, M.D., Johan Szamosi, M.Sc

NR2-119

CONSTRUCT VALIDITY OF A SUICIDE TRIGGER STATE

Zimri Yaseen, Zimri Yaseen, MD, Matthew Johnson, PhD, Igor I. Galynker, MD, PhD

NR2-120

LEAVING LAS VEGAS: HOMICIDE ON TELEVISION VS. UNITED STATES HOMICIDE DATA

Christopher Janish B.A., Melanie Buskirk, B.S., Timothy Lineberry, M.D.

NR2-121

THE ART OF PSYCHO-TRAUMATOLOGY (INTRODUCING THE HEALING ENVIRONMENT)

Omar Mohamed M.D.

NR2-122

LITERATURE REVIEW OF CARVING AS DOMESTIC VIOLENCE: CASE REPORT OF SPOUSE CARVING

Lissette Rodriguez M.D., Indhira Almonte, MD

NR2-123

POSTTRAUMATIC EMBITTERMENT DISORDER: SERBIAN WAR VETERANS' EXPERIENCE

Radimir Samardzic M.D., Zeljko Spiric, M.D., Ph.D., G. Mandic-Gajic, M.D., Ph.D., Natasa Milosevic, M.D.

NR2-124

GENDER DIFFERENCES IN TORTURE VICTIMS IMPRISONED DURING CIVIL WAR IN EX-YUGOSLAVIA

Zeljko Spiric M.D., Radimir Samardzic, M.D., Ph.D., Goran Knezevic, PhD, Vladimir Jovic, M.D., Ph.D.; Goran Opacic, Ph.D., Ivanka Vidakovic

NR2-125

TRAUMA COPING MECHANISMS & PSYCHOLOGICAL DISTRESS AMONG SOLDIERS DEPLOYED IN AFGHANISTAN

Jan Vevera M.D., M Preiss Ph.D., I Provoost Ph.D., Z Bubenik MD, M Psutka MD, M Plodr MD Ph.D., J Bancarel MD, P Bob Ph.D.

NR2-126

RISK FACTORS IN POSTPARTUM PSYCHIATRIC DISORDERS

Nesrin Karamustafalioglu, Nesrin Tomruk, M.D., Evrim Oztekin, M.D., Ozlem Tanriover, M.D., Rahsan Erim, M.D., Cahide Ucar, M.D., Nihat Alpaya, M.D.



NR2-127

REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (RTMS) IN PREGNANT WOMEN WITH MAJOR DEPRESSIVE DISORDER

Deborah Kim M.D., Deborah R. Kim, M.D., Juan M. Gonzalez, M.D., Pilar Cristancho, M.D., Laura Wakil, M.D., Samuel Parry, M.D., Michal A. Elovitz, M.D., Karl Rickels, M.D., Michael E. Thase, M.D., John P. O'Reardon, M.D.

NR2-128

ABUSE EXPERIENCES BEFORE AND DURING PREGNANCY AND THEIR RELATIONSHIP WITH ANTENATAL DEPRESSION AND EATING DISORDERS

Antoinette M. Lee, Ph.D., Catherine S. K. Tang, Ph.D., C. Y. Chan, BSoc. Sc., Siu-Keung Lam, M.D., Kwok-Yin Leung, M.B.B.S., M.Sc., F.R.C.O.G.

NR2-129

PREDICTORS OF INCIDENCE OF PPD: THE POTENTIAL ROLE OF SEPARATION ANXIETY

Mauro Mauri, MD, Mary Katherine Shear, MD, Susanna Banti, MD, Annalisa Oppo, Psy D., Chiara Borri, MD, Valeia Camilleri, Daniele Ramacciotti, MD, Maria Sole Montagnani, MD, Sonia Cortopassi, MD, Cristina Rambelli, MD

NR2-130

MOTHER-INFANT ANTIDEPRESSANT LEVELS AND MATERNAL DEPRESSION: IMPACT ON NEONATAL OUTCOMES

Dorothy Sit M.D., Eydie Moses-Kolko, M.D., Diane Hunker, Ph.D., M.B.A., Sonia Jones-Ivy, M.D., Joseph Helsel, B.S., James Perel, Ph.D. and Katherine L. Wisner, M.D., M.S.

NR2-131

THYROID HORMONE LEVELS AND THYROID ANTIBODIES IN POSTPARTUM PSYCHIATRIC INPATIENTS

Nesrin Tomruk M.D., Nesrin Karamustafalioglu, M.D., Ozlem Tanriover, M.D., Rahsan Erim, M.D., Nihat Alpay, M.D., Evrim Oztekin, M.D., Gozde Yapici, M.D.

Monday, May 18, 2009

3:00 p.m. - 5:00 p.m.

**Hall D, Exhibit Level,
Moscone Convention Center**

**New Research Poster Session 3:
Young Investigator Poster Session 1**

NR3-001

PSYCHIATRIC COMORBIDITY IN SOCIAL PHOBIA RELATIONSHIP WITH DURATION OF UNTREATED PERIOD

Hong-min Choi M.D., Young-Do Kwon, M.D., Se-Won Lim, M.D., Kang-Seob Oh, M.D., Ph.D.

NR3-002

STARTLE REACTIVITY IN SOCIAL ANXIETY DISORDER DURING SPEECH ANTICIPATION IN VIRTUAL REALITY

Randi Heller B.A., Brian R. Cornwell, Ph.D., Arter Biggs, B.A., Daniel S. Pine, M.D., Christian Grillon, Ph.D.

NR3-003

POSSIBILITY OF QT DISPERSION AS NEUROPHYSIOLOGICAL MARKER IN SOCIAL PHOBIA

Youngdo Kwon M.D., Hong-min choi, M.D., Se-won Lim, M.D., Ph.D., Kang-seob Oh, M.D., Ph.D.

NR3-004

AN OPEN STUDY OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER

Se Jounge Lee, Young-Eun Jung, MD, Ho-Jun Seo, MD, Won-Myong Bahk, MD, PhD, Tae-Youn Jun, MD, PhD, Jeong-Ho Chae, MD, PhD

NR3-005

PSYCHOLOGICAL TESTS AS PREDICTORS OF FEAR CONDITIONING AND EXTINCTION IN HUMANS

Karen Martinez M.D., Franco JA; Ojeda B; Castro-Couch M; Segura G; Milad MR; Quirk GJ

NR3-006

PREGABALIN: BEYOND THE GENERALIZED ANXIETY DISORDER

Alfonso Mozos-Ansorena, M.D., Pérez-García M., M.D., Pérez-Pérez J., M.D., Páramo-Fernández M., Ph.D., Núñez-Iglesias J., M.Ph.D., Brenlla-Gonzalez, J, Ph.D., Portillo-Díez J.; Alonso San-Gregorio J., M.D., Tortajada-Bonasselt I., M.D.

NR3-007

ALEXITHYMIA IN OBSESSIVE-COMPULSIVE DISORDER

Daeyoung Roh, Chan-Hyung Kim, M.D., Ph.D., Se-Joo Kim, M.D., Ph.D.

NR3-008

SYMPATHETIC NERVOUS FUNCTION AND CATECHOL-O-METHYLTRANSFERASE GENETIC POLYMORPHISM IN PATIENTS WITH PANIC DISORDER

Song Yoon-Jae, Woo-Yong Shin, M.D., Eun-Ho Kang, M.D., Hoondong Choe, M.D, Bum-Hee Yu, M.D.



NR3-009

SUBGENUAL CINGULATE GYRUS DEEP BRAIN STIMULATION FOR REFRACTORY MAJOR DEPRESSIVE DISORDER: A MULTICENTRE UPDATE

Peter Giacobbe B.S.C., Sidney H. Kennedy MD FRCPC, Helen S. Mayberg MD, Andres M. Lozano MD PhD FRCSC, Raymond W. Lam MD FRCPC, Guy Debonnel MD FRCPC, Theodore Kolivakis MD FRCPC, Andrew Howard MD FRCPC, Abbas Sadikot MD PhD FRCSC, Christopher Honey MD PhD FRCSC

NR3-010

UNUSUAL PRESENTATION OF HYPOXIC DELIRIUM

Stanislav Grabylnikov M.D., Irmute Usiene M.D.PGY II, Amel Badr M.D., Javed Iqbal M.D., Mohammad Niazi M.D.

NR3-011

CHANGES IN RCBF AFTER LEFT HIGH FREQUENCY AND RIGHT LOW FREQUENCY RTMS ON DLPFC IN REFRACTORY DEPRESSIVE AND ANXIETY DISORDERS

Eun Jin Jahng M.D., Jung-Ah Min, M.D., Hyewon Lee, M.D., Ho-Jun Seo, M.D., Yong-An Chung, M.D., Jeong-Ho Chae, M.D, Ph.D.

NR3-012

EARLY LIFE STRESS AND BRAIN CONNECTIVITY : WHITE MATTER DEFICITS IN VARIABLE FORAGING DEMAND SUBJECTS

Lina Villegas M.D., Lina Villegas MD, Jeremy D. Coplan M.D, Cheuk Y. Tange, PhD, Sanjay J. Mathew MD, Jose Martinez MA, Patrick R. Hoff MD,PhD, Eric L.P. Smith PhD, Andrew J. Dworkd MD, Tarique D. Pererac MD, Leonard A. Rosenbluma PhD, Jack M. Gorman MD, Dikoma C. Shungue, k PhD, Joel Gelernterh,MD, Arie Kaffmanh MD PhD, Andrea Jackowskih PhD, Joan Kaufmanh, MD

NR3-013

ASSOCIATION BETWEEN DOPAMINE D2-RECEPTORS IN LIMBIC BRAIN REGIONS AND THE PERSONALITY TRAIT SOCIAL DESIRABILITY: IMPLICATIONS FOR SOCIAL PHOBIA

Simon Cervenka M.D., Christer Halldin, Ph.D., Lars Farde, M.D., Ph.D.

NR3-014

AN FMRI STUDY FOR READING THE MIND IN MALE SCHIZOPHRENIC PATIENTS

Inkyung Oh M.D., Jung-Woo Son, M.D., Ph.D., Sang-Ick Lee, M.D., Ph.D., Chul-Jin Shin, M.D., Ph.D., Sie-Kyeong Kim, M.D., Ph.D.

NR3-015

THE RELATIONSHIP BETWEEN SEXUAL RESPONSE-RELATED BRAIN ACTIVITY AND SEXUAL HORMONES IN HEALTHY HETEROSEXUAL MALES: FMRI STUDY

Young Hee Seo, Bumseok Jeong, M.D., Ph.D., Jeewook Choi, M.D.,Ph.D., Ji-Woong Kim, M.D., Ph.D.

NR3-016

CHANGES IN BRAIN GLUCOSE METABOLISM AFTER 12-WEEK TREATMENT WITH ESCITALOPRAM IN PATIENTS WITH PANIC DISORDER: 18FDG-PET STUDY

Woo-Yong Shin M.D., Yoon-Jae Song, M.D.Eun-Ho Kang, M.D., Hoondong Choe, M.D., Bum-Hee Yu, M.D, Ph.D.

NR3-017

ADDING CBT TO THE ACUTE IMPATIENT TREATMENT OF UNIPOLAR DEPRESSIVE DISORDERS

Stephan Koehler, Koehler S., Hoffmann S., Unger T.,Fyrich T., Mackert A.,Steinacher B.

NR3-018

QUALITY OF SUICIDE ASSESSMENT IN THE PSYCHIATRIC EMERGENCY SETTING

Christopher Chee B.S., Benjamin K.P. Woo, M.D., Satinder Mahal, B.S., Conrado Sevilla, M.D., and Tai P. Yoo, M.D.

NR3-019

VALIDITY OF THE GENERAL PRACTITIONER ASSESSMENT OF COGNITION(GPCOG) IN COMMUNITY

Bokyung Sohn M.D., Lee DW,M.D.,Ph.D.,Choi YM.M.D.Ph.D., Kim BS.M.D.Ph.D.,Kim MS.,M.D.

NR3-020

SCREENING FOR DISSOCIATIVE DISORDERS AT INTAKE INTERVIEW: EXPERIENCES IN AN OUTPATIENT PSYCHIATRY TRAINING CLINIC

Laura Diamond M.D., Laura Diamond, M.D, Victoria Balkoski, M.D., Robert Hubbell, Psy.D

NR3-021

COMPARATIVE STUDY IN AN ACUTE PSYCHIATRIC UNIT: DIFFERENCES BETWEEN PERSONALITY DISORDER INPATIENTS AND GENERAL PSYCHIATRIC INPATIENTS

David Lopez M.D., David López Gómez, M.D., Jesús J. Marín Lozano, M.D., M^a Eva Román Mazuecos, M.D., Ainoa Muñoz San José, M.D., Santiago Kassem Vargas, M.D., M^a Fe Bravo Ortiz, M.D. Ph. D.

NR3-022

NEUROPSYCHIATRIC OUTCOMES IN PATIENTS RECEIVING CARDIOTHORACIC TRANSPLANTATION AT THE MAYO CLINIC: A SINGLE INSTITUTION, TWENTY-YEAR COHORT

Farrak Mateen M.D., Sheila Jowsey, MD, Diederik van de Beek, MD, PhD, Eelco F.M. Wijdicks, MD, PhD.

NR3-023

META-ANALYSIS OF PATERNAL AGE AND RISK OF SCHIZOPHRENIA IN THE OFFSPRING

Brian Miller M.D., Erick Messias, MD, PhD, MPH, Jouko Miettunen, PhD, Johanna Löhönen, MSc, Antti Alaräisänen, MD, Marjo-Riita Järvelin, MD, PhD, Hannu Koponen, MD, PhD, Pirkko Räsänen, MD, PhD, Brian Kirkpatrick, MD, MSPH, Matti Isohanni, MD, PhD

NR3-024

INSOMNIA IN THE UNITED STATES: PREVALENCE AND ASSOCIATED FACTORS; RESULTS FROM NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES 2004-2005)

Tuan-Anh Nguyen M.D., Gilbert Ramos, MA,Stephanie Riolo, MD, MPH.

NR3-025

GLOBAL MENTAL HEALTH: AN UPDATE

Geoffrey Oravec M.D.

NR3-026

RISK FACTORS FOR DEPRESSION WITHIN OBESE POPULATIONS: RESULTS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES 2004-2005)

Stephanie Riolo M.D., Tuan-Anh Nguyen, MD, MPH



NR3-027

2-YEAR NATURALISTIC DEPRESSIVE SYMPTOM IN CHINESE COLLEGE STUDENTS

Song Yuqing, Yueqin Huang, Ph.D, Dan Liu, Ph.D, Johmy. S.H. Kwan, Fuquan Zhang, MD, Pak C. Sham MBBS, Ph.D, Siu Wa Tang, MD, Ph.D

NR3-028

EFFECTS OF PRENATAL EXPOSURE TO MATERNAL MALNUTRITION ON ADULT RISK OF SCHIZOPHRENIA

Ming-Qing Xu Ph.D., Ezra Susser, M.D. DrPH, David St. Clair, M.D. Ph.D., Lin He, Ph.D.

NR3-029

CONVERGENT EVIDENCE SHOWS A POSITIVE ASSOCIATION OF THE INTERLEUKIN-1 GENE COMPLEX LOCUS WITH SUSCEPTIBILITY TO SCHIZOPHRENIA

Ming-Qing Xu Ph.D., David St. Clair, M.D. Ph.D., Lin He, Ph.D.

NR3-030

TPH1 IS ASSOCIATED WITH MAJOR DEPRESSIVE DISORDER AND FLUOXETINE TREATMENT RESPONSE IN TAIWANESE PATIENTS

Hui Hua Chang, M.S., Po See Chen, M.D., Ph.D., Po-Wu Gean, Ph.D.

NR3-031

ETHNIC DIFFERENCES IN THE PERCEPTION OF GENETIC RISK IN A BIPOLAR GENETIC STUDY

Olusola Fagbami M.B.B.S, Evaristus A. Nwulia, M.D., MHS, Maria Hipolito, M.D, Mariano Erpe, MS, William B. Lawson, M.D. Ph.D.

NR3-032

ASSOCIATION OF THE SEROTONIN TRANSPORTER PROMOTER AND DOPAMINE D4 RECEPTOR GENE POLYMORPHISMS WITH DECISION-MAKING IN HEALTHY VOLUNTEERS

Rayeon Ha, Se Joo Kim, M.D., Ph.D., Jee In Kang, M.D., Kee Namkoong, M.D., Ph.D.

NR3-033

GENOTYPING IN TDM – AN EQUATION

Astrid Hader, T. Jahner, D. Melchner, J. Kirchheiner, E. Haen

NR3-034

GENETIC MARKERS FOR SUICIDE RISK IN SCHIZOPHRENIA

Eric Olsson M.D., Urban Ösby, M.D., Ph.D.

NR3-035

GENE X ENVIRONMENT INTERACTION: THE SEROTONIN TRANSPORTER GENE POLYMORPHISM AND ABUSE HISTORY INFLUENCING THE CHARACTERISTICS OF DEPRESSED INPATIENT

Gen Shinozaki M.D., Victoria Passov, M.D., Magdalena Romanowicz, M.D., Simon Kung, M.D., Renato D. Alarcon, M.D., M.P.H, David A. Mrazek, M.D.

NR3-036

FUNCTIONAL EFFECTS OF POLYMORPHISMS IN THE HUMAN CORTICOTROPIN-RELEASING HORMONE RECEPTOR 1 (CRHR1) GENE

Kirstin Thode M.D., Consuelo Walss-Bass, Ph.D., Karen Munoz, M.S., Ahmad Hariri, Ph.D., Rene Olvera, M.D., Douglas E. Williamson, Ph.D.

NR3-037

THE MITOCHONDRIAL A3243G MUTATION: SAME GENOTYPE, DIFFERENT PHENOTYPE - A MOTHER AND HER DAUGHTER WITH PSYCHIATRIC MANIFESTATION OF MELAS

Maarten Van Den Bossche M.D., Ann T. Van Vre, M.D., Manuel Morrens, M.D., Ph.D.

NR3-038

INCREASED INCIDENCE OF SCHIZOPHRENIA IN MIGRANTS: ARE DRUGS TO BLAME?

Maarten Van Den Bossche M.D., Jean-Paul Selten, M.D., Ph.D.

NR3-039

EFFECT OF THE DYSBINDIN GENE ON ANTIMANIC AGENTS IN PATIENTS WITH BIPOLAR I DISORDER

Dong Hwan Yoon M.D., Chi-Un Pae, MD, PhD, Jung-Jin Kim, MD, PhD

NR3-040

A SIB-PAIR STUDY OF PERSONALITY TRAITS IN BIPOLAR DISORDER

Karla Almeida M.D., Beny Lafer, M.D., Ph.D.

NR3-041

MEDICAL CO MORBIDITIES IN BIPOLAR PATIENTS INCREASE THE RISK FOR SUICIDAL ATTEMPTS

Mahboob Aslam M.D., Gulam Noorani, M.D., D.Korya, J.Bibawy, C. Charoonbara.

NR3-042

RAPID CYCLING MOODS: MEDIATED BY ANTIBODIES?

Ajay Bhatia M.D., Ajay Bhatia, M.D., and Hossam H. Guirgis, M.D.

NR3-043

DEVELOPMENT OF THE KOREAN AFFECTIVE WORDS

Bo Ra Kim MD, Jin Young Park MD, Jee In Kang MD, Eun Lee MD, PhD, Suk Kyoan An MD, PhD

NR3-044

PREDICTIVE VALUE BIPOLAR-SPECTRUM CLINICAL FEATURES IN A LARGE COHORT OF FLUOXETINE TREATED PATIENTS WITH MAJOR DEPRESSIVE DISORDER

Francesco Casamassima M.D., Fava M., M.D., Clain A., Ph.D., Jonathan P. Stange, B.A., Roy H. Perlis, M.D., M.Sc

NR3-045

INTERNET ADDICTION AS A SYMPTOM OF DEPRESSIVE MOOD DISORDERS IN A SAMPLE OF KOREAN ADOLESCENTS

Jung Eun-Jung M.D., Hyun-Jae Woo, M.D.

NR3-046

BIPOLAR DISORDER IMPAIRS PHYSICAL HEALTH AS MUCH AS SCHIZOPHRENIA

Maria Garcia-Portilla M.D., Susana Santamarina, M.D., Pilar A. Saiz, M.D.Ph.D., Maria T. Bascaran, M.D., Celso Iglesias, M.D., Ph.D., Julio Bobes, M.D., Ph.D.

NR3-047

WHAT'S IN THE PIPELINE FOR MAJOR DEPRESSIVE DISORDER?

Aarti Gupta M.B.B.S, Rajnish Mago, M.D, Michelle Shwarz, M.S.Ed.



NR3-048

PERSONALITY DIFFERENCES IN DEPRESSED POPULATION ACROSS NINE CENTRES IN EUROPE

Bhanu Gupta M.B.B.S, Robert Keers, B.Sc., Anne Farmer M.D., Peter McGuffin Ph.D., Rudolph Uher Ph.D., Wolfgang Maier M.D., Joanna Hauser Ph.D., Ole Mors Ph.D., Ann S Kristensen Ph.D., Marcella Rietschel M.D., Astrid W Zobel M.D., J Perez Ph.D., Caterina Giovannini, Andrej Marusic Ph.D., Dejan Kozel B.Sc., Julien Mendlewicz M.D., Neven Henigsberg Ph.D., Katherine J Aitchison Ph.D.

NR3-049

DEPRESSION AND ATTENTION DEFICIT HYPERACTIVITY DISORDER: RESULTS FROM AN EXPERIMENTAL STUDY

Désirée Harnic M.D., Marianna Mazza, M.D., Ph.D., Valeria Catalano, Giuseppe Marano, Marco Di Nicola, M.D., Giovanni Martinotti, M.D., Luigi Janiri, M.D., Pietro Bria, M.D.

NR3-050

MANIC PATIENTS SHOW MOOD-CONGRUENT BIAS IN AFFECTIVE GO/NO-GO TASK USING SCENERY PICTURES BUT NOT WORDS OR FACIAL PICTURES

Seung Jun Kim MD, Jee In Kang MD, Ji Hyun Lee MA, Suk Kyoon An MD, PhD, Hyun-Sang Cho MD, PhD.

NR3-051

THE RELATIONSHIP BETWEEN STIGMA, MOOD, AND QUALITY OF LIFE IN BIPOLAR PATIENTS AND THEIR FAMILIES PRESENTING FOR FAMILY TREATMENT

Allison Lee M.D., Annie Steele, Jena Bobish, Ashley Kronen, Lisa Cohen Ph.D., Igor I. Galynker, M.D., Ph.D.

NR3-052

DIFFERENTIAL EXPRESSION OF ATYPICAL DEPRESSION IN AFRICAN AMERICANS AND ITS ASSOCIATION WITH CARDIOVASCULAR RISK FACTORS AND DISEASES

Oreisa O'Neil M.P.H., Yu Dong, M.D., Ph.D., William B. Lawson, M.D., Ph.D., Douglas Levinson, M.D., Evaristus Nwulia, M.D., MHS

NR3-053

MISDIAGNOSIS OF BIPOLAR DISORDER AMONG PATIENTS WITH SUBSTANCE ABUSE

Anoosh Salman M.B.B.S, Mahboob Aslam, M.D., Steven Kwok, Amir Aryaie, Alisha Oelke, M.S., Javed Iqbal, M.D.

NR3-054

CO-OCCURRENCE OF BIPOLAR AND ATTENTION-DEFICIT HYPERACTIVITY DISORDERS IN CHILDREN: A CASE REPORT

Anoosh Salman M.B.B.S, Abderrahmane Richane, M.D., Khaja Faisal, M.D., Javed Iqbal, M.D.

NR3-055

EFFECT OF LONG-TERM ANTIDEPRESSANT TREATMENT TO SERUM BRAIN-DERIVED NEUROTROPHIC FACTOR

Lee Seungyoun, Doh Kwan Kim, M.D., Jae-Won Chung, M.D., Shinn-Won Lim, M.D.

NR3-056

ALTERATIONS OF EXPRESSION AND FUNCTION OF CREB IN LYMPHOCYTE OF DEPRESSED PATIENTS DURING SSRI TREATMENT

Lee Seungyoun, Doh Kwan Kim, M.D., Jae-Won Chung, M.D., Shinn-Won Lim, Ph.D.

NR3-057

ETHNICITY AND PREVALENCE OF BIPOLAR DISORDER: A REVIEW

Jacqueline Shafiroff, B.A., Sophia Haeri, B.S., Alexis Newmark, B.A., Jamie Johnson, B.A., Igor Galynker, M.D., PhD.

NR3-058

THE ROLE OF ANTIDEPRESSANTS FOR BIPOLAR-DEPRESSION: AN UPDATED AND EXPANDED META-ANALYSIS

Michelle Sidor M.S.C., Glenda M. MacQueen, M.D., Ph.D.

NR3-059

INTUITION-CREATIVITY RELATIONSHIPS IN MOOD DISORDER PATIENTS, HEALTHY CONTROLS AND HIGHLY CREATIVE INDIVIDUALS

Shefali Srivastava M.D., Meredith Childers, M.A., Connie M. Strong, Ph.D., Kimberley Warsett, M.A., Jennifer L. Culver, Ph.D., Po W. Wang, M.D., Terence A. Ketter, M.D.

NR3-060

SATISFACTION WITH MEDICATION AND RESPONSE TO TREATMENT WITH ESCITALOPRAM COMPARED TO PLACEBO AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS

Malcolm Lader, M.D., Ph.D., Elin Heldbo Reines, M.D., Sara Larsson Lönn, Koen Demyttenaere, Ph.D.

NR3-061

NEUROTOXICITY RELATED TO TRACE ELEMENTS IN BIPOLAR DISORDER: A HIPOTHESIS ABOUT COGNITIVE IMPAIRMENT

Kazuhiro Tajima M.D., Rafael Fernandez Garcia-Andrade MD, Javier Fernandez Aurrecoechea MD, Virginia Vidal Martinez MD, Diana Zambrano-Enriquez Gandolfo MD, Ana Montes Montero MD, Helena Fernandez Garcimartin MD, Jose Luis Carrasco Perera MD, Marina Diaz Marsa MD.

NR3-062

SEASONAL DEPRESSION SEVERITY AS A PREDICTOR OF HEALTH SERVICE UTILIZATION IN A COMMUNITY-BASED SAMPLE

Simone N Vigod M.D., Anthony J Levitt, MBBS, FRCPC

NR3-063

TYPE OF RESIDUAL SYMPTOM AND RISK OF RELAPSE DURING THE CONTINUATION/MAINTENANCE PHASE TREATMENT OF MAJOR DEPRESSIVE DISORDER WITH THE SELECTIVE SEROT

Huaiyu Yang M.D., Sarah Chuzi, B.A., Lara Sinicropi-Yao, B.A., Dan Johnson, B.A., Ying Chen, M.D., M.S., Alisabet Clain, M.S., Lee Baer, Ph.D., Patrick J. McGrath, M.D., Jonathan W. Stewart, M.D., Maurizio Fava, M.D., George I. Papakostas, M.D.

NR3-064

CHANGES IN REGIONAL CEREBRAL BLOOD FLOW AND CLINICAL EFFECTS IN PATIENTS WITH PANIC DISORDER TREATED BY GROUP COGNITIVE BEHAVIORAL THERAPY

Min Jung-Ah, Jung-Ah Min, MD, Eun-Jin Jahng, MD, Ho-Jun Seo, MD, Young-Eun Jung, MD, Won-Myong Bahk, MD, PhD, Tae-Youn Jun, MD, PhD, Jeong-Ho Chae, MD, PhD



NR3-065

CHANGES IN NEUROIMAGING EVOKED BY MASKED TRAUMATIC STIMULI IN POSTTRAUMATIC STRESS DISORDER: A FUNCTIONAL MRI STUDY

Jung-Ah Min, MD, Eun-Jin Jahng, MD, Young-Eun Jung, MD, Ho-Jun Seo, MD, Won-Myong Bahk, MD, PhD, Tae-Youn Jun, MD, PhD, Jeong-Ho Chae, MD, PhD

NR3-066

A NEUROCOGNITIVE ASSESSMENT OF MOTOR INHIBITION AND COGNITIVE FLEXIBILITY IN PATHOLOGICAL SKIN PICKING

Brian Odlaug B.A., Samuel R. Chamberlain, M.D., Ph.D., Jon E. Grant, M.D., J.D., M.P.H.

NR3-067

DOES COGNITIVE PERFORMANCE CORRELATE WITH SUBJECT AND INJURY CHARACTERISTICS IN SURVIVORS OF COMBAT-RELATED TRAUMATIC BRAIN INJURY: A PILOT STUDY

Brian Writer D.O., Jason Schillerstrom, M.D., Heather Regwan, D.O., Brent Harlan, M.D., Jackie L. Reeves, MSN, RN, Melissa Keough, M.Ed., Mark Shapiro PA-C, Manuel Nunez, M.D., Jan Kennedy, Ph.D

NR3-068

CLINICAL AND SOCIODEMOGRAPHIC PROFILE OF PERSONALITY DISORDERS IN AN ACUTE PSYCHIATRIC UNIT

Eva Roman Mazuecos M.D., M^a Eva Román Mazuecos, M.D., David López Gómez, M.D., Jesús J. Marín Lozano, M.D., Ainoa Muñoz San José, M.D., Belén Bardón Rivera, M.D., M^a Fe Bravo Ortiz, M.D. Ph.D

NR3-069

A CASE STUDY: LITHIUM TOXICITY AND ACE INHIBITORS

Patricia Bauza M.D., Gabrielle Melin, M.D

NR3-070

THE EFFECT OF ANTIPSYCHOTIC POLIPHARMACY WITH HALOPERIDOL ON QTC INTERVAL IN ACUTE PSYCHIATRIC SETTING

Salvatore Calò M.D., Gianfranco Amodio, MD., Guido Di Sciascio, Psy.D.

NR3-071

LITHIUM-INDUCED NEUROLEPTIC MALIGNANT SYNDROME WITHOUT ANTIPSYCHOTICS: A CASE REPORT

Aya Hojo, M.D., Takafumi Shimada, M.D., Koji Kasanuki, M.D., Hozumi Kyono, M.D., Takao Nishimura, M.D.

NR3-072

PSYCHOPHARMACOLOGY INTERACTIVE TRAINING ALGORITHM

Nicole Hraniotis M.D., Anthony Tobia, M.D.

NR3-073

THE LONG TERM EFFECTIVENESS OF QUETIAPINE PLUS LAMOTRIGINE THERAPY IN BIPOLAR PATIENTS

Kaja Johnson, Meredith Childers, M.A., John O. Brooks, M.D. Shefali Srivastava, M.D. Jennifer C. Hoblyn, M.D., Terence A. Ketter, M.D.

NR3-074

AUDITORY EVENT-RELATED POTENTIAL P300 IN BIOLOGICAL EQUIVALENCY STUDY: A HYPNOTIC ZOLPIDEM

Namkwon Kim, E-Jin Park, MD., Chin-Yang Kang, PhD., Yang-Whan Jeon, MD, PhD

NR3-075

DOPAMINE PARTIAL AGONIST EFFECTS ON THE CHANGES IN PSYCHOTIC AND MOTOR SYMPTOMS IN PARKINSON'S PATIENTS WITH PSYCHOTIC SYMPTOMS

Sehee Kim M.D., Han Doug Hyun, MD, Ph.D, NA Churl, MD, Ph.D, Min-Kyung Joon, MD, Ph.D, Son In Ki, MD, Ph.D, Shin Ho Cheol MD, Kim Tae Ho, MD, Ph.D

NR3-076

CLINICAL OUTCOMES OF SWITCHING STRATEGIES FROM PREVIOUS ANTIPSYCHOTICS TO ARIPIRAZOLE: 1-YEAR, NATURALISTIC STUDY

Won-hyoung Kim M.D., Tae-Yeon Seo, MD., Won-Hyoung Kim, MD., Min-Hee Kang, MD, Ph.D., Jeong-Seop Lee, MD, Ph.D., Jae Nam Bae, MD, Ph.D., Chul-Eung Kim, MD, Ph.D.

NR3-077

RELATIONSHIPS OF MENTAL DISORDERS WITH OBESITY IN THE KOREAN ADULT POPULATION

Won-hyoung Kim M.D., Young-kyung Sunwoo, MD., Jae-Nam Bae, MD, Ph.D., Won-hyoung Kim, MD., Sung Man Chang, MD, Ph.D., Hong Jin Jeon, MD, Ph.D., Jin-Yeong Kim, MD, Ph.D., Jun-Young Lee, MD, Ph.D., Jin-Pyo Hong, MD, Ph.D., Maeng Je Cho, MD, Ph.D

NR3-078

CHEMOKINE (C-C MOTIF) RECEPTOR 3 (CCR3) GENE HAPLOTYPE IS ASSOCIATED WITH SCHIZOPHRENIA IN KOREAN POPULATION

Woojae Kim M.D., Jiyoung Song, Ph.D., MD., Ahrang Cho, Ph.D., MD., Jaejin Lee, MD., Sukang Kim, Ph.D., MD., Jongwoo Kim, Ph.D., MD.

NR3-079

CASE STUDY OF A LATE ONSET BUPROPION ER-INDUCED SEIZURE

Woojae Kim M.D., Jiyoung Song, Ph.D., MD., Jongwoo Kim, Ph.D., MD., Gunho Bahn, Ph.D., MD., Ahrang Cho, Ph.D., MD., Byungkuk Lee, MD., Jongwoo Paik, Ph.D., MD.

NR3-080

COMPARISON ON THE EFFICACY OF QUETIAPINE VERSUS HALOPERIDOL IN THE TREATMENT OF DELIRIUM : PROSPECTIVE, RANDOMIZED, DOUBLE BLIND TRIAL

Yujin Lee M.D., Han-Yong Jung, M.D., Ph.D., Soyoung Irene Lee, M.D., Ph.D., Shin Gyeom Kim, M.D., Eun Young Shin, M.D., Joonho Park, Ph.D., Hyunil Moon, M.D., Yeonjung Lee, M.D.

NR3-081

OPISTHOTONOS WITH LOW DOSES OF QUETIAPINE

Susana Martinez, Jasna Raventós Simic, Psychiatry Resident.

NR3-082

SODIUM VALPROATE INDUCED HYPONATREMIA

Kajal Patel M.D., Anil Meesala, M.D., Joseph Stanilla, M.D.

NR3-083

VARENICLINE INDUCED ACUTE EXACERBATION OF SCHIZOAFFECTIVE DISORDER: A CASE REPORT AND REVIEW OF THE LITERATURE

Akshat Pujara B.A., Smitha Battula, M.D., Xiangyang Zhao, M.D., M.S., Toni Johnson, M.D., Lendita Haxhiu-Erhardt, M.D.



NR3-084

CHRONIC IMPRAMINE DOWNREGULATES CYCLIC AMP SIGNALING IN RAT HIPPOCAMPUS

Gillian Reiersen, Claudio Mastronardi, Ph.D., Julio Licinio, M.D., Ma-Li Wong, M.D.

NR3-085

JUMPING TO CONCLUSIONS OR NON-COMPREHENSION? A RE-EXAMINATION OF THE “BEADS TASK”

Ryan Balzan, Paul H. Delfabbro, PhD, Cherrie Galletly, M.D., PhD

NR3-086

ANTIPSYCHOTIC COMBINATION IN PATIENTS DIAGNOSED WITH TREATMENT-RESISTANT SCHIZOPHRENIA RECEIVING CLOZAPINE

María Benítez Alonso M.D., J.J. De Frutos Guijarro M.D., A. García Rosales M.D., M. B. Bardón Rivera M.D., E. Román Mazuecos M.D., S. Kassem Vargas M.D., J.J. Marín Lozano M.D., M.F. Bravo Ortiz M.D.

NR3-087

MEDICATION CONCORDANCE AMONGST PEOPLE WITH SCHIZOPHRENIA

Lucinda Clifford

NR3-088

MAGNETIZATION TRANSFER IN INITIAL EPISODES OF SCHIZOPHRENIA

Rafael Fernandez Garcia-Andrade M.D., Marina Diaz Marsa M.D., Javier Fernandez Aurrecoechea MD, Virginia Vidal Martinez MD, Kazuhiro Tajima Pozo MD, Diana Zambrano-Enriquez Gandolfo MD, Ana Montes Montero MD, Helena Fernandez Garcimartin MD, Jose Luis Carrasco Perera MD,

NR3-089

CTLA-4 AND CD28 GENE POLYMORPHISMS AND SUSCEPTIBILITY TO SCHIZOPHRENIA AND ITS SYMPTOMATOLOGY IN POLISH LOWER SILESIA POPULATION

Dorota Frydecka M.D., Prof. Andrzej Kiejna, M.D.Ph.D., Aleksander Beszlej, M.D., Ph.D., Monika Szewczuk-Boguslawska, M.D., Ph.D., Marcin Szechinski, M.D., Ph.D., Piotr Baranowski M.D., Ph.D.

NR3-090

TEMPORAL BEHAVIOR OF BIRTHS OF SCHIZOPHRENIC PATIENTS FROM 1976 TO 1987 IN SANTA MARTA-COLOMBIA: A STUDY ABOUT SEASONALITY OF SCHIZOPHRENIA ON TROPICS

Jairo González Díaz, Beatriz Caamaño, M.D., Beatriz Gómez, Jimmy Arévalo, Harold Garizábal

NR3-091

DOES INSIGHT INTO DIAGNOSIS AFFECT SATISFACTION WITH CARE IN SCHIZOPHRENIA SPECTRUM PATIENTS?

Sophia Haeri B.A., Sophia Haeri BA, Jenny Williams BA, Irina Kopeykina BA, Igor Galynker MD PhD, Lisa Cohen PhD

NR3-092

INVESTIGATION OF HIPPOCAMPAL VOLUME AND SHAPE IN SUBJECTS AT ULTRA-HIGH RISK FOR SCHIZOPHRENIA

Chi-Won Kim M.D., Do-Hyung Kang, M.D., Jung-Seok Choi, M.D., Ji-Young Park, M.A., Wi Hoon Jung, M.S., Chi-Hoon Choi, M.D., Myung Hun Jung, M.D., Jun Hwan Jang, M.D., Sun Hyung Kim, Ph.D., Jong-Min Lee, Ph.D, Jun Soo Kwon, M.D., Ph.D

NR3-093

PROGRESSIVE WHITE MATTER CHANGES IN FIRST EPISODE SCHIZOPHRENIA: A 4-YEAR LONGITUDINAL MAGNETIC RESONANCE STUDY USING VOXEL-BASED MORPHOMETRY

Anna Mane M.D., Carles Falcon, Ph.D, Guillermo Horga, M.D., Jose J. Mateos, M.D., Ph.D., Emilio Fernandez-Egea M.D., Francisco Lomeña M.D., Ph.D., Nuria Bargalló, M.D., Ph.D., Miguel Bernardo M.D., Ph.D., Eduard Parellada M.D., Ph.D.

NR3-094

ELECTROPHYSIOLOGICAL EVIDENCE OF MIRROR NEURON DYSFUNCTION IN SCHIZOPHRENIA

Laurie McCormick M.D., Laurie M. McCormick, M.D., Michael C. Brumm, B.S., Nancy C. Andreasen, M.D., Ph.D.

NR3-095

BORDERLINE PERSONALITY TRAITS AND TRANSITION TO PSYCHOSIS IN A “ULTRA HIGH RISK” (UHR)POPULATION: A CASE CONTROL STUDY

Karen O’Connor M.D., Nilufar Mossaheb M.D., Barnaby Nelson Ph.D., Isobel Domingues, Andreas Bechdolf M.D., Alison Yung M.D., Andrew Thompson M.D.

NR3-096

ARE YOU LOOKING AT ME? SOCIAL PHOBIA AND PSYCHOSIS A CASE SERIES AND REVIEW OF THE EPIDEMIOLOGICAL AND PSYCHOLOGICAL LITERATURE

Karen O’Connor, M.D., Paul Scully MD.

NR3-097

RESPIRATORY HEALTH IN PSYCHOTIC DISORDERS: A POPULATION STUDY

Krista Partti, Tuula Vasankari, M.D., Ph.D, Jonna Perälä, M.D., Samuli I. Saarni, M.D., Ph.D., Sami Heistaro, M.D., Ph.D., Pekka Jousilahti, M.D., Ph.D., Jouko Lönnqvist, M.D., Ph.D., Jaana Suvisaari, M.D., Ph.D.

NR3-098

NEUROCOGNITIVE EFFICACY OF CLOZAPINE-ZIPRASIDONE COMBINATION THERAPY IN TREATMENT-RESISTANT SCHIZOPHRENIA

Seon-Jin Yim M.D., Hwang-Bin Lee, M.D., Minyoung Sim, M.D., Hae-Joo Yoon, Ph.D.

NR3-099

THE RELATIONSHIP BETWEEN PLASMA LEVEL OF LEPTIN, BODY MASS INDEX AND SLEEP QUALITY IN HEALTHY VOLUNTEERS

Wei Tzeng Chen M.D., Tzung Lieh Yeh, M.D., I Hui Lee, M.D., Po See Chen, Ph.D., Kao Ching Chen, M.D., Yeng Kuang Yang, M.D.

NR3-100

EXCESSIVE DAYTIME SLEEPINESS IN DEPRESSED WOMEN

Enrique Gaspar M.D., Raffaella Calati, Ph.D., Carlos S. Cruz-Fuentes, Ph.D., Alejandro Nenclares, M.D., Alejandro Jimenez-Genchi, M.D., Diana De Ronchi, M.D., Ph.D., Alessandro Serretti, M.D., Ph.D.



NR3-101

T311C CLOCK GENE POLYMORPHISM IS NOT ASSOCIATED WITH SLEEP DISTURBANCES IN DEPRESSED PATIENTS

Enrique Gaspar M.D., Raffaella Calati, Ph.D., Carlos S. Cruz-Fuentes, Ph.D., Martha P. Ontiveros-Uribe, M.D., Diana De Ronchi, M.D., Ph.D., Alessandro Serretti, M.D., Ph.D.

NR3-102

THE ASSOCIATION BETWEEN SELF-PERCEIVED SLEEP LATENCY AND SEROTONIN TRANSPORTER AVAILABILITY IN HEALTHY VOLUNTEERS-A SPECT STUDY WITH [123I]ADAM

Huichun Huang M.D., Yen-Kuang Yang, M.D., Po-See Chen, M.D., Ph.D., Tzung-Lieh Yeh, M.D., I-Hui Lee, M.D., Kao-Ching Chen, M.D., Wei-Jen Yao, M.D., Ru-Band Lu, M.D.

NR3-103

COMPARISON BETWEEN BOTH WRIST ACTIGRAPHIC INDICES AND THEIR CORRELATION WITH APNEA-HYPOPNEA INDEX OF NOCTURNAL POLYSOMNOGRAPH

Hong Jun Jeon M.D., Doo-Heum Park

NR3-104

DETRENDED FLUCTUATION ANALYSIS OF HEART RATE VARIABILITY IN OBSTRUCTIVE SLEEP APNEA

Gawon Ju M.D., Chul-Jin Shin, M.D., Doo-Heum Park, M.D.

NR3-105

SLEEP PROBLEMS IN ELEMENTARY SCHOOL CHILDREN IN KOREA

Min-Ji Kim, M.D., Jong-Bum Lee, M.D., Ph.D., Bon-Hoon Koo, M.D., Ph.D., Jun-Yeob Lee M.D., Shin-Ho Song M.D., Hye-Jeong Hong, M.A., Yoon-Jung An, M.S.W.

NR3-106

THE RELATION OF RESTLESS LEGS SYNDROME AND SERUM FERRITIN -COMPARISON WITH PRIMARY INSOMNIA

Younghee Kim, Seung-Chul Hong, M.D., Ph.D., Jong-Hyun Jeong, M.D., Ph.D.

NR3-107

THE ASSOCIATION BETWEEN CENTRAL APNEA AND ANXIETY AMONG MIDDLE AGED ADULTS

Leon Tourian M.D., Sok S. Lee, B.Sc., Brian J. Murray, M.D., M.Sc., Nancy C.P. Low, M.D., M.Sc.

NR3-108

THE EFFECT OF SELECTIVE SEROTONIN RE-UP TAKE INHIBITORS ON PERIODIC LIMB MOVEMENTS AND RESTLESS LEG SYNDROME IN DEPRESSED PATIENTS

Fahd Zarrouf M.D., Kumaraswamy Budur, M.D.

NR3-109

THE PREVALENCE OF BODY DYSMORPHIC DISORDER IN A KOREAN MEDICAL STUDENT SAMPLE

Hyun-Jin Kim, M.D., 640 Daesa-dong, Jung-gu, Daejeon, Korea, Department of Medicine, Chungnam National University; Seung-Min Cha, M.D., Tae-Kyung Lee, M.D., Jung-Lan Kim, M.D., Ph.D., Seung-Keun Wang, M.D., Ph.D., Iik-Seung Chee, M.D. Ph.D.

NR3-110

PREVALENCE AND ETHNIC DIFFERENCES OF SOMATIZATION DISORDERS IN A RURAL CALIFORNIA COMMUNITY

Bernardo Ng M.D., Lianne M Tomfohr, B.S., Alvaro Camacho, M.D., Joel E. Dimsdale M.D.

NR3-111

SALIVARY MHPG LEVELS AFTER VIDEO CHALLENGE PREDICT PERITRAUMATIC DISTRESS AND PTSD SYMPTOMS IN A PROSPECTIVE STUDY OF URBAN POLICE OFFICERS

Brigitte Apfel M.D., Sabra S. Inslicht, Ph.D., Shannon E. McCaslin, Ph.D., Thomas Metzler, M.A., Thomas C. Neylan, M.D., Charles R. Marmar, M.D.

NR3-112

CAREGIVER BURDEN, QUALITY OF LIFE AND IN MOTHERS OF CHILDREN WITH CHRONIC NEUROLOGICAL ILLNESS: A COMPARISON OF MITOCHONDRIAL DISEASE AND EPILEPSY

Kyung Ran Kim, M.D., Lee Eun, M.D., Namkoong Kee, M.D., Lee YoungMook, M.D.

NR3-113

INCREASING CRF EXPRESSION IN AMYGDALA BY VISCERAL PAIN IN RATS

Hoseon Lee M.D., Seok Hyeon Kim, M.D., PH.D., Younghwa Oh, M.D., Hyeon Park, M.D., Sangwon Jeon, M.D.

NR3-114

STRESS RELATED SLEEP DISTURBANCES: RISK FACTOR OF ABDOMINAL OBESITY

Asad Mehdi M.D., Calhoun SL, Vgontzas AN, Bixler EO., Susan L. Calahoun, PhD, Alexandros N. Vgontzas, MD, Edward O. Bixler, PhD

NR3-115

CLINICAL ACUITY AND CIVIL COMMITMENT OF NOT COMPETENT, NOT RESTORABLE FORENSIC PATIENTS COMPARED TO OTHER INPATIENTS IN AN ACUTE PSYCHIATRIC SETTING

Kelly Tyler M.D., Liliane Arenzon, MD, Illa Vora, MD, Gwen Levitt, DO, Gilbert Ramos, MA, David Drachman, PhD



Tuesday, May 19, 2009

12:00 p.m. - 2:00 p.m.

Hall D, Exhibit Level,

Moscone Convention Center

New Research Poster Session 4:

New Research: Anxiety and Mood Disorder

NR4-001

RAPID ONSET OF ACTION IN PATIENTS WITH GENERALIZED ANXIETY DISORDER TREATED WITH PD332334, A NOVEL 5-HT_{1A} LIGAND: RESULTS FROM A 4-WEEK TRIAL

Vamsi Bollu, Ph.D., M.B.A., Robert J Morlock, Ph.D., Kathy Tobias, MD., Michael Smith, Ph.D.

NR4-002

PHARMACOKINETIC AND SAFETY PROFILE OF PD332334, A NOVEL 5-HT_{1A} LIGAND FOR GENERALIZED ANXIETY DISORDER IN HEALTHY VOLUNTEERS

Candace Bramson, MD, M.S., Thomas Stock, DO., Christine Alvey, BS., William Bullen, MS, Wahni Abdulnabi, Ph.D., Allen Moton, PharmD., Susan Hurst, Ph.D., Peter Lockwood, MS., Loretta Cox, MS., R Scott Obach, Ph.D., Kathy Tobias, MD.

NR4-003

A SINGLE-DOSE FOOD EFFECT AND RELATIVE BIOAVAILABILITY STUDY OF PD332334 SOLUTION AND CAPSULES IN HEALTHY VOLUNTEERS

William Bullen, MS., Radhika Abdulnabi, Ph.D., Christine Alvey, BS., Candace Bramson, MD, Peter Lockwood, MS., Allen Moton, PharmD.

NR4-004

COGNITIVE DEFICITS ASSOCIATED WITH POSTTRAUMATIC STRESS DISORDER

Moon Yong Chung, Tae Yong Kim, M.D., Hong Shick Lee, M.D., Hae Gyung Chung, M.D., Jin Hee Choi, M.D., Han Sang Shin, M.D., Dong Ho Song, M.D., Tae Young Lee, M.D.

NR4-005

DRIVING SAFETY IN YOUNG ADULTS DIAGNOSED WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH AND WITHOUT LONG ACTING TRANSDERMAL METHYPHENIDATE

Daniel Cox Ph.D., Roger C. Burket, M.D., Margaret T. Davis, B.A., Atinyene Ibia, Amori Yee Mikami, Ph.D., Michelle Friebe, M.D., Mayin Wong, M.D., Elizabeth Gillespie, M.D., Richard Lawrence Merkel, M.D., Ph.D.

NR4-006

EVALUATING CHILDHOOD EXPERIENCES AS POTENTIAL RISK FOR ADULT ANXIETY DISORDERS: PD, GAD, AND GSP

Marilla Geraci M.S.N., Co Authors, David Luckenbaugh MA, Karina Blair PhD, Daniel Bradford BS, Meena Vythilingam MD, Shmuel Lissek PhD, Christian Grillon PhD, James Blair PhD, Daniel Pine, MD

NR4-007

A COMPARISON OF OBSESSIVE COMPULSIVE DISORDER AND PATHOLOGICAL SKIN PICKING: CLINICAL CHARACTERISTICS AND DISEASE SEVERITY

Jon Grant M.D., Brian L. Odlaug, B.A.

NR4-008

QUETIAPINE MONOTHERAPY IN CHRONIC POSTTRAUMATIC STRESS DISORDER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Mark Hamner M.D., Jose Canive, M.D., Sophie Robert Pharm.D., Gerardo Villareal, M.D., Valerie Durkalski, Ph.D.

NR4-009

COMPARISON OF SLEEP OUTCOMES IN GENERALIZED ANXIETY DISORDER FOLLOWING TREATMENT WITH PREGABALIN OR VENLAFAXINE-XR

Ashish Joshi Ph.D., Francine S. Mandel, Ph.D., Edward Schweizer, M.D., Barry Herman, M.D., M.M.M.

NR4-010

RANDOMIZED TRIAL OF A MULTI-FAITH SPIRITUAL INTERVENTION FOR GENERALIZED ANXIETY DISORDER: A PILOT STUDY

Diana Koszycki Ph.D., Kelley Raab, Ph.D., Fahad Aldosary, M.D., Jacques Bradwejn, M.D.

NR4-011

EFFICACY OF EXTENDED RELEASE QUETIAPINE FUMARATE: POOLED ANALYSIS IN PATIENTS WITH SEVERE GENERALIZED ANXIETY DISORDER

Julie Locklear Pharm.D., Stuart A. Montgomery, M.D., Henrik Svedsäter, Ph.D., Hans Eriksson, M.D., Ph.D., M.B.A.

NR4-012

DOSE-RESPONSE RELATIONSHIP OF PD332334 BASED ON A JOINT ANALYSIS OF PD332334 AND PREGABALIN CLINICAL STUDY DATA

Peter Lockwood, MS, Gad W Mandema, Ph.D., Michael Smith, Ph.D.

NR4-013

SUBJECTIVE PERCEPTIONS OF OCD

Catherine Mancini M.D., Michael Van Ameringen, M.D., F.R.C.P.C., William Simpson, B.Sc., Beth Patterson, B.ScN., B.Ed.

NR4-014

EFFICACY AND TOLERABILITY OF EXTENDED RELEASE QUETIAPINE FUMARATE IN THE TREATMENT OF GENERALIZED ANXIETY DISORDER (GAD): AN ANALYSIS OF POOLED DATA

Charles Merideth, Borwin Bandelow M.D., Dan Stein M.D., Ph.D., Bengt Olausson M.D., Ph.D., Johan Szamosi M.Sc., Hans Eriksson, M.D., Ph.D., M.B.A.

NR4-015

ADJUNCTIVE PREGABALIN TREATMENT AFTER PARTIAL RESPONSE IN GENERALIZED ANXIETY DISORDER (GAD): RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Jeffrey Miceli Ph.D., Tanya Ramey, M.D., Ph.D., Jerry Weaver, M.S., Jeffrey Gleit, B.S., Lloyd Knapp, Pharm.D.



NR4-016

A NEW TRAUMA FOCUSED PSYCHOTHERAPY FOR POST TRAUMATIC STRESS DISORDER

Nick Miller, M.D., Fabien Jeker MSc., Corneliu Feroiu, M.D., M.D., Eric Adam, MSc., Coralie Laignac, M.D., Cristian Damsa, M. D.

NR4-017

TENSION IN GENERALIZED ANXIETY DISORDER: A RELATIVELY NEGLECTED TREATMENT TARGET

Dan Stein M.D., Francine S. Mandel, Ph.D., Piotr Szczypa, M.D., M.Sc., Edward Schwiezer, M.D., Barry Herman, M.D., M.M.M.

NR4-018

SINGLE-DOSE PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PD332334 CHARACTERIZING SAFETY AND TOLERABILITY IN HEALTHY ADULTS AND ELDERLY SUBJECTS

Thomas Stock, DO, Kathy Tobias, MD., Doug Kalunian, MD., William Bullen, MS., Peter Lockwood, MS., Sheela Kolluri, Ph.D., Kelly Diringer Getz, BS.

NR4-019

EFFECTS OF EXTENDED RELEASE QUETIAPINE FUMARATE (QUETIAPINE XR) ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH GENERALIZED ANXIETY DISORDER

Henrik Svedsäter Ph.D., Julie Locklear, Pharm.D., M.B.A., Jean Endicott, Ph.D.

NR4-020

EFFICACY OF PD332334 IN GENERALIZED ANXIETY DISORDER – RESULTS OF A 4 WEEK PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Kathy Tobias, MD., Peter Lockwood, MS., Douglas Felmer, MD., Michael Smith, PhD, Thomas Shiovitz, MD.

NR4-021

A PILOT STUDY OF THE POTENTIAL USE OF INTERNET-BASED SCREENING FOR ANXIETY DISORDERS

Michael Van Ameringen M.D., Catherine Mancini, M.D., F.R.C.P.C., William Simpson, B.Sc., Beth Patterson, B.ScN., B.Ed.

NR4-022

EEG ASYMMETRY IN INFANTS OF MOTHERS WITH SOCIAL PHOBIA

Susan L. Warren, M.D., Kirsten VanMeenen, Ph.D., Jill Settle, B.A., Samuel J. Simmens, Ph.D.

NR4-023

SUBTHERAPEUTIC DOSING AND ADHERENCE IN THE USE OF ANTIDEPRESSANT MEDICATIONS IN THE TREATMENT OF DEPRESSION OR ANXIETY

Stephen Able Ph.D., Stacey Bledsoe, M.S.N.; Steven Gelwicks, M.S.; Peter Watson, M.S.

NR4-024

FIRST DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE-REFERENCED STUDY OF LU AA21004 IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)

Francesc Artigas Ph.D., Marianne Dragheim, M.D., Henrik Loft, M.Sc., Victor Perez, M.D., Enric Alvarez, M.D.

NR4-025

LATITUDE, CLIMATE, SEASON AND SELF-REPORTED MOOD IN BIPOLAR DISORDER

Michael Bauer M.D., Tasha Glenn, Ph.D., Paul Grof, M.D., Natalie L Rasgon, M.D., Wendy Marsh, M.D., Kemal Sagduyu, M.D., Martin Alda, M.D., Greg Murray, Ph.D., Danilo Quiroz, M.D., Yanni Malliaris, BSc (Hons), Johanna Sasse, M.D., Peter C Whybrow, M.D.

NR4-026

SSRI ENHANCES KILLER LYMPHOCYTE (NK/CD8) NON-CYTOLYTIC HIV SUPPRESSION IN HIV/AIDS IN A CHRONIC T-CELL MODEL OF HIV

Tami Benton M.D., Kevin G. Lynch, Ph.D., Steven D. Douglas, M.D., Benoit Dube, M.D., David R. Gettes, B.S., Nancy B. Tustin, MLT., (ASCP)HEW., Jian Ping Lai, M.D., David Metzger, Ph.D., Joshua Blume, M.D., Dwight L. Evans M.D.

NR4-027

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RESPONSE STUDY OF PALIPERIDONE ER FOR ACUTE MANIC AND MIXED EPISODES IN BIPOLAR I DISORDER

Joris Berwaerts M.D., Haiyan Xu, Ph.D., Isaac Nuamah, Ph.D., Pilar Lim, Ph.D., David Hough, M.D.

NR4-028

THE EFFICACY OF QUETIAPINE MONOTHERAPY IN BIPOLAR DEPRESSION: COMBINED DATA FROM THE BOLDER AND EMBOLDEN STUDIES

Joseph Calabrese M.D., Allan H. Young, M.B., Ch.B., M.Phil., Ph.D., Urban Gustafsson, Ph.D., Björn Paulsson, M.D.

NR4-029

COMMON MENTAL DISORDERS IN COLOMBIAN WOMEN: PREVALENCE AND SOME ASSOCIATED FACTORS

Adalberto Campo-Arias M.D., Edwin Herazo, MD, MSc, Jaider Alfonso Barros-Bermudez, MD, German Eduardo Rueda-Jaimes, MD, Luis Alfonso Diaz-Martinez, MD, MSc.

NR4-030

ADJUNCTIVE ARIPIRAZOLE TREATS SYMPTOMS OF CORE DEPRESSION, ANXIETY, AND INSOMNIA IN PATIENTS WITH ANXIOUS OR NON-ANXIOUS MDD (CN138-139/163/165)

Berit Carlson Ph.D., Michael Nashat, Pharm.D., James Eudicone, M.S., Quynh-Van Tran, Pharm.D., Andrei Pikalov M.D., Ph.D., Ronald N Marcus, M.D., Robert M Berman, M.D.

NR4-031

LONG-ACTING RISPERIDONE IN THE PREVENTION OF RE-HOSPITALIZATION IN SCHIZOAFFECTIVE AND BIPOLAR DISORDER

Piero Castro-Loli M.D., Andrea Murru, M.D., Antoni Benabarre, Ph.D., Alessandra Nivoli, M.D., Jose Sánchez-Moreno, Psy. D., Anabel Martínez-Arán, Ph.D., Manuel Salamero, Ph.D., Maria Reñares, Ph.D., Eduard Vieta, M.D., Ph.D.

NR4-032

A PROSPECTIVE FOLLOW-UP STUDY OF MOOD SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE REFERRED FOR DEEP BRAIN STIMULATION

Amit Chopra MBBS, Sarah Lageman PhD, Shirlene Sampson MD, Joseph Matsumoto MD, Andrea Adams MD, S. Matt Stead MD PhD, Kendall Lee MD PhD, Alexis Sharp, MBA, Mark Frye M.D.



NR4-033

DETECTING CINGULATE ABNORMALITIES IN MAJOR DEPRESSION WITH PREFRONTAL MIDLINE EEG

Ian Cook M.D., Aimee M. Hunter, Ph.D., Haleh Farahbod, Ph.D., Alexander Korb, B.S., Andrew F. Leuchter, M.D.

NR4-034

A NEW DIAGNOSTIC CRITERIA FOR DEPRESSION (THE CDAD/IDASD SYSTEM)

Amelia Cordero, Psy.D., Ramos J, Psy.D., Gutierrez R, Psy.D., Zamorro ML, Psy.D.

NR4-035

THE PREVALENCE AND IMPLICATIONS OF RESIDUAL INSOMNIA IN EUTHYMIC BIPOLAR PATIENTS

Colleen Cowperthwait B.A., Aleena C. Hay, B.A., Michael J. Ostacher, M.D., M.P.H., Gary S. Sachs, M.D., Andrew A. Nierenberg, M.D., Roy H. Perlis, M.D., M.Sc.

NR4-036

WHICH CLINICAL AND SOCIODEMOGRAPHICS FACTORS ARE ASSOCIATED TO THE PRESENCE OF SUBSYNDROMIC SYMPTOMS IN BIPOLAR DISORDER?

Consuelo De Dios M.D., Elena Ezquiaga, M.D. Ph.D., Aurelio García, M.D. Ph.D., Agustín Madoz-Gúrpide M.D. Ph.D., Begoña Soler, M.D.

NR4-037

PATTERNS OF PSYCHIATRIC COMORBIDITY IN RELATION TO AGE IN PATIENTS WITH BIPOLAR DISORDER: A CROSS-SECTIONAL ANALYSIS

Bernardo Dell'Osso M.D., Massimiliano Buoli, M.D., Sara Bortolussi, M.D., Maria Carlotta Palazzo, M.D., Giulia Camuri, M.D., Carlo A. Altamura, M.D.

NR4-038

TRANSCRANIAL MAGNETIC STIMULATION (TMS) IN THE TREATMENT OF PHARMACORESISTANT DEPRESSION: EXAMINATION OF COGNITIVE FUNCTION DURING ACUTE TREATMENT

Mark A. Demitrack, MD, Colleen Loo, MD, Daniel Maixner, MD, David Avery, MD, Keith Isenberg, MD, Sheila Dowd, PhD, John P. O'Reardon, MD, Pilar Cristancho, MD, Harold A. Sackeim, PhD

NR4-039

COURSE OF SEXUAL FUNCTIONING DURING LONG-TERM DULOXETINE TREATMENT IN PATIENTS WITH RECURRENT MAJOR DEPRESSIVE DISORDER

Michael Detke M.D., David G. S. Perahia, M.D., M.R.C. Psych., Melissa E. Spann, Ph.D., Fujun Wang, Ph.D., Daniel J. Walker, Ph.D., Charles R. Yang, Ph.D., Montejo A.L., M.D. Ph.D.

NR4-040

CIGARETTE SMOKING ENHANCES DEPRESSION TREATMENT OUTCOME

Dale D'Mello M.D., Alric Hawkins, M.D.

NR4-041

DOPAMINE FUNCTION AND CORTISOL SECRETION IN DEPRESSION

Fabrice Duval M.D., Marie-Claude Mokrani, Felix Gonzalez Lopera, Thanh Son Diep, Hassen Rabia

NR4-042

DOPAMINERGIC, NORADRENERGIC, ADRENAL AND THYROID ABNORMALITIES IN AFFECTIVE AND PSYCHOTIC DISORDERS

Fabrice Duval M.D., Marie-Claude Mokrani, Ph.D., Felix Gonzalez Lopera, M.D., Thahn Son Diep, M.D., Hassen Rabia, M.D., Said Fattah, M.D.

NR4-043

EXTENDED RELEASE QUETIAPINE FUMARATE ADJUNCT TO ANTIDEPRESSANTS FOR MDD: POOLED ANALYSIS OF SUSTAINED RESPONSE (STUDIES D1448C00006 AND D1448C00007)

Willie Earley M.D., Michael Bauer, M.D., Ph.D., Eduard Vieta, M.D., Ph.D., Johan Szamosi, M.Sc., Helena Schiöler M.Sc., Hans Eriksson, M.D., Ph.D., M.B.A.

NR4-044

EFFECTIVENESS OF PSYCHOTROPIC MEDICATIONS IN THE MAINTENANCE PHASE OF BIPOLAR DISORDER: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Mattias Ekman Ph.D., Eduard Vieta, M.D., Ph.D., Julie Locklear, Pharm.D., M.B.A., Carolin Miltenburger, Ph.D., Mary Lou Chatterton, Pharm.D., Mikael Åström, M.Sc., Ph.L., Björn Paulsson, M.D.

NR4-045

COST-EFFECTIVENESS OF QUETIAPINE IN PATIENTS WITH ACUTE BIPOLAR DEPRESSION AND IN MAINTENANCE TREATMENT AFTER AN ACUTE DEPRESSIVE EPISODE

Ekman Mattias, M.D., Peter Lindgren, Ph.D., Carolin Miltenburger, Ph.D., Genevieve Meier, B.Pharm., M.Sc., Julie C. Locklear, Pharm.D., M.B.A., Mary Lou Chatterton, Pharm.D.

NR4-046

ANTIDEPRESSANT-ASSOCIATED MANIA OR HYPOMANIA: A COMPARISON WITH PERSONALITY AND BIPOLARITY FEATURES OF BIPOLAR I DISORDER

Rahsan Erim M.D., Omer Saatcioglu, M.D., Nesrin Tomruk, M.D., Timucin Oral, M.D., Nihat Alpay, M.D.

NR4-047

IS EUTHYMIA AN UTOPIA IN BIPOLAR DISORDER PATIENTS? THE IMPORTANCE OF SUBSYNDROMAL SYMPTOMS

Elena Ezquiaga, Ph.D., Begoña Soler, MDConsuelo de Dios, M.D., Aurelio García, Ph.D., Agustín Madoz-Gúrpide, Ph.D.

NR4-048

10-YEAR COURSE OF SOCIAL ADJUSTMENT OF MAJOR DEPRESSION

Toshiaki A. Furukawa M.D., Hiroshi Takeuchi, M.D., Ph.D., Hideki Azuma, M.D., Ph.D., Toshiaki Imaizumi, M.D., Hirofumi Ueki, M.D., Ph.D., Kazuhira Miki, M.D., Ph.D., Toshinori Kitamura, FRCPsych, Kiyohisa Takahashi, M.D., Ph.D.

NR4-049

DEPRESSIVE SYMPTOMS IN BIPOLAR PATIENTS ADMITTED INTO A PSYCHIATRIC UNIT DUE TO AN ACUTE MANIC EPISODE

Jaime Galan M.D., Ana Gonzalez-Pinto, M.D., Ph.D., Eduard Vieta, M.D., Ph.D., Manuel Martin, M.D.



NR4-050

THE SENSITIVITY AND TOLERABILITY OF QUETIAPINE-XR IN THE TREATMENT OF BIPOLAR DEPRESSION, MAJOR DEPRESSIVE DISORDER, AND GENERALIZED ANXIETY DISORDER

Keming Gao M.D., David E. Kemp, M.D., Stephen J. Ganocy, Ph.D., Joseph R. Calabrese, M.D.

NR4-051

A PROSPECTIVE COHORT STUDY TO ASSESS SUBSYNDROMAL AFFECTIVE SYMPTOMS IN BIPOLAR PATIENTS: DESCRIPTION OF THE SAMPLE

Aurelio García-López M.D., Ph.D., Consuelo de Dios, M.D., Elena Ezquiaga, M.D. Ph.D., Agustín Madoz M.D. Ph.D., Begoña Soler, M.D.

NR4-052

PREDICTORS OF DULOXETINE TREATMENT PERSISTENCE FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER

Steven Gelwicks M.S., Douglas E. Faries, Ph.D.; Wenyu Ye, Ph.D.; Xianchen Liu, M.D., Ph.D.

NR4-053

24 MONTH OUTCOMES FROM THE FRENCH COHORT OF THE EUROPEAN MANIA IN BIPOLAR LONGITUDINAL EVALUATION OF MEDICATION (EMBLEM) STUDY

Stephanie Gerard Pharm.D., Jean-Michel Azorin, M.D., Ph.D., Elodie Aubrun, Jordan Bertsch, Catherine Reed, Stephanie Gerard, Pharm.D., Michael Lukasiewicz, M.D.

NR4-054

RESPIRATORY FUNCTION AND DEPRESSIVE SYMPTOMS IN LATER LIFE IN ITALIAN AND FINNISH MEN

Erik J. Giltay, MD, PhD, Aulikki Nissinen, MD, PhD, Simona Giampaoli, MD, Frans G. Zitman, MD, PhD, Daan Kromhout, MPH, PhD.

NR4-055

SUBSYNDROMAL DEPRESSIVE SYMPTOMS AFTER SYMPTOMATIC RECOVERY FROM MANIA ARE ASSOCIATED WITH DELAYED FUNCTIONAL RECOVERY

Michael Gitlin M.D., Jim Mintz, Ph.D., Kenneth Sokolski, M.D., Connie Hammen, Ph.D., Lori L. Altshuler, M.D.

NR4-056

PREBIS: PREDICTIVE FACTORS OF RECURRENCE AND BIPOLAR DISORDER MANAGEMENT IN SPAIN.: A 6 MONTHS FOLLOW UP INTERIM ANALYSIS

Jose Goikolea M.D., Consuelo de Dios, M.D. Ph.D., Eduard Vieta, M.D. Ph.D., Jeronimo Sainza Ruiz, M.D. Ph.D., Ana González-Pinto, M.D. Ph.D., José M. Montes, M.D. Ph.D., Inmaculada León, Mónica Tafalla, M.D. Ph.D., Susana Majadas, M.D.

NR4-057

MIND THEIR HEARTS: PREVALENCE AND CORRELATES OF CORONARY HEART DISEASE AND HYPERTENSION IN BIPOLAR I DISORDER

Benjamin Goldstein M.D., Patricia Houck, MSH, Andrea Fagiolini, MD

NR4-058

OMEGA-3 FATTY ACIDS AS ADJUNCTIVE OF ANTIDEPRESSANT THERAPY AND ITS EFFECTS ON BRAIN-DERIVED NEUROTROPHIC FACTOR IN SERUM AND LYMPHOCYTES

Alfonso Gonzalez Ph.D., Paul Sánchez, MD., Dacia González, MD., Salvador Mata, MD., Ph. D., Mary Urbina BSc., Fili Fazzino BSc, MSc., Lucimey Lima MD., Ph. D.

NR4-059

EVERYDAY PRACTICE OF FRENCH PSYCHIATRISTS IN THE DRUG TREATMENT OF BIPOLAR DISORDERS

Sebastien Guillaume M.D., Ludovic Samalin, M.D., Pierre-Michel Llorca, M.D. Ph.D.

NR4-060

RECURRENT MANIA REVISITED: A STUDY FROM NORTH INDIA

Nitin Gupta M.D., M Phani Prasant, M.D., Savita Malhotra, M.D., Ph.D., F.A.M.S.

NR4-061

FEASIBILITY OF A STRUCTURAL NEUROIMAGING STUDY IN MAJOR DEPRESSION USING LEGACY MRI DATA

Dan Iosifescu M.D., Wouter S. Hoogenboom, MS, Roy H. Perlis, MD, Jordan W. Smoller, MD, Qing Zeng-Treitler, PhD, Vivian S. Gainer, MS, Shawn N. Murphy, MD, PhD, Susanne E. Churchill, PhD, Isaac Kohane, MD, PhD, Martha E. Shenton, PhD

NR4-062

THE PREVALENCE AND IMPACT OF COMORBID MIGRAINE ON INDIVIDUALS WITH BIPOLAR DISORDER

Christine I. Kinsky, B.A, Rebecca M. Ametrano, BA, Michael J. Ostacher, MD, MPH, Roy H. Perlis, MD, MSc, Gary S. Sachs, MD, Andrew A. Nierenberg, MD.

NR4-063

PREDICTIVE EFFECT OF METABOLIC SYNDROME ON ARIPIPRAZOLE TREATMENT RESPONSE (CN138-010)

David Kemp M.D., James M Eudicone, M.S., Andrei Pikalov, M.D., Ph.D., Richard Whitehead, B.S., Ross A Baker Ph.D., M.B.A., Jessie S Chambers, Ph.D.

NR4-064

ACUTE EVENTS RISK PREDICTION AMONG ANTIPSYCHOTIC AGENTS IN THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

Jennifer Kim Pharm.D., Arthur Lazarus, M.D., MBA

NR4-065

ANGER EXPERIENCE IN PATIENTS WITH DEPRESSIVE DISORDERS

Jeong-Lan Kim, Byung-Hun Ahn, M.D., Jin-Gu Lee, M.D., Seung-Kun Wang, M.D., Ik-Seung Chee, M.D.

NR4-066

THE EFFECT OF COGNITIVE BEHAVIOR THERAPY PERFORMED IN FOREST ENVIRONMENT ON REMISSION AND PHYSIOLOGIC RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

Won Kim M.D., Jong-Min Woo, M.D., Ph.D.

WITHDRAWN



NR4-067

NEUROANATOMICAL CORRELATES OF THERAPEUTIC EFFICACY OF TRANSCRANIAL MAGNETIC STIMULATION IN TREATMENT-RESISTANT DEPRESSION

Shinsuke Kito M.D., Takashi Hasegawa, M.D., Kenichi Fujita, M.D., Ph.D., Yoshihiko Koga, M.D., Ph.D.

NR4-068

A NEW CLINICAL RATING SCALE FOR WORK PRODUCTIVITY: VALIDATION STUDIES IN PATIENTS WITH DEPRESSION

Raymond Lam M.D.

NR4-069

THE ASSOCIATION BETWEEN BRAIN-DERIVED NEUROTROPHIC FACTOR GENEPOLYMORPHISM (VAL66MET) AND SERUM BRAIN-DERIVED NEUROTROPHIC FACTOR LEVELS

Youngmin Lee M.D., Ym Lee, M.P.H., Jm Park, Ph.D., CJ Kang, Ph.D., Bd Lee, M.P.H.

NR4-070

SEROTONIN 5-HT₇ RECEPTORS, PROLIFERATION, AND CAMP IN LYMPHOCYTES OF MAJOR DEPRESSION PATIENTS

Lucimey Lima M.D., Fili Fazzino, M.Sc.; Humberto Spinetti, M.D., Ph.D.; Rafael Arciniegas, M.D.; Isabel Carreira, M.D.; Salvador Mata, M.D., Ph.D. Alfonso González, M.D., Ph.D.

NR4-071

CHRONIC PAIN ASSOCIATED WITH INCREASED USE OF HYPNOTICS AND ANXIOLYTICS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

Xianchen Liu M.D., Wenyu Ye, Ph.D.; Madelaine M. Wohlreich, M.D.; James M. Martinez, M.D.

NR4-072

CORRELATION OF LEVELS OF DEPRESSIVENESS AND CHOICE OF ELECTIVE SUBJECTS IN MEDICAL STUDENTS

Rudolf Ljubcic M.D., Ivana Ljubcic Bistrovic M.D., MSc, Ivana Balic M.D.

NR4-073

VALIDATION OF A BRIEF VERSION OF THE CENTER FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE (CES-D) IN COLOMBIAN ADULTS

Maria Teresa Lopez-Carmargo M.D., German Eduardo Rueda-Jaimes, MD, Luis Alfonso Díaz-Martínez, MD, MSc, Adalberto Campo-Arias, MD.

NR4-074

FIBROMYALGIA AND COMORBID MAJOR DEPRESSIVE DISORDER: ASSESSMENT OF MOOD AND PAIN RESPONSE TO DULOXETINE HYDROCHLORIDE COMPARED TO PLACEBO

Lauren Marangell M.D., Laurence Bradley, Ph.D., Ernest Choy, M.D., Daniel Clauw, M.D., Philip Mease, M.D., Scarlett Shoemaker, M.S.N., Fujun Wang Ph.D., Madelaine Wohlreich, M.D.

NR4-075

USE OF TRADITIONAL AND ALTERNATIVE MEDICINES IN PEOPLE WHO SUFFER BIPOLAR DISORDERS: IMPACT ON COMPLIANCE

Eliana Marengo M.D., Maria Jose Sarmiento M.D., Maria Scapola Psy.D., Laura M.D.; Diego Martino M.D.; Ana Igoa M.D., Carlos Gomez M.D.; Sergio Strojilovich M.D.

NR4-076

INCREASED DEPRESSIVE SYMPTOMS IN PERIMENOPAUSAL AGE WOMEN WITH BIPOLAR DISORDER: AGE AND GENDER COMPARISON

Wendy K. Marsh M.D., Terence A. Ketter M.D., Natalie L. Rasgon, Ph.D.

NR4-077

ADJUNCTIVE ARIPIPIRAZOLE IMPROVES CORE DEPRESSIVE SYMPTOMS ON CLINICIAN AND PATIENT MEASURES: A POOLED MADRS/IDS CROSS CORRELATION LINE-ITEM ANALYSIS

Michael Martin M.D., Fred W Reimherr, M.D., James M Eudicone, M.S., Barrie K Marchant, M.S., Quynh-Van Tran, Pharm.D., Andrei Pikalov, M.D., Ph.D., Berit X Carlson, Ph.D., Ronald N Marcus, M.D., Robert M Berman, M.D.

NR4-078

INTERVENTIONS FOR THE FAMILIES OF BIPOLAR PATIENTS: IMPACT ON FAMILIES

Nancy Maruyama M.D., Allison M.R. Lee, M.D., Igor I. Galynker, Ph.D.

NR4-079

SEROTONIN SYNTHESIS AND PRESENCE OF TRYPTOPHAN HYDROXYLASE IN LYMPHOCYTES OF MAJOR DEPRESSION PATIENTS TREATED WITH FLUOXETINE AND FOLIC ACID

Salvador Mata M.D., Mary Urbina BSc., Renée Lavie MD., Gustavo Resler MD., Julio Campos MD., Ph. D., Alfonso González MD., Ph. D., Salvador Mata, MD., Ph. D., Lucimey Lima MD., Ph. D.

NR4-080

A RETROSPECTIVE STUDY OF FASTING BLOOD GLUCOSE LEVELS IN PSYCHIATRIC INPATIENTS WITH PSYCHOTIC VS NON-PSYCHOTIC MAJOR DEPRESSIVE DISORDER

John Matthews M.D., Elizabeth A. Davis, M.D., Caleb J. Siefert, Ph.D., Sarah Stone, M.P.H., Nelson Tauro, Adrienne O. van Nieuwenhuizen, B.A., Lawrence T. Park, M.D., Kaloyan Tanev, M.D., David W. Abramson, M.D., Maurizio Fava, M.D.

NR4-081

ASENAPINE EFFICACY IN PATIENT SUBPOPULATIONS EXPERIENCING MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: A POOLED ANALYSIS

Roger McIntyre, Miriam Cohen, Jun Zhao, John Panagides

NR4-082

EFFECTS OF QUETIAPINE FUMARATE ON SLEEP ARCHITECTURE IN PATIENTS WITH DEPRESSION – AN OPEN LABEL STUDY

Roumen Milev M.D., Lauren Lazowski, B.Sc., Ruzica Jokic, M.D., FRCP(C), Alan Lowe, M.D., FRCP(C), Regina du Toit, M.D., FRCP(C)

NR4-083

ACUPUNCTURE AUGMENTATION THERAPY IN ANTIDEPRESSANT PARTIAL AND NON-RESPONDERS WITH MAJOR DEPRESSIVE DISORDER: INTERIM ANALYSIS

David Mischoulon M.D., Ph.D., Albert S. Yeung, M.D., Sc.D., Sarah E. Chuzy, B.A., Victoria E. Ameral, B.A., Maurizio Fava, M.D.



NR4-084

QUALITY OF LIFE AND EATING DISTURBANCES IN PATIENTS DIAGNOSED WITH BIPOLAR DISEASE TYPE I WITH SYNDROMIC REMISSION (REMFYS STUDY)

Alonso Montoya M.D., Vieta E, Montoya A, Casillas M, Polavieja P, Chacón F, Gilaberte I and Tohen M

NR4-085

RANDOMIZED PLACEBO-CONTROLLED TRIAL OF RAMELTEON FOR DEPRESSIVE SYMPTOMS IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER

Edward R Norris M.D., Karen Burke, R.N., Carol Foltz, Ph.D., Emily Bates, B.A., Kenneth J. Zemanek, M.D., Michael Kaufmann, M.D.

NR4-086

SOCIAL ANXIETY AS A CONSEQUENCE OF SELF-STIGMATIZATION AND LOW SELF-ESTEEM IN REMITTED BIPOLAR PATIENTS

Aydemir Omer M.D., Cengiz Akkaya, M.D.

NR4-087

IMPACT OF CHILDHOOD TRAUMA ON THE CLINICAL COURSE OF BIPOLAR I DISORDER

Ilker Özyildirim M.D., Sibel Çakır, M.D., Olcay Yazıcı, M.D.

NR4-088

BILATERAL VERSUS MONOLATERAL LOW-FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION AS ADD-ON TREATMENT IN RESISTANT DEPRESSION

Stefano Pallanti M.D., Leonardo Quercioli, MD., Andrea DiRollo, MD., Silvia Bernardi, MD.

NR4-089

LONG-TERM SAFETY OF DULOXETINE IN THE OPEN-LABEL COMPASSIONATE TREATMENT OF PATIENTS WHO COMPLETED PREVIOUS DULOXETINE CLINICAL TRIALS

Beth Pangallo R.N., Durisala Desai, Ph.D., Qi Zhang, Ph.D., David G. S. Perahia, M.D., MRCPsych, Michael J. Detke, M.D., Ph.D., Sidney H. Kennedy, M.D.

NR4-090

THE IMPACT OF GALANTAMINE HBR ON COGNITION AND MOOD DURING ELECTROCONVULSIVE THERAPY

Lawrence Park M.D., John D. Matthews, M.D., Caleb J. Siefert, Ph.D., Mark Blais, Psy.D., Adrienne O. van Nieuwenhuizen, B.A., Kathryn Rooney, B.A., Nelson Tauro, Charles Welch, M.D., Kaloyan Tanev, M.D., Maurizio Fava, M.D.

NR4-091

BRIEF DEPRESSIVE EPISODES' IMPACT IN THE OUTCOME OF MOOD DISORDERS:A NATURALISTIC STUDY

Sara Pozzoli, Francesca Colombo, M.D., Alessandra Albano, M.D., Sara Bortolussi, M.D., Ilaria Balossi, M.D., Lucio Oldani, M.D., Massimiliano Buoli, M.D., Bernardo Dell'Osso, M.D., A.Carlo Altamura, M.D.

NR4-092

RANDOMIZED, PLACEBO-CONTROLLED, LONG-TERM STUDY OF RISPERIDONE LONG-ACTING INJECTABLE IN RELAPSE PREVENTION IN BIPOLAR I DISORDER PATIENTS

Jorge A. Quiroz M.D., Lakshmi N. Yatham M.D., Joseph M. Palumbo, M.D., Keith Karcher, M.S., Stuart Kushner, M.D., Vivek Kusumakar, M.D.

NR4-093

EARLY RESPONSE AS PREDICTOR OF GOOD OUTCOME IN THE PROGNOSIS OF A DEPRESSIVE EPISODE: RESULTS FROM A 1-YEAR FOLLOW-UP LARGE EPIDEMIOLOGICAL STUDY

Miquel Roca, M.D., Ph.D., Antonio Ciudad, M.D., Ph.D., Enrique Álvarez, M.D., Ph.D., Enrique Baca, M.D., Ph.D., Luis Caballero, M.D., Ph.D., Marta Casillas, Ph.D., Pepa García de Polavieja, BsSci, Amparo Valladares PharmD., Belén Yrurettagoyena, Ph.D., Inmaculada Gilaberte, M.D., Ph.D.

NR4-094

CORTISOL METABOLISM IN DEPRESSED PATIENTS AND HEALTHY CONTROLS

Benedikt Römer, Sabina Lewicka, Dr., Michael Deuschle, Prof. Dr.

NR4-095

AN ADJUNCTIVE MANAGEMENT OF DEPRESSION PROGRAM FOR PATIENTS WITH DIFFICULT-TO-TREAT DEPRESSION AND THEIR FAMILIES - RESULTS AT 48 WEEKS

Christine Ryan Ph.D., Gabor I. Keitner, M.D., Stephen Bishop, Ph.D., Michaela F. Jamiel, Anna Eng, Joan Kelley

NR4-096

ILLNESS EXPERIENCE AND REASONS FOR NON-ADHERENCE AMONG INDIVIDUALS WITH BIPOLAR DISORDER WHO ARE POORLY ADHERENT WITH MEDICATION

Martha Sajatovic M.D., Jennifer Levin, Ph.D., Edna Fuentes-Casiano, BSW, Jamis Jenkins, Ph.D.

NR4-097

USE OF BIPOLAR DISORDER TREATMENT GUIDELINES BY FRENCH PSYCHIATRISTS FOR CLINICAL DECISION MAKING

Ludovic Samalin, Sebastien Guillaume, M.D., Pierre-Michel Llorca, Ph.D.

NR4-098

BIPOLAR DISORDER IMPAIRS PHYSICAL HEALTH AS MUCH AS SCHIZOPHRENIA

Susana Santamarina, Garcia Portilla MP, Saiz PA, Bascaran MT, Iglesias C, Bobes J

NR4-099

BIPOLAR DISORDER IMPAIRS QUALITY OF LIFE LESS THAN SCHIZOPHRENIA

Susana Santamarina, Garcia-Portilla MP, Saiz PA, Bascaran MT, Iglesias C, Bobes J

NR4-100

COMPARISON OF DIFFERENT TREATMENT OPTIONS FOLLOWING INITIATION DOSE OF 10MG ESCITALOPRAM

Delphine Saragoussi, M.D., M.P.H., Thibaut Sanglier, M.Sc., Dominique Milea, Pharm.D., M.Sc.

NR4-101

A POPULATION-BASED COMPARISON OF SUICIDALITY AMONG BIPOLAR DISORDER AND MAJOR DEPRESSIVE DISORDER SUBJECTS

Ayal Schaffer M.D., Ayal Schaffer, MD, John Cairney, PhD, Scott Veldhuizen, BA, Amy Cheung, MD, Paul Kurdyak, MD, Anthony Levitt, MD



NR4-102

COGNITIVE FUNCTIONING IN DEPRESSED PSYCHIATRIC INPATIENTS: A PILOT STUDY PREDICTING LENGTH OF STAY (LOS) ON AN ACUTE MEDICAL PSYCHIATRIC UNIT

Caleb Siefert Ph.D., Larry Park, M.D., Katherine O. Rooney, B.S., Adrienne O. Van Nieuwenhuizen, B.S., Nelson Prakash Tauro, M.D., Kaloyan Tanev, M.D., John D. Matthews, M.D.

NR4-103

AGE OF ONSET AND SUICIDE RISK IN BIPOLAR DISORDER

Jonathan Stange B.A., Michael J. Ostacher, M.D., M.P.H., Andrew A. Nierenberg, M.D., Roy H. Perlis, M.D., MSc, Gary S. Sachs, M.D.

NR4-104

PSYCHIATRIC SYMPTOMS IN CAREGIVERS OF PATIENTS WITH BIPOLAR DISORDER

Annie Steele B.A., Nancy C. Maruyama, M.D., Igor I. Galynker, M.D., Ph.D.

NR4-105

FREQUENCY EXPOSURE TO ANTIDEPRESSANTS AND MOOD STABILIZER IN THE LONG-TERM BIPOLAR DISORDER TREATMENT

Sergio Strojilevich M.D., Diego Martino MD, Ana Igoa MD, Eliana Marengo MD, Guillermo Fassi MD, S. Nassir Ghaemi PhD

NR4-106

EXTENDED RELEASE QUETIAPINE FUMARATE MONOTHERAPY FOR THE TREATMENT OF MDD: POOLED ANALYSIS OF SUSTAINED RESPONSE (STUDIES D1448C00001 AND D1448C00002)

Johan Szamosi M.S.C., Roger S. McIntyre M.D., Stuart Montgomery M.D., Helena Schiöler M.Sc., Hans Eriksson M.D., Ph.D., M.B.A., Willie Earley M.D.

NR4-107

THE COST-EFFECTIVENESS OF QUETIAPINE AS AN ADJUNCT TO A MOOD STABILIZER IN THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

Eskinder Tafesse Ph.D., Arthur Lazarus, M.D., MBA

NR4-108

A STUDY OF COGNITION IN UNAFFECTED FULL BIOLOGICAL SIBLINGS OF PATIENTS WITH BIPOLAR DISORDER TYPE I

Jitendra Trivedi M.D., Himanshu Sareen, MBBS, P.K. Dalal, MD, P.K. Sinha, DSQ, Mohan Dhyani, MD

NR4-109

USE OF A RELAPSE MONITORING BOARD FOR INDEPENDENT ASSESSMENT OF THE PRIMARY ENDPOINT IN AN INTERNATIONAL CLINICAL TRIAL OF BIPOLAR DISORDER

Norris Turner Pharm.D., Wayne Macfadden, M.D., Mark Hyman Rapaport, M.D., Ravi Anand, M.D., Sumant Khanna, M.D., Ph.D., M.A.M.S., M.R.C.Psych., J. Thomas Haskins, Ph.D., Ibrahim Turkoz, M.S., Larry Alphs, M.D., Ph.D.

NR4-110

GENDER DIFFERENCES IN SYMPTOMS AND COMORBIDITY IN A NATURALISTIC SAMPLE OF DEPRESSIVE OUTPATIENTS: THE LEIDEN ROUTINE

OUTCOME MONITORING STUDY

Martijn Van Noorden M.D., Erik J. Giltay, M.D. Ph.D., Margien E. den Hollander-Gijsman, M.Sc., Nic J.A. van der Wee, M.D. Ph.D., Yanda R. van Rood, Ph.D., Rosalind Van Der Lem, M.D., Frans G. Zitman, M.D. Ph.D.

NR4-111

EFFECT OF ESCITALOPRAM ON DEPRESSED PATIENTS WITH CROHN'S DISEASE: A PLACEBO – CONTROLLED PILOT STUDY

Indu Varia M.D., Jennifer B. Reese, Ph.D., Margatha N. Kuchibhatla, Ph.D., Prakash Masand, M.D., Kenneth Gersing, M.D., Audrey Broome, N.P., Jane Onken, M.D.

NR4-112

GENDER-RELATED LIPID ABNORMALITIES IN OUTPATIENTS WITH BIPOLAR DISORDER

Mytilee Vemuri M.D., Mytilee Vemuri, M.D., M.B.A., Terence A. Ketter, M.D., Heather A. Kenna, M.A., Uma Saha, M.D., Anna Morenkova, M.D., Po W.Wang, M.D., Natalie L. Rasgon M.D., Ph.D.

NR4-113

TEMPERAMENTS AND TREATMENT OUTCOMES IN MOOD DISORDERS: PROSPECTIVE DATA

Elizabeth Whitham B.A., Sairah Thommi, B.A., SN Ghaemi, M.D., M.P.H.

NR4-114

LOCUS OF CONTROL, LIFE EVENTS, TREATMENT HISTORY AND LONGITUDINAL OUTCOMES OF TREATMENT FOR DEPRESSION

Stephen B. Woolley, D.Sc., Brenda A. Woznicki, B.A., M.P.H., John W. Goethe, M.D., Shani Bardack, B.A., Naila Azhar, M.D.

NR4-115

LIFESTYLE, SOCIOECONOMICS, AND HEALTH HISTORY VERSUS MEDICATIONS AS PREDICTORS OF METABOLIC SYNDROME

Stephen B. Woolley D.Sc., M.P.H., Charles F. Caley, Pharm.D., John W. Goethe, M.D., David Bardack, B.A., Toni Martello, B.A., Naila Azhar, M.D., Gualberto Ruano, M.D., Ph.D., Andreas Windemuth, Ph.D.

NR4-116

THE EFFICACY OF QUETIAPINE MONOTHERAPY IN BIPOLAR II DEPRESSION: COMBINED DATA FROM THE BOLDER AND EMBOLDEN STUDIES

Allan Young Ph.D., Ch.B., M.Phil., Ph.D., Joseph R. Calabrese, M.D., Urban Gustafsson, Ph.D., Björn Paulsson, M.D., Gin S. Malhi, M.B., Ch.B., M.D., David J. Bond, M.D., I. Nicol Ferrier, M.D.

NR4-117

THE IN VITRO PROFILE OF LU AA21004, A NOVEL MULTI-TARGET DRUG FOR THE TREATMENT OF MOOD DISORDERS

Huailing Zhong Ph.D., Tine B. Stensbøl, Ph.D., Kristen Frederiksen, Ph.D., Benny Bang-Andersen, Ph.D.

NR4-118

PSYCHIATRIC DIAGNOSES IN PATIENTS PREVIOUSLY OVERDIAGNOSED WITH BIPOLAR DISORDER

Mark Zimmerman M.D., Camilo Ruggero, Ph.D., Iwona Chelminski, Ph.D., Diane Young, Ph.D.



NR4-119

UNDERRECOGNITION OF CLINICALLY SIGNIFICANT SIDE EFFECTS IN DEPRESSED OUTPATIENTS

Mark Zimmerman M.D., Janine Galione, B.S., Naureen Attiullah, M.D., Michael Friedman, M.D., Cristina Toba, M.D., Daniela Boerescu, M.D., Moataz Ragheb, M.D.

NR4-120

AUTONOMIC, ENDOCRINE AND NEUROPHYSIOLOGIC CORRELATES OF HUMAN-ANIMAL INTERACTION

Sandra Barker Ph.D., Anand K. Pandurangi, M.D., Janet S. Knisely, Ph.D., Nancy L. McCain, D.S.N., Christine M. Schubert, Ph.D., Evren Buragkazi, M.D.

NR4-121

STRESS SYMPTOMS AND LOST PRODUCTIVITY IN PHYSICIANS TREATING BATTLE INJURED SOLDIERS

Thomas Grieger M.D., Christopher A. Alfonzo, M.D., David M. Benedek, M.D., D.F.A.P.A

Tuesday, May 19, 2009

3:00 p.m. - 5:00 p.m.

**Hall D, Exhibit Level,
Moscone Convention Center**

**New Research Poster Session 5:
Young Investigator Poster Session 2**

NR5-001

A STUDY ON THE CAUSAL INFLUENCE PHYSIOLOGICAL RESPONSE LEVEL HAS ON DRINKING MOTIVATION AND DRINKING PROBLEMS AMONG COLLEGE STUDENTS

Il Kang, H.J. Lee, M.D.; S.W. Ki, M.D.; J. W. Kim, M.D., Ph.D.; S.E. Kim, M.D.

NR5-002

COPING STRATEGIES IN TOGOLESE SUBSTANCE USERS

Kossi Kounou M.A., Eric Bui, M.D., Laurent Schmitt, M.D.

NR5-003

THE ROUGH ENDOPLASMIC RETICULUM'S GLUTAMATE DEHYDROGENASE IN ALCOHOLICS' SERA

Matej Kravos M.D., Ivan Malešić, M.Pharm., Ph.D.

NR5-004

THE INCIDENCE OF BIPOLAR DISORDER IN ALCOHOL-DEPENDENT PATIENTS

Damian McGovern M.D., Daniel K. Hall-Flavin, M.D., P. Mark Frye, M.D.

NR5-005

MANAGEMENT OF COCAINE ABUSE (MOCA) STUDY: EVALUATION OF CARDIAC COMPLICATIONS IN COCAINE ADDICTED PATIENTS IN THE PSYCHIATRIC EMERGENCY DEPARTMENT

Gulam Noorani M.D., Mahboob Aslam MD, Javed Iqbal MD, Valerie D'Aurora, BSc, John Charoonbara, BSc

NR5-006

SUBSTANCE INDUCED PSYCHOTIC DISORDER IN A PATIENT WITH 43 DAY EXPOSURE TO TOLUENE - A CASE REPORT

Gulam Noorani M.D., Mahboob Aslam M.D, Javed Iqbal M.D, Hanif Ramay M.D., D.F.A.P.A and Sam Clinch

NR5-007

THE INTERACTION BETWEEN PAIN AND DEPRESSIVE SYMPTOMS IN POLYDRUG DEPENDENT INDIVIDUALS IN EARLY METHADONE MAINTENANCE TREATMENT

David Tompkins M.D., Annie Umbrecht, M.D., Erin Winstanley, Ph.D., George Bigelow, Ph.D.

NR5-008

PSYCHIATRIC COMORBIDITY RELATED TO DRUG ABUSE AMONG MEXICAN ADDICTIVE CLINIC

Mirna Trancoso M.D., Ricardo Nanni, M.D.



NR5-009

DOUBLE-BLIND, CROSSOVER, PLACEBO-CONTROLLED PILOT STUDY OF VARENICLINE FOR METHAMPHETAMINE DEPENDENCE

Todd Zorick M.D., Karen Miotto, M.D., Steve Shoptaw, Ph.D., Aimee-Noelle Swanson, Ph.D., Clayton Clement, B.Sci., Richard De La Garza II, Ph.D., Thomas Newton, M.D., Edythe London, Ph.D.

NR5-010

A BRAZILIAN HIV PREVENTION INTERVENTION FOR ADULTS WITH SEVERE MENTAL ILLNESS: A RANDOMIZED CLINICAL TRIAL FEASIBILITY STUDY

Lorraine Lothringer M.D., Cristiane Borges, M.D., Katherine Elkington, Ph.D., Claudio Gruber Mann, R.N., Milton Wainberg, M.D.

NR5-011

ATTENTION DISORDERS IN METHADONE-TREATED OPIATE-DEPENDENT PATIENTS

Amanda Ellenwood M.S., Amanda Ellenwood M.S., Adashima Muhammad M.P.H., Caroline Marvin B.A., James Prosser M.D., Igor Galynker M.D., Ph.D.

NR5-012

PSYCHIATRIC DISORDERS AND ALCOHOLISM COMORBID IN A SAMPLE OF MEXICAN WOMEN

Armida Granados M.D., Rosa Díaz, M.D., Francisco López, M.D.

NR5-013

COMPLETION OF INPATIENT ALCOHOL TREATMENT PROGRAM AND READMISSION : DIFFERENCES IN CLINICAL CHARACTERISTICS

ByungOok Lee M.D.

NR5-014

MAOA GENE INTERACTS WITH ALDH2 GENE IN ANXIETY-DEPRESSION ALCOHOLISM

Sheng-Yu Lee M.D., Cheng-Yi Hahn, M.D., M.S., Jia-Fu Lee, M.D., Ph.D., San-Yuan Huang, M.D., Ph.D., I-Hui Lee, M.D., Tzung-Lieh Yeh, M.D., Yen-Kuang Yang, M.D., Shih-Heng Chen, Ph.D., Huei-Chen Ko, Ph.D., Po-Hsiu Kuo, Ph.D., Ru-Band Lu, M.D.

NR5-015

SPANISH VALIDATION OF THE ADULT ADHD RATING SCALE: RELEVANCE OF SUBTYPES

Rosa Bosch, JA Ramos-Quiroga MD., M Nogueira Ph.D., N Gómez-Barros MD, M Corrales Ph.D., G Palomar MD., S Valero Ph.D. and M Casas Ph.D, MD.

NR5-016

NOCTURNAL BINGE EATING IN ATTENTION DEFICIT HYPERACTIVITY DISORDER

Anoop Karipott M.D.

NR5-017

MATERNAL DEPRESSION AND PARENTING BEHAVIOR IN MOTHERS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER CHILDREN

Hye Ji Min M.D., Jeong-Ho Seok, MD, PhD, Na Rei Hong, MD, PhD, Duk-In Jon, MD, PhD, Young Shin Kim, MD, PhD, Hyun Ju Hong, MD,

NR5-018

RISK FOR OVERT AGGRESSION AND PROACTIVE-REACTIVE AGGRESSIVE MOTIVATION IN REFERRED CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER

Ellen Preen Psy.D., Ellen C. Preen, Psy.D., Karen G. Chartier, Ph.D., Richard F. Kaplan, Ph.D., Daniel F. Connor, M.D.

NR5-019

CASE-CONTROL STUDY OF SIX GENES ASYMMETRICALLY EXPRESSED IN THE TWO CEREBRAL HEMISPHERES: EVIDENCE OF ASSOCIATION OF BAIAP2 WITH ADULTHOOD ATTENTION-D

J. Antoni Ramos-Quiroga M.D., M Ribasés Ph.D, R Bosch Ph.D, A Hervás MD, A Bielsa MD, X Gastaminza MD, S Guijarro-Domingo Ph.D, M Nogueira Ph.D, N Gómez-Barros MD, S Kreiker MD, Silke Groß-Lesch MD, CP Jacob MD, KP Lesch Ph.D, MD, A Reif Ph.D, MD S Johansson Ph.D, M Dramsdahl MD, K von Plessen MD, PM Knappskog MD, J Haavik Ph.D, MD X Estivill Ph.D, MD , M Casas Ph.D, MD, M Bayés Ph.D and B Cormand Ph.D

NR5-020

PREVALENCE OF ASPERGERS SYNDROME IN ADULT ADHD

Mandy Roy, Wolfgang Dillo, M.D., Vanessa Prox-Vagedes, M.D., Marc Ziegenbein, M.D., Martin D. Ohlmeier, M.D.

NR5-021

PSYCHOLOGICAL AND PHYSIOLOGICAL MARKERS AND THE METABOLIC CONTROL OF TYPE 1 DIABETES MELLITUS

Bianca Andreica, Bogdan Lucian, MD, Simona Cainap, MD, Mariana Andreica, MD Ph.D.

NR5-022

SPORTS PARTICIPATION AS A PROTECTIVE FACTOR AGAINST DEPRESSION AND SUICIDAL IDEATIONS AS MEDIATED BY SELF ESTEEM AND SOCIAL SUPPORT

Lindsay Babiss B.S., James E. Gangwisch, Ph.D.

NR5-023

INVESTIGATING THE IMPACT OF LIGHT THERAPY ON PERFORMANCE OF ADHD CHILDREN ON NEUROPSYCHOLOGY TASKS

Johanna A. Cabassa, MD, Gloria M. Reeves, MD, Manana Lapidus, MD, Patricia Langerberg, Ph.D., Gina Han, BS, Mary Johnson, Ph.D., Teodor T. Postolache, MD.

NR5-024

THE PATTERN OF STANFORD-BINET IQ PROFILES OF LANGUAGE DEVELOPMENTAL DISORDERS IN TAIWAN

Yi-ling Chien M.D., Shang-wen Chang, M.D., Huei-ting Kuo, Hsieh Ru-lan, M.D.

NR5-025

PARENT RATINGS OF SOCIAL RESPONSIVENESS IN CHILDREN WITH CEREBELLAR TUMORS

Talar Hopyan Ph.D., Maureen Dennis, Ph.D.



NR5-026

PSYCHIATRIC COMORBIDITY AMONG YOUTH RECEIVING SUBSTANCE ABUSE TREATMENT: PREVALENCE AND THE EFFECTS OF INTERVENTION IN REDUCING SYMPTOMS AND INCIDENT

Viviana Horigian M.D., Carl Weems, PhD; Jessica Ucha-Vieta, M. Ed., Michael S. Robbins, Ph.D

NR5-027

ADOLESCENTS' PSYCHOPATHOLOGY RELATED TO DISCREPANCIES BETWEEN ADOLESCENTS' SELF-REPORT AND PARENTS' REPORT OF ADOLESCENTS' PROBLEM BEHAVIOR

Sojin Lee M.D., Bong Cho Kim, M.D., Ph.D., Cheol Soon Lee, M.D., Dong Yun Lee, M.D., Ji Yun Sohn, M.D., Sun Mi Kim, M.D., Seung Nam Kim, M.D

NR5-028

AN EXAMINATION OF PTSD AND SUBSTANCE USE IN A SAMPLE OF ADOLESCENTS PRESENTING FOR TREATMENT

Ruby Lekawuwa B.S., Ernestine C. Briggs-King, Ph.D., Sarah A. Ostrowski, Ph.D., Lisa M. Amaya-Jackson, M.D., M.P.H.

NR5-029

PSYCHIATRIC COMORBIDITIES AMONG ADOLESCENTS WITH PERSISTENT AND REMITTED ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

Hsing-Chang Ni M.D., Susan Shur-Fen Gau, M.D., Ph.D., Wei-Tsuen Soong, M.D., Yu-Yu Wu, M.D., Liang-Ying Lin, M.D., Yen-Nan Chiu, M.D.

NR5-030

METABOLIC EFFECTS OF ANTIPSYCHOTICS IN CHILDREN: PRELIMINARY RESULTS FROM THE MEAC STUDY

Ginger E. Nicol, M.D.; Dan W. Haupt, M.D.; Karen S. Flavin, R.N., C.C.R.C.; Julia A. Schweiger, C.C.R.C.; Martha J. Hessler, B.S.; Emily J. Hessler, B.S.; Susanna B. Thach, B.S.; Michael D. Yingling, B.S.; John W. Newcomer, M.D.

NR5-031

CHANGES IN ADIPOSITY AND METABOLIC MEASURES DURING MEDICATION SWITCHES TO ARIPIPRAZOLE FROM OTHER ATYPICAL ANTIPSYCHOTICS

Ginger Nicol M.D., Dan W. Haupt, MD; Ginger E. Nicol, MD; Michael D. Yingling, BS; Peter A. Fahnestock, MD; Karen S. Flavin, RN, CCRC; Julia A. Schweiger, CCRC; Elizabeth T. Westerhaus, MA; Angela M. Stevens, BS; John W. Newcomer, MD

NR5-032

ANXIETY, DEPRESSION AND ALEXITHYmia IN MEXICAN ADOLESCENTS WITH SOMATIC SYMPTOMS ATTENDING A GENERAL PEDIATRIC HOSPITAL.

Rosalba Ochoa M.D., Diana Molina PhD, Maria Juana Piña Psy.

NR5-033

IS SELECTIVE MUTISM AN ANXIETY DISORDER? A CASE STUDY OF A SUCCESSFUL TREATMENT

Eduardo Prado, Mirian C. Revers, Rogério Marrocos, MD, Ricardo de Oliveira-Souza, Ph.D., Ana C. S. Congio, Kamyille M. Pompeu

NR5-034

THREE-YEAR LONGITUDINAL STUDY COMPARING BULLYING AND VICTIMIZATION: FROM MIDDLE SCHOOL TO FRESHMAN YEAR OF HIGH SCHOOL

Darren Richmond, Charlotte Richmond, Ph.D., Thomas Prihoda, Ph.D.

NR5-035

ASPERGER'S DISORDER AND SIBLING BIRTH ORDER

Karmen Schmidt Ed.M., Christine Ferrone, M.A., Charles A. Henry M.D

NR5-036

DIGITAL MEDIA (INTERNET, VIDEOGAMES, SOCIAL NETWORKS, CELL PHONES, MUSIC PLAYERS...): BENEFITS IN THE PSYCHOTHERAPY AND FAMILY LIVES OF YOUTH

Eitan D. Schwarz, M.D., D.L.F.A.P.A., F.A.A.C.A.P.

NR5-037

BEHAVIORAL MANAGEMENT OF A PATIENT WITH AICARDI'S SYNDROME -CASE REPORT

Amin Shamal M.D., Summer Jaffrey M.D, Mahboob Aslam M.D., Edward Hall M.D., Javed Iqbal M.D.

NR5-038

SIGNIFICANCE OF ROUTINE LABORATORY MONITORING OF LIVER FUNCTION DURING VALPROATE THERAPY

Amin Shamal M.D., Abderrahmanne Richane M.D., Mahboob Aslam M.D., Amel Badr M.D., Gulam Noorani M.D., Ajay Lall, Javed Iqbal M.D.

NR5-039

LONG TERM STEROID EXPOSURE AND PSYCHOSIS IN CONGENITAL ADRENAL HYPERPLASIA: A CASE STUDY

Jahanara Zahid M.D., Anoop Karippot ,MD, RPSGT, FAASM, D ABSM, CBSM

NR5-040

MILITARY BEHAVIORAL HEALTH CERTIFICATION: SPECIALIZED TRAINING TO MEET THE UNIQUE MENTAL HEALTH NEEDS OF VETERANS AND THEIR FAMILIES

Elizabeth Brent M.D., Judy Kovell, M.D.

NR5-041

THE SPECTRUM OF AFRICAN-AMERICAN RACE: EXPLORING RACIAL IDENTITY ATTITUDES, DEPRESSION STIGMA, AND TREATMENT-RELATED ATTITUDES AND BEHAVIORS

Enrico Castillo, B.A., Kyaieen O. Conner, Ph.D., L.S.W., M.P.H., Nancy Grote, Ph.D., Valire Carr Copeland, M.P.H., Ph.D., Charles F. Reynolds, III, M.D., Charlotte Brown, Ph.D.

NR5-042

GENDER DIFFERENCES IN LATINO PSYCHIATRIC AMBULATORY PATIENTS

Raquel Choua M.D., Maria I. Zapata Vega, MD, Martin Maurer, MD

NR5-043

MONOAMINE OXIDASE INHIBITOR USAGE IN A PACIFIC ISLAND SETTING

John Huh M.D., Junji Takeshita, MD, Deborah Goebert, DrPH, Diane Thompson, MD, Brett Lu, MD, and Russ Muramatsu, MD

2009 Annual Meeting • New Research



NR5-044

EFFECT OF A CULTURALLY-MODIFIED WEIGHT LOSS PROGRAM FOR LATINOS WITH SEVERE AND PERSISTENT MENTAL ILLNESS IN A COMMUNITY MENTAL HEALTH CLINIC

Christina Mangurian M.D., Simriti Chaudhry, B.A., Felicia Rosario, B.A., Jonathan Amiel, M.D., Michael Devlin, M.D., John Newcomer, M.D., Rohan Ganguli, M.D., Francine Cournos, M.D., Carlos Jackson, Ph.D., Diane Barrett, R.D., Lucia Capitelli, R.N., Dianna Dragatsi, M.D., Jules Ranz, M.D., Susan Essock, Ph.D.

NR5-045

NATIONAL ORIGIN DIFFERENCES IN THE EXPRESSION OF THE SYMPTOM “HEARING VOICES” IN INMIGRANTS VICTIM OF TRAUMA

Andres Monleon, M.D., Ruth Kizza, M.D., Lawrence Hipshman M.D., Ph.D., Pablo J. Monleon M.D., Ph.D., David J. Kinzie M.D., Ph.D., Vicente J. Monleon, Ph.D.

NR5-046

ENHANCING MEDICATION ADHERENCE TO ORLISTAT WITH ADAPTED GROUP DIALECTICAL BEHAVIORAL THERAPY AMONG OVERWEIGHT BINGE EATERS

Kim Chu M.S., Debra Safer, M.D., Sarah Adler, M.S.

NR5-047

USE OF PSYCHOTROPIC DRUGS IN ADULTS INPATIENTS DIAGNOSED WITH EATING DISORDER

Juan Jose De Frutos Guijarro M.D., A. A. García Rosales M.D., M. Benítez Alonso M.D., M. B. Bardón Rivera M.D., E. Román Mazuecos M.D., M. F. Bravo Ortiz.

NR5-048

PRESCRIBING PRACTICES FOR INPATIENTS DIAGNOSED OF EATING DISORDERS, BOTH IN CHILD AND ADOLESCENT, AND ADULT PSYCHIATRIC ACUTE WARDS

Alejandra Garcia Rosales M.D., J.J. De Frutos Guijarro M.D., M. Graell Berna M.D. PhD, M. Benítez Alonso M.D., M. B. Bardón Rivera M.D., E. Román Mazuecos M.D., G. Morandé Lavín M.D. PhD, M.F. Bravo Ortiz M.D. PhD.

NR5-049

USE OF PSYCHOTROPIC DRUGS IN A MONOGRAPHIC EATING DISORDER INPATIENT UNIT FOR CHILDREN AND ADOLESCENTS

Montserrat Graell Berna M.D., A. A. García Rosales M.D., J.J. De Frutos Guijarro M.D., M. Benítez Alonso M.D., G. Morandé Lavín M.D. PhD.

NR5-050

CHOCOLATE CRAVING, UNCONTROLLED EATING AND BODY DISSATISFACTION: EXPLORING THE AMBIVALENCE MODEL

Rachel Rodgers M.A., Eric Bui, M.D., Karine Faure, M.D., Henri Chabrol, Ph.D.

NR5-051

INFORMED CONSENT FOR MOOD STABILIZING AGENTS IN WOMEN OF CHILDBEARING AGE

Mitzi Albright M.D., Erick Messias, MD, PhD, Carmen Nichita, MD

NR5-052

THERAPEUTIC ALLIANCE IN FORENSIC MENTAL HEALTH

Vidis Donnelly M.D., Aideen Lynch, B.A Psychology; Conal Devlin, M.B. BSc; Damian Mohan, BSc M.D.; Prof. Harry Kennedy, BSc M.D.

NR5-053 - CANCELLED

NR5-054

GENDER INFLUENCE IN CLINICAL, DEMOGRAPHIC AND TREATMENT RELATED CHARACTERISTICS AMONG ADULT INPATIENTS IN AN ACUTE PSYCHIATRIC UNIT

Ainoa Muñoz San José, M.D., Jesús J. Marín Lozano, M.D., David López Gómez, M.D., M^a Eva Román Mazuecos, M.D., Rosa Villanueva Peña, M.D., M^a Fe Bravo Ortiz, M.D. Ph.D.

NR5-055

CHARLES-BONNET SYNDROME IN THE ELDERLY: DIAGNOSTIC CLUES AND MANAGEMENT

Jacqueline Dahl M.D., Maria I. Lapid, M.D., Jarrett W. Richardson, M.D.

NR5-056

THE ELDERLY IN THE PSYCHIATRIC EMERGENCY SERVICE: IS A DIFFERENT ASSESSMENT NEEDED?

Kathleen Diller M.D., Ruth M. Lamdan, M.D.

NR5-057

OUTLOOK AT DIOGENES SYNDROME (SELF NEGLECT SYNDROME IN ELDERLY POPULATION) - A CASE REPORT

Marina Haghour-Vwich M.D., Natasha G. Baron, M.D; Amel Badr M.D., M. Javed Iqbal, M.D.

NR5-058

CLINICAL USEFULNESS OF THE COMBINATION OF K-BNT & DELAYED RECALL OF SVLT IN DIAGNOSING DEMENTIA OF THE ALZHEIMER'S TYPE

Jun-Yeob Lee M.D., Bon-Hoon Koo, M.D., Ph.D., Shin-Ho Song, M.D., Jong-Bum Lee, M.D., Ph.D., Yoon-Jung An, M.S.W

NR5-059

EFFECTS OF APOLIPOPROTEIN E E4 ALLELE ON NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE

Eunyoung Shin M.D., Han Yong Jung, MD, PhD, Shin Gyeom Kim, MD, So Young Lee, MD, PhD, Yu Jin Lee, MD, Joon Ho Park, PhD, Yeon Jung Lee MD

NR5-060

A COMPARATIVE ANALYSIS OF THE INTERPERSONAL CONFLICT TACTICS USED BY OLDER ADULTS WITH SCHIZOPHRENIA AND THEIR AGE PEERS IN THE GENERAL COMMUNITY

Dimple Sodhi M.B.B.S, Carl I. Cohen, M.D., Paul M. Ramirez, Ph.D

NR5-061

A COMPARISON OF TMS ADMINISTERED 3 DAYS/ WEEK AND TMS ADMINISTERED 5 DAYS/WEEK IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Stacy Bell, Cherrie Galletly, MBChB, DPM, FRANZCP, PhD, Shane Gill, BMBS, FRANZCP, Dip Psychotherapy, Patrick Clarke, MBBS FRANZP, Jody Williams, B. Nursing



NR5-062

IS NEWER BETTER? A COMPARISON OF DIRECT AND INDIRECT META-ANALYSES OF DESVENLAFAXINE AND VENLAFAXINE FOR MAJOR DEPRESSIVE DISORDER

Samuel Huber M.D., Matthew D. Engel, B.S.

NR5-063

EMERGENCY PSYCHIATRY: LITERATURE OVERVIEW WITH STATISTICS FROM PARIS, FRANCE

Gabriella Inczedy-Farkas M.D., Carl D. Hanson, MD, Orsolya Hadarits

NR5-064

THE PREVALENCE OF NEUROPSYCHIATRIC DISORDERS IN VETERANS AND SERVICE MEMBERS OF OPERATIONS ENDURING FREEDOM AND IRAQI FREEDOM (OEF/OIF)

Patrick Link M.D., Alexander S. Young, M.D., M.S.H.S.

NR5-065

SYMPTOMATIC IMPROVEMENTS ARE ASSOCIATED WITH FUNCTIONAL IMPROVEMENTS IN VETERANS WITH DEPRESSION, ANXIETY, AND POST-TRAUMATIC STRESS

Brian Shiner M.D., Bradley V. Watts M.D., M.P.H., Yinong Young-Xu Sc.D.

NR5-066

ATTRIBUTION AND RESPONSE TO CHANGES IN MOOD AND BEHAVIOR AS RELATED TO PREVIOUS PSYCHIATRIC DIAGNOSIS

Meredith Theeman M.S.C.

NR5-067

FACTORS AND BARRIERS THAT LEAD TO ABSENCES AT INITIAL PSYCHIATRIC APPOINTMENTS

Adrienne Turner M.D., Anita H. Clayton, MD

NR5-068

THE CO-OCCURRING STATE INCENTIVE GRANT IN DELAWARE STATE

Cynthia Zubritsky Ph.D., Gerald Gallucci, MD MHS, Cynthia Zubritsky, PhD, Aileen Rothbard, SCD, Melissa Smith, MA, Steven Dettwyler, PhD, Kimberly Beniquez, MS

NR5-069

NEURAL CORRELATES OF INTERNET GAME ADDICTION: AN FMRI STUDY

Hyoungyoon Chang, Shin YJ, M.D., Ph.D., Park HJ, M.D., Ph.D., Kim JH, Ph.D., Kim EJ, M.D., Park IC, M.D., Kim MK

NR5-070

A STUDY ON THE EFFECTS OF THE PSYCHIATRIC PATIENTS' REPEATEDLY JOINING WEIGHT CONTROL GROUP

Lo Wei-Chi M.D., Yuh-Ming Hou, M.D., Hui-Ling Chiu

NR5-071

THE NATURALISTIC STUDY OF THE EFFECTS OF EEG BIOFEEDBACK IN ADULT PATIENTS WITH PSYCHIATRIC DISORDERS

Bon-Hoon Koo M.D., Jong-Bum Lee, M.D., Ph.D., Jun-Yeob Lee M.D., Shin-Ho Song M.D., Min-Ji Kim, M.D.

NR5-072

PERCEPTION DIFFERENCES TOWARDS ECT AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND SEVERE MENTAL ILLNESS AND THEIR RELATIVES

Angelica Ramirez-Cardenas M.D., Cesar Gonzalez-Gonzalez, M.D., Eduardo Valle-Ochoa, M.D.

NR5-073

A BIOPSYCHOSOCIAL APPROACH TO PAIN MANAGEMENT

Sunny Aslam M.D., Chris Faubel, MD, Adekola O. Alao, MD

NR5-074

MAJOR DEPRESSIVE DISORDER AND THE RISK OF DEVELOPMENT OF TYPE II DIABETES

Faiz Cheema M.D., Amel Badr, M.D., Amin Shamal, M.D., Summer Jaffrey, M.D., Nadia Khan, Mahboob Aslam, M.D., Asghar Hossain, M.D., Javed Iqbal, M.D.

NR5-075

THE IMPORTANCE OF PSYCHOEDUCATION IN THE TREATMENT OF BIPOLAR DISORDER: AN ITALIAN EXPERIENCE

Marianna Mazza M.D., Hadjichristos A., MD, Mazza M., MD, PhD, Bandini I., Mammone I., Perri R., Cristiano M.C., Harnic D., MD, Catalano V., Marano G., Janiri L., MD, Bria P, MD.

NR5-076

CLINICAL DECISION MAKING BIASES IN A GROUP OF MENTAL HEALTH PROVIDERS

Sarah A. Romeo, B.A., Kelly M. Sutton-Skinner, B.A., Timothy J. Petersen, Ph.D., Steven Sloman, Ph.D., Lee Baer, Ph.D., Jeff C. Huffman, M.D., Charissa F. Andreotti, Sc.B., John A. Fromson, M.D., Robert J. Birnbaum, M.D., Ph.D.

NR5-077

PERFORMANCE DISPARITIES BY HEALTHCARE PROVIDER DISCIPLINE UTILIZING A PSYCHIATRIC CLINICAL CASE VIGNETTE

Kelly Sutton-Skinner B.A., Sarah A. Romeo, B.A., Lee Baer, Ph.D., Robert J. Birnbaum, M.D., Ph.D., Timothy J. Petersen, Ph.D., Jeff C. Huffman, M.D.

NR5-078

EFFECTIVENESS, SAFETY AND TOLERABILITY OF CLOMIPRAMINE AUGMENTATION OF SSRI IN TREATMENT-RESISTANT OBSESSIVE-COMPULSIVE DISORDER

Pino Alonso M.D., Jose M. Menchon, M.D., Ph.D., Cinto Segalàs, M.D., Javier Labad, M.D., Eva Real, M.D., Alberto Pertusa, M.D., Susana Jiménez-Murcia, Psy.D., Blanca Bueno, Psy.D.

NR5-079

TREATMENT OF MUTISM WITH ORAL OLANZAPINE: A CASE STUDY

Gregory Boyarsky M.D., Janay Fake, M.D., Robin Tassinari, M.D

NR5-080

DO PERSONALITY TRAITS AFFECT SUBJECTIVE OUTCOMES FOLLOWING TOTAL KNEE ARTHROPLASTY?

Heather Church M.D., Raymond J. Walls, M.D., Kieran Hirpara, M.D., John M O'Byrne, M.D.



NR5-081

DEPRESSION, ANXIETY AND QUALITY OF LIFE IN HEMODIALYSIS PATIENTS

Seyeon Lee M.D., Jong-Hyun Jeong, M.D., Seung-Chul Hong, M.D., Jin-Hee Han, M.D., Sung-Pil Lee, M.D.

NR5-082

PARTIALLY REVERSIBLE DEMENTIA ASSOCIATED WITH NAPHTHALINE ABUSE IN A CASE OF A THIRTY TWO YEAR OLD FEMALE PATIENT

Victoria Passov M.D., James R. Rundell, M.D.

NR5-083

A COMPARISON OF LOW VS. HIGH UTILIZERS OF SERVICES IN AN URBAN PSYCHIATRIC EMERGENCY SERVICE

Guillermo Portillo M.D., Barbara Sparacino, M.D., William R. Dubin, M.D.

NR5-084

METABOLIC SYNDROME AWARENESS IN BIPOLAR AND SCHIZOPHRENIC PATIENTS AND PHARMACOTHERAPY IMPACT QUESTIONNAIRE: A VENEZUELAN PSYCHIATRISTS REALITY

Gustavo Resler M.D.

NR5-085

HOMOCYSTEINE AND CHOLESTEROL LEVELS AND TYPES A/B AND D PERSONALITY IN PATIENTS WITH RECURRENT DEPRESSIVE DISORDER, BIPOLAR DISORDER, & SCHIZOPHRENIA

Radmila Topic M.D., Ivona Markelic, Bjanka Vuksan-Cusa M.D., Darko Marcinko Ph.D., Miro Jakovljevic Ph.D.

NR5-086

HOMOCYSTEINE AND CHOLESTEROL LEVELS AND TYPES A/B AND D PERSONALITY IN PSYCHIATRIC PATIENTS WITH AND WITHOUT CARDIOVASCULAR DISORDERS

Radmila Topic M.D., Ivona Markelic, Bjanka Vuksan-Cusa M.D., Darko Marcinko Ph.D., Miro Jakovljevic Ph.D.

NR5-087

PERCEPTIONS OF MENTAL HEALTH DISORDERS IN AMERICAN MUSLIM WOMEN

Rania Awaad M.D., Natalie Rasgon, M.D., Ph.D., Heather Kenna, M.S.

NR5-088

SPIRITUALITY AND SUICIDE: RESULTS FROM THE NATIONAL COMORBIDITY SURVEY REPLICATION

Erica Smith M.D., Erick Messias, MD, PhD

NR5-089

CORRELATES OF FATIGUE IN MEDICAL RESIDENTS: LOOKING BEYOND SLEEP DEPRIVATION

Kanwar Ajit Sidhu M.D., Cristian Sirbu, Ph.D., Veena Bhanot, M.D., John Linton, Ph.D., Mary Emmett, Ph.D., T.O. Dickey, M.D., Martin Komor, M.D.

NR5-090

DEPRESSION IN INTERNS: USE OF MENTAL HEALTH SERVICES AND BARRIERS TO USE

Heather Speller, Constance Guille, M.D., C. Neill Epperson, M.D., Srijan Sen, M.D., Ph.D.

NR5-091

PROJECT ANTI-BULLY: BULLYING IN MIDDLE SCHOOLS YEAR TWO SURVEY

Fabianna Pergolizzi

NR5-092

IS CHILDHOOD PSYCHOPATHOLOGY PREDICT TO INTERNALIZING PROBLEM IN ADOLESCENCE : A 8-YEAR POPULATION-BASED FOLLOW-UP STUDY IN KOREA

Yunmi Shin M.D., Sun-Mi Cho, Ph.D., Hey Young Kang, M.D.

NR5-093

WHY PATIENTS MISS APPOINTMENTS: BARRIERS TO MENTAL HEALTH TREATMENT ENGAGEMENT AMONG A VETERAN POPULATION

Lauren Gerlach B.S., Shahrzad Mavandadi, Ph.D., David Oslin, MD

NR5-094

WHAT DO PATIENTS WANT TO KNOW? AN UPDATED ANALYSIS OF THE QUESTIONS POSTED BY USERS OF AN INTERNET-BASED INFORMATION SERVICE ON MENTAL DISORDERS

Antonio Nascimento M.D., Joao A. Carvalho (MD, PhD) Marco A. A. Brasil (MD, PhD)

NR5-095

CORRELATES OF SELF-STIGMA AMONG CONSUMER FAMILY MEMBERS

Deborah Perlick, Ph.D., Ann Nelson, BSN, Silvia Corbera, Ph.D., Jennifer Edidin, M.A., Lisa Costello, B.A., Masai McIntosh, B.A., Victoria Adzhishvili, B.A., Jim Seltzer, Ph.D.

NR5-096

BEHAVIORAL PATTERN, PHYSICAL APPEARANCE AND PSYCHIATRIC ILLNESS ASSOCIATED WITH CHILDREN WHO ARE A PART OF A NEW EMOTIONAL GROUP CALLED "EMO-CULT"

Lorerky Ramirez Moya M.D., Gulam A.Noorani M.D.,M.P.H

NR5-097

SUICIDE ATTEMPTS ARE ASSOCIATED WITH WORSE QUALITY OF LIFE IN PATIENTS WITH BIPOLAR DISORDER

Lena Abreu M.D., Fabiano G. Nery, M.D., Karla Mathias Almeida, M.D. Bernardo Carramao Gomes, Maria A. Oquendo, M.D., Beny Lafer, M.D, PhD.

NR5-098

A NOVEL WORKSHOP FOR HEALTHCARE WORKERS DEALING WITH TBI PATIENTS

Dimitri Bollegala B.S.C., Lori Wasserman, M.D., Michael Vu, Najma A. Ahmed, M.D., Ph.D., Tammy Shaw, B.Sc., M.D., Clara Ko, B.Sc., Mary Preisman, B.Sc., M.D., Shree Bhalerao, B.A., B.Sc., M.D.

NR5-099

ANTIDEPRESSANTS AND YOUTH SUICIDE IN MIAMI-DADE COUNTY, 1990-2007

Edmi Cortes M.D., Antonio Cubano, M. D., John E. Lewis, Ph.D., Daniel Castellanos, M. D.



NR5-100

PANIC ATTACK AND SUICIDE RISK: A MULTIVARIATE LOGISTIC REGRESSION ANALYSIS OF THE NATIONAL EPIDEMIOLOGICAL SURVEY OF ALCOHOLISM AND RELATED CONDITIONS

*Curren Katz Ed.M., Ramin Mojtabai, M.D. Ph.D. M.P.H.,
Janine Samuel, BA, Kathleen Cammacho, BA, Igor Galynker, M.D. Ph.D.*

NR5-101

PSYCHOPATHOLOGY IN PATIENTS WITH SUICIDAL ATTEMPT IN A MEXICAN PSYCHIATRIC HOSPITAL

Tizbé Sauer M.D., Mirna Trancoso, M.D.

NR5-102

ONE HOUR OF BRIGHT LIGHT VERSUS PLACEBO LIGHT TREATMENT FOR WINTER SEASONAL DEPRESSION

*Manana Lapidus, MD, Gloria Reeves, MD, Gagan Virk, MD,
Johanna Cabassa, MD, Soren Sniitker, MD, Debra Scrandis, Ph.D.,
Mary Johnson, Ph.D, Alvaro Guzman, MD, Patricia Langenberg, PhD,
Leonardo Tonelli, Ph.D, Teodor Postolache, MD.*

NR5-103

THE COURSE OF POSTTRAUMATIC STRESS SYMPTOMS OVER 66 MONTHS AFTER AN INDUSTRIAL DISASTER: A STRUCTURAL EQUATION MODELLING STUDY

*Eric Bui M.D., Laurent Tremblay, M.A., Rachel Rodgers, M.A.,
Alain Brunet, Ph.D., Stephane Vautier, Ph.D.,
Philippe Birmes, M.D., Ph.D.*

NR5-104

SEXUAL ASSAULT AND LIFETIME DIAGNOSIS OF PSYCHIATRIC DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS

*Laura Chen B.S., M. Hassan Murad, M.D., Molly L. Paras, B.S.,
Erin N. Goranson, B.S., Amelia L. Sattler, B.S.,
Kristina M. Colbenson, B.S., Mohamed B. Elamin, M.B.B.S.,
Richard Seime, Ph.D, L.P., Larry J. Prokop, M.L.S., Ali Zirakzadeh, M.D.*

NR5-105

VIOLENT BEHAVIOR AND ITS PREDICTORS IN SCHIZOPHRENIA PATIENTS IN HONG KONG

Kavin Chow

NR5-106

CHANGES OF PSYCHOPATHOLOGY OF KOREAN-TALIBAN HOSTAGES: 1-YEAR FOLLOW-UP STUDY

Soyong Eom, Jeon WT, Ph.D, Lee Y, M.A.

NR5-107

THE EFFECTS OF DAILY EXPERIENCES DURING CAPTIVITY ON MENTAL HEALTH OF KOREAN-TALIBAN HOSTAGES

Youngjoon Lee M.A., Jeon WT, Ph.D, Eom SY, M.A.

NR5-108

SUDANESE REFUGEES IN CAIRO, EGYPT: A RANDOMIZED CONTROLLED TRIAL OF INTERPERSONAL PSYCHOTHERAPY FOR TRAUMA, DEPRESSION AND INTERPERSONAL VIOLENCE

*Susan M. Meffert M.D., M.P.H., Magda Ali, M.B. B.Ch., MSc.,
Yassir Mostafa, Sahar Yousif, Afrah Abdel Rahim, Omayma Fargouny,
Akram Osman Abdo, Charles R. Marmar, M.D.*

NR5-109

SYMPTOMS OF TRAUMA SCALE: DEVELOPING A PSYCHOMETRIC TOOL FOR PTSD

Michael Pratts M.D.

NR5-110

THE SIGNIFICANT IMPACT OF CHILD ABUSE ON THE WIDE RANGE OF CHARACTERISTICS OF DEPRESSED INPATIENTS

*Magdalena Romanowicz M.D., Gen Shinozaki, M.D.,
Victoria Passov, M.D., Simon Kung, M.D., Renato D. Alarcon, M.D., M.P.H.,
David A. Mrazek, M.D., F.R.C.Psych*

NR5-111

COMPARISON OF THE PES MANAGEMENT BETWEEN THE FIRST AND SECOND YEAR GENERAL PSYCHIATRY RESIDENTS: A PILOT STUDY

Xiangyang Zhao M.D., Toni Love Johnson M.D.

NR5-112

PEDIATRIC PSYCHIATRIC EMERGENCIES AFTER TWO SCHOOL SHOOTING INCIDENTS

Xiangyang Zhao M.D., Toni Love-Johnson, M.D.

NR5-113

DEFICIT IN EYE CONTACT IN NEGATIVE EMOTIONAL SITUATION DURING INTERACTION WITH VIRTUAL AVATAR IN PATIENTS WITH SCHIZOPHRENIA

*Soo-hee Choi, M.D., Jeonghun Ku, Ph.D., Kiwan Han, M.S.,
Sun I. Kim, Ph.D., Eosu Kim, M.D., Jae-Jin Kim, M.D., Ph.D.*

NR5-114

FACTORS ASSOCIATED WITH MEDICATION TREATMENT DECISIONS AMONG PREGNANT WOMEN WITH BIPOLAR DISORDER

*Rachel Vanderkruik, Adele C. Viguera, M.D., Theodore Hatch Whitfield,
Sc.D., Ross J. Baldessarini, M.D., Lee S. Cohen, M.D.*



Wednesday, May 20, 2009

**12:00 p.m. - 2:00 p.m.
Hall D, Exhibit Level,
Moscone Convention Center**

**New Research Poster Session 6:
New Research: Treatment &
Treatment Settings**

NR6-001

THE TRIAL-BASED THOUGHT RECORD, A NEW COGNITIVE THERAPY STRATEGY TO CHANGE CORE BELIEFS IN SOCIAL PHOBIA

Irismar Reis De Oliveira M.D., Vania Powell, Camila Pereira, Claudia de Almeida, Maria Conceição Grangeon, Milke Caldas, Thais Bonfim, Martha Castro, Amanda Galvão, Roberta Moraes, Amy Wenzel, Donna Sudak

NR6-002

DEVELOPING CULTURALLY SENSITIVE COGNITIVE BEHAVIOUR THERAPY FOR PSYCHOSIS FOR ETHNIC MINORITY PATIENTS

Shanaya Rathod M.D., Prof David Kingdon, MD. Peter Phiri

NR6-003

IS COMBINED TREATMENT BETTER THAN USUAL CARE IN IMPROVING QUALITY OF LIFE IN A ONCOLOGIC DEPRESSED SAMPLE?

Beatriz Rodríguez Vega M.D., Angela Palao, Guillermo Benito, Guadalupe Torres, Ana Hospital, Carmen Bayón.

NR6-004

FACTORS AFFECTING MENTAL FITNESS FOR WORK IN A SAMPLE OF MENTALLY ILL PATIENTS

Yasser Elsayed M.D., Mohamed Al-Zahrani, PhD., Mahmoud Rashad, PhD

NR6-005

CHARACTERISTICS OF MENTALLY ILL OFFENDERS FROM 100 PSYCHIATRIC COURT REPORT

Yasser Elsayed M.D., Mohamed Al-Zahrani, PhD., Mahmoud Rashad, PhD

NR6-006

IS THE CRIMINAL JUSTICE SYSTEM GETTING IT RIGHT? A SIX MONTH RETROSPECTIVE STUDY OF COURT REQUESTED FORENSIC REPORTS IN THE REPUBLIC OF IRELAND

Grainne Flynn M.D., Conor O Neill, MD, MRCPsych

NR6-007

EEG ABNORMALITIES IN DIFFERENT TYPES OF CRIMINAL BEHAVIOR

Ilja Zukov M.D., Radek Ptacek, Ph.D., Slavomil Fischer, Ph.D., Jiri Raboch, Ph.D., Daniela Domluyilova, M.D., Petr Kozelek, M.D.

NR6-008

REDUCING AGGRESSIVE BEHAVIOR ON A CHILD DAY TREATMENT UNIT: THE DEVELOPMENT AND USE OF A COMMUNITY MEETING FOR CHILDREN

Melissa Greene Ph.D., Lisa Defelice, M.Ed., Kathleen Clarkson, M.S.W

NR6-009

DEEP BRAIN STIMULATION OF THE VENTRAL CAPSULE/VENTRAL STRIATUM FOR TREATMENT-RESISTANT DEPRESSION

Donald Malone M.D., Darin Dougherty, M.D., Ali Rezaei, M.D., Linda Carpenter, M.D., Gerhard Friehs, M.D., Emad Eskandar, M.D., Scott Rauch, M.D., Steven Rasmussen, M.D., Andre Machado, M.D., Cynthia Kubu, Ph.D., Audrey Tyrka, M.D. Ph.D., Lawrence Price, M.D., Paul Stypulkowski, Ph.D., Jonathon Giftakis, Ph.D., Mark Rise, Ph.D., Paul Malloy, Ph.D., Stephen Salloway, M.D. Ph.D., Benjamin Greenberg, Ph.D.

NR6-010

COMBINED USE OF ELECTROCONVULSIVE THERAPY AND PSYCHIATRIC MEDICATION IN PSYCHIATRIC DISORDERS

Omer Saatcioglu M.D., Murat Kalkan M.D., Esra Ugurlu M.D., Ertugrul Cekic M.D., Nesrin Tomruk M.D., Dogan Yesilbursa M.D.

NR6-011

0.5 MS PULSEWIDTH PREVENTS BASIC ECT SIDE EFFECTS, AND PROPOFOL INTERRUPTION DIMINISHES EVEN SUBTLE SIDE EFFECTS

Ronald Warnell M.D., Conrad M. Swartz, Ph.D., M.D., Alice Thomson, Ph.D.

NR6-012

ROLE OF ACUTE AND MAINTENANCE ECT IN CHRONIC PAIN: NEW CASE REPORTS AND CLINICAL LITERATURE REVIEW

Muhammad A. Abbas, M.D., Mitchell J.M. Cohen, M.D., John M. Balacius, M.D.

NR6-013

THE EFFECT OF MILNACIPRAN ON PAIN MODULATION IN FIBROMYALGIA: AN FMRI ANALYSIS

Ernest Choy M.D., Frank Petzke, M.D., Hanke Marcus, M.D., Karen Jensen, M.D., Eva Kosek, M.D., Martin Ingvar, M.D., Olivier Vitton, M.D., Yves Mainguy, M.D., Richard H. Gracely, Ph.D.

NR6-014

A DAY-TO-DAY ANALYSIS OF THE ANALGESIC EFFICACY OF MILNACIPRAN IN THE TREATMENT OF FIBROMYALGIA

R. Michael Gendreau M.D., Philip Mease, M.D., Robert H. Palmer, M.D., Ph.D., Yong Wang, Ph.D., Michael R. Hufford, Ph.D., Srinivas Rao, M.D., Ph.D.

NR6-015

EFFECT OF MILNACIPRAN ON FATIGUE AND COGNITIVE DYSFUNCTION IN FIBROMYALGIA PATIENTS

Alan Manevitz M.D., Kim Thacker, M.D., Joel Trugman, Ph.D., Srinivas G. Rao, M.D., Ph.D., Yong Wang, Ph.D.

NR6-016

EFFICACY OF MILNACIPRAN IN FIBROMYALGIA IS INDEPENDENT OF ANTIDEPRESSANT PROPERTIES: A EUROPEAN MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Michael Spaeth M.D., Jaime Branco, M.D., Bjorn Bragee, M.D., Olaf Zachrisson, M.D., Ph.D., Knut Mikkelsen, M.D., Luis De Teresa, M.D., Yves Mainguy, M.D.



NR6-017

MILNACIPRAN IMPROVES FUNCTIONING IN PATIENTS WITH FIBROMYALGIA (FM): RESULTS FROM A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Vibeke Strand M.D., David A. Williams, Ph.D., Daniel J. Clauw, M.D., Robert H. Palmer, M.D., Ph.D., R. Michael Gendreau, M.D., Ph.D., Rong Zablocki, Ph.D., Wei Chen, Ph.D.

NR6-018

POSTTRAUMATIC STRESS SYMPTOMS AFTER ADMISSION TO THE EMERGENCY ROOM FOR DELIBERATE SELF POISONING

Benjamin Bousquet, Bui Eric, M.D., Ladois Agnes, Cailhol Lionel, M.D., Schmitt Laurent, M.D., Arbus Christophe, M.D., Birnes Philippe, M.D., Ph.D.

NR6-019

THE EFFECTIVENESS OF “HOME TREATMENT” FOR THE ACUTELY MENTALLY ILL IN A RURAL CATCHMENT AREA IN SOUTHERN GERMANY

Karel Frasch M.D., Miriam Ott, Henriette Jahn, M.D., Annett Rauscher, Markus Jaeger, M.D., Thomas Becker, M.D., Reinhold Kilian, Ph.D.

NR6-020

PATIENT RELOCATION TO A NEW HOSPITAL: SOME CLINICAL PARAMETERS

David Mayerhoff M.D., Steven J. Schleifer, MD, Jeffrey R. Nurenberg, MD, Roland Limosnero, MD, Paresh Kasabwala, Psy.D.

NR6-021

A TWO-STATE ANALYSIS OF EMERGENCY DEPARTMENT UTILIZATION BY PERSONS WITH MENTAL HEALTH AND/OR SUBSTANCE ABUSE DISORDERS

Meera Narasimhan M.D., Elsie Freeman, Benjamin Druss, Joe Morrissey, Jeanne Rivard and John Magill

NR6-022

OPEN ACCESS TO ANTIPSYCHOTIC AND PRESCRIBING TRENDS AND QUALITY OF LIFE

Meera Narasimhan M.D., Robert Bank, John Magill

NR6-023

THE USE OF FILM PRODUCTION ABOUT MENTAL HEALTH ON REHABILITATION OF PATIENTS WITH CHRONIC PSYCHOSIS: WELL BEING AND QUALITY OF LIFE OF PARTICIPANTS

Mauro Giovanni Carta M.D., Enrico Pau, Giovanni Piras, Laura Pilitzu, Carlo Zuddas, Psy.D., Maria Carolina Hardoy, M.D., Ph.D.

NR6-024

THE PRACTICE OF RECOVERY: A DESCRIPTIVE ANALYSIS OF A COMMUNITY MENTAL HEALTH PROGRAM

Chih-Tao Cheng M.D., Leonard S. Miller, Ph.D., Sheng-Chang Wang M.D., M.Sc., Yi-Ling Chien M.D.

NR6-025

MENTAL HEALTH DISPARITIES AMONG ASIAN AMERICAN AND PACIFIC ISLANDERS IN CALIFORNIA: AN APPLICATION OF THE INSTITUTE OF MEDICINE HEALTH DISPARITY MODEL

Chih-Tao Cheng M.D., Diana D. McDonnell, Ph.D. Hyun-Ju Lee, B.A., Joel M. Moskowitz, Ph.D., Sheng-Chang Wang M.D., M.Sc., Yi-Ling Chien M.D.

NR6-026

PSYCHOSOCIAL REHABILITATION’S IMPACT ON THE NUMBER AND TOTAL LENGTH OF INPATIENTS’ ADMISSIONS

Tiago Rodrigues M.D., Rosa Quelhas, M.D., Joaquim Ramos, M.D.

NR6-027

PALIPERIDONE PALMITATE: CLINICAL RESPONSE IN SUBJECTS WITH SCHIZOPHRENIA WITH RECENT VS. LONGER-TERM DURATION OF ILLNESS

Larry Alphs M.D., Cynthia Bossie, Ph.D., Jennifer Kern-Sliwa, Pharm.D., B.C.P.P., Yi-Wen Ma, Ph.D., J. Thomas Haskins, Ph.D.

NR6-028

EVALUATING THE EFFECT OF DESVENLAFAXINE AND PAROXETINE ON THE CYP2D6-MEDIATED BIOTRANSFORMATION OF CODEINE TO MORPHINE

Susan Baird-Bellaire Ph.D., Stéphan Chalon, M.D., Ph.D, Jeffrey Paul, Ph.D, Alice Nichols, Ph.D

NR6-029

METFORMIN FOR BODY WEIGHT AND METABOLIC CONTROL IN PATIENTS WITH SCHIZOPHRENIA DURING LONG-TERM CLOZAPINE ADMINISTRATION

Trino Baptista M.D., Edgardo Carrizo, MD., Virginia Fernandez MD, Ignacio Sandia, MD, Lisette Connell, MSci., Dexy Prieto, MD., Dummys Valbuena, MSci., Iliana Fernández, MSci.

NR6-030

QUETIAPINE INDUCED PROLONGED QTC INTERVAL IN PREGNANCY

Smitha Battula, M.B.B.S., M.D., Mary L. Miller, M.D., Ph.D.

NR6-031

LEVETIRACETAM DECREASES CORTISOL REACTIVITY IN HEALTHY WOMEN

Linda Carpenter M.D., Aaron P. Tracy, B.A., Audrey R. Tyrka, M.D., Ph.D., Charles W. Wilkinson, Ph.D, Lawrence H. Price M.D.

NR6-032

RELATIONSHIP BETWEEN NEUROCOGNITION AND SYMPTOMS IMPROVEMENT WITH RISPERIDONE LONG-ACTING INJECTABLE

Rosa Catalan M.D., Penadés, R., Masana, G., Navarro, V., Guarch, J., Gastó, C

NR6-033

A PILOT STUDY OF DIFFERENTIAL EFFECTS OF DYSLIPIDEMIA ON NEURO-COGNITION WITH ATYPICAL ANTIPSYCHOTIC TREATMENT IN SCHIZOPHRENIA

Simon Chiu M.D., Zack Cernovsky PhD, Mariwan Husni MD, John Copen MD M.Sc., Jason Carr PhD



NR6-034

SUICIDE IN A PROSPECTIVE COHORT OF PATIENTS WITH SCHIZOPHRENIA TREATED WITH SERTINDOLE OR RISPERIDONE

Marc-Antoine Crocq M.D., Malcolm H. Lader, M.D., Aurélie Mittoux, Ph.D., Per Tanghøj, Ph.D., Florence Thibaut, M.D., Jozef Peuskens, M.D., Brian Everitt, Ph.D., Ronald Mann, M.D., Nicholas D. Moore, M.D., Dieter Naber, M.D.

NR6-035

EFFICACY AND SAFETY OF LURASIDONE IN PHASE 2/3 ACUTE SCHIZOPHRENIA TRIALS

Josephine Cucchiaro Ph.D., Antony Loebel, M.D., Robert Silva, Ph.D., Debra Philips, M.S., Masaaki Ogasa, M.S., Jane Xu, Ph.D.

NR6-036

LATE-DAY SUSTAINED PLASMA CONCENTRATIONS FOLLOWING ARMODAFINIL ADMINISTRATION

Mona Darwish, Ph.D., Mary Kirby, M.S., Edward T. Hellriegel, Ph.D.

NR6-037

ARMODAFINIL AND MODAFINIL HAVE SUBSTANTIALLY DIFFERENT PHARMACOKINETIC PROFILES DESPITE SIMILAR TERMINAL HALF-LIVES

Mona Darwish, Ph.D., Mary Kirby, M.S., Edward T. Hellriegel, Ph.D.

NR6-038

ARIPRAZOLE AUGMENTATION OF STANDARD TREATMENTS IN PATIENTS WITH RESISTANT OBSESSIVE COMPULSIVE DISORDER: A PILOT STUDY

Roberto Delle Chiaie M.D., Pierluigi Scarciglia, MD; Maria Caredda, MD; Massimo Pasquini MD and Massimo Biondi MD

NR6-039

AN OPEN-LABEL STUDY OF COMBINATION THERAPY WITH NALTREXONE SR + BUPROPION SR FOR NICOTINE DEPENDENCE IN OVERWEIGHT AND OBESE SUBJECTS

Eduardo Dunayevich M.D., Janelle Erickson, Ph.D., Charles Wilcox, Ph.D., Nader Oskooilar, M.D., Ph.D., Sonja K Billes, Ph.D.

NR6-040

TOLERABILITY AND ADHERENCE OF RISPERIDONE LONG ACTING INJECTABLE (RLAI) IN SEVERE SCHIZOPHRENIC PATIENTS

Juan Fernandez-Miranda M.D., Victoria Caramés-García, M.D., Arantxa Sánchez-García, M.D.

NR6-041

EFFECT OF ARIPIRAZOLE ADDITION TO ANTIPSYCHOTIC TREATMENT IN SCHIZOPHRENIC PATIENTS

Felix Gonzales M.D., Fabrice Duval, M.D., Marie-Claude Mokrani, Ph.D., Thanh Son Diep, M.D., Hassen Rabia, M.D.

NR6-042

DESVENLAFAXINE 50 MG/D IMPROVES FUNCTIONING AND QUALITY-OF-LIFE MEASURES IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

Christine Guico-Pabia M.D., Qin Jiang, M.S., Bruno Pitrosky, Ph.D., Karen A. Tourian, M.D.

NR6-043

ONDANSETRON AUGMENTATION IN TREATMENT RESISTANT OCD: A PRELIMINARY SINGLE-BLIND PROSPECTIVE STUDY

Eric Hollander M.D., Silvia Bernardi, M.D., Sarah Antonini, M.D., Nikhilesh Singh, Ph.D., Stefano Pallanti, M.D., Ph.D.

NR6-044

RECEPTOR BINDING PROFILE OF LURASIDONE: A NOVEL PSYCHOTROPIC AGENT UNDER DEVELOPMENT FOR SCHIZOPHRENIA AND BIPOLAR DISORDER

Tomoko Horisawa B.S., Kumiko Tokuda, B.S., Tadashi Ishibashi, Ph.D.

NR6-045

ANTIPSYCHOTIC-RELATED DIABETES MAY BE REVERSIBLE IF TREATED EARLY: TWO-YEAR CASE SERIES WITH ONE-YEAR FOLLOW-UP

Shang-Chien Huang M.D., Hsiang-Hsiung Huang, M.D., Hsiang-Ping Huang, M.S.N., Bing-Wen Soong, M.D., Ph.D.

NR6-046

THE EFFICACY OF QUETIAPINE IN PATIENTS WITH BIPOLAR DEPRESSION: A MULTI-CENTER, PROSPECTIVE, OPEN-LABEL, OBSERVATIONAL STUDY (QUEEN STUDY)

Jong-Hyun Jeong M.D., Won-Myong Bahk, M.D., Chan Hyung Kim, M.D., Young Sup Woo, M.D., Ho-Jun Seo, M.D., Duk-In Jon, M.D., Hyun-Sang Cho, M.D., So Young Yoo, M.D., Kyung Joon Min, M.D., Bo-Hyun Yoon, M.D.

NR6-047

ASSESSMENT OF SUBJECTIVE QUALITY OF LIFE IN STABLE SCHIZOPHRENIC PATIENTS AFTER SWITCHING ATYPICAL ANTIPSYCHOTICS

Song Jin Ok M.D., Lee JH, Psy.D., Lee SJ, Psy.D.

NR6-048

A PRACTICAL, RANDOMIZED COMPARISON OF THE EFFECTIVENESS OF RISPERIDONE, OLANZAPINE, QUETIAPINE, AND ZIPRASIDONE

Erik Johnsen M.D., Rune A. Kroken, M.D., Tore Wentzel-Larsen, Hugo A. Jørgensen, M.D., Ph.D.

NR6-049

A RANDOMIZED CONTROLLED, PILOT STUDY OF ZIPRASIDONE IN THE TREATMENT OF DELIRIUM

Sung Won Jung M.D., Kyung Sik Kim, M.D.

NR6-050

ASSESSING THE PHARMACOKINETICS OF VENLAFAXINE ER 75 MG AND DESVENLAFAXINE 50 MG IN CYP2D6 EXTENSIVE AND POOR METABOLIZERS

Cecelia Kane M.D., Alice Nichols, Ph.D., Kristin Focht, M.B.A., Qin Jiang, Sheldon Preskorn, M.D.

NR6-051

NEW COST-EFFECTIVE HPLC/UV-SYSTEM FOR THERAPEUTIC DRUG MONITORING OF ANTIDEMENTIA DRUGS IN MEDICAL ROUTINE ANALYSIS SHOWN BY THE EXAMPLE OF MEMANTINE

Ralf Koeber, Hans-Hermann Klauenemann, Reinhold Waimer, Sandra Beck, Tatjana Jahner, Doris Melchner, Ekkehard Haen



NR6-052

ONCE-DAILY TRAZODONE: OVERVIEW OF PHARMACOKINETIC PROPERTIES

William Kramer Ph.D., Caroline Fradette, Ph.D., Claire Brullé, M.D., Arnelle Mostert, MBChB, Tanja Cronjé, MBChB, David Karhu, B.Sc.

NR6-053

ANTIPSYCHOTIC TREATMENT OF SCHIZOPHRENIA IN NORWEGIAN EMERGENCY WARDS

Rune Kroken M.D., Erik Johnsen, M.D., Torleif Ruud, M.D., Tore Wentzel-Larsen, Hugo A. Jørgensen, M.D., Ph.D.

NR6-054

A POSITIVE ASSOCIATION BETWEEN SERUM PROLACTIN LEVEL AND PSYCHOPATHOLOGY AMONG PEOPLE WITH SCHIZOPHRENIA IN 3-MONTH ARIPIRAZOLE TREATMENT

Tsuo-Hung Lan M.D., Chin Cheng, MD, Hsien-Jane Chiu, MD, Ph.D., Yu-Chuan Wu, Bo-Jian Wu, MD, M.S., Chin-Hong Chan, MD, eMBA

NR6-055

ZIPRASIDONE AUGMENTATION OF CLOZAPINE IN REFRACTORY SCHIZOPHRENIA

Hwang Bin Lee M.D., Joon-Noh Lee, MD; Minyoung Sim, MD; Seon-jin Yim, MD; Keum-Hee Ok, MD

NR6-056

AN EXPLORATORY STUDY ON THE CLINICAL USAGE OF AMISULPRIDE IN A PSYCHIATRIC HOSPITAL IN TAIWAN

Shih-Ku Lin M.D., Yen-Feng Lin, M.D.

NR6-057

NATURALISTIC USE OF THE CONVENTIONAL COATED AND ORALLY DISINTEGRATING TABLETS OF OLANZAPINE IN SCHIZOPHRENIC AND BIPOLAR OUTPATIENTS (EUROPEAN COHORT)

Michael Lukasiewicz, M.D., Florence Chartier, M.D., Catherine Beal, Stephanie Tcherny-Levy, M.D., Susanne Kraemer, M.D., Vassiliki Psarra, M.D., Frederic Rouillon, Ph.D. ZEN investigators group

NR6-058

HYPERGLYCEMIA IN ASIAN PATIENTS TREATED WITH SECOND GENERATION ANTIPSYCHOTICS

Rathi Mahendran M.B.B.S, Margaret Hendricks, BSc.

NR6-059

LURASIDONE IS ASSOCIATED WITH ANXIOLYTIC AND ANTIDEPRESSANT EFFECTS IN RODENT MODELS

Yuji Matsumoto M.S., Kenji Matsumoto, B.S., Tomoko Horisawa, B.S., Kazuki Yabuuchi, Ph.D., Tadashi Ishibashi, Ph.D.

NR6-060

VALPROIC ACID AND THE INCIDENCE OF FALLS IN AN INPATIENT SETTING

Harlan Mellk M.D., Jeffrey R. Nurenberg, M.D., David I. Mayerhoff, M.D., Milton Luria, M.D., Steven J. Schleifer, M.D.

NR6-061

TO ENHANCE TOLERABILITY, PHYSICIANS TREATING MAJOR DEPRESSIVE DISORDER TYPICALLY INITIATE SNRI TREATMENT AT A SUB-THERAPEUTIC DOSAGE BEFORE TITRATI

Jeff Musgnung, Christine C. Quico-Pabia, M.D. M.B.A., M.P.H., Michael Foisy

NR6-062

LURASIDONE IN THE TREATMENT OF ACUTE SCHIZOPHRENIA: A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Mitsutaka Nakamura Ph.D., Masaaki Ogasa, M.S. John Guarino, Ph.D., Debra Philips, A.S., Joseph Severs, M.S., Josephine Cucchiaro, Ph.D., Antony Loebel, M.D.

NR6-063

REDUCED EPS RISK WITH LURASIDONE, A NOVEL PSYCHOTROPIC AGENT UNDER DEVELOPMENT FOR SCHIZOPHRENIA AND BIPOLAR DISORDER

Hiroyuki Nishikawa Ph.D., Kumiko Tokuda, B.S., Kenji Matsumoto, B.S., Yoko Ueda, B.S., Tadashi Ishibashi, Ph.D.

NR6-064

EFFECT OF LURASIDONE ON DEPRESSIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA

Masaaki Ogasa M.S., Antony Loebel, M.D., Josephine Cucchiaro, Ph.D., Joseph Severs, M.S., Mitsutaka Nakamura, Ph.D., John Guarino, Ph.D.

NR6-065

PREGABALIN AUGMENTATION OF ANTIDEPRESSANTS IN PATIENTS WITH ACCIDENT-RELATED POSTTRAUMATIC STRESS DISORDER: AN OPEN LABEL PILOT STUDY

Chi-Un Pae M.D., David M. Marks, M.D., Ashwin A. Patkar, M.D., Prakash S. Masand, M.D.

NR6-066

TESTING ANXIOUS DEPRESSION AS A PREDICTOR AND MODERATOR OF SYMPTOM IMPROVEMENT IN MAJOR DEPRESSIVE DISORDER

George Papakostas M.D., George I. Papakostas, M.D., Klaus Larsen, Ph.D, M.Sc.

NR6-067

A DOUBLE-BLIND COMPARISON OF THE SAFETY AND EFFICACY OF LURASIDONE AND ZIPRASIDONE IN STABLE OUTPATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDE

Steven Potkin M.D., Josephine Cucchiaro, Ph.D., Masaaki Ogasa, M.S., Antony Loebel, M.D.

NR6-068

CHANGE OF METABOLIC PARAMETERS DURING PSYCHIATRIC INPATIENT TREATMENT: A PROSPECTIVE NATURALISTIC STUDY

Hans Rittmannsberger M.D., Christian Foff, M.D., Robert Frühwirth, M.D., Hildegard Lindner, M.D., Rosa Mayr, M.D., Vera Pihurik, M.D. Thomas Zaunmüller M.D.

NR6-069

ATYPICAL ANTIPSYCHOTIC METABOLISM/ BIOTRANSFORMATION AND EXCRETION

John Sheehan R.Ph., Jennifer Kern-Sliwa, Pharm.D., B.C.P.P., Augusto Grinspan, M.D., Joan C. Amatriek, M.D., Carla M. Canuso, M.D.

NR6-070

A MULTI-SITE, OPEN-LABEL, RANDOMISED, HALOPERIDOL-CONTROLLED STUDY TO EVALUATE QUETIAPINE AS MONOTHERAPY IN THE TREATMENT OF AGITATED ACUTE SCHIZOPHRENIA

Tianmei Si, Huang Ji Zhong, MD, Su Yun' Ai, MD, PhD, Tang Mao Qin, MD, Li Ke Qing, MD, Yang Pu De, MD, Shu Liang, MD.

WITHDRAWN



NR6-071

EFFICACY, SAFETY, AND TOLERABILITY OF DESVENLAFAXINE 50 MG/D IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

Karen Tourian M.D., James Groark, M.D., Claudine Brisard, M.D., Qin Jiang, M.S., Bruno Pitrosky, Ph.D., Michael R. Liebowitz, M.D.

NR6-072

MEDICATION ACCESS/CONTINUITY PROBLEMS AND SUICIDAL IDEATION AND BEHAVIOR AMONG DUAL ELIGIBLE PSYCHIATRIC PATIENTS UNDER MEDICARE PART D

Joyce West Ph.D., Joshua E. Wilk, Ph.D., Eve Moscicki, Ph.D., Donald S. Rae, M.S., Maritza Rubio Stipic, Sc.D., Darrel A. Regier, M.D., M.P.H.

NR6-073

DO TRAMADOL AND DOPAMINE-BLOCKING AGENTS ENHANCE THE RISK OF MIRTAZAPINE-ASSOCIATED RESTLESS LEGS SYNDROME?

Jin-Sang Yoon M.D., Sung-Wan Kim, M.D., Yo-Han Lee, M.D., Il-Seon Shin, M.D., Jae-Min Kim, M.D., Tak Youn, M.D., Jun-Young Cho, M.D., Yong-Hwan Kim, M.D., Jeong-Hoon Lee, M.D.

NR6-074

MILD COGNITIVE DISORDER AND DEPRESSION: TREATMENT WITH ASSOCIATION BETWEEN GALANTAMINE AND ESCITALOPRAM

Julio Zarra, Schmidt Luisa, MD

NR6-075

PREVALENCE OF DEPRESSION AND ANXIETY IN PERITONEAL DIALYSIS PATIENTS AND POSSIBLE CORRELATIONS WITH MORTALITY AND MORBIDITY

Sinem Gonenli M.D., Oguz K. Karamustafalioglu, M.D., Abdulkadir Unsal M.D.

NR6-076

PARENTAL QUALITY OF LIFE AND DISTRESS IN X-LINKED MUSCULAR DYSTROPHY

Hwang Jun Won M.D., Seung Ug Yoon, M.D., Sung Jong Park, M.D., Hong Sup Yoo, M.D., Soo Churl Cho, M.D., Ph.D., Jong Hee Chae, M.D., Ph.D., Bong Jin Hahm, M.D., Ph.D., Hong Jin Jeon, M.D., Ph.D.

NR6-077

THE PREVALENCE OF ANXIETY AND IMPACT OF UNRECOGNIZED ANXIETY ON HEALTH-RELATED QUALITY OF LIFE IN KOREAN PATIENTS WITH FUNCTIONAL DYSPEPSIA

Sang-Yeol Lee Psy.D., Duk-In Jon, MD, Ph.D., Bo-Hyun Yoon, MD, Ph.D., Young Chul Schi, MD, Ph.D., Kyung Joon Min, MD, Ph.D., Won-Myong Bahk, MD, Ph.D.

NR6-078

EFFECT OF MINDFULNESS BASED GROUP PSYCHOTHERAPY ON DEPRESSION, QUALITY OF LIFE AND HEART RATE VARIABILITY IN PATIENTS WITH BREAST CANCER

Sang-Yeol Lee Psy.D., Min-Cheol Park, MD, Ph.D., In-Sook Kim, Ph.D., Young-Hoon Cheon, MD.

NR6-079

PSYCHOLOGICAL CHARACTERISTICS AND COPING STYLE IN HOSPITALIZED PNEUMOCONIOSIS PATIENTS

Sae-Han Park M.D., Joung-Sook Ahn, M.D., Ph.D.

NR6-080

COMMUNITY INTEGRATION AND ASSOCIATED FACTORS AMONG OLDER ADULTS WITH SCHIZOPHRENIA

Chadi Abdallah M.D., Carl I. Cohen, M.D., Miguel Sanchez-Almira, M.D., Pia Reyes, M.D., Paul M. Ramirez, Ph.D.

NR6-081

A FACTOR ANALYSIS OF DIFFERENT TEMPERAMENT DOMAINS IN A BORDER REGION IN RURAL SOUTHERN CALIFORNIA

Alvaro Camacho M.D., Alan N. Simmons, Ph.D., Bernardo Ng, M.D., Scott C. Matthews, M.D., Hagop S. Akiskal, M.D.

NR6-082

THE EFFECTIVENESS OF SUICIDE PREVENTION PROGRAM IN A TAIWAN METROPOLITAN CITY

Frank Huang-Chih Chou, Psy.D., Wei-Jen Chen, Psy.D., Cheng-Chung Chen, Psy.D., Ph.D., Chi-Kung Ho, M.D., Ming-Hui Kuo, M.S., Chao-Yueh Su, M.S., Ming-Bing Lee, Psy.D.

NR6-083

THE RELATIONSHIP AMONG SCHIZOPHRENIA CAREGIVERS' BURDEN, QUALITY OF LIFE AND SCHIZOPHRENIA SYMPTOM SEVERITY IN TAIWAN

Frank Huang-Chih Chou, Chao-Yueh Su, M.S., Ming-Hui Kuo, M.S., Frank Huang-Chih, Psy.D., Ph.D. Shih-Pei Shen, Li-Hsing Chang, M.S., Shih-Shih Chao, M.S.

NR6-084

THE EFFECTIVENESS OF THE CRISIS INTERVENTION TRAINING (CIT) PROGRAM ON OFFICER EFFECTIVENESS AND BURNOUT

Shah Jalees M.D., Mark R. Munetz, MD., Jennifer L.S. Teller, Ph.D., Karen M. Gil, Ph.D.

NR6-085

THE VARIABLES AFFECTING THE JUDGMENT FOR CONTINUING HOSPITALIZATION IN PATIENTS WITH MENTALLY ILL IN KOREA

Min-Cheol Park M.D., San-Su Lee, M.D., Chong-Il Park, Hyo-Sun Ko, M.D., Yong-Hoon Shon, M.D.

NR6-086

PROJECT ANTI-BULLY: BULLYING IN MIDDLE SCHOOLS YEAR TWO SURVEY

Fabianna Pergolizzi, Darren Richmond, Joseph Pergolizzi, M.D., and the Project Anti Bully Study Group

NR6-087

COMPARISON OF PERSONALITY DIMENSIONS IN BODY DYSMORPHIC DISORDER AND OBSESSIVE-COMPULSIVE DISORDER

Megan Kelly Ph.D., Nicole C. McLaughlin, Ph.D., Benjamin D. Greenberg, M.D., Ph.D., Katharine A. Phillips, M.D.

NR6-088

PHYSICAL FUNCTIONING AND PHYSICAL HEALTH-RELATED QUALITY OF LIFE IN BODY DYSMORPHIC DISORDER

Katharine Phillips M.D., Megan M. Kelly, Ph.D., William Menard, B.A.



NR6-089

EYE-TO-EYE TELEPSYCHIATRY: UNLOCKING THE GOAL OF SPECIALIST PSYCHIATRIC TREATMENT ON A BROADER BASIS, TO A CHEAPER COST

Agneta Ekman M.D.

NR6-098

PRELIMINARY RESULT OF A PILOT STUDY ON RTMS TREATMENT OF BIPOLAR DEPRESSION

Guohua Xia M.D., Cameron S. Carter, M.D., Donald M. Hilty, M.D., David Whitney, PhD, Robert E. Hales, M.D., M.B.A.

NR6-090

RESEARCH ASSESSMENT OF DEPRESSION DIAGNOSIS AND SEVERITY: COMPARABILITY OF TELEPHONE AND IN-PERSON INTERVIEW

William Yavorsky Ph.D., Janet B.W. Williams, D.S.W.

NR6-099

EFFICACY OF QUETIAPINE IN ACUTE BIPOLAR I OR II DEPRESSION: A KOREAN MULTI-CENTER, PROSPECTIVE, OPEN-LABEL, 8 WEEKS OBSERVATIONAL STUDY

Bo-Hyun Yoon M.D., Won-Myong Bahk, M.D.,Ph.D., Duk-In Jon, M.D.,Ph.D., Myung-Kyu Kim,M.D.,Ph.D., Sang-Yol Lee,M.D.,Ph.D., Sang-Keun Chung, M.D.,Ph.D.

NR6-091

FREQUENCY AND PREDICTORS OF LAMOTRIGINE-RELATED SERIOUS RASH AND INFLAMMATORY REACTIONS: SYSTEMATIC REVIEW AND META-ANALYSIS

Laura Caldwell B.A., SN Ghaemi, M.D., M.P.H.

NR6-100

EFFECT OF QUETIAPINE ON THE SUBJECTIVE ESTIMATES OF SLEEP IN THE 8 WEEKS TREATMENT OF ACUTE BIPOLAR DEPRESSION

Bo-Hyun Yoon M.D., Won-Myong Bahk, M.D.,Ph.D., Duk-In Jon, M.D.,Ph.D., Myung-Kyu Kim, M.D.,Ph.D., Sang-Yol Lee, M.D.,Ph.D., Sang-Keun Chung, M.D.,Ph.D.

NR6-092

THE ROLE OF PATIENT ATTACHMENT STYLE IN PREDICTING TREATMENT RETENTION AND OUTCOME IN SHORT-TERM PSYCHOTHERAPY

Nivea Calico M.D., Arnold Winston, M.D., Catherine Eubanks-Carter, Ph.D.

NR6-093

TREATMENT PATTERNS BY RACE/ETHNICITY AND HOUSEHOLD INCOME AMONG ATTENTION-DEFICIT HYPERACTIVITY DISORDER SUBJECTS TREATED WITH STIMULANTS

Laura Christensen M.S., Heather Aeder, M.A., Rahul Sasané, Ph.D., Carolyn Harley, Ph.D., Paul Hodgkins, Ph.D.

NR6-094

CLINICAL PATHWAYS FOR PSYCHIATRIC PATIENT CARE: STAFF OPINIONS AND CLINICAL OUTCOMES IN A TERTIARY PSYCHIATRIC HOSPITAL

Margaret Hendriks B.S.N., Rathi Mahendran, MBBS.,MMed(Psych),FAMS

NR6-095

BURDEN OF ILLNESS AND COMORBIDITIES IN ADULT PATIENTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER COMPARED TO PATIENTS WITH DEPRESSION

Rahul Sasané, Ph.D., Leslie Montejano, B.A., Paul Hodgkins, Ph.D., Dan Huse, M.A.

NR6-096

PERSONALITY DISORDER AND TREATMENT OUTCOME IN PATIENTS WITH UNIPOLAR DEPRESSION

Theresa Unger, Sabine Hoffmann, Stephan Koehler, Barbara Ross, MD., Arthur Mackert, Prof., Thomas Fydrich, Prof.

NR6-097

INCIDENCE OF METABOLIC SYNDROME AND RESPONSE TO METFORMIN TREATMENT IN PATIENTS ON ASSERTIVE COMMUNITY TREATMENT TEAMS

Caroline Williams M.D., David Lindy, M.D., Doreen Wall, R.N., MacDara O'Sullivan, MSW.



Wednesday, May 20, 2009

**3:00 p.m. - 5:00 p.m.
Hall D, Exhibit Level,
Moscone Convention Center**

New Research Poster Session 7

NR7-001

NEUROBIOLOGICAL CHANGES AFTER 40 DAYS OF FASTING: SELF-RESTRAINT AS A COGNITIVE BEHAVIORAL THERAPEUTIC MODALITY

Tunku-A.R. Ben Abubakar M.D.

NR7-002

MICROMETER SIZED THREADLIKE AND/OR SPHERICAL PARTICLES IN CEREBROSPINAL FLUID (CSF) OF PATIENTS WITH BIPOLAR DISORDERS

Ullvi Båve M.D., Rolf Nybom, Mikael Landén, M.D. Ph.D., Lennart Wetterberg, M.D. Ph.D.

NR7-003

LEFT-RIGHT INFORMATION TRANSMISSION ASSESSED FROM BILATERAL ELECTRODERMAL ACTIVITY REFLECTS LEVEL OF HYPNOTIC EXPERIENCE

Petr Bob Ph.D., Marek Susta, Ph.D.

NR7-004

STRESS, LIMBIC IRRITABILITY AND CHAOTIC PATTERNS OF HEART RATE DYNAMICS IN PATIENTS WITH UNIPOLAR DEPRESSION

Petr Bob Ph.D., Marek Susta, Ph.D.

NR7-005

INHALED LOXAPINE RAPIDLY IMPROVES ACUTE AGITATION IN SCHIZOPHRENIC PATIENTS

James Cassella Ph.D., Dan Spyker, PhD,MD, Robert Fishman, MD

NR7-006

INHALED LOXAPINE RAPIDLY IMPROVES ACUTE AGITATION IN PATIENTS WITH BIPOLAR DISORDER

Robert Fishman M.D., Daniel A. Spyker, Ph.D. M.D., James V. Cassella, Ph.D.

NR7-007

THE EFFECT OF IMAGERY OF WORD ON PRIMING EFFECT: A FMRI STUDY

Bumseok Jeong, Jeewook Choi, M.D., Ph.D., Ji-Woong Kim, M.D., Ph.D.

NR7-008

ABNORMAL CORTICAL EXCITABILITY IN OBSESSIVE-COMPULSIVE DISORDER

Jee In Kang, Deog-Young Kim, M.D., Kee Namkoong, Psy.D., Chan-Hyung Kim, Psy.D., Min Joon, M.D., Se Joo Kim, Psy.D.

NR7-009

COMMON EFFECT OF ANTIPSYCHOTICS ON BIOSYNTHESIS AND REGULATION OF FATTY ACIDS AND CHOLESTEROL SUPPORTS A ROLE OF LIPID HOMEOSTASIS IN SCHIZOPHRENIA

Christian Lavedan Ph.D., Simona Volpi, Ph.D., Louis Licamele, M.S., Shruti N. Mitkus, Ph.D., Kendra Mack, M.S., Andrew Thompson, B.S., Mihael H. Polymeropoulos, M.D.

NR7-010

ASSOCIATION OF ARACHIDONATE 12-LIPOXYGENASE (ALOX12) GENE AND SCHIZOPHRENIA IN KOREAN POPULATION

Jaemin Lee M.D., Jiyoung Song, Ph.D., M.D., Ahrang Cho, Ph.D., M.D., Woojae Kim M.D., Tae Kim M.D.

NR7-011

THE NON-PHARMACOLOGICAL THERAPIES IN PSYCHIATRIC RESIDENCY TRAINING PROGRAMS IN KOREA IN 2008

Jae-jin Lee, SJ Moon, M.D., GH Bahn, M.D., Ph.D.

NR7-012

EMOTIONAL AND COGNITIVE EFFECTS OF DEEP BRAIN STIMULATION FOR TREATMENT RESISTANT DEPRESSION

Mircea Polosan M.D., Lhommée E, Wauquiez G, Chabardes S, M.D., Ph.D., Seigneuret E, M.D., Benabid AL; M.D., Ph.D., Bougerol T, M.D., Ph.D.

NR7-013

IL-6, DEPRESSION AND TRAUMATIC STRESS

Jiri Raboch M.D., Petr Bob, Ph.D.

NR7-014

MULTIANALYTE BIOMARKER BLOOD TEST TO AID IN DIAGNOSIS, TREATMENT AND MANAGEMENT OF MAJOR DEPRESSIVE DISORDER

Perry Renshaw, MD, PhD; John Bilello, PhD, Bo Pi, PhD; John Bilello, PhD

NR7-015

EFFECTS OF PHOSPHODIESTERASE TYPE-5 INHIBITOR, TADALAFIL ON APOPTOTIC NEURONAL CELL DEATH AND CELL PROLIFERATION IN MATERNAL-SEPARATED RAT PUPS

Baek Sang-Bin M.D., Geon-ho Bahn, M.D., Ph.D., Chang-Ju Kim, M.D., Ph.D., Mal-Soon Shin, Ph.D.

NR7-016

OXIDATIVE STRESS AND COGNITIVE ABILITY IN ADULTS WITH DOWN SYNDROME

Andre Strydom, Ph.D., Mark Dickinson, MRCPsych, Sima Shende, MD, Domenico Pratico, Ph.D., Zuzana Walker, Ph.D.

NR7-017

THYROID HORMONE LEVELS AND GOITRE IN ACUTE PSYCHIATRIC IN-PATIENTS

Taner Tosun, Nesrin Tomruk, M.D., Timucin Oral, M.D., Nihat Alpay, M.D.



NR7-018

POSITIVE CORRELATION BETWEEN BLOOD S100B PROTEIN AND CLOZAPINE CONCENTRATION IN SCHIZOPHRENIC PATIENTS

Sheng-Chang Wang M.D., Yu-Li Liu, Ph.D., Yu-Ping Su, M.D., Shi-Chin Guo, M.D., Keh-Ming Lin, M.D., M.P.H.

NR7-019

ASSESSMENT OF CEREBRAL REGIONS ASSOCIATED WITH SEXUAL AROUSAL IN DEPRESSIVE MALES BEFORE AND AFTER ANTIDEPRESSANT TREATMENT USING BOLD-FMRI

Jong-Chul Yang M.D., Sang K. Chung, M.D., Hyeon Jeong, M.D., Soon-Ah Kang, M.A., Seog-Ju Kim, M.D., Sung-Jong Eun, Ph.D., Gwang-Woo Jeong, Ph.D.

NR7-020

LU AA21004: EFFICACY AT LOW SEROTONIN TRANSPORTER OCCUPANCY AT CLINICALLY EFFECTIVE DOSES - FROM ANIMAL STUDIES TO DEPRESSED PATIENTS

Johan Areberg Ph.D., Marianne Dragheim, M.D., Lise Brennum, M.Sc., Tine B. Stensbøl Ph.D., Arne Mørk, Ph.D.

NR7-021

LIMBIC AND CORPUS CALLOSUM ABERRATIONS IN ADOLESCENTS WITH BIPOLAR DISORDER: A TRACT-BASED SPATIAL STATISTICS ANALYSIS

Naama Barnea-Goraly M.D., Naama Barnea-Goraly, M.D., Kiki D. Chang, M.D., Asya Karchemmskiy, M.S., Meghan E. Howe, M.S.W., Allan L. Reiss, M.D.

NR7-022

DULOXETINE MODULATES PAIN-RELATED BRAIN RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

Narcís Cardoner M.D., Marina López-Solá, Ph.D., Jesús Pujol, M.D., Rosa Hernández-Ribas, M.D., Joan Deus, Ph.D., Hector Ortiz, Laura López-Araquistain, M.D., Erica Martínez-Amorós, M.D., Carles Soriano-Mas, Ph.D., Jose M. Menchón, M.D., Ben J. Harrison, Ph.D.

NR7-023

FUNCTIONAL NEUROIMAGING EVIDENCE AND NEUROANATOMICAL MECHANISM FOR THE DISSOCIATION OF CONSCIOUS AND UNCONSCIOUS MEMORY

Sang-Keun Chung M.D., Jong C. Yang, M.D., Hyeon Jeong, M.D., Soon A. Kang, M.A., Seog J. Kim, M.D., Sung J. Eun, Ph.D., Gwang W. Jeong, Ph.D.

NR7-024

ALTERED HIPPOCAMPAL FUNCTIONAL CONNECTIVITY LINKS DEPRESSIVE SYMPTOMS AND MEMORY DEFICITS IN AMNESTIC MILD COGNITIVE IMPAIRMENT

Joseph Goveas M.D., Chunming Xie, M.D., Wenjun Li, B.S., Zhilin Wu, Ph.D., Jennifer L. Jones, M.S., Piero G. Antuono, M.D., Shi-Jiang Li, Ph.D.

NR7-025

DECLARATIVE LONG-TERM MEMORY NETWORK IN EARLY ALZHEIMER'S DISEASE

Shirin Meyer, Thomas Brauer, M.D., Markus Donix, M.D., Katrin Poettrich, Ph.D., Annett Werner, Ph.D., Ruediger Von Kummer, M.D., Vjera A. Holthoff, M.D.

NR7-026

MAGNETIC RESONANCE IMAGING AND MAGNETIC RESONANCE SPECTROSCOPY IN DOWN'S SYNDROME

Diane Mullins M.D., Melissa Lamar, Ph.D., Eileen Daly, B.Sc., Andy Simmons Ph.D., Kieran C. Murphy, M.D., Ph.D., Declan G. Murphy, M.D.

NR7-027

A PET SCAN STUDY OF OLANZAPINE TREATMENT IN BORDERLINE PERSONALITY DISORDER

S. Charles Schulz M.D., Jose V. Pardo, Ann Romine, Jazmin Camchong, Kelvin O. Lim

NR7-028

THE EFFECT OF YOGA AND WALKING ON BRAIN GABA LEVELS

Chris C. Streeter, M.D., Theodore H. Whitfield, Sc.D., Robert B. Saper, M.D., M.P.H., Liz Owen, B.A., Nancy Turnquist, M.A., Maria Gensler, Aleksandra Yakhkind, B.A., Surya K. Karri, M.D., M.P.H., Andrew P. Prescott, Ph.D., J. Eric Jensen, Ph.D.

NR7-029

CREATIVITY INDUCED BY DOPAMINE AGONISTS IN PARKINSON'S DISEASE

Eugénie Lhomme, M.A., Alina Batir, M.D., Claire Ardouin, M.A., Valérie Fraix M.D., Eric Seigneuret M.D., Stephan Chabardes M.D., Alim-Louis Benabid M.D., Pierre Pollak M.D., Paul Krack M.D.

NR7-030

THE EFFECT OF SPONTANEOUS CREATIVE EXPRESSION ON ANXIETY AND DEPRESSION IN PSYCHIATRIC INPATIENTS

Joanna MacLean, Gabor Keitner, M.D.

NR7-031

ASSESSMENT OF VERIFIABLE OBSERVABLE EVIDENCE OF ANXIETY IS INHIBITED BY PSYCHIATRY RESIDENCY TRAINING

Conrad Swartz M.D.

NR7-032

DISSOCIATIVE CATATONIA: CLINICAL PRESENTATION AND RESPONSE TO BENZODIAZEPINES

Joseph Lee M.D.

NR7-033

IMPACT OF SUBSTANCE USE DISORDER ON THE OCCURRENCE OF OTHER MENTAL DISORDERS

Sung Man Chang, Maeng Je Cho, M.D., Ph.D., Jin-Yeong Kim, M.D., Ph.D., Jun-Young Lee, M.D., Ph.D., Hong Jin Jeon, M.D., Ph.D., Bong-Jin Hahm, M.D., Ph.D., Seong-Jin Cho, M.D., Ph.D., Hae Woo Lee, M.D., Jae-Nam Bae, M.D., Ph.D., Yanghyun Lee, M.D., Ph.D.

NR7-034

NEGATIVE ATTITUDES TOWARD HELP SEEKING FOR MENTAL ILLNESS IN TWO POPULATION-BASED SURVEYS FROM THE UNITED STATES AND CANADA

Amit Jagdeo M.D., Sareen J., M.D., Cox B.J., Ph.D., Stein M.B., M.D.



NR7-035

LIFETIME PREVALENCE AND RISK FACTORS OF SUICIDAL IDEATION, PLAN, SINGLE, AND MULTIPLE ATTEMPTS IN A NATIONWIDE SAMPLE OF KOREA

Hong Jin Jeon, M.D., Ph.D., Jun-Young Lee, M.D., Ph.D., Bong-Jin Hahm, M.D., Ph.D., Jin Pyo Hong, M.D., Ph.D., Jae Nam Bae, M.D., Ph.D., Seong-Jin Cho, M.D., Ph.D., Hae Woo Lee, M.D., Maeng Je Cho, M.D., Ph.D.

NR7-036

PREVALENCE, COMORBIDITIES, AND QUALITY OF LIFE IN KOREAN ADULTS WITH INTERNET ADDICTION

Hae Woo Lee, M.D., Bong-Jin Hahm, M.D., Jae Nam Bae, M.D., Dong Woo Lee, M.D., Seong In Cho, M.D., Jong Ik Park, M.D., Sung Man Jang, M.D., Jun-Young Lee, M.D., Sang Bin Baek, M.D., Maeng Je Cho, M.D.

NR7-037

PARENTAL AGE AT BIRTH: CONTRIBUTION TO PSYCHOPATHOLOGY

Jorge Lopez-Castroman M.D., Hilario Blasco-Fontecilla, M.D., Ph.D., David Delgado-Gomez, Ignacio Basurte Villamor, M.D., Ph.D., Antonio Artes, Maria A. Oquendo, M.D., Ph.D., Marta Reyes-Torres M, M.D., Enrique Baca-Garcia, M.D., Ph.D.

NR7-038

THE PREVALENCE OF PSYCHIATRIC DISORDERS IN PRIMARY CARE IN CHILE

Benjamin Vicente M.D., Robert Kohn, M.D.; Sandra Saldivia, Ph.D.

NR7-039

NO ASSOCIATION BETWEEN THE SEROTONIN TRANSPORTER GENE REGULATORY REGION POLYMORPHISM (5-HTTLPR) AND PERSONALITY TRAITS AND PERSONALITY TYPE

Ik-Seung Chee M.D., Ik-Seung Chee, M.D., Ph.D., Daesa-Dong, Jung-Gu, Daejeon; MK Lee, M.D., JI Kim, M.D., Ph.D., SK Wang, M.D., Ph.D., HJ Kim, M.D.

NR7-040

INTERACTIONS OF SEROTONIN-RELATED GENES WITH SHORT-TERM ANTIDEPRESSANT RESPONSE IN MAJOR DEPRESSIVE DISORDERS

Po See Chen, M.D., Ph.D., Eugene Lin, Ph.D., Hui Hua Chang, M.S., Po-Wu Gean, Ph.D., Hsin Chun Tsai, M.D.

NR7-041

THE INFLUENCE OF CHILDHOOD TRAUMA, GABRA2 AND THEIR INTERACTION ON ALCOHOL, HEROIN AND COCAINE DEPENDENCE IN AFRICAN AMERICAN MEN

Mary-Anne Enoch M.A., Colin A. Hodgkinson, Ph.D., Qiaoping Yuan, Ph.D., Pei-Hong Shen, M.S., David Goldman, M.D., Alec Roy, M.D.

NR7-042

ASSOCIATION STUDY OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) GENE AND BIPOLAR DISORDER IN KOREA

Duk-In Jon M.D., Hye Ji Min, MD, Jeong-Ho Seok, MD, Ph.D., Eun Lee, MD, Ph.D., Hyun Sang Cho, MD, Ph.D.,

NR7-043

ASSOCIATION ANALYSIS OF HEAT SHOCK PROTEIN 70 GENE POLYMORPHISMS IN SCHIZOPHRENIA

Tae-Youn Jun M.D., Jun Ty, Kim JJI, Lim HK, Pae CU, Serretti A, Paik IH

NR7-044

IS THERE PROTECTIVE HAPLOTYPE OF DYSBINDIN GENE (DTNBP1) 3 POLYMORPHISMS FOR MAJOR DEPRESSIVE DISORDER

Tae-Youn Jun M.D., Jun Ty, Kim JJ, Lim HKI, Pae CU, Serretti A, C Lee

NR7-045

ASSOCIATION BETWEEN TRYPTOPHAN HYDROXYLASE-2 GENE VARIATIONS AND THE PERSONALITY TRAITS OF NOVELTY SEEKING AND HARM AVOIDANCE

Chan-Hyung Kim M.D., Yoon-Young Nam, M.D., Hong Shick Lee, M.D., Ph.D.

NR7-046

PROTECTIVE EFFECT OF DYSBINDIN GENE (DTNBP1) TO SCHIZOPHRENIA IN KOREAN POPULATION

Jung Jin Kim M.D., Chi Un Pae, M.D., Chang Uk Lee, M.D., Chul Lee, M.D., In Ho Paik, M.D.

NR7-047

PATIENT AND PHYSICIAN SATISFACTION WITH PHARMACOGENOMIC TESTING FOR DEPRESSED INPATIENTS AT THE MAYO CLINIC MOOD DISORDERS UNIT

Simon Kung M.D., Joel G. Winner, M.D., Josiah D. Allen, B.S., Karen A. Snyder, B.S., Renato D. Alarcon, M.D., M.P.H., David A. Mrazek, M.D.

NR7-048

PILOT STUDIES FOR FINEMAPPING OF CHROMOSOME 18 IN METHAMPHETAMINE ABUSERS: MAPK4 AS THE CANDIDATE GENE FOR COMORBIDITY OF PSYCHOSIS AND ADDICTION

Byung-Dae Lee, M.D., Eun-Young Kim, M.D., Jung-Hyun Lee, M.D., Do-Hoon Kwon, M.D., Yang-Tae Kim, M.D., Byung-Kook Ryu, M.D., Moon-Jin Kim, Sung-Nam Cho, M.D., Young-In Jeong, M.D., Je-Min Park, M.D., Sung-Gon Kim, M.D., Cheol-Joong Kang, M.D., Ji-Hoon Kim, M.D., Young-Min Lee, M.D., Michael A. Escamilla, M.D.

NR7-049

ASSOCIATION BETWEEN DRDS AND SCHIZOPHRENIA IN KOREAN POPULATION: MULTI-STAGE ASSOCIATION ANALYSES

Kyu Young Lee M.D., Eun-Jeong Joo, M.D., PhD, Yong Sik Kim. M.D., PhD

NR7-050

THE ASSOCIATION OF SEROTONIN 1A RECEPTOR POLYMORPHISM WITH RESPONSES TO MIRTAZAPINE IN MAJOR DEPRESSIVE DISORDER

Min-Soo Lee, M.D., Ph.D, Hwa-Young Lee, M.D, Ph.D., Rhee-Hun Kang, M.D., Ph.D., Hun Soo Chang, Ph.D., Jong-Woo Paik, M.D., Ph.D., Young-Hoon Ko, M.D., Ph.D., Hyang-Mi Kim, M.S.



NR7-051

ASSOCIATION BETWEEN H111H POLYMORPHISM AND GENE EXPRESSION OF BETA ARRESTIN 1 GENE (ARRB1) IN MAJOR DEPRESSIVE DISORDER

Min-Soo Lee, M.D., Ph.D., Hun Soo Chang, Ph.D., Rhee-Hun Kang, M.D., Ph.D., Hwa-Young Lee, M.D., Ph.D., Yoo-Jung Jeong, M.S., Jong-Woo Paik, M.D., Ph.D., Young-Hoon Ko, M.D., Ph.D.,

NR7-052

PHARMACOGENETIC STUDIES OF ZIPRASIDONE, OLANZAPINE AND PERAZINE IN PARANOID SCHIZOPHRENIA

Jerzy Samochowiec M.D., Tybura P, M.D., Ph.D., Justyna Pelka Wysiecka, M.D., Ph.D.

NR7-053

POLYMORPHISMS OF HTR2C AND LEPTIN GENES AND METABOLIC SYNDROME & WEIGHT CHANGE IN PATIENTS WITH SCHIZOPHRENIA TAKING CLOZAPINE MORE THAN ONE YEAR

Kang Shi Hyun M.D., Jongil Lee, M.D., Mina So, M.D., Gahee Lee, M.D., Kwonyoung Kang, M.D.

NR7-054

ASSOCIATION BETWEEN THE SEROTONIN TRANSPORTER GENE AND MAJOR DEPRESSIVE DISORDER IN THREE MAJOR ETHNIC GROUPS IN MALAYSIA

Nor Zainal M.B.B.S, Zahurin M, Lian L Hoong, Vijaya L Raj, Elsa H M Mohamed, Loke A Chin

NR7-055

PRESCRIBING PRACTICES AND SUBSEQUENT SECLUSION AND RESTRAINT: A FAILURE MODE EFFECTS ANALYSIS

David Goldbloom M.D., Ramin Mojtabai, M.D., Ph.D., Michael Serby, M.D.

NR7-056

ATTITUDE OF PATIENTS AND THEIR CAREGIVERS TOWARDS PSYCHOTROPIC MEDICATIONS: A STUDY FROM INDIA

Sandeep Grover, Subho Chakrabarti, M.D., MRCPsych., Shikha Tyagi, Aarti Sharma

NR7-057

PERSONAL AND OCCUPATIONAL CHARACTERISTICS OF WORKERS PRESENTING TO A SPECIALIZED WORKERS' COMPENSATION BOARD PSYCHOLOGICAL TRAUMA PROGRAM

Jennifer Hensel M.D., Ash Bender, MD., Jason Bacchiocchi, Ph.D., Carolyn S. Dewa, Ph.D.

NR7-058

ONE-YEAR HOSPITAL UTILISATION AND LONG-ACTING INJECTABLE RISPERIDONE: A MIRROR IMAGE STUDY WITH A NATIONAL CLAIM-BASED DATABASE IN TAIWAN

Kuan-Pin Su, M.D., Ph.D., Hui-Chih Chang, M.H.A., Shih-Jen Tsai, M.D., Chao-Hsiun Tang, Ph.D.

NR7-059

NEEDS OF PATIENTS WITH SCHIZOPHRENIA: A STUDY FROM INDIA

Parmanand Kulhara M.D., Ajit Avasthi, M.D., Sandeep Grover, M.D., Pratap Sharan, M.D., Ph.D., Parveen Sharma, M.D., Sameer Malhotra, M.D., Sapna Gill, M. Phil.

NR7-060

METABOLIC TESTING RATES IN THREE STATE MEDICAID PROGRAMS AFTER FDA WARNINGS ON ANTIPSYCHOTIC DRUGS AND DIABETES

Elaine H. Morrato, Dr.P.H., M.P.H., Benjamin Druss, M.D. M.P.H., Daniel M. Hartung, Pharm.D., M.P.H., Robert J. Valuck, Ph.D., Richard Allen, M.S., Elizabeth Campagna, M.S., John W. Newcomer, M.D.

NR7-061

PREDICTIVE FACTORS OF PSYCHIATRIC ADMISSIONS' LENGTH OF STAY AND EARLY READMISSIONS

Rosa Quelhas M.D., Tiago Rodrigues, M.D., Henrique Pereira, M.D.

NR7-062

SPECIALTY CARE COSTS IN CONTINUOUSLY ENROLLED INDIVIDUALS WITH BIPOLAR DISORDER ARE HIGHER THAN THOSE WITH INDIVIDUALS WITH DEPRESSION OR DIABETES

Mark Williams M.D., Nilay Shah, Ph.D., Amy Wagie, Mark A. Frye, M.D., Douglas Wood, MD

NR7-063

HISTORICAL EVOLUTION OF DISSOCIATION CONCEPT: ORIGIN OF MULTIPLE PERSONALITY

Agueda Rojo M.D., José L. Fernández, M.D.

NR7-064

SOFTWARE SUPPORTED SEMI-AUTOMATIC GENERATION OF LABORATORY REPORTS IN A NEUROCHEMICAL LAB

Anton Köstlbacher M.A., Alexander Haas, Ralf Köber, Ekkehard Haen

NR7-065

COST EFFECTIVENESS OF RISPERIDONE LONG ACTING INJECTION IN SEVERE AND ENDURING PSYCHIATRIC DISORDERS: A 22 MONTH MIRROR IMAGE ANALYSIS

Utpal Goswami M.B.B.S, H. Rao, MBBS

NR7-066

PREDICTORS OF NON ADHERENCE TO TREATMENT OF BIPOLAR DISORDER: THE RESULTS OF THE EPHEAR OBSERVATIONAL TRIAL

Alessandra Barraco, Francesca Mancini, M.O.S.; Andrea Rossi, M.O.S.; Giovanni Biggio, Giovanni Battista Cassano, Prof, MD.

NR7-067

EXECUTIVE FUNCTIONS AS AN IMPORTANT TARGET OF INTERVENTION IN BRAZILIAN SAMPLES OF PATIENTS WITH SCHIZOPHRENIA

Arthur Berberian M.S., Alessandra G S Capovilla, Ph.D., Bruna T. Trevisan, José Ari C Oliveira, M.D., Ph.D., Ary G. A. Ararape Neto, M.D.



NR7-068

TREATING DEPRESSION IN TEMPORAL LOBE EPILEPSY: A CONTROLLED CLINICAL TRIAL OF COGNITIVE BEHAVIORAL THERAPY .V.S. PHARMACOTHERAPY

Daniel Crail M.D, Alberto Herrera-Melo, Psy.D, Mario López-Gómez,MD.

NR7-069

PHENOMENOLOGICAL DIVERSITY OF HUNTINGTON'S DISEASE WITH DOMINATING PSYCHIATRIC SYMPTOMS :CHALLENGES TRADITIONAL CONCEPTS IN NEUROLOGY AND PSYCHIATRY

Cho D. Hwan M.D., Ho-Joon Je, M.D.

NR7-070

CORRELATIONS OF SOMATIC AND BRAIN METABOLIC ALTERATION IN NONHUMAN PRIMATES UNDER VARIABLE FORAGING DEMAND CONDITION

Dunyue Lu M.D., Jeremy D. Coplan, MD, John Kral, MD, PhD, Prakasi Chandra, MD, Aaron Pinkhasov, MD.

NR7-071

RELATIONSHIP BETWEEN SLEEP PATTERNS AND CLINICAL SYMPTOMS IN ELDERLY HOSPITALIZED PATIENTS WITH DEMENTIA

Kaloyan Tanev M.D., Marilyn Sablosky, M.S., Donal O'Hanlon, M.D., Caleb J. Siefert, Ph.D., John D. Matthews, M.D., Lawrence T. Park, M.D., Maurizio Fava, M.D., Adrienne O. van Nieuwenhuizen, B.A., Nelson Tauro, Andrew Winokur, M.D. Adrienne O. van Nieuwenhuizen, B.A.

NR7-072

IMPAIRED RECOGNITION OF EMOTIONAL PROSODY IN ADOLESCENTS WITH BORDERLINE PERSONALITY DISORDER: A COMPARATIVE STUDY

Stephanie Colin M.D., Pham-Scottez Alexandra, M.D. Bertoz Sylvie, Ph.D., Robin Marion, M.D., Curt Florence, M.D., Corcos Maurice, M.D., Ph.D.

NR7-073

DIRECT AND INDIRECT EFFECTS OF THE TEMPERAMENT AND CHARACTER ON ALEXITHYMIA: A PATHWAY ANALYSIS WITH DEPRESSION & ANXIETY

Seog Ju Kim M.D., Yu-Jin Lee, M.D., Ph.D., In Hee Cho, M.D., Ph.D., Jee Hyun Ha, M.D., Ph.D., Jong-Chul Yang, M.D., Ph.D., Sang-Keun Chung, M.D., Ph.D., Seong-Jin Cho, M.D., Ph.D.

NR7-074

A LONGITUDINAL STUDY OF THE 10-YEAR COURSE OF IMPULSIVE SYMPTOMS IN BORDERLINE PERSONALITY DISORDER

D. Bradford Reich M.D., Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D.

NR7-075

INFLUENCE OF FAMILY HISTORY OF ASPD ON CLINICAL CHARACTERISTICS OF PSYCHIATRIC OUTPATIENTS

Lei Wei D.O., Lei Wei, D.O., Elizabeth J. Nickel, M.A., Elizabeth C. Penick, Ph.D., Ekkehard Othmer, M.D., Ph.D., Barry Liskow, M.D., Marsha Read, Ph.D., Ned Hunter, Ph.D., William F. Gabrielli, M.D., Ph.D.

NR7-076

ANALYSIS OF MENTAL HEALTH CARE POLICY IN MEXICO

Gabriel Sotelo M.D., Armida Granados, M.D., Mirna A. Trancoso, M.D., Carlos Campillo, M.D.

NR7-077

RECRUITING THE NEXT GENERATION OF PSYCHIATRISTS – THE EVALUATION OF A PSYCHIATRY RECRUITMENT PROGRAM

Kien Dang M.D., Lisa Andermann, M.D., Matthew Levy, M.D., Taylor Armstrong, M.D., Claire De Souza, M.D.

NR7-078

A METHOD FOR EVALUATION OF COMPETENCY IN RISK ASSESSMENT FOR SUICIDE

Erick Hung, Dale E. McNiel, Ph.D., Samantha R. Fordwood, Ph.D., Stephen E. Hall, M.D., and Renee L. Binder, M.D.

NR7-079

DIURNAL VARIATION IN PLASMA BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) LEVEL IN HUMAN: GENDER DIFFERENCE

Joon-Ho Ahn M.D., Sam-Wook Choi, M.D., Sooyoung Bang, M.D.

NR7-080

RESEARCH ISSUES IN SURVEY MEASUREMENT OF BEHAVIORS INDICATING DIVERSION OF PRESCRIPTION MEDICATIONS FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

Douglas Currivan Ph.D., Larry A. Kroutil, M.P.H., Jill Ruppenkamp, M.S., Scott Novak, Ph.D.

NR7-081

QUALITY OF CARE AND THERAPEUTIC ALLIANCE IN EMERGENCY PSYCHIATRY: A NEW VALIDATE QUESTIONNAIRE

Coralie Laignac, M.D., Cristian Damsa, M. D. Eric Adam, MSc., Salvatore Virgillito MSc., Adrian Coman, M.D.

NR7-082

A COMPARISON OF PSYCHIATRY AND INTERNAL MEDICINE: A BIBLIOMETRIC STUDY OF RESEARCH FOCUS

Karina Stone M.D., SN Ghaemi, M.D., M.P.H.

NR7-083

LONGITUDINAL CONSENT-RELATED ABILITIES AMONG RESEARCH PARTICIPANTS WITH SCHIZOPHRENIA: RESULTS FROM THE CATIE STUDY

Thomas Stroup M.D., Paul S. Appelbaum, MD, Hongbin Gu, Ph.D.

NR7-084

METHODOLOGICAL ISSUES IN RESEARCH OF EARLY INTERVENTION IN PTSD: ARE ADEQUATELY-POWERED PREVENTION STUDIES FEASIBLE?

Joseph Zohar M.D., Ehud Klein, M.D., Gavriel Schreiber, M.D., Arieh Y. Shalev, M.D., Zeev Kaplan, M.D., A. Cohen, Ph.D.



NR7-085

GABAPENTIN ENACARBIL IMPROVES SLEEP IN SUBJECTS WITH MODERATE-TO-SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

Philip Becker M.D., Clete A. Kushida, M.D., Ph.D., Aaron L. Ellenbogen, DO., MPH., Daniel M. Canafax, PharmD., Eileen T. Monaghan, Ronald W. Barrett, Ph.D.

NR7-086

GABAPENTIN ENACARBIL RELIEVES PAIN ASSOCIATED WITH RESTLESS LEGS SYNDROME (RLS)

Daniel Canafax Pharm.D., Clete A. Kushida, M.D., Ph.D., Philip M. Becker, M.D., Aaron L. Ellenbogen, D.O., M.P.H., Eileen T. Monaghan., Ronald W. Barrett, Ph.D.

NR7-087

ASSOCIATION BETWEEN ANTIPSYCHOTIC-INDUCED RESTLESS LEGS SYNDROME AND TYROSINE HYDROXYLASE GENE POLYMORPHISM

Chul-Hyun Cho M.D., Seung-Gul Kang, M.D., Ph.D., Heon-Jeong Lee, M.D., Ph.D., Min-Soe Lee, M.D., Ph.D., Leen Kim, M.D., Ph.D.

NR7-088

CAN AN INSOMNIA THERAPY TREAT SLEEP MAINTENANCE WITHOUT SUPPRESSING AROUSABILITY: EFFECTS OF DOXEPIN 1, 3, & 6 MG ACROSS PHASE 3 TRIALS

H. Heith Durrence Ph.D., Philip Jochelson, M.D., Roberta Rogowski, BSN

NR7-089

GABAPENTIN ENACARBIL IMPROVES MOOD, QUALITY OF LIFE, AND FUNCTIONING IN SUBJECTS WITH MODERATE-TO-SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

Aaron Ellenbogen D.O., Philip M. Becker, M.D., Clete A. Kushida, M.D., Ph.D., Daniel M. Canafax, PharmD., Eileen T. Monaghan, Ronald W. Barrett, Ph.D.

NR7-090

ARMODAFINIL IMPROVES WAKEFULNESS THROUGHOUT THE DAY IN PATIENTS WITH RESIDUAL EXCESSIVE SLEEPINESS ASSOCIATED WITH TREATED OSA

Max Hirshkowitz, Ph.D., Alan Lankford, Ph.D., Ronghua Yang, Ph.D., Gregory A. Rippon, M.D., M.S., Thomas Roth, Ph.D.

NR7-091

EFFECTS OF DOXEPIN 1 AND 3 MG ON EARLY MORNING AWAKENINGS IN ELDERLY ADULTS WITH PRIMARY INSOMNIA

Philip Jochelson M.D., Roberta Rogowski, BSN, H. Heith Durrence, Ph.D.

NR7-092

CORRELATIONS OF SUBJECTIVE REPORTS & POLYSOMNOGRAPHIC FINDINGS IN OBSTRUCTIVE SLEEP APNEA PATIENTS

Seong Hwan Kim M.D., Sang-Myung Chun M.D., Ph.D., Assist. Professor, Chul-Jung Kang, M.D., Ph.D., Assist. Professor, Jae-Hong Park M.D.

NR7-093

LOW-DOSE ZOLPIDEM TARTRATE SUBLINGUAL LOZENGE (INTERMEZZO®) SAFELY AND EFFECTIVELY TREATS INSOMNIA FOLLOWING MOTN AWAKENING

Andrew Krystal M.D., Andrew Krystal, M.D., Russell Rosenberg, Ph.D., David Seiden, M.D., Milton Erman, M.D., Thomas Roth, Ph.D.

NR7-094

EFFECTS OF DOXEPIN 1, 3, AND 6 MG ON SLEEP EFFICIENCY BY HOUR FROM TWO LONG-TERM TRIALS OF CHRONIC INSOMNIA

Alan Lankford Ph.D., Philip Jochelson, M.D., H. Heith Durrence, Ph.D.

NR7-095

CLINICAL & GENETIC CHARACTERISTICS OF OBSTRUCTIVE SLEEP APNEA SYNDROME AND NARCOLEPSY IN KOREAN PATIENTS

Hamin Lee M.D., Seung-Chul Hong, M.D., Ph.D., Jong-Hyun Jeong, M.D., Ph.D., Jin-Hee Han, M.D., Ph.D., Sung-Pil Lee, M.D., Ph.D.

NR7-096

EFFECT OF EPLIVANSERIN ON DRIVING AND COGNITIVE/PSYCHOMOTOR TASKS IN A STUDY OF PATIENTS WITH INSOMNIA CHARACTERIZED BY SLEEP MAINTENANCE DIFFICULTIES

Remi Luthringer Ph.D., Anne Floch, Pharm.D, Ph.D., Astrid Delfolie, M.S., Olivier Nicolas, Pharm.D., Ph.D., Aurelie Brunet, Pharm.D., Jean-Louis Piquier, M.D.

NR7-097

RANDOMIZED PLACEBO- & ACTIVE-CONTROLLED STUDY OF EPLIVANSERIN: A NOVEL SLEEP AGENT, ON NEXT-DAY PSYCHOMOTOR & COGNITIVE TASKS IN HEALTHY SUBJECTS

Joelle Micallef-Roll Ph.D., Christine Roy, M.D., Ph.D., Astrid Delfolie, M.S., Jean-Louis Piquier, M.D., Olivier Blin, Ph.D.

NR7-098

EFFECT OF A PERIOD 3 (PER3) POLYMORPHISM ON SLEEP ARCHITECTURE IN PHASE ADVANCED TRANSIENT INSOMNIA

Shrutti Mitkus Ph.D., Gunther Birznieks, M.S., Charles A. Czeisler Ph.D., M.D., Andrew Thompson B.S., Christian Lavedan Ph.D.

NR7-099

NIGHT 1/WEEK 1 EFFECTS OF DOXEPIN 1, 3, AND 6 MG ON SLEEP ONSET ACROSS PHASE 3 TRIALS OF TRANSIENT AND CHRONIC INSOMNIA

Roberta Rogowski B.S.N., Philip, Jochelson, M.D., H. Heith Durrence, Ph.D.

NR7-100

EFFECT OF MELATONIN AGONIST TASIMELTEON ON SLEEP PARAMETERS AND ARCHITECTURE IN A PHASE ADVANCE MODEL OF TRANSIENT INSOMNIA

Russell Rosenberg Ph.D., Gunther Birznieks, M.S., Christin H. Scott, M.S., Paolo Baroldi, M.D., Ph.D., Mihael H. Polymeropoulos, M.D., Thomas Roth, Ph.D.

NR7-101

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ARMODAFINIL IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH JET LAG DISORDER

Thomas Roth Ph.D., Thomas Roth, Ph.D., Richard Bogan, M.D., James Youakim, M.D., Ronghua Yang, Ph.D., Jane Tiller, F.R.C.Psych



NR7-102

EVALUATION OF POLYSOMNOGRAPHIC SLEEP PARAMETERS IN PATIENTS WITH PRIMARY INSOMNIA TREATED WITH TASIMELTEON

*James Walsh Ph.D., Gregory Birznieks, M.S.,
Mihael Polymeropoulos, M.D., Paolo Baroldi, M.D., Ph.D.,
Rosa Torres, Ph.D., Christin Scott, M.S., Carole Welsch, Ph.D.,
John Feeney, M.D.*

NR7-103

POOLED ANALYSIS OF THE EFFECTS OF RAMELTEON 8 MG ON LATENCY TO PERSISTENT SLEEP IN ADULTS WITH CHRONIC INSOMNIA CHARACTERIZED BY SEVERE BASELINE SLEEP

Sherry Wang-Weigand M.D., Louis Mini, M.D., Francis Ogrinc, Ph.D.

NR7-104

EFFECTS OF RAMELTEON ON SLEEP ONSET AND PHASE-SHIFT IN INDIVIDUALS WITH DELAYED SLEEP PHASE DISORDER

*Phyllis Zee Ph.D., Sherry Wang-Weigand, M.D., Ph.D.,
Francis Ogrinc, Ph.D., Thomas Roth, Ph.D.*

NR7-105

SLEEP CORRELATES IN CHILDHOOD DEPRESSION: A STUDY IN AN EGYPTIAN SAMPLE

*Tarek Asaad M.D., Yasser Abdel Razek, M.D., Ghada Abdel Razek, M.D.,
Mona Abdel Hady, M.D.*

NR7-106

TOTAL SERUM CHOLESTEROL AND SUICIDALITY IN MAJOR DEPRESSIVE DISORDER

*Tarek Asaad M.D., Khaled Abdel Azim, M.D., S. Eid, M.D.,
Yasser Abdel Razek, M.D.*

Author / Presenter Index



A

Abbas, Muhammad A.	35
Abdallah, Chadi	39
Abd-Elseyed, Alaa	9
Able, Stephen	22
Abreu, Lena.....	33
Abubakar, Tunku-A.R Ben	41
Ahn, Joon-Ho.....	45
Alain, Katic	8
Albright, Mitzi	31
Almeida, Karla	16
Alonso, Pino	32
Alphs, Larry	6
Alzahrani, Mohamed.....	7
Amatniek, Joan	1
Amir, Asad	10
Ando, Shuntaro	13
Andreica, Bianca.....	29
Anthony, Lawson	1
Antonucci, Donna	8
Apfel, Brigitte	20
Areberg, Johan	42
Armstrong, Robert	8
Arrojo-Romero, Manuel	1
Artigas, Francesc.....	22
Asaad, Tarek.....	47
Ascher-Svanum, Haya	1
Aslam, Mahboob.....	16
Aslam, Sunny	32
Athappilly, Geena	11
Avasthi, Ajit	12
Awaad, Rania	33

B

Babiss, Lindsay	29
Bahk, Won-Myong.....	1
Baird-Bellaire, Susan	36
Baker, Ross	1
Balzan, Ryan	19
Baptista, Trino.....	36
Barker, Sandra.....	28
Barnea-Goraly, Naama.....	42
Barraco, Alessandra	44
Barros-Bermudez, Jaider.....	7
Battula, Smitha.....	36
Bauer, Michael	22
Bauza, Patricia	18
Båve, Ullvi	41
Becker, Philip.....	46
Bell, Stacy	31
Benítez Alonso, María	19
Benton, Tami	22
Berberian, Arthur	44
Berna, Montserrat Graell	31
Berwaerts, Joris.....	22
Bhatia, Ajay.....	16
Bhupendra, Gupta	8
Birgit, Amann.....	8
Bobes, Julio.....	1

Bob, Petr	41
Boess, Frank.....	1
Bolge, Susan	1
Bollegala, Dimitri	33
Bollu, Vamsi.....	21
Bosch, Rosa.....	29
Bossu, Paola.....	11
Bousquet, Benjamin.....	36
Boyersky, Gregory	32
Bramson, Candace	21
Brent, Elizabeth.....	30
Brunner, Elizabeth	1
Bui, Eric	34
Bullen, William.....	21

C

Cabassa, Johanna A.....	29
Calabrese, Joseph.....	22
Caldwell, Laura.....	40
Calico, Nivea.....	40
Calò, Salvatore.....	18
Camacho, Alvaro.....	39
Campo-Arias, Adalberto	22
Canafax, Daniel.....	46
Canuso, Carla.....	1
Cardoner, Narcís	42
Carlson, Berit	22
Carothers, Jennifer	1
Carpenter, Linda.....	36
Casamassima, Francesco.....	16
Cassella, James	41
Castillo, Enrico	30
Castro-Loli, Piero.....	22
Catalan, Rosa	36
Cernovsky, Zack	7
Cervenka, Simon.....	15
Chang, Hui Hua	16
Chang, Hyoungyoon	32
Chang, Sung Man.....	42
Charnsil, Chawanun.....	10
Chee, Christopher	15
Chee, Ik-Seung.....	43
Cheema, Faiz.....	32
Cheng, Chih-Tao.....	36
Chen, Laura.....	34
Chen, Po See	43
Chen, Wei Tzeng.....	19
Chen, Ying-Sheue	10
Cheon, Jin Sook	12
Chien, Yi-ling	29
Chiu, Simon	36
Cho, Chul-Hyun.....	46
Choi, Hong-min	14
Choi, Jeewook.....	10
Choi, Soo-hee.....	34
Chopra, Amit.....	22
Choua, Raquel.....	30
Chou, Frank Huang-Chih.....	39
Chow, Kevin	34

Choy, Ernest.....	35
Christensen, Laura	40
Chu, Kim.....	31
Chung, Jaewon.....	12
Chung, Moon Yong.....	21
Chung, Sang-Keun.....	42
Church, Heather.....	32
Clifford, Lucinda.....	19
Cognata-Smith, Christina.....	1
Cohen, Lisa	2
Colin, Stephanie.....	45
Connor, Daniel.....	10
Cook, Ian.....	23
Cordero, Amelia.....	23
Corey-Lisle, Patricia.....	10
Correll, Christoph	2
Cortes, Edmi	33
Cowperthwait, Colleen	23
Cox, Daniel	21
Crail, Daniel.....	45
Crivera, Concetta	2
Crocq, Marc-Antoine	37
Cucchiario, Josephine	37
Cummings, Elizabeth.....	13
Curriuan, Douglas	45

D

Dahl, Jacqueline	31
Damsa, Cristian.....	2
Dang, Kien	45
Darwish, Mona.....	37
De Dios, Consuelo	23
De Frutos Guijarro, Juan Jose.....	31
DeGreef, Rik	2
Delgado, Antonio	2
Delgado, Ofelia	2
Delle Chiaie, Roberto.....	37
Dell'Osso, Bernardo	23
Demitrack, Mark A.	23
De Oliveira, Irismar Reis	35
Dervic, Kanita.....	13
Detke, Holland	2
Detke, Michael.....	23
Diamond, Laura	15
Diller, Kathleen.....	31
D'Mello, Dale	23
Dodson, William.....	8
Dogterom, Peter	2
Donnelly, Vidis.....	31
Duisin, Dragana	12
Dunayevich, Eduardo.....	37
Durell, Todd	8
Durkin, Michael	8
Durrence, H. Heith.....	46
Duval, Fabrice.....	23

E

Earley, Willie.....	23
Ekman, Agneta.....	40

Author / Presenter Index



Ekman, Mattias	23
Ellenbogen, Aaron.....	46
Ellenwood, Amanda.....	29
Elsayed, Yasser.....	35
Enoch, Mary-Anne.....	43
Eom, Soyong.....	34
Epstein-Lubow, Gary	12
Erim, Rahsan.....	23
Ermer, James.....	8
Eun-Jung, Jung.....	16
Ezquiaga, Elena.....	23

F

Fagbami, Olusola	16
Faridi, Kia	2
Farlow, Martin.....	11
Feeney, John.....	2
Fernandez Biesa, Silvia.....	11
Fernandez-Miranda, Juan.....	37
Findling, Robert	8
Fishman, Robert.....	41
Fleischhacker, W. Wolfgang.....	2
Flynn, Grainne	35
Frasch, Karel	36
Frazier, Thomas.....	8
Frydecka, Dorota.....	19
Furukawa, Toshiaki A.	23

G

Gagnon, Pierre	11
Galan, Jaime.....	23
Galletly, Cherrie	2
Galvin, James E.	11
Gao, Keming	24
Garcia-Andrade, Rafael	19
García-López, Aurelio.....	24
Garcia-Portilla, Maria	16
Garcia-Sosa, Icelini.....	2
Gaspar, Enrique.....	19, 20
Gattaz, Wagner.....	2
Gelwicks, Steven.....	24
Gendreau, R. Michael	35
Geraci, Marilla	21
Gerard, Stephanie.....	24
Gerlach, Lauren.....	33
Giacobbe, Peter.....	15
Giblin, John.....	8
Giltay, Erik J.	24
Gines, Jose	7
Ginsberg, Lawrence	8
Giovanni Carta, Mauro	36
Gitlin, Michael	24
Glatt, Stephen.....	8
Goikolea, Jose.....	24
Goldbloom, David.....	44
Goldstein, Benjamin	24
Gonenli, Sinem	39
Gonzales, Felix	37
Gonzalez, Alfonso.....	24

González Díaz, Jairo	19
Goodman, David.....	8
Gopal, Sri	2
Goswami, Utpal	44
Goveas, Joseph.....	42
Grabylnikov, Stanislav	15
Graham, Stephen.....	11
Granados, Armida	29
Grant, Jon.....	21
Greene, Melissa.....	35
Greenhagen, Jason	12
Grieger, Thomas.....	28
Grinspan, Augusto.....	2
Grossberg, George	11
Grover, Sandeep.....	44
Guico-Pabia, Christine.....	37
Guillaume, Sebastien	24
Gupta, Aarti.....	16
Gupta, Bhanu	17
Gupta, Nitin.....	24

H

Hader, Astrid	16
Haeri, Sophia.....	19
Haghour-Vwich, Marina	31
Hamilton, Jennifer.....	3
Hammond, Christopher.....	7
Hamner, Mark	21
Ha, Rayeon.....	16
Hardy, Thomas	3
Harnic, Désirée	17
Harvey, Philip D.....	3
Haskins, J. Thomas	3
Hellidin, Lars	3
Heller, Randi	14
Hendriks, Margaret	40
Hensel, Jennifer.....	44
Herazo, Edwin	13
Hirshkowitz, Max	46
Hofbauer, Robert.....	11
Hoffmann, Vicki.....	3
Ho, Hon.....	10
Hojo, Aya	18
Hollander, Eric	37
Hong, Liu-Seifert	3
Hopyan, Talar.....	29
Horigian, Viviana	30
Horisawa, Tomoko	37
Hraniotis, Nicole.....	18
Huang, Huichun	20
Huang, Shang-Chien	37
Huber, Samuel.....	32
Huh, John	30
Hulskotte, Ellen.....	3
Hung, Erick	45
Hwan, Cho D.	45
Hwang, Jaerin	7
Hyun, Kang Shi.....	44

I

Ibrahim, Fayaz	12
Ilanovic, Lana Marija.....	3
Inczedi-Farkas, Gabriella.....	32
Iosifescu, Dan	24
Iragorri, Angela.....	11

J

Jagdeo, Amit	42
Jahng, Eun Jin	15
Jalees, Shah.....	39
Janish, Christopher.....	13
Jeong, Bumseok	41
Jeong, Jong-Hyun	37
Jeon, Hong Jun.....	20
Jochelson, Philip	46
Johnsen, Erik.....	37
Johnson, Kaja.....	18
Jon, Duk-In	43
Joshi, Ashish	21
Joy, Javed	8
Ju, Gawon	20
Jung-Ah, Min	17
Jung, Sung Won	37
Jun, Tae-Youn.....	43
Jun Won, Hwang.....	39
Jurjanz, Luisa	12

K

Kahn, Rene.....	3
Kamen, Lisa	10
Kane, Cecelia	37
Kang, Il	28
Kang, Jee In	41
Kansky, Christine I.....	24
Kapetanovic, Suad	7
Karamustafalioglu, Nesrin	13
Karayal, Onur.....	3
Karippot, Anoop.....	29
Karslioglu, Ersin Hatice.....	3
Kasckow, John	13
Katz, Curren.....	34
Kaunismaki, Yvette	13
Kelly, Megan.....	39
Kemp, David	24
Kim, Bo Ra	16
Kim, Chan-Hyung.....	43
Kim, Chi-Won.....	19
Kim, Chul Eung	3
Kim, Deborah.....	14
Kim, Hyun-Jin.....	20
Kim, Jennifer.....	24
Kim, Jeong-Lan.....	24
Kim, Jin-Sung	11
Kim, Jung Jin	43
Kim, Kyung Ran	20
Kim, Min-Ji.....	20
Kim, Namkwon.....	18

Author / Presenter Index



Ogasa, Masaaki	38	Raun, Melmed	9	Seungyoung, Lee.....	17
O’Gorman, Cedric.....	5	Razek, Ghada Abdel	7	Shaffiroff, Jacqueline.....	17
Oh, Inkyung	15	Reed, Michael	9	Shahid, Mohammed	5
Ok, Song Jin.....	37	Reich, D. Bradford.....	45	Shamal, Amin.....	30
Olin, Jason.....	12	Reiersen, Gillian	19	Shanahan, Brian	12
Olsson, Eric.....	16	Reimherr, Frederick	9	Sheehan, John	38
Omer, Aydemir	26	Renshaw, Perry	41	Shim, Se-hoon.....	10
O’Neil, Oreisa	17	Resler, Gustavo	33	Shiner, Brian	32
Oravec, Geoffrey.....	15	Richmond, Darren.....	30	Shin, Eunyoung.....	31
Owens, Judith.....	9	Riolo, Stephanie	15	Shinozaki, Gen	16
Özyildirim, Ilker	26	Rittmannsberger, Hans	38	Shin, Woo-Yong	15
P		Robb, Adelaide	5	Shin, Yunmi.....	33
Pae, Chi-Un.....	38	Roca, Miquel.....	26	Shrivastava, Amresh K.....	6
Pallanti, Stefano	26	Rocca, Cristiana	13	Shur-Fen Gau, Susan.....	8
Pandina, Gahan	5	Rodgers, Rachel	31	Sidhu, Kanwar Ajit.....	33
Pangallo, Beth.....	26	Rodrigues, Tiago	36	Sidor, Michelle.....	17
Panish, Jessica.....	5	Rodriguez, Lisette	13	Siefert, Caleb.....	27
Papakostas, George	38	Rodriguez, Stephen	5	Sikirica, Mirko	6
Pappadopoulos, Elizabeth	5	Rodríguez Vega, Beatriz	35	Singh, Mala	6
Park, Lawrence	26	Rogowski, Roberta.....	46	Sit, Dorothy.....	14
Park, Min-Cheol.....	39	Roh, Daeyoung	14	Si, Tianmei	38
Park, Sae-Han	39	Rojo, Agueda.....	44	Sliwa, Jennifer Kern.....	3
Partti, Krista	19	Romanowicz, Magdalena.....	34	Smith, Erica.....	33
Passov, Victoria.....	33	Romeo, Sarah A.	32	Sodhi, Dimple	31
Patel, Kajal.....	18	Römer, Benedikt	26	Sohn, Bokyoung.....	15
Patil, Uday.....	10	Rosales, Alejandra Garcia.....	31	Soo-Churl, Cho	10
Patkar, Ashwin A.....	10	Rosenberg, Ilyse.....	12	Sotelo, Gabriel	45
Pendlebury, John	5	Rosenberg, Russell.....	46	Spaeth, Michael.....	35
Pergolizzi, Fabianna	33, 39	Roth, Thomas.....	46	Speller, Heather.....	33
Perlick, Deborah	33	Roy, Mandy.....	29	Spiric, Zeljko.....	13
Peuskens, Joseph.....	5	Rubin, Richard	9	Srivastava, Shefali.....	17
Pham-Scottetz, Alexandra	12	Rueda-Jaimes, German	13	Stange, Jonathan	27
Phillips, Katharine.....	39	Ryan, Christine.....	26	Starr, H. Lynn	9
Pikalov, Andrei.....	10	S		Stauffer, Virginia.....	6
Polosan, Mircea.....	41	Saad, Ana	7	Steele, Annie	27
Portillo, Guillermo	33	Sa, Antonio.....	5	Stein, Dan.....	22
Potkin, Steven	38	Saatcioglu, Omer.....	35	Stewart, Michelle	10
Powers, Pauline.....	12	Sachs, Gabriele	5	Stock, Thomas.....	22
Pozzoli, Sara	26	Sadowsky, Carl	12	Stone, Karina.....	45
Prado, Eduardo.....	30	Safadi, Ziad	5	Strand, Vibeke	36
Pratts, Michael	34	Saiz-Ruiz, Jerónimo.....	5	Streeter, Chris C.....	42
Preen, Ellen	29	Sajatovic, Martha	26	Strejilevich, Sergio.....	27
Pujara, Akshat	18	Salman, Anoosh	17	Stroup, Thomas	45
Pulas, Troy	7	Samalin, Ludovic	26	Strydom, Andre	41
Q		Samardzic, Radomir.....	13	Suk, Lee Jung.....	3
Quelhas, Rosa	44	Samochowiec, Jerzy.....	44	Su, Kuan-Pin	44
Quiroz, Jorge A.	26	Sang-Bin, Baek	41	Surman, Craig	9
R		San José, Ainoa Muñoz.....	31	Susta, Marek	6
Raboch, Jiri	41	San, Luis	5	Sutton-Skinner, Kelly.....	32
Raja, Shubha	7	Santamarina, Susana	26	Svedsäter, Henrik	22
Ramírez-Cardenas, Angelica.....	32	Saragoussi, Delphine.....	26	Swartz, Conrad.....	42
Ramos-Quiroga, J. Antoni.....	29	Sasané, Rahul.....	40	Szamosi, Johan.....	27
Rangel-Martinez-Villalba, Andres	13	Sauer, Tizbé.....	34	T	
Rapin, Lucile.....	5	Schaffer, Ayal	26	Tafesse, Eskinder	27
Rathod, Shanaya	35	Schmidt, Karmen	30	Taha, Ghada	11
		Schulz, S. Charles	42	Tajes-Alonso, María.....	12
		Schwarz, Eitan D.	30	Tajima, Kazuhiro.....	17
		Seo, Young Hee.....	15	Tanev, Kaloyan.....	45

Author / Presenter Index



Theeman, Meredith	32
Thode, Kirstin	16
Thompson, Andrew	6
Tobias, Kathy	22
Tompkins, David	28
Tomruk, Nesrin	14
Topic, Radmila	33
Tosun, Taner	41
Tourian, Karen	39
Tourian, Leon	20
Townsend, Jennifer	9
Trancoso, Mirna	28
Treuer, Tamas	6
Trivedi, Jitendra	27
Turgay, Atilla	9
Turner, Adrienne	32
Turner, Norris	27
Tyler, Kelly	20

U

Unger, Theresa	40
----------------------	----

V

Van Ameringen, Michael	22
Van Den Bossche, Maarten	16
Vanderkruik, Rachel	34
Van Noorden, Martijn	27
Varia, Indu	27
Vemuri, Mytilee	27
Ventura, Daniel	11
Vevera, Jan	13
Vicente, Benjamin	43
Vieta, Eduard	6
Vigod, Simone N.	17
Villegas, Lina	15
Volpi, Simona	6
Von Der Goltz, Christoph	7

W

Walsh, James	47
Wang, Sheng-Chang	42
Wang-Weigand, Sherry	47
Warnell, Ronald	35
Warren, Susan L.	22
Wei-Chi, Lo	32
Wei, Lei	45
Weisler, Richard	13
West, Joyce	39
Whitehead, Richard	11
Whitham, Elizabeth	27
Wichniak, Adam	6
Wigal, Sharon	9
Wilens, Timothy	9
Williams, Caroline	40
Williams, Mark	44
Wolfgang, Curt	6
Woolley, Stephen B.	27
Writer, Brian	18

X

Xia, Guohua	40
Xu, Ming-Qing	16

Y

Yang, Huaiyu	17
Yang, Jong-Chul	42
Yaseen, Zimri	13
Yavorsky, William	40
Yim, Seon-Jin	19
Yingling, Michael	6
Yoon, Bo-Hyun	40
Yoon, Dong Hwan	16
Yoon-Jae, Song	14
Yoon, Jin-Sang	39
Young, Allan	27
Young-Hoon, Ko	11
Young, Joel	9
Yuqing, Song	16

Z

Zahid, Jahanara	30
Zainal, Nor	44
Zapata-Vega, Maria	11
Zarra, Julio	39
Zarrouf, Fahd	20
Zee, Phyllis	47
Zhao, Fangyi	6
Zhao, Xiangyang	34
Zhong, Huailing	27
Zimmerman, Mark	27, 28
Zohar, Joseph	45
Zorick, Todd	29
Zubritsky, Cynthia	32
Zukov, Ilja	35

NEW YORK CITY

OCTOBER 8–11, 2009

Save the date now to attend the American Psychiatric Association's **61st Institute on Psychiatric Services**, APA's leading educational conference on clinical issues and community mental health to meet the service needs of people with severe mental illness. Check out our website at www.psych.org/IPS.

Pride and Practice: Bringing Innovation Into Our Treatments

This four-day event will feature popular networking events, more than 100 exhibits that complement the educational program, and over 200 expertly-led educational sessions on topics including: Violence, Trauma, and Victimization; Social and Community Psychiatry; Psychopharmacology; Resident and Medical Student Concerns; Disorders; Cross-Cultural and Minority Issues; Child and Adolescent Issues; Treatment Techniques and Outcome Studies; Cognitive Disorders; Health Service Research; Mood Disorders; Schizophrenia, Addiction, and much more...


Who Should Attend?

- All APA Members
- Psychiatrists and mental health professionals in community practice or the public sector, including state and Veterans Affairs hospitals, community clinics, jails and prisons
- Psychiatric Administrators
- Mental health professionals interested in social issues that have an impact on patients and their families
- Minority psychiatrists and International Medical Graduates
- Psychiatric Residents (only \$60 for advance registration)
- Nonmember Residents and Advocacy Group Members (only \$85 for advance registration)
- Medical Students (free registration)

Why Should You Attend?

- This activity has been approved for CME credit and CEs have been applied for
- Receive a 40% discount on APA member registration fees
- Network with colleagues at receptions and other events
- Valuable exhibit hall prizes drawn each day
- **Immersion Courses are NEW and FREE this year.** They offer intensive all day sessions which will provide a new and clinically applicable skill set to attendees. A certificate of participation/certification will be available for some sessions.

The IPS is going "GREEN" this year; therefore, the *Preliminary Program*, which includes registration, housing, and travel information will be available online only in May at www.psych.org/IPS. Online registration and hotel reservations at the Sheraton New York Hotel and Towers will begin on June 1.



APA's Leading Educational Conference on Public and Community Psychiatry

For more information, please contact:

American Psychiatric Association
1000 Wilson Blvd., Suite 1825
Arlington, VA 22209-3901
Phone: 1-888-35-PSYCH
or (703) 907-7300
Fax: (703) 907-1090
E-mail: apa@psych.org
Web: www.psych.org/IPS



Co-sponsored by
Drexel University College of Medicine/
Behavioral Healthcare Education